# EDGAR Filing Document

**Accession Number:** 0001492448
**File Stem:** 0001553350-25-000218
**Filing Date:** 2025-12
**Character Count:** 597834
**Document Hash:** 2513c18ad512f15ede0419536b09a3ce
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001553350-25-000218.hdr.sgml**: 20251231

**ACCESSION NUMBER**: 0001553350-25-000218

**CONFORMED SUBMISSION TYPE**: 1-A POS

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20251231

**DATE AS OF CHANGE**: 20251231

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Exousia Pro, Inc.
- **CENTRAL INDEX KEY:** 0001492448
- **STANDARD INDUSTRIAL CLASSIFICATION:** COMMUNICATION SERVICES, NEC [4899]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 272616571
- **STATE OF INCORPORATION:** FL
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 1-A POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 024-12629
- **FILM NUMBER:** 251615731

**BUSINESS ADDRESS:**
- **STREET 1:** 7901 4TH STREET N #23494
- **CITY:** ST. PETERSBURG
- **STATE:** FL
- **ZIP:** 33702
- **BUSINESS PHONE:** 509-605-6533

**MAIL ADDRESS:**
- **STREET 1:** 7901 4TH STREET N #23494
- **CITY:** ST. PETERSBURG
- **STATE:** FL
- **ZIP:** 33702

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GRN Holding Corp
- **DATE OF NAME CHANGE:** 20190822

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Discovery Gold Corp
- **DATE OF NAME CHANGE:** 20120713

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NORMAN CAY DEVELOPMENT, INC.
- **DATE OF NAME CHANGE:** 20100520

## Part

**Post-Qualification Offering Circular Amendment No. 1**

**File No. 024-12629**

**<u>OFFERING CIRCULAR</u>**

**Exousia Pro, Inc.**

***(formerly Marijuana, Inc.)***

**Up to 15,000,000 Shares of Common Stock Offered by the Company**

**Up to 4,245,569 Shares of Common Stock Offered by the Selling Shareholders**

This Post-Qualification Offering Circular Amendment No. 1 amends the Offering Circular of Exousia Pro, Inc., formerly Marijuana, Inc., a Florida corporation (the "Company"), dated September 9, 2025, as supplemented December 4, 2025, and as may be amended and supplemented from time to time, to: (1) revise downward the number of shares of Company common stock to be offered by the Company to 15,000,000 shares (the "Company Offered Shares"); (2) increase the number of shares of Company common stock to be offered by selling shareholders (the "Selling Shareholders") from 1,000,000 shares to 4,575,000 shares (the "Selling Shareholder Offered Shares"); and (3) revise the offering price of the 14,916,666 Company Offered Shares that remain unsold (the "Remaining Company Offered Shares") and the 3,904,431 Selling Shareholder Offered Shares that remain unsold (the "Remaining Selling Shareholder Offered Shares") to $[0.06-0.12].

By this Offering Circular, the Company is offering for sale a maximum of 15,000,000 Company Offered Shares, of which 83,334 shares have been sold for cash in the total amount of $10,000 and of which 14,916,666 shares, the Remaining Company Offered Shares, at a fixed price of $[0.06-0.12] per share, pursuant to Tier 1 of Regulation A of the United States Securities and Exchange Commission (the "SEC"). A minimum purchase of $5,000 of the Company Offered Shares is required in this offering; any additional purchase must be in an amount of at least $1,000. This offering is being conducted on a best-efforts basis, which means that there is no minimum number of Company Offered Shares that must be sold by us for this offering to close; thus, we may receive no or minimal proceeds from this offering. All proceeds from this offering will become immediately available to us and may be used as they are accepted. Purchasers of the Company Offered Shares will not be entitled to a refund and could lose their entire investments.

Also by this Offering Circular, the Selling Shareholders are offering for sale a maximum of 4,245,569Selling Shareholder Offered Shares, of which 670,569 shares have been sold for cash in the total amount of $100,585, and 3,575,000 shares, the Remaining Selling Shareholder Offered Shares, at a fixed price of $[0.06-0.12]. Currently, $350,000 of principal amount convertible notes (including prior-converted notes, the "Subject Convertible Notes"), are convertible into shares of Company common stock (the shares of our common stock issued upon conversion of the Subject Convertible Notes are referred to sometimes as the "Conversion Shares" and are also referred to sometimes as the Selling Shareholder Offered Shares or the Remaining Selling Shareholder Offered Shares). As of the date of this Post-Qualification Offering Circular Amendment No. 1, $97,500 of principal of, and $3,085 of accrued interest on, the Subject Convertible Notes has been converted into a total of 670,569 Conversion Shares, all of which have been sold for a total of $100,585 in cash. Following each issuance of Conversion Shares, we intend to file a supplement to this Offering Circular pursuant to Rule 253(g)(2), wherein the exact number of Conversion Shares issued in payment of the Subject Convertible Notes will be disclosed. We will not receive any of the proceeds from the sale of the Selling Shareholder Offered Shares in this offering. A minimum purchase of $5,000 of the Selling Shareholder Offered Shares is required in this offering; any additional purchase must be in an amount of at least $1,000. We will pay all of the expenses of this offering (other than discounts and commissions payable with respect to the Selling Shareholder Offered Shares sold in the offering, if any). Our company will not be involved in any manner in the sales of the Selling Shareholder Offered Shares by the Selling Shareholder. (See "[Use of Proceeds](#a_006)," "[Plan of Distribution](#a_007)" and "[Selling Shareholder](#a_008)").

Please see the "[Risk Factors](#a_004)" section, beginning on page 3, for a discussion of the risks associated with a purchase of the Offered Shares.

This offering commenced September 9, 2025, and will terminate at the earliest of (a) the date on which all of the Offered Shares (Remaining Company Offered Shares and Remaining Selling Shareholder Shares), (b) December 24, 2026, or (c) the date on which this offering is earlier terminated by us, in our sole discretion. (See "[Plan of Distribution](#a_007)").

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Title of Class of Securities Offered and Offering Party** | **Total Number of Shares Offered** | **Number of Shares Sold to Date** | **Proceeds to Offeror(s) of Shares** | **Number of Remaining Shares to Be Sold** | **Price to Public of Remaining Shares to Be Sold** | **Proceeds to Offeror of Remaining Shares** |  | **Commissions <sup>(1)</sup>** | **Total Proceeds to Offeror(s) of Shares <sup>(2)</sup>** |  |
| Common Stock Offered by Our Company | 15000000 (A) | 83334 | $10000 | 14916666 (A) | $[0.06-0.12] | $1790000 |  | $-0- | $1800000 |  |
| Common Stock Offered by the Selling Shareholders | 4245569 (B)(3)(4) | 670569 | $100585 | 357500 (B) | $[0.06-0.12] | $429000 | (5) | $-0- | $529585 | (6) |
| **Totals** | **19245569** | **753903** | $**110585** | **18491666** |  | $**2219000** |  | $**-0-** | $**2329585** |  |

---

(A) These securities are being qualified pursuant to subparagraph (F) of Rule 251(d)(3)(i).

(B) These securities are being qualified pursuant to subparagraph (A) of Rule 251(d)(3)(i).

(1) Our
 company will not pay any commissions for the sale of Company Offered Shares in this Offering. We do not intend to offer and sell
 the Company Offered Shares through registered broker-dealers or utilize finders. However, should we determine to employ a registered
 broker-dealer or finder, information as to any such broker-dealer or finder shall be disclosed in a post-qualification amendment
 to this Offering Circular.

(2) Does not account for payment of expenses of this offering, which are estimated to not exceed $15,000 and which include, among other expenses, legal fees, accounting costs, administrative services, Blue Sky compliance and actual out-of-pocket expenses incurred by us in selling the Company Offered Shares. We will pay all of the expenses of this offering (other than selling commissions payable with respect to the Selling Shareholder Offered Shares sold in this offering, if any), but we will not receive any of the proceeds from the sales of Selling Shareholder Offered Shares in this offering. (See " [Plan of Distribution](#a_007) " and " [Selling Shareholder](#a_008) ").

(3) As
 of the date of this Post-Qualification Offering Circular No. 1, 670,569 of these shares of common stock has been issued as
 Conversion Shares. The unconverted Subject Convertible Notes are, by their terms, eligible for conversion into up to 3,575,000
 Conversion Shares, at the election of the Selling Shareholders, at the offering price for all of the Offered Shares, $0.10 per share
 converted. Following all such issuances, we intend to file a supplement to this Offering Circular pursuant to Rule 253(g)(2),
 wherein the exact number of Offered Shares issued in payment of the Subject Convertible Notes to be offered by the Selling
 Shareholders in this offering will be disclosed. References herein to the "Offered Shares" include the Remaining Selling
 Shareholder Offered Shares, unless the context requires otherwise. (See " [Use of Proceeds](#a_006) ,"
 " [Plan of Distribution](#a_007) " and " [Selling Shareholder](#a_008) ").

(4) This number of Remaining Selling Shareholder Offered Shares was determined
by adding the principal amounts of the unconverted Subject Convertible Notes, $350,000, and an assumed $7,500 of interest thereon, then
dividing that sum, $357,500, by $0.10, for a result of 3,575,000 shares.

(5) Because the unconverted Subject Convertible Notes may be converted into Conversion
Shares at $0.10 per share, this amount represents the maximum amount that the Selling Shareholders would be able to derive from the sale
of all Remaining Selling Shareholder Offered Shares.

(6) We
 will not receive any of the proceeds from the sale of the Remaining Selling Shareholder Offered Shares in this offering. (See
 " [Use of Proceeds](#a_006) " and " [Selling Shareholders](#a_008) ").

The terms of this offering were determined arbitrarily by our company. The offering price for the Offered Shares (Remaining Company Offered Shares and Remaining Selling Shareholder Offered Shares) does not necessarily bear any relationship to our company's assets, book value, earnings or other established criteria of valuation. Accordingly, the offering price of the Offered Shares should not be considered as an indication of any intrinsic value of such securities. (See "[Risk Factors](#a_004)—Risks Related to a Purchase of Offered Shares" and "[Dilution](#a_005)").

There is no escrow established for the proceeds from sales of the Company Offered Shares in this offering. (See "[Risk Factors](#a_004)—Risks Related to a Purchase of Offered Shares").

Our common stock is quoted in the over-the-counter under the symbol "MAJI" in the OTC Pink marketplace of OTC Link. On December 29, 2025, the closing price of our common stock was $0.0575 per share.

**Investing in the Offered Shares is speculative and involves substantial risks, including the superior voting rights of our outstanding shares of Series A Preferred Stock, which preclude current and future owners of our common stock, including the Offered Shares, from influencing any corporate decision. The Series A Preferred Stock has the following voting rights: the holders of the Series A Preferred Stock shall, as a class, have rights in all matters requiring shareholder approval to a number of votes equal to two (2) times the sum of: (a) the total number of shares of common stock which are issued and outstanding at the time of any election or vote by the shareholders; plus (b) the number of votes allocated to shares of Preferred Stock issued and outstanding of any other class that shall have voting rights.**

**Our Chief Executive Officer, Michael Sheikh, as the owner of the outstanding share of the Series A Preferred Stock, will, therefore, be able to control the management and affairs of our company, as well as matters requiring the approval by our shareholders, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets, and any other significant corporate transaction. (See "[Risk Factors](#a_004)—Risks Related to a Purchase of the Offered Shares").**

**THE SEC DOES NOT PASS UPON THE MERITS OF, OR GIVE ITS APPROVAL TO, ANY SECURITIES OFFERED OR THE TERMS OF THE OFFERING, NOR DOES IT PASS UPON THE ACCURACY OR COMPLETENESS OF ANY OFFERING CIRCULAR OR OTHER SOLICITATION MATERIALS. THESE SECURITIES ARE OFFERED PURSUANT TO AN EXEMPTION FROM REGISTRATION WITH THE SEC. HOWEVER, THE SEC HAS NOT MADE AN INDEPENDENT DETERMINATION THAT THE SECURITIES OFFERED ARE EXEMPT FROM REGISTRATION.**

**The use of projections or forecasts in this offering is prohibited. No person is permitted to make any oral or written predictions about the benefits you will receive from an investment in Offered Shares.**

**No sale may be made to you in this offering if you do not satisfy the investor suitability standards described in this Offering Circular under "Plan of Distribution-State Law Exemption" and "Offerings to Qualified Purchasers-Investor Suitability Standards" (page 2). Before making any representation that you satisfy the established investor suitability standards, we encourage you to review Rule 251(d)(2)(i)(C) of Regulation A. For general information on investing, we encourage you to refer to *www.investor.gov*.**

This Offering Circular follows the disclosure format of Form S-1, pursuant to the General Instructions of Part II(a)(1)(ii) of Form 1-A.

The date of this Post-Qualification Offering Circular Amendment No. 1 is December 30, 2025.

**FOR FLORIDA RESIDENTS:**

**PURSUANT TO SECTION 517.061(11)(A)(5) OF THE FLORIDA STATUTES, FLORIDA INVESTORS HAVE A THREE-DAY RIGHT OF RESCISSION. IF A FLORIDA INVESTOR HAS EXECUTED A SUBSCRIPTION AGREEMENT AND TENDERED THE CONSIDERATION FOR THE PURCHASE, HE MAY ELECT, WITHIN THREE BUSINESS DAYS AFTER SIGNING THE SUBSCRIPTION AGREEMENT OR BEING FIRST NOTIFIED OF THIS RIGHT, WHICHEVER IS LATER, TO WITHDRAW FROM THE SUBSCRIPTION AGREEMENT AND RECEIVE A FULL REFUND AND RETURN (WITHOUT INTEREST) OF ANY MONEY PAID BY HIM. A FLORIDA INVESTOR'S WITHDRAWAL WILL BE WITHOUT ANY FURTHER LIABILITY TO ANY PERSON. TO ACCOMPLISH SUCH WITHDRAWAL, A FLORIDA INVESTOR NEED ONLY SEND A LETTER OR TELEGRAM TO THE COMPANY AT THE ADDRESS SET FORTH IN THIS MEMORANDUM INDICATING HIS INTENTION TO WITHDRAW. SUCH LETTER OR TELEGRAM MUST BE SENT AND POSTMARKED PRIOR TO THE END OF THE AFOREMENTIONED THIRD BUSINESS DAY. IF A FLORIDA INVESTOR SENDS A LETTER, IT IS PRUDENT TO SEND IT BY CERTIFIED MAIL, RETURN RECEIPT REQUESTED, TO AN OFFICER OF THE COMPANY TO ENSURE THAT IT IS RECEIVED AND ALSO TO EVIDENCE THE TIME AND DATE WHEN IT IS MAILED. SHOULD A FLORIDA INVESTOR MAKE THIS REQUEST ORALLY, HE SHOULD ASK FOR WRITTEN CONFIRMATION THAT HIS REQUEST HAS BEEN RECEIVED. THE FOREGOING IS INTENDED TO CONSTITUTE THE NOTICE REQUIRED UNDER THE FLORIDA STATUTES. ACCORDINGLY, EACH PURCHASER WILL HAVE THREE DAYS AFTER THE FIRST TENDER OF CONSIDERATION IS MADE BY SUCH PURCHASER TO VOID HIS PURCHASE OF THESE SECURITIES.**

**_______________________________________________________________**

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
|  | **Page** |
| [Cautionary Statement Regarding Forward-Looking Statements](#a_001) | 1 |
| [Offering Circular Summary](#a_002) | 2 |
| [Risk Factors](#a_004) | 3 |
| [Dilution](#a_005) | 8 |
| [Use of Proceeds](#a_006) | 9 |
| [Plan of Distribution](#a_007) | 10 |
| [Selling Shareholders](#a_008) | 12 |
| [Description of Securities](#a_009) | 13 |
| [Business](#a_010) | 14 |
| [Management's Discussion and Analysis of Financial Condition and Results of Operations](#a_011) | 15 |
| [Directors, Executive Officers, Promoters and Control Persons](#a_012) | 18 |
| [Executive Compensation](#a_013) | 20 |
| [Security Ownership of Certain Beneficial Owners and Management](#a_014) | 21 |
| [Certain Relationships and Related Transactions](#a_015) | 22 |
| [Legal Matters](#a_016) | 22 |
| [Where You Can Find More Information](#a_017) | 22 |
| [Index to Financial Statements](#a_018) | F-1 |

---

**CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS**

The information contained in this Offering Circular includes some statements that are not historical and that are considered forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding our development plans for our business; our strategies and business outlook; anticipated development of our company; and various other matters (including contingent liabilities and obligations and changes in accounting policies, standards and interpretations). These forward-looking statements express our expectations, hopes, beliefs and intentions regarding the future. In addition, without limiting the foregoing, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words anticipates, believes, continue, could, estimates, expects, intends, may, might, plans, possible, potential, predicts, projects, seeks, should, will, would and similar expressions and variations, or comparable terminology, or the negatives of any of the foregoing, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

The forward-looking statements contained in this Offering Circular are based on current expectations and beliefs concerning future developments that are difficult to predict. We cannot guarantee future performance, or that future developments affecting our company will be as currently anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.

All forward-looking statements attributable to us are expressly qualified in their entirety by these risks and uncertainties. These risks and uncertainties, along with others, are also described below in the Risk Factors section. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on any forward-looking statements and should not make an investment decision based solely on these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

**OFFERING CIRCULAR SUMMARY**

The following summary highlights material information contained in this Offering Circular. This summary does not contain all of the information you should consider before purchasing our common stock. Before making an investment decision, you should read this Offering Circular carefully, including the Risk Factors section and the unaudited consolidated financial statements and the notes thereto. Unless otherwise indicated, the terms we, us and our refer and relate to Exousia Pro, Inc., formerly Marijuana, Inc., a Florida corporation, including its subsidiaries.

**Our Company**

*<u>History</u>*. We were incorporated in the State of Nevada on April 28, 2010, under the name Norman Cay Development, Inc. On July 12, 2012, our corporate name changed to Discovery Gold Corporation. On August 19, 2019, our corporate name changed to GRN Holding Corporation. On August 4, 2022, our company redomiciled to the State of Florida. On November 13, 2023, our corporate name changed to Marijuana, Inc.

*On April 2, 2025, our corporate name changed to Exousia Pro, Inc. The effective time, as it relates to the stock trading market, of this corporate action, which will include a change to our trading symbol, will depend on the date on which FINRA issues its approval of our related filing. We are unable to predict the date on which FINRA will issue such approval.*

*<u>Recent Change in Control</u>*. Effective October 30, 2024, a change in control of our company occurred. On such date, Earth Onyx, LLC, a company owned by our former Sole Director and Officer, sold 100 shares (the "Control Shares"), or 100% of the outstanding shares, of our Series A Preferred Stock to our current Sole Director and Chief Executive Officer. Mr. Sheikh paid $60,000 in cash and delivered a promissory note (the "Closing Note") to Earth Onyx, LLC in payment of the Control Shares. The Closing Note has a principal amount of $100,000 and is due on the later of 60 days from October 30, 2024, and the date on which Mr. Steinberg shall have delivered ready-to-file federal tax returns for the years ended December 31, 2022 and 2023, of our company. Mr. Sheikh and Earth Onyx, LLC entered into Pledge Agreement, to secure Mr. Sheikh's payment obligations under the Closing Note.

*<u>Recent Acquisition; Exiting "Shell Company" Status</u>*. Effective December 31, 2024, pursuant to a stock purchase agreement with Ludwig Enterprises, Inc. ("Ludwig"), a publicly-traded company (symbol: LUDG), we acquired 100% of Exousia Ai, Inc., a Wyoming corporation (Exousia AI), and related assets, in consideration of a $100,000 promissory note (the "Ludwig Note"), the principal and interest of which is due on December 31, 2025, and 10,000 shares of our Series B Convertible Preferred Stock. In conjunction with the issuance of the Ludwig Note, we entered into a pledge agreement with Ludwig, to secure our timely payment of the Ludwig Note. Exousia AI is a biotechnology company in the field of exosomes. In the transaction, we secured a worldwide license for certain exosome technologies. (See "[Business](#a_010)").

With the acquisition of Exousia AI, our company exited "shell company" status.

*<u>Plan and Agreement of Reorganization – Exousia AI</u>*. On November 11, 2025, pursuant to a Plan and Agreement of Reorganization (the "Reorganization Agreement"), L A M Y, a Wyoming corporation ("LMMY"), acquired our 70%-owned subsidiary, Exousia Ai, in exchange for shares of LMMY common stock. Following the closing of the Reorganization Agreement, our company holds 41,223,000 shares, or approximately 51% (as measured after the transaction), of LMMY common stock. Our company's President, Matthew Dwyer, serves as LMMY's sole officer and director.

The transaction with LMMY was pursued and consummated by the Company, after the Company's Board of Directors had determined, after investigating the LMMY opportunity, that the best interests of the Company and its shareholders would be best served by acquiring a controlling interest in LMMY, in exchange for its ownership in Exousia Ai.

*<u>Current Business</u>*. Our company is a clinical stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused in the field of oncology. Our proprietary manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications, including dermatology and dentistry. Our proprietary loading technology can infuse a range of molecules from drugs to DNA. Because our company owns control of LMMY, the operations of Exousia AI are presented in the following discussion. (See "[Business](#a_010)").

**Offering Summary**

---

| | |
|:---|:---|
| *Securities Offered by our Company* | 15,000,000 Offered Shares (the Company Offered Shares), including the 14,916,666 Remaining Company Offered Shares. |
| <br> *Offering Price* | <br> $[0.06-0.12] per Remaining Company Offered Share and per Remaining Selling Shareholder Offered Share.<br>|
| *Shares Outstanding*<br> *Before This Offering* | 41,048,470 shares issued and outstanding as of the date hereof. |
| <br> *Shares Outstanding*<br> *After This Offering* | <br> 59,623,470 shares issued and outstanding, assuming the sale of all of the Remaining Company Offered Shares hereunder and the issuance of 3,575,000 Conversion Shares to the Selling Shareholders, upon conversion of the unconverted Subject Convertible Notes.<br>|
| *Minimum Number of Company Offered Shares*<br> *to Be Sold in This Offering* | There is no minimum number of Remaining Company Offered Shares to be sold in this offering. A minimum purchase of $5,000 of the Offered Shares, whether Remaining Company Offered Shares or Remaining Selling Shareholder Offered Shares, is required in this offering; any additional purchase must be in an amount of at least $1,000. |
| <br> *Selling Shareholder* | <br> As of the date of this Post-Qualification Offering Circular No. 1, 670,569 of these shares of common stock has been issued as Conversion Shares. The unconverted Subject Convertible Notes are, by their terms, eligible for conversion into up to 3,575,000 Conversion Shares, at the election of the Selling Shareholder, at $0.10 per share converted. Following each issuance of Conversion Shares, we intend to file a supplement to this Offering Circular pursuant to Rule 253(g)(2), wherein the exact number of Conversion Shares issued in payment of the Subject Convertible Notes will be disclosed. but we will pay all of the expenses of this offering (other than discounts and commissions payable with respect to the Selling Shareholder Offered Shares sold in the offering, if any). Our company will not be involved in any manner in the sales of the Selling Shareholder Offered Shares by the Selling Shareholders. (See "[Use of Proceeds](#a_006)," "[Plan of Distribution](#a_007)" and "[Selling Shareholder](#a_008)").<br>|
| *Disparate Voting Rights* | Our outstanding shares of Series A Preferred Stock possess superior voting rights, which preclude current and future owners of our common stock, including the Offered Shares, from influencing any corporate decision. The Series A Preferred Stock has the following voting rights: the holders of the Series A Preferred Stock shall, as a class, have rights in all matters requiring shareholder approval to a number of votes equal to two (2) times the sum of: (a) the total number of shares of common stock which are issued and outstanding at the time of any election or vote by the shareholders; plus (b) the number of votes allocated to shares of Preferred Stock issued and outstanding of any other class that shall have voting rights.<br>Our Chief Executive Officer, Michael Sheikh, as the owner of the outstanding share of the Series A Preferred Stock, will, therefore, be able to control the management and affairs of our company, as well as matters requiring the approval by our shareholders, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets, and any other significant corporate transaction. (See "[Risk Factors](#a_004)—Risks Related to a Purchase of the Offered Shares"). |
| <br> *Investor Suitability Standards* | <br> The Offered Shares (Remaining Company Offered Shares and Remaining Selling Shareholder Offered Shares) may only be purchased by investors residing in a state in which this Offering Circular is duly qualified who have either (a) a minimum annual gross income of $70,000 and a minimum net worth of $70,000, exclusive of automobile, home and home furnishings, or (b) a minimum net worth of $250,000, exclusive of automobile, home and home furnishings.<br>|
| *Market for our Common Stock* | Our common stock is quoted in the over-the-counter market under the symbol "MAJI" in the OTC Pink marketplace of OTC Link. |
| <br> *Termination of this Offering* | <br> This offering commenced September 9, 2025, and will terminate at the earliest of (a) the date on which all of the Offered Shares (Remaining Company Offered Shares and Remaining Selling Shareholder Shares) the maximum offering has been sold, (b) December 24, 2026, or (c) the date on which this offering is earlier terminated by us, in our sole discretion.<br>|
| *Use of Proceeds* | We will apply the cash proceeds from sales of Company Offered Shares in this offering for investigational new drug trials, new product development, acquisition of lab equipment, marketing and working capital. (See "[Use of Proceeds](#a_006)"). |
| <br> *Risk Factors* | <br> An investment in the Offered Shares (Remaining Company Offered Shares and Remaining Selling Shareholder Offered Shares) involves a high degree of risk and should not be purchased by investors who cannot afford the loss of their entire investments. You should carefully consider the information included in the Risk Factors section of this Offering Circular, as well as the other information contained in this Offering Circular, prior to making an investment decision regarding the Offered Shares (Remaining Company Offered Shares and Remaining Selling Shareholder Offered Shares).<br>|
| *Corporate Information* | Our principal executive offices are located at 7901 4th Street N #23494, St. Petersburg, Florida 33702; our telephone number is 509-605-6533; our corporate website is located at www.exousiapro.com. No information found on our company's website is part of this Offering Circular. |

---

**Continuing Reporting Requirements Under Regulation A**

As a Tier 1 issuer under Regulation A, we will be required to file with the SEC a Form 1-Z (Exit Report Under Regulation A) upon the termination of this offering. We will not be required to file any other reports with the SEC following this offering.

However, during the pendency of this offering and following this offering, we intend to file quarterly and annual financial reports and other supplemental reports with OTC Markets, which will be available at www.otcmarkets.com.

All of our future periodic reports, whether filed with OTC Markets or the SEC, will not be required to include the same information as analogous reports required to be filed by companies whose securities are listed on the NYSE or NASDAQ, for example.

**RISK FACTORS**

*[<u>Note</u>: References in this Risk Factors section to "Offered Shares" include the Remaining Company Offered Shares and the Remaining Selling Shareholder Offered Shares, unless specifically indicated otherwise.]*

An investment in the Offered Shares involves substantial risks. You should carefully consider the following risk factors, in addition to the other information contained in this Offering Circular, before purchasing any of the Offered Shares. The occurrence of any of the following risks might cause you to lose a significant part of your investment. The risks and uncertainties discussed below are not the only ones we face, but do represent those risks and uncertainties that we believe are most significant to our business, operating results, prospects and financial condition. Some statements in this Offering Circular, including statements in the following risk factors, constitute forward-looking statements. (See "[Cautionary Statement Regarding Forward-Looking Statements](#a_001)").

**Risks Related to Our Company**

***We have incurred losses in prior periods, and losses in the future could cause the quoted price of our common stock to decline or have a material adverse effect on our financial condition, our ability to pay our debts as they become due, and on our cash flows.*** We have incurred losses in prior periods. For the nine months ended September 30, 2025 and 2024, we incurred a net loss of $330,084 (unaudited) and $34,529 (unaudited), respectively, and, as of September 30, 2025, we had an accumulated deficit of $13,338,152 (unaudited). For the years ended December 31, 2024 and 2023, our predecessor operations reported a net loss of $164,001 (unaudited) and $10,384 (unaudited), respectively, and, as of December 31, 2024, we had an accumulated deficit of $13,008,068 (unaudited).

These foregoing operational results are those of our accounting predecessor. For several years prior to December 31, 2024, the date of our acquisition of Exousia AI, we were a "shell company."

Any losses in the future could cause the quoted price of our common stock to decline or have a material adverse effect on our financial condition, our ability to pay our debts as they become due, and on our cash flows.

***There is doubt about our ability to continue as a viable business.*** We have not earned a profit from our operations during recent financial periods. There is no assurance that we will ever earn a profit from our operations in future financial periods.

***We may be unable to obtain sufficient capital to implement our full plan of business.*** Currently, we do not have sufficient financial resources with which to establish our growth strategies. There is no assurance that we will be able to obtain sources of financing, including in this offering, in order to satisfy our working capital needs.

***We do not have a successful operating history.*** For several years prior to December 31, 2024, the date of our acquisition of Exousia AI, we were a "shell company," that is, our company had minimal assets, generated no revenues and incurred a net loss from operations. Because neither our company nor Exousia AI, our accounting predecessor, has never earned a profit, an investment in the Offered Shares is speculative in nature. Because of this lack of operating success, it is difficult to forecast our future operating results. Additionally, our operations will be subject to risks inherent in the implementation of new business strategies, including, among other factors, efficiently deploying our capital, developing and implementing our marketing campaigns and strategies and developing greater awareness. Our performance and business prospects will suffer if we are unable to overcome the following challenges, among others:

---

| |
|:---|
| our dependence upon external sources for the financing of our operations, particularly given that there are concerns about our ability to continue as a going concern; |
| our ability to execute our business strategies; |
| our ability to manage our expansion, growth and operating expenses; |
| our ability to finance our business; |
| our ability to compete and succeed in highly a competitive industry; and |
| future geopolitical events and economic crisis. |

---

***There are risks and uncertainties encountered by under-capitalized companies.*** As an under-capitalized company, we are unable to offer assurance that we will be able to overcome our lack of capital, among other challenges.

***We may not be successful in establishing our exosome-based business model.*** We are unable to offer assurance that we will be successful in establishing our exosome-based business model. Should we fail to do so, you can expect to lose your entire investment in the Offered Shares.

***We may never earn a profit in future financial periods.*** Because we lack a successful operating history, we are unable to offer assurance that we will ever earn a profit in future financial periods.

***If we are unable to manage future expansion effectively, our business may be adversely impacted.*** In the future, we may experience rapid growth in our operations, which could place a significant strain on our company's infrastructure, in general, and our internal controls and other managerial, operating and financial resources, in particular. If we are unable to manage future expansion effectively, our business would be harmed. There is, of course, no assurance that we will enjoy rapid development in our business.

***We currently depend on the efforts of executive officers; the loss of these persons could disrupt our operations and adversely affect the further development of our business.*** Our success in establishing implementing our exosome-based business strategies will depend, primarily, on the continued service of our executive officers, Michael Sheikh and Matthew Dwyer. The loss of one or both of such executive officers, for any reason, could seriously impair our ability to execute our business strategies, which could have a materially adverse effect on our business and future results of operations. We have not entered into employment agreements with either of Messrs. Sheikh and Dwyer. We have not purchased any key-man life insurance.

***If we are unable to recruit and retain key personnel, our business may be harmed.*** If we are unable to attract and retain key personnel, our business may be harmed. Our failure to enable the effective transfer of knowledge and facilitate smooth transitions with regard to our key employees could adversely affect our long-term strategic planning and execution.

***Our exosome-based strategies are not based on independent market studies.*** We have not commissioned any independent market studies with respect to the potential markets for our exosome-based products. Rather, our implementation plans and achieving profitability are based on the experience, judgment and assumptions of our management. If these assumptions prove to be incorrect, we may not be successful in establishing our business.

***Our Board of Directors may change our policies without shareholder approval.*** Our policies, including any policies with respect to investments, leverage, financing, growth, debt and capitalization, will be determined by our Board of Directors or officers to whom our Board of Directors delegates such authority. Our Board of Directors will also establish the amount of any dividends or other distributions that we may pay to our shareholders. Our Board of Directors or officers to which such decisions are delegated will have the ability to amend or revise these and our other policies at any time without shareholder vote. Accordingly, our shareholders will not be entitled to approve changes in our policies, which policy changes may have a material adverse effect on our financial condition and results of operations.

**Risks Related to Our Business**

***We are in competition with companies that are larger, more established and better capitalized than are we***. We are in competition with companies that are larger, more established and better capitalized than are we. The medical products development industry and the consumer medical products industry are highly competitive, rapidly evolving and subject to constant change. The number of competitors in each of these industries is substantial. We expect that, if our products establish a market niche, competition will arise from a variety of sources, including from large health-related companies to other smaller national and regional health-related companies.

Many of our potential competitors possess:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● greater financial, technical, personnel, promotional and marketing resources;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● longer operating histories;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● greater name recognition; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● larger consumer bases.

We cannot assure you that we will be able to compete effectively in our extremely competitive industry.

***Our planned consumer medical products will compete in highly competitive markets, which would result in pressure on our profit margins and limit our ability to establish, maintain and increase the market share of our products.*** All of our future products will be subject to significant competition and pricing pressures. We will experience significant competitive pricing pressures, as well as competitive products. While we expect that our exosome-infused products will possess unique competitive features as compared to those offered by other companies, several competitors can be expected to offer products with prices that may match or are lower than ours.

It is possible that one or more of our competitors could develop a significant research advantage over our company that allows them to provide superior products or pricing, which could put us at a competitive disadvantage. Continued pricing pressure or improvements in research and shifts in customer preferences away from products such as our planned products could adversely impact our customer base or pricing structure and have a material and adverse effect on our business, financial condition, results of operations and cash flows.

***Any future adverse publicity or consumer perception of our planned products and any similar products distributed by others could harm our reputation and adversely affect our sales and revenues.*** We expect that we will be highly dependent upon positive consumer perceptions of the quality of our planned products, as well as similar products distributed by other companies. Consumer perception of our products can be substantially influenced by scientific research or findings, national media attention and other publicity about product use. Adverse publicity from these sources regarding the safety, quality or efficacy of our products, or products similar to ours, could harm our reputation and results of operations. The mere publication of news articles or reports asserting that such products may be harmful or questioning their efficacy could have a material adverse effect on our business, financial condition and results of operations, regardless of whether such news articles or reports are scientifically supported or whether the claimed harmful effects would be present at the dosages recommended for such products.

***If we are unable to develop and later market our products under development in a timely manner or at all, or if competitors develop or introduce similar products that achieve commercialization before our products enter the market, the demand for our products may decrease or the products could become obsolet***e. Our planned products will compete in extremely competitive markets, where competitors may already be well established. We expect that competitors will continue to innovate and to develop and introduce similar products that could be competitive in both price and performance. Competitors may succeed in developing or introducing similar products earlier than, obtaining regulatory approvals and clearances for such products before our products are approved and cleared, or developing more effective products. In addition, competitors may have products which may achieve commercialization before our products enter the market.

***If our planned products do not provide the beneficial effects intended, our business may suffer.*** Our planned products are expected to contain exosomes and other innovative ingredients or combinations of ingredients. It is possible that one or more of our planned products could have certain side effects if not used as directed or if used by a consumer that has certain medical conditions. Furthermore, there can be no assurance that any of our planned products, even when used as directed, will have the effects intended or will not have harmful side effects. Should any of our planned products cause unwanted side effects or not have the results intended, it could have a material adverse effect on our business, financial condition and results of operations.

***Our marketing strategies for our planned products may not be successful***. We will be required to attract customers to our products, all of which will be new upon their introduction. Should our marketing strategies fail to establish sales of our planned products, our operations will be adversely affected.

***Our business may be affected by litigation and government investigations.*** We may, from time to time, receive inquiries and subpoenas and other types of information requests from government authorities and others and we may become subject to claims and other actions related to our business activities. While the ultimate outcome of investigations, inquiries, information requests and legal proceedings is difficult to predict, defense of litigation claims can be expensive, time-consuming, and distracting, and adverse resolutions or settlements of those matters may result in, among other things, modification of our business practices, costs and significant payments, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects.

***There will be no third-party oversight over the manufacturer of our planned products, should we determine to contract for their manufacture***. For our planned products, we may elect to engage one or more third-party manufacturers whose facilities are FDA-approved. While such facilities are inspected by the FDA, FDA inspections may not be conducted on a regular basis. Further, we do not intend to employ an independent third party to inspect regularly any such facility nor will our management regularly visit such facility to conduct a quality control review. As such, there is a risk that the quality of our planned products could decline. Any decline, or perception of decline, in the quality of our planned products could adversely affect our reputation and consequently adversely affect our results of operations and revenue.

***The sale of our planned products will involve product liability and related risks that could expose us to significant insurance and loss expenses.*** We will face an inherent risk of exposure to product liability claims if the use of our planned products results in, or is believed to have resulted in, illness or injury. In addition, interactions of these planned products with other products, prescription medicines and over-the-counter drugs have not been fully explored or understood and may have unintended consequences.

Any product liability claim may increase our costs and adversely affect our revenue and operating income. Moreover, liability claims arising from a serious adverse event may increase our costs through higher insurance premiums and deductibles and may make it more difficult to secure adequate insurance coverage in the future. In addition, our product liability insurance may fail to cover future product liability claims, which, if adversely determined, could subject us to substantial monetary damages.

***We will be subject to product recalls.*** Manufacturers and distributors of products are sometimes subject to the recall or return of their products for a variety of reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packaging safety and inadequate or inaccurate labeling disclosure. If any of our planned products are recalled due to an alleged product defect or for any other reason, we could be required to incur the unexpected expense of the recall and any legal proceedings that might arise in connection with the recall. We may lose a significant amount of sales and may not be able to replace those sales at an acceptable margin or at all. In addition, a product recall may require significant management attention. There can be no assurance that any quality, potency or contamination problems will be detected in time to avoid unforeseen product recalls, regulatory action or lawsuits. Additionally, if one of our products were subject to recall, the image of that product and our company could be harmed. A recall for any of the foregoing reasons could lead to decreased demand for our products and could have a material adverse effect on our results of operations and financial condition. Additionally, product recalls could lead to increased scrutiny of our operations by the FDA or other regulatory agencies, requiring further management attention and potential legal fees and other expenses.

***Our intellectual property rights are valuable, and any inability to protect them could reduce the value of our products and brand***. We have invested, and will continue to invest, resources to protect our brands and intellectual property rights. However, we may be unable or unwilling to strictly enforce our intellectual property rights, including our patents and trademarks, from infringement. Our failure to enforce our intellectual property rights could diminish the value of our brands and product offerings and harm our business and future growth prospects.

***If we are unable to obtain and maintain protection of our intellectual property, which are costly to maintain, the value of our products may be adversely affected.*** Our industry is characterized by vigorous pursuit and protection of intellectual property rights, which has resulted in protracted and expensive litigation for several companies. Third parties may assert claims of misappropriation of trade secrets or infringement of intellectual property rights against us or against our end customers or partners for which we may be liable.

As our business expands, the number of products and competitors in our markets can be expected to increase and product overlaps to occur, and infringement claims may increase in number and significance. Intellectual property lawsuits are subject to inherent uncertainties due to the complexity of the technical issues involved, and we cannot be certain that we would be successful in defending ourselves against intellectual property claims. Further, many potential litigants have the capability to dedicate substantially greater resources than we can to enforce their intellectual property rights and to defend claims that may be brought against them. Furthermore, a successful claimant could secure a judgment that requires us to pay substantial damages or prevents us from distributing products or performing certain services.

We will attempt to protect our intellectual property position, in part, by filing patent applications related to our developed proprietary technologies, inventions and improvements that are important to our business. However, our patent and trademark positions are not likely, by themselves, to prevent others from commercializing products that compete directly with our products. In addition, any patents and trademarks that may be owned by us or issued to us could be challenged, invalidated or held to be unenforceable. We also note that any patent granted may not provide a competitive advantage to us. Our competitors may independently develop technologies that are substantially similar or superior to our technologies. Further, third parties may design around our proprietary products and technologies.

We rely on certain trade secrets and we may not be able to adequately protect our trade secrets even with contracts with our personnel and third parties. Also, any third party could independently develop and have the right to use, our trade secret, know-how and other proprietary information. If we are unable to protect our intellectual property rights, our business, prospects, financial condition and results of operations could suffer materially.

**Risks Related to Compliance and Regulation**

***We will not have reporting obligations under Sections 14 or 16 of the Securities Exchange Act of 1934, nor will any shareholders have reporting requirements of Regulation 13D or 13G, nor Regulation 14D.*** So long as our common shares are not registered under the Exchange Act, our directors and executive officers and beneficial holders of 10% or more of our outstanding common shares will not be subject to Section 16 of the Exchange Act. Section 16(a) of the Exchange Act requires executive officers and directors and persons who beneficially own more than 10% of a registered class of equity securities to file with the SEC initial statements of beneficial ownership, reports of changes in ownership and annual reports concerning their ownership of common shares and other equity securities, on Forms 3, 4 and 5, respectively. Such information about our directors, executive officers and beneficial holders will only be available through periodic reports we file with OTC Markets.

Our common stock is not registered under the Exchange Act and we do not intend to register our common stock under the Exchange Act for the foreseeable future; provided, however, that we will register our common stock under the Exchange Act if we have, after the last day of any fiscal year, more than either (1) 2,000 persons; or (2) 500 shareholders of record who are not accredited investors, in accordance with Section 12(g) of the Exchange Act.

Further, as long as our common stock is not registered under the Exchange Act, we will not be subject to Section 14 of the Exchange Act, which, among other things, prohibits companies that have securities registered under the Exchange Act from soliciting proxies or consents from shareholders without furnishing to shareholders and filing with the SEC a proxy statement and form of proxy complying with the proxy rules.

The reporting required by Section 14(d) of the Exchange Act provides information to the public about persons other than the company who is making the tender offer. A tender offer is a broad solicitation by a company or a third party to purchase a substantial percentage of a company's common stock for a limited period of time. This offer is for a fixed price, usually at a premium over the current market price, and is customarily contingent on shareholders tendering a fixed number of their shares.

In addition, as long as our common stock is not registered under the Exchange Act, our company will not be subject to the reporting requirements of Regulation 13D and Regulation 13G, which require the disclosure of any person who, after acquiring directly or indirectly the beneficial ownership of any equity securities of a class, becomes, directly or indirectly, the beneficial owner of more than 5% of the class.

***There may be deficiencies with our internal controls that require improvements.*** Our company is not required to provide a report on the effectiveness of our internal controls over financial reporting. We are in the process of evaluating whether our internal control procedures are effective and, therefore, there is a greater likelihood of undiscovered errors in our internal controls or reported financial statements as compared to issuers that have conducted such independent evaluations.

**Risks Related to Our Organization and Structure**

***As a non-listed company conducting an exempt offering pursuant to Regulation A, we are not subject to a number of corporate governance requirements, including the requirements for independent board members.*** As a non-listed company conducting an exempt offering pursuant to Regulation A, we are not subject to a number of corporate governance requirements that an issuer conducting an offering on Form S-1 or listing on a national stock exchange would be. Accordingly, we are not required to have (a) a board of directors of which a majority consists of independent directors under the listing standards of a national stock exchange, (b) an audit committee composed entirely of independent directors and a written audit committee charter meeting a national stock exchange's requirements, (c) a nominating/corporate governance committee composed entirely of independent directors and a written nominating/ corporate governance committee charter meeting a national stock exchange's requirements, (d) a compensation committee composed entirely of independent directors and a written compensation committee charter meeting the requirements of a national stock exchange, and (e) independent audits of our internal controls. Accordingly, you may not have the same protections afforded to shareholders of companies that are subject to all of the corporate governance requirements of a national stock exchange.

***Our holding company structure makes us dependent on our subsidiaries for our cash flow and could serve to subordinate the rights of our shareholders to the rights of creditors of our subsidiaries, in the event of an insolvency or liquidation of any such subsidiary.*** Our company acts as a holding company and, accordingly, substantially all of our operations are conducted through our subsidiaries. Such subsidiaries will be separate and distinct legal entities. As a result, substantially all of our cash flow will depend upon the earnings of our subsidiaries. In addition, we will depend on the distribution of earnings, loans or other payments by our subsidiaries. No subsidiary will have any obligation to provide our company with funds for our payment obligations. If there is an insolvency, liquidation or other reorganization of any of our subsidiaries, our shareholders will have no right to proceed against their assets. Creditors of those subsidiaries will be entitled to payment in full from the sale or other disposal of the assets of those subsidiaries before our company, as a shareholder, would be entitled to receive any distribution from that sale or disposal.

**Risks Related to a Purchase of the Offered Shares**

***The outstanding shares of Series A Preferred Stock preclude current and future owners of our common stock from influencing any corporate decision.*** Our Chief Executive Officer, Michael Sheikh, owns all of the outstanding shares of our Series A Preferred Stock. The Series A Preferred Stock has the following voting rights: the holders of the Series A Preferred Stock shall, as a class, have rights in all matters requiring shareholder approval to a number of votes equal to two (2) times the sum of: (a) the total number of shares of common stock which are issued and outstanding at the time of any election or vote by the shareholders; plus (b) the number of votes allocated to shares of Preferred Stock issued and outstanding of any other class that shall have voting rights. Mr. Sheikh will, therefore, be able to control the management and affairs of our company, as well as matters requiring the approval by our shareholders, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets, and any other significant corporate transaction. (See "[Security Ownership of Certain Beneficial Owners and Management](#a_014)").

***The outstanding shares of our Series B Convertible Preferred Stock represent potential significant future dilution in ownership of our common stock, including the Offered Shares (Remaining Company Offered Shares and Remaining Selling Shareholder Offered Shares).*** The outstanding shares of our Series B Convertible Stock may be converted into a total of 47,000,000 shares of common stock, at any time, after the date that is six months immediately following the effective date of our common stock's uplisting to any tier of the NASDAQ Stock Market (including NASDAQ Capital Market), the NYSE American or any successor to such markets.

Were these shares of Series B Convertible Preferred Stock to be converted into shares of common stock immediately after this offering, and assuming the sale of all Company Offered Shares, we would be required to issue 47,000,000 shares of common stock to the holder(s) of the Series B Convertible Preferred Stock. These issuances would cause holders of our common stock, including the Offered Shares (Remaining Company Offered Shares and Remaining Selling Shareholder Offered Shares), to incur significant dilution in their ownership of our company. We are unable to predict the effect that any such conversion event would have on the market price of our common stock. (See "Dilution–Ownership Dilution").

***The market overhang represented by the potential conversions of our outstanding shares of Series B Convertible Preferred Stock into our common stock could have a negative impact on the market price of our common stock and could impair our ability to obtain needed capital.*** The market overhang represented by the potential conversions of our outstanding shares of Series B Convertible Preferred Stock into a large number of shares of our common stock could cause the market for our common stock to remain or, eventually, become weak, due to market fears of such conversions. However, we are unable to predict the effect that any such conversion event would have on the market price of our common stock.

Additionally, the existence of such market overhang could result in our inability to obtain capital, including in this offering, on favorable terms or at all. In such circumstance, our ability to pursue our plan of business and to earn a profit would be impaired. There is no assurance that we will be able to overcome any adverse effects resulting from the existence of such market overhang.

***There is no minimum offering and no person has committed to purchase any of the Offered Shares.*** We have not established a minimum offering hereunder, which means that we will be able to accept even a nominal amount of proceeds, even if such amount of proceeds is not sufficient to permit us to achieve any of our business objectives. In this regard, there is no assurance that we will sell any of the Offered Shares or that we will sell enough of the Offered Shares necessary to achieve any of our business objectives. Additionally, no person is committed to purchase any of the Offered Shares.

***We may seek additional capital that may result in shareholder dilution or that may have rights senior to those of our common stock.*** From time to time, we may seek to obtain additional capital, either through equity, equity-linked or debt securities. The decision to obtain additional capital will depend on, among other factors, our business plans, operating performance and condition of the capital markets. If we raise additional funds through the issuance of equity, equity-linked or debt securities, those securities may have rights, preferences or privileges senior to the rights of our common stock, which could negatively affect the market price of our common stock or cause our shareholders to experience dilution.

***You may never realize any economic benefit from a purchase of Offered Shares (Remaining Company Offered Shares and Remaining Selling Shareholder Offered Shares).*** Because our common stock is volatile and thinly traded, there is no assurance that you will ever realize any economic benefit from your purchase of Offered Shares (Remaining Company Offered Shares and Remaining Selling Shareholder Offered Shares).

***We do not intend to pay dividends on our common stock.*** We intend to retain earnings, if any, to provide funds for the implementation of our business strategy. We do not intend to declare or pay any dividends in the foreseeable future. Therefore, there can be no assurance that holders of our common stock will receive cash, stock or other dividends on their shares of our common stock, until we have funds which our Board of Directors determines can be allocated to dividends.

***Our shares of common stock are Penny Stock, which may impair trading liquidity.*** Disclosure requirements pertaining to penny stocks may reduce the level of trading activity in the market for our common stock and investors may find it difficult to sell their shares. Trades of our common stock will be subject to Rule 15g-9 of the SEC, which rule imposes certain requirements on broker-dealers who sell securities subject to the rule to persons other than established customers and accredited investors. For transactions covered by the rule, broker-dealers must make a special suitability determination for purchasers of the securities and receive the purchaser's written agreement to the transaction prior to sale. The SEC also has rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks generally are equity securities with a price of less than $5.00 (other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in that security is provided by the exchange or system). The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer's account. The bid and offer quotations, and the broker-dealer and salesperson compensation information, must be given to the customer orally or in writing prior to effecting the transaction and must be given to the customer in writing before or with the customer's confirmation.

***Our common stock is thinly traded and its market price may become highly volatile.*** There is currently only a limited market for our common stock. A limited market is characterized by a relatively limited number of shares in the public float, relatively low trading volume and a small number of brokerage firms acting as market makers. The market for low priced securities is generally less liquid and more volatile than securities traded on national stock markets. Wide fluctuations in market prices are not uncommon. No assurance can be given that the market for our common stock will continue. The price of our common stock may be subject to wide fluctuations in response to factors such as the following, some of which are beyond our control:

- quarterly variations in our operating results;

- operating results that vary from the expectations of investors;

- changes in expectations as to our future financial performance, including financial estimates by investors;

- reaction to our periodic filings, or presentations by executives at investor and industry conferences;

- changes in our capital structure;

- announcements of innovations or new services by us or our competitors;

- announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments;

- lack of success in the expansion of our business operations;

- announcements by third parties of significant claims or proceedings against our company or adverse developments in pending proceedings;

- additions or departures of key personnel;

- asset impairment;

- temporary or permanent inability to operate our retail location(s); and

- rumors or public speculation about any of the above factors.

***The terms of this offering were determined arbitrarily.*** The terms of this offering were determined arbitrarily by us. The offering price for the Offered Shares does not necessarily bear any relationship to our company's assets, book value, earnings or other established criteria of valuation. Accordingly, the offering price of the Offered Shares should not be considered as an indication of any intrinsic value of such securities. (See "[Dilution](#a_005)").

***Our common stock is subject to price volatility unrelated to our operations.*** The market price of our common stock could fluctuate substantially due to a variety of factors, including market perception of our ability to achieve our planned growth, quarterly operating results of other companies in the same industry, trading volume in our common stock, changes in general conditions in the economy and the financial markets or other developments affecting our company's competitors or our company itself. In addition, the over-the-counter stock market is subject to extreme price and volume fluctuations in general. This volatility has had a significant effect on the market price of securities issued by many companies for reasons unrelated to their operating performance and could have the same effect on our common stock.

***Future sales of our common stock, or the perception in the public markets that these sales may occur, could reduce the market price of our common stock.*** In general, our officers and directors and major shareholders, as affiliates, under Rule 144 may not sell more than one percent of the total issued and outstanding shares in any 90-day period, and must resell the shares in an unsolicited brokerage transaction at the market price. The availability for sale of substantial amounts of our common stock under Rule 144 or otherwise could reduce prevailing market prices for our common stock.

***You will suffer dilution in the net tangible book value of the Offered Shares you purchase in this offering.*** If you acquire any Offered Shares, you will suffer immediate dilution, due to the lower book value per share of our common stock compared to the purchase price of the Offered Shares in this offering. (See "[Dilution](#a_005)").

***As an issuer of penny stock, the protection provided by the federal securities laws relating to forward looking statements does not apply to us.*** Although federal securities laws provide a safe harbor for forward-looking statements made by a public company that files reports under the federal securities laws, this safe harbor is not available to issuers of penny stocks. As a result, we will not have the benefit of this safe harbor protection in the event of any legal action based upon a claim that the material provided by us contained a material misstatement of fact or was misleading in any material respect because of our failure to include any statements necessary to make the statements not misleading. Such an action could hurt our financial condition.

**DILUTION**

**Ownership Dilution**

*[<u>Note</u>: References in this Ownership Dilution section to "Offered Shares" include the Remaining Company Offered Shares and the Remaining Selling Shareholder Offered Shares, unless specifically indicated otherwise.]*

The information under "Investment Dilution" below does not take into account the potential conversion of the outstanding shares of Series B Convertible Preferred Stock any time after the date that is six months immediately following the effective date of our common stock's uplisting to any tier of the NASDAQ Stock Market (including NASDAQ Capital Market), the NYSE American or any successor to such markets. However, the conversion of the shares of Series B Convertible Preferred Stock into shares of our common stock would cause holders of our common stock, including the Offered Shares, to incur significant dilution in their ownership of our company. (See "Risk Factors—Risks Related to a Purchase of the Offered Shares," "Description of Securities—Series B Convertible Preferred Stock" and "Security Ownership of Certain Beneficial Owners and Management").

**Investment Dilution**

Dilution in net tangible book value per share to purchasers of our common stock in this offering represents the difference between the amount per share paid by purchasers of the Offered Shares (Remaining Company Offered Shares and Remaining Selling Shareholder Offered Shares) in this offering and the net tangible book value per share immediately after completion of this offering. In this offering, dilution is attributable primarily to our negative net tangible book value per share.

If you purchase Remaining Company Offered Shares in this offering, your investment will be diluted to the extent of the difference between your purchase price per Remaining Company Offered Share and the net tangible book value of our common stock after this offering. Our net tangible book value as of September 30, 2025, was $(663,649) (unaudited), or $(0.02) (unaudited) per share. Net tangible book value per share is equal to total assets ($195,544) minus the sum of total liabilities ($676,780) and intangible assets ($182,413) divided by the total number of shares outstanding at September 30, 2025 (40,607,067 shares).

Without taking into account issuances of shares of our common stock occurring after September 30, 2025, after deducting estimated offering expenses payable by us of $15,000, the tables below illustrate the dilution to purchasers of Company Offered Shares in this offering, on a pro forma basis, assuming 100%, 75%, 50% and 25% of the Company Offered Shares are sold at a per share price of $0.12.

---

| | |
|:---|:---|
| ***Assuming the Sale of 100% of the Remaining Company Offered Shares*** | |
| Assumed offering price per share | $0.12 |
| **Net tangible book value per share as of September 30, 2025 (unaudited)** | $(0.02) |
| Increase in net tangible book value per share after giving effect to this offering | $0.14 |
| Pro forma net tangible book value per share as of September 30, 2025 (unaudited) | $0.02 |
| **Dilution in net tangible book value per share to purchasers of Remaining Company Offered Shares in this offering** | $**0.10** |
| ***Assuming the Sale of 75% of the Remaining Company Offered Shares*** |  |
| Assumed offering price per share | $0.12 |
| **Net tangible book value per share as of September 30, 2025 (unaudited)** | $(0.02) |
| Increase in net tangible book value per share after giving effect to this offering | $0.13 |
| Pro forma net tangible book value per share as of September 30, 2025 (unaudited) | $0.01 |
| **Dilution in net tangible book value per share to purchasers of Remaining Company Offered Shares in this offering** | $**0.11** |
| ***Assuming the Sale of 50% of the Remaining Company Offered Shares*** |  |
| Assumed offering price per share | $0.12 |
| **Net tangible book value per share as of September 30, 2025 (unaudited)** | $(0.02) |
| Increase in net tangible book value per share after giving effect to this offering | $0.12 |
| Pro forma net tangible book value per share as of September 30, 2025 (unaudited) | $0.00 |
| **Dilution in net tangible book value per share to purchasers of Remaining Company Offered Shares in this offering** | $**0.12** |
| ***Assuming the Sale of 25% of the Remaining Company Offered Shares*** |  |
| Assumed offering price per share | $0.12 |
| **Net tangible book value per share as of September 30, 2025 (unaudited)** | $(0.02) |
| Increase in net tangible book value per share after giving effect to this offering | $0.12 |
| Pro forma net tangible book value per share as of September 30, 2025 (unaudited) | $(0.00) |
| **Dilution in net tangible book value per share to purchasers of Remaining Company Offered Shares in this offering** | $**0.12** |

---

**USE OF PROCEEDS**

As of the date of this Offering Circular, we have sold a total of 83,334 Company Offered Shares, for an aggregate of $10,000 in proceeds. We have applied such proceeds for working capital.

The table below sets forth the estimated proceeds we would derive from this offering, assuming the sale of 25%, 50%, 75% and 100% of the Remaining Company Offered Shares at a per share price of $0.12. There is, of course, no guaranty that we will be successful in selling any of the Remaining Company Offered Shares in this offering.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Assumed Percentage of Company Offered Shares**<br> **Sold in This Offering** | **Assumed Percentage of Company Offered Shares**<br> **Sold in This Offering** | **Assumed Percentage of Company Offered Shares**<br> **Sold in This Offering** | **Assumed Percentage of Company Offered Shares**<br> **Sold in This Offering** |
|  | **25%** | **50%** | **75%** | **100%** |
| Offered Shares sold | 3729167 | 7458333 | 11187500 | 14916666 |
| Gross proceeds | $447500 | $895000 | $1342500 | $1790000 |
| Offering expenses**<sup>(1)</sup>** | 15000 | 15000 | 15000 | 15000 |
| Net proceeds | $432500 | $880000 | $1327500 | $1775000 |

---

______________________

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Offering expenses include the following items, certain of which are estimated for purposes of this table: administrative expenses, legal and accounting fees, publishing/EDGAR and Blue-Sky compliance.

The table below sets forth the proceeds we would derive from the sale of assuming the sale of 25%, 50%, 75% and 100% of the Remaining Company Offered Shares at a per share price of $0.12, assuming the payment of no sales commissions or finder's fees and assuming the payment of expenses associated with this offering of $15,000. There is, of course, no guaranty that we will be successful in selling any of the Remaining Company Offered Shares. All amounts set forth below are estimates.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Use of Proceeds for Assumed Percentage of**<br> **Remaining Company Offered Shares Sold in This Offering<sup>(1)</sup>** | **Use of Proceeds for Assumed Percentage of**<br> **Remaining Company Offered Shares Sold in This Offering<sup>(1)</sup>** | **Use of Proceeds for Assumed Percentage of**<br> **Remaining Company Offered Shares Sold in This Offering<sup>(1)</sup>** | **Use of Proceeds for Assumed Percentage of**<br> **Remaining Company Offered Shares Sold in This Offering<sup>(1)</sup>** |
|  | **25%** | **50%** | **75%** | **100%** |
| Investigational New Drug trials | $200000 | $400000 | $600000 | $800000 |
| New Product Development | 62500 | 165000 | 267500 | 345000 |
| Acquisition**<sup>(2)</sup>** | 50000 | 100000 | 150000 | 200000 |
| Lab Equipment | 50000 | 100000 | 150000 | 200000 |
| Marketing | 50000 | 75000 | 100000 | 150000 |
| Working Capital**<sup>(3)</sup>** | 20000 | 40000 | 60000 | 80000 |
| Total | $432500 | $880000 | $1327500 | $1775000 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) The Subject Convertible Notes were issued, as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) On
 November 18, 2024, we issued a $25,000 principal amount convertible promissory note to NLF Support Services, LLC, a wholly-owned
 services subsidiary of our legal counsel, Newlan Law Firm, PLLC, that bore interest at 8% per annum, was due on November 18, 2025,
 and was convertible at this holder's election, into Conversion Shares. This convertible promissory note was issued in payment
 of legal services. This convertible promissory note was converted into 177,564 Conversion Shares. (See " [Plan of Distribution](#a_007) " and " [Selling Shareholder](#a_008) ").

(b) On
 June 10, 2025, we issued a $20,000 principal amount convertible promissory note to NLF Support Services,
 LLC, a wholly-owned services subsidiary of our legal counsel, Newlan Law Firm, PLLC, that bore interest
 at 8% per annum, was due on June 10, 2026, and was convertible at this holder's election, into
 Conversion Shares. This convertible promissory note was issued in payment of legal services. This
 convertible promissory note was issued in payment of legal services. This convertible promissory
 note was converted into 136,003 Conversion Shares. (See " [Plan of Distribution](#a_007) "
 and " [Selling Shareholder](#a_008) ").

(c) On June 10, 2025, we issued a $52,500 principal amount convertible promissory
note to NLF Support Services, LLC, a wholly-owned services subsidiary of our legal counsel, Newlan Law Firm, PLLC, that bore interest
at 8% per annum, was due on June 10, 2026, and was convertible at this holder's election, into Conversion Shares. This convertible
promissory note was issued in payment of legal services. This convertible promissory note was issued in payment of legal services. This
convertible promissory note was converted into 357,002 Conversion Shares. (See " [Plan of Distribution](#a_007) " and " [Selling Shareholder](#a_008) ").

(d) On December 17, 2025, we issued a $100,000 principal amount convertible
promissory note to Newlan Law Firm, PLLC, our legal counsel, that bears interest at 8% per annum, is due on December 17, 2026, and is
convertible at this holder's election, into Conversion Shares. This convertible promissory note was issued in payment of legal services. (See " [Plan of Distribution](#a_007) " and " [Selling Shareholder](#a_008) ").

(e) On December 17, 2025, we
 issued a $125,000 principal amount convertible promissory note to Red Phoenix Rising, LLC, that bears interest at 8% per annum, is
 due on December 17, 2026, and is convertible at this holder's election, into Conversion Shares. This convertible promissory
 note was issued in payment of consulting services. (See " [Plan of Distribution](#a_007) " and " [Selling Shareholder](#a_008) ").

(f) On
 December 17, 2025, we issued a $125,000 principal amount convertible promissory note to Red Phoenix Rising, LLC, that bears interest
 at 8% per annum, is due on December 17, 2026, and is convertible at this holder's election, into Conversion Shares. This
 convertible promissory note was issued in payment of consulting services. (See " [Plan of Distribution](#a_007) " and " [Selling Shareholder](#a_008) ").

(2) We have entered into three non-binding letters of
intent for the acquisition of separate companies. Definitive agreements with respect to such acquisitions have not been completed. We
are unable to predict if and when one or more definitive agreements will be signed and closed. (See " [Business—Recent Letters of Intent](#recent_letters) ").

&nbsp;&nbsp;&nbsp;&nbsp;(3) None of the proceeds in this
 offering derived from sales of Remaining Company Offered Shares will be used to compensate our officers and directors, nor will any
 such proceeds be used to discharge indebtedness.

We reserve the right to change the foregoing use of proceeds, should our management believe it to be in the best interest of our company. The allocations of the proceeds of this offering presented above constitute the current estimates of our management and are based on our current plans, assumptions made with respect to the beverage industry, general economic conditions and our future revenue and expenditure estimates.

Investors are cautioned that expenditures may vary substantially from the estimates presented above. Investors must rely on the judgment of our management, who will have broad discretion regarding the application of the proceeds of this offering. The amounts and timing of our actual expenditures will depend upon numerous factors, including market conditions, cash generated by our operations (if any), business developments and the rate of our growth. We may find it necessary or advisable to use portions of the proceeds of this offering for other purposes.

In the event we do not obtain the entire offering amount hereunder, we may attempt to obtain additional funds through private offerings of our securities or by borrowing funds. Currently, we do not have any committed sources of financing.

**PLAN OF DISTRIBUTION**

**In General**

Our company is offering a maximum of 15,000,000 Company Offered Shares, including the 14,916,666 Remaining Company Offered Shares, on a best-efforts basis. The Remaining Company Offered Shares are being offered at a fixed price of $[0.06-0.12] per Remaining Company Offered Share; any funds derived from this offering will be immediately available to us for our use. There will be no refunds. This offering commenced September 9, 2025, and will terminate at the earliest of (a) the date on which all of the Offered Shares (Remaining Company Offered Shares and Remaining Selling Shareholder Shares) have been sold, (b) December 24, 2026, or (c) the date on which this offering is earlier terminated by us, in our sole discretion.

In addition, the Selling Shareholders are offering up to 4,245,569 Selling Shareholder Offered Shares, including the 3,575,000 Remaining Selling Shareholder Offered Shares. We will not receive any of the proceeds from the sale of the Remaining Selling Shareholder Offered Shares in this offering. We will pay all of the expenses of the offering (other than the discounts and commissions payable with respect to the Remaining Selling Shareholder Offered Shares sold in the offering). Our company will not be involved in manner way in the sales of the Remaining Selling Shareholder Offered Shares by the Selling Shareholders. (See "[Selling Shareholder](#a_008)").

There is no minimum number of Company Offered Shares that we are required to sell in this offering. All funds derived by us from this offering will be immediately available for use by us, in accordance with the uses set forth in the Use of Proceeds section of this Offering Circular. No funds will be placed in an escrow account during the offering period and no funds will be returned, once an investor's subscription agreement has been accepted by us.

We intend to sell the Company Offered Shares, including the Remaining Company Offered Shares, in this offering through the efforts of our Chief Executive Officer, Michael Sheikh. Mr. Sheikh will not receive any compensation for offering or selling the Company Offered Shares. We believe that Mr. Sheikh is exempt from registration as a broker-dealer under the provisions of Rule 3a4-1 promulgated under the Securities Exchange Act of 1934 (the Exchange Act). In particular, Mr. Sheikh:

---

| |
|:---|
| is not subject to a statutory disqualification, as that term is defined in Section 3(a)(39) of the Securities Act; and |
| is not to be compensated in connection with his participation by the payment of commissions or other remuneration based either directly or indirectly on transactions in securities; and |
| is not an associated person of a broker or dealer; and |
| meets the conditions of the following: |
| primarily performs, and will perform at the end of this offering, substantial duties for us or on our behalf otherwise than in connection with transactions in securities; and |
| was not a broker or dealer, or an associated person of a broker or dealer, within the preceding 12 months; and |
| did not participate in selling an offering of securities for any issuer more than once every 12 months other than in reliance on paragraphs (a)(4)(i) or (iii) of Rule 3a4-1 under the Exchange Act. |

---

As of the date of this Offering Circular, we have not entered into any agreements with selling agents for the sale of the Company Offered Shares, including the Remaining Company Offered Shares. However, we reserve the right to engage FINRA-member broker-dealers. In the event we engage FINRA-member broker-dealers, we expect to pay sales commissions of up to 8.0% of the gross offering proceeds from their sales of the Company Offered Shares, including the Remaining Company Offered Shares. In connection with our appointment of a selling broker-dealer, we intend to enter into a standard selling agent agreement with the broker-dealer pursuant to which the broker-dealer would act as our non-exclusive sales agent in consideration of our payment of commissions of up to 8.0% on the sale of Company Offered Shares, including the Remaining Company Offered Shares, effected by the broker-dealer. Should we determine to employ a registered broker-dealer, information as to any such broker-dealer shall be disclosed in a post-qualification amendment to this Offering Circular.

**Procedures for Subscribing**

*<u>In General</u>*. If you are interested in subscribing for Remaining Company Offered Shares in this offering, please submit a request for information by e-mail to Mr. Sheikh at: msheikh@exousiapro.com; all relevant information will be delivered to you by return e-mail via electronic PDF format. Additionally, this Offering Circular will be available for viewing and download 24 hours per day, 7 days per week on our website at www.exousiapro.com, as well as on the SEC's website, www.sec.gov.

Thereafter, should you decide to subscribe for Remaining Company Offered Shares, you are required to follow the procedures described therein, which are:

- Electronically execute and deliver to us a subscription agreement via e-mail to: msheikh@exousiapro.com; and

- Deliver funds directly by check or by wire or electronic funds transfer via ACH to our specified bank account.

*<u>Subscription Review Process</u>*. After we receive your complete, executed subscription agreement and the funds required under the subscription agreement have been transferred to us and shall have cleared, we have the right to review and accept or reject your subscription, in whole or in part. In determining whether to accept or reject a subscription, we will consider the following factors: whether the subscriber or an affiliate of the subscriber qualifies as a "bad actor" as defined in Rule 262(d) of the SEC; the reputation of the subscriber and its affiliates within the securities industry; our then-current need for a cash investment; the state of the securities markets, in general, and the market for our common stock, in particular.

Within three (3) days after we receive your complete, executed subscription agreement and the funds required under the subscription agreement have been transferred to us and shall have cleared, we will notify you of our decision, and the reason therefor, to reject or accept your subscription.

*Rejection of Subscriptions*. Should we determine to reject your subscription, we will return all monies from your rejected subscription via wire transfer (or such other method as directed by you) within one (1) business day of our notifying you of such determination, without interest or deduction.

*Acceptance of Subscriptions*. Should we determine to accept your subscription, we will countersign the subscription agreement and, within one (1) business day, issue and deliver the Remaining Company Offered Shares subscribed in accordance with your delivery instructions. Once your subscription has been accepted by us, you may not revoke or change your subscription or request the return of your subscription funds. All accepted subscription agreements are irrevocable.

An investor will become a shareholder of our company, upon our acceptance of our acceptance of a subscription, with the Remaining Company Offered Shares being issued immediately thereafter. For clarity, the subscription settlement will not occur until an investor's funds have cleared and we accept an investor's subscription.

By executing the subscription agreement and paying the total purchase price for the Remaining Company Offered Shares subscribed, each investor agrees to accept the terms of the subscription agreement and attests that the investor meets certain minimum financial standards. (See "State Law Exemption and Offerings to Qualified Purchasers" below).

An approved trustee must process and forward to us subscriptions made through IRAs, Keogh plans and 401(k) plans. In the case of investments through IRAs, Keogh plans and 401(k) plans, we will send the confirmation and notice of our acceptance to the trustee.

**Minimum Purchase Requirements**

You must initially purchase at least $5,000 of the Offered Shares (Remaining Company Offered Shares or Remaining Selling Shareholder Offered Shares) in this offering. If you have satisfied the minimum purchase requirement, any additional purchase must be in an amount of at least $1,000.

**State Law Exemption and Offerings to Qualified Purchasers**

*<u>State Law Exemption</u>*. This Offering Circular does not constitute an offer to sell or the solicitation of an offer to purchase any Offered Shares, whether Company Offered Shares or Selling Shareholder Offered Shares, in any jurisdiction in which, or to any person to whom, it would be unlawful to do so. An investment in the Offered Shares involves substantial risks and possible loss by investors of their entire investments. (See "[Risk Factors](#a_004)").

The Offered Shares (Remaining Company Offered Shares or Remaining Selling Shareholder Offered Shares) have been qualified under the securities laws of Colorado, Delaware and New York, and it is possible that we would determine to qualify Offered Shares (Remaining Company Offered Shares or Remaining Selling Shareholder Offered Shares) in all states. In the case of each state in which Offered Shares (Remaining Company Offered Shares or Remaining Selling Shareholder Offered Shares) are offered and sold, we will qualify the Offered Shares (Remaining Company Offered Shares or Remaining Selling Shareholder Offered Shares) for sale with the applicable state securities regulatory body or the Offered Shares (Remaining Company Offered Shares or Remaining Selling Shareholder Offered Shares) will be offered and sold pursuant to an exemption from registration found in the applicable state's securities, or Blue Sky, law.

Certain of our company's offerees may be broker-dealers registered with the SEC under the Exchange Act, who may be interested in reselling the Company Offered Shares, including the Remaining Company Offered Shares, to others. Any such broker-dealer will be required to comply with the rules and regulations of the SEC and FINRA relating to underwriters.

*<u>Investor Suitability Standards</u>*. The Offered Shares (Remaining Company Offered Shares and Remaining Selling Shareholder Offered Shares) may only be purchased by investors residing in a state in which this Offering Circular is duly qualified who have either (a) a minimum annual gross income of $70,000 and a minimum net worth of $70,000, exclusive of automobile, home and home furnishings, or (b) a minimum net worth of $250,000, exclusive of automobile, home and home furnishings.

**Issuance of the Company Offered Shares**

Upon settlement, that is, at such time as an investor's funds have cleared and we have accepted an investor's subscription agreement, we will either issue such investor's purchased Company Offered Shares, including the Remaining Company Offering Shares, in book-entry form or issue a certificate or certificates representing such investor's purchased Company Offered Shares, including the Remaining Company Offering Shares.

**Transferability of the Offered Shares**

The Offered Shares (Remaining Company Offered Shares and Remaining Selling Shareholder Offered Shares) will be generally freely transferable, subject to any restrictions imposed by applicable securities laws or regulations.

**Advertising, Sales and Other Promotional Materials**

We have not used, and we do not intend to use, any advertising, sales and other promotional materials outside of this Offering Circular, including "testing the waters" materials under the authorization of Rule 255.

**SELLING SHAREHOLDERS**

As of the date of this Post-Qualification Offering Circular No. 1, 670,569 Conversion Shares have been issued and subsequently sold by a Selling Shareholder for cash at the then-offering price applicable to Selling Shareholders of $0.15 per share, a total amount of $100,585. The remaining $350,000 of principal amount unconverted Subject Convertible Notes are, by their terms, eligible for conversion into up to 3,575,000 Conversion Shares, at the election of the Selling Shareholders, at $0.10 per share converted. Following all such issuances, we intend to file a supplement to this Offering Circular pursuant to Rule 253(g)(2), wherein the exact number of Offered Shares issued in payment of the Subject Convertible Notes to be offered by the Selling Shareholders in this offering will be disclosed.

The shareholders named in the table below are the "Selling Shareholders." The Selling Shareholders intend to sell up to 3,575,000 Remaining Selling Shareholder Offered Shares at the offering price for all of the Offered Shares, $[0.06-0.12] per share. The Selling Shareholders are third parties. Our company will not be involved in any manner in the sales of the Remaining Selling Shareholder Offered Shares by the Selling Shareholders.

We will pay all of the expenses of this offering (other than the selling commissions payable with respect to the Selling Shareholder Offered Shares, including the Remaining Selling Shareholder Offered Shares, sold in this offering, if any), but we will not receive any of the proceeds from the sales of Selling Shareholder Offered Shares, including the Remaining Selling Shareholder Offered Shares, in this offering.

Neither of the Selling Shareholders is associated with a broker-dealer.

The Selling Shareholders intend to sell the Remaining Selling Shareholder Offered Shares in market transactions or in negotiated private transactions at the per share offering price for all of the Offered Shares, $[0.06-0.12] per share. The Selling Shareholders may be deemed to be "underwriters" of the shares of our common stock offered by the Selling Shareholders in this offering. In this regard, the Selling Shareholders intend to deliver to a purchaser this Offering Circular before or with the sale of Remaining Selling Shareholder Offered Shares. It is expected that, in sales of Remaining Selling Shareholder Offered Shares in market transactions, if any, this Offering Circular would be delivered in digital format with the relevant sale confirmation.

A minimum purchase of $5,000 of the Selling Shareholder Offered Shares, including the Remaining Selling Shareholder Offered Shares, is required in this offering; any additional purchase must be in an amount of at least $1,000.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | **Prior to this Offering** | **Prior to this Offering** | | **After this Offering** | **After this Offering** |
| <br>**Name of**<br> **Selling Shareholder** | <br>**Position, Office**<br> **or Other**<br> **Material**<br> **Relationship** | **# of Shares**<br> **Beneficially**<br> **Owned(1)** | **%**<br> **Beneficially**<br> **Owned**<br> **(2)** |<br>**# of Shares**<br> **to be Offered**<br> **for the**<br> **Account**<br> **of the Selling**<br> **Shareholder** | **# of Shares**<br> **Beneficially**<br> **Owned** | **%**<br> **Beneficially**<br> **Owned**<br> **(3)** |
| Newlan Law Firm, PLLC**<sup>(4)</sup>** | See Note 4 | 1025000 | 2.26% | 1025000 | 0 | 0% |
| Red Phoenix Rising, LLC**<sup>(5)</sup>** | See Note 5 | 2550000 | 5.63%(7) | 2550000 | 0 | 0% |
| Newlan Support Services, LLC**<sup>(6)</sup>** | See Note 6 |  |  |  |  |  |

---

(1) None of these shares has been issued, but underlie the Subject Convertible Notes. Rather, the share numbers in this column are estimates of the number of Selling Shareholder Offered Shares that the listed holder may acquire from our company. Following each issuance of Conversion Shares (Selling Shareholder Offered Shares), we intend to file a supplement to this Offering Circular pursuant to Rule 253(g)(2), wherein the exact number of Conversion Shares (Selling Shareholder Offered Shares) issued in payment of the Subject Convertible Notes will be disclosed.

(2) Based on 44,623,470 shares outstanding, assuming the issuance of 4,245,569 Conversion Shares, before this offering.

(3) Based on 59,623,470 shares outstanding, assuming the sale of all of the Remaining Company Offered Shares and the issuance and subsequent sale of 3,575,000 Conversion Shares underlying the unconverted Subject Convertible Notes, after this offering.

(4) This entity is our legal counsel, the Managing Member of which is Eric Newlan. The address of this Selling Shareholder is 2201 Long Prairie Road, Suite 107-762, Flower Mound, Texas 75022.

(5) Thomas Roland is the owner of this entity. The address of this Selling Shareholder is 7957 N. University Drive, #147, Parkland, Florida 33076.

(6) Prior to the date of this Offering Circular, this Selling Shareholder converted three of the Subject Convertible Notes into a total of 670,569 Conversion Shares and, thereafter, sold such Conversion Shares for a total of $100,585 in cash, a per share sale price of $0.15, the then-current offering price applicable to Selling Shareholder Offered Shares. This entity is a wholly-owned services subsidiary of our legal counsel, Newlan Law Firm, PLLC, the Managing Member of which is Eric Newlan. The address of this Selling Shareholder is 13680 CR 306, Buena Vista, Colorado 81211.

**DESCRIPTION OF SECURITIES**

**General**

Our authorized capital stock consists of (a) 250,000,000 shares of common stock, $.001 par value per share; and (b) 10,000,000 shares of Preferred Stock, $.001 par value per share, (1) 100 of which have been designated Series A Preferred Stock and (2) 10,000 of which have been designated Series B Convertible Preferred Stock.

As of the date of this Offering Circular, there were (x) 41,048,470 shares of our common stock issued and outstanding held by 82 holders of record; (y) 100 shares of Series A Preferred Stock issued and outstanding held by one (1) holder of record; and (z) 10,000 shares of Series B Convertible Preferred Stock issued and outstanding held by one (1) holder of record.

**Common Stock**

*<u>General</u>*. The holders of our common stock currently have (a) equal ratable rights to dividends from funds legally available therefore, when, as and if declared by our Board of Directors; (b) are entitled to share ratably in all of our assets available for distribution to holders of common stock upon liquidation, dissolution or winding up of the affairs of our company; (c) do not have preemptive, subscriptive or conversion rights and there are no redemption or sinking fund provisions or rights applicable thereto; and (d) are entitled to one non-cumulative vote per share on all matters on which shareholders may vote. Our Bylaws provide that, at all meetings of the shareholders for the election of directors, a plurality of the votes cast shall be sufficient to elect. On all other matters, except as otherwise required by Nevada law or our Articles of Incorporation, as amended, a majority of the votes cast at a meeting of the shareholders shall be necessary to authorize any corporate action to be taken by vote of the shareholders.

*<u>Non-cumulative Voting</u>*. Holders of shares of our common stock do not have cumulative voting rights, which means that the holders of more than 50% of the outstanding shares, voting for the election of directors, can elect all of the directors to be elected, if they so choose, and, in such event, the holders of the remaining shares will not be able to elect any of our directors.

Further, the outstanding shares of Series A Preferred Stock are beneficially owned by our Chief Executive Officer, Michael Sheikh. Mr. Sheikh, thus, controls all corporate matters of our company. (See "[Security Ownership of Certain Beneficial Owners and Management](#a_014)" and "[Certain Relationships and Related Transactions](#a_015)").

*<u>Pre-emptive Rights</u>*. As of the date of this Offering Circular, no holder of any shares of our capital stock has pre-emptive or preferential rights to acquire or subscribe for any unissued shares of any class of our capital stock not otherwise disclosed herein.

**Series A Preferred Stock**

*<u>Voting</u>*. The holders of the Series A Preferred Stock shall, as a class, have rights in all matters requiring shareholder approval to a number of votes equal to two (2) times the sum of: (a) the total number of shares of common stock which are issued and outstanding at the time of any election or vote by the shareholders; plus (b) the number of votes allocated to shares of Preferred Stock issued and outstanding of any other class that shall have voting rights.

*<u>Dividends</u>*. The Series A Preferred Stock is not entitled to receive any dividends.

*<u>Liquidation Preference</u>*. The Series A Preferred Stock is not entitled to any amount upon any liquidation, dissolution or winding up of our company, either voluntary or involuntary.

*<u>Conversion</u>*. The Series A Preferred Stock has no rights of conversion.

**Series B Convertible Preferred Stock**

*<u>Voting Rights</u>*. Each share of Series B Convertible Preferred Stock shall be entitled to one (1) vote in all matters requiring shareholder approval.

*<u>Dividends</u>*. The Series B Convertible Preferred Stock shall be treated *pari passu* with our common stock, except that the dividend on each share of Series B Convertible Preferred Stock shall be equal to the amount of the dividend declared and paid on each share of our common stock multiplied by the conversion rate.

*<u>Liquidation</u>*. Upon any liquidation, dissolution or winding up of our company, whether voluntary or involuntary, payments to the holders of Series B Convertible Preferred Stock shall be treated *pari passu* with our common stock, except that the payment on each share of Series B Convertible Preferred Stock shall be equal to the amount of the payment on each share of our common stock multiplied by the conversion rate.

*<u>Conversion</u>*. Each share of the Series B Convertible Preferred Stock shall be convertible into 4,700 shares of our common stock; a holder of shares of Series B Convertible Preferred Stock shall be required to convert all of such holder's shares of Series B Convertible Preferred Stock, should any such holder exercise his, her or its rights of conversion; the Series B Convertible Preferred Stock may be converted into shares of our common stock any time after the date that is six months immediately following the effective date of our common stock's uplisting to any tier of the NASDAQ Stock Market (including NASDAQ Capital Market), the NYSE American or any successor to such markets.

**Dividend Policy**

We have never declared or paid any dividends on our common stock. We currently intend to retain future earnings, if any, to finance the expansion of our business. As a result, we do not anticipate paying any cash dividends in the foreseeable future.

**Shareholder Meetings**

Our bylaws provide that special meetings of shareholders may be called only by our Board of Directors, the chairman of the board, or our president, or as otherwise provided under Florida law.

**Transfer Agent**

Currently, the transfer agent for our common stock is Securities Transfer Corporation. However, on approximately June 30, 2025, the transfer agent for our common stock will become ClearTrust, LLC, 16540 Pointe Village Dr Suite 210, Lutz, FL 33558. ClearTrust's website is located at: www.cleartrustonline.com No information found on ClearTrust's website is part of this Offering Circular.

**BUSINESS**

**History**

We were incorporated in the State of Nevada on April 28, 2010, under the name Norman Cay Development, Inc. On July 12, 2012, our corporate name changed to Discovery Gold Corporation. On August 19, 2019, our corporate name changed to GRN Holding Corporation. On August 4, 2022, our company redomiciled to the State of Florida. On November 13, 2023, our corporate name changed to Marijuana, Inc.

*On April 2, 2025, our corporate name changed to Exousia Pro, Inc. The effective time, as it relates to the stock trading market, of this corporate action, which will include a change to our trading symbol, will depend on the date on which FINRA issues its approval of our related filing. We are unable to predict the date on which FINRA will issue such approval.*

**Recent Change in Control**

Effective October 30, 2024, a change in control of our company occurred. On such date, Earth Onyx, LLC, a company owned by our former Sole Director and Officer, sold 100 shares (the "Control Shares"), or 100% of the outstanding shares, of our Series A Preferred Stock to our current Sole Director and Chief Executive Officer. Mr. Sheikh paid $60,000 in cash and delivered a promissory note (the "Closing Note") to Earth Onyx, LLC in payment of the Control Shares. The Closing Note has a principal amount of $100,000 and is due on the later of 60 days from October 30, 2024, and the date on which Mr. Steinberg shall have delivered ready-to-file federal tax returns for the years ended December 31, 2022 and 2023, of our company. Mr. Sheikh and Earth Onyx, LLC entered into Pledge Agreement, to secure Mr. Sheikh's payment obligations under the Closing Note.

**Recent Acquisition; Exiting "Shell Company" Status**

Effective December 31, 2024, pursuant to a stock purchase agreement with Ludwig Enterprises, Inc. ("Ludwig"), a publicly-traded company (symbol: LUDG), we acquired 100% of Exousia Ai, Inc., a Wyoming corporation (Exousia AI), and related assets, in consideration of a $100,000 promissory note (the "Ludwig Note"), the principal and interest of which is due on December 31, 2025, and 10,000 shares of our Series B Convertible Preferred Stock. In conjunction with the issuance of the Ludwig Note, we entered into a pledge agreement with Ludwig, to secure our timely payment of the Ludwig Note. Exousia AI is a biotechnology company in the field of exosomes. In the transaction, we secured a worldwide license for certain exosome technologies. (See "Business").

With the acquisition of Exousia AI, our company exited "shell company" status.

**Plan and Agreement of Reorganization – Exousia AI**

On November 11, 2025, pursuant to a Plan and Agreement of Reorganization (the Reorganization Agreement), LMMY acquired our 70%-owned subsidiary, Exousia Ai, in exchange for shares of LMMY common stock. Following the closing of the Reorganization Agreement, our company holds 41,223,000 shares, or approximately 51% (as measured after the transaction), of LMMY common stock. Our company's President, Matthew Dwyer, serves as LMMY's sole officer and director.

The transaction with LMMY was pursued and consummated by the Company, after the Company's Board of Directors had determined, after investigating the LMMY opportunity, that the best interests of the Company and its shareholders would be best served by acquiring a controlling interest in LMMY, in exchange for its ownership in Exousia Ai.

**Recent Letters of Intent**

In December 11, 2025, we executed letters of intent for the acquisition of a tele-health platform, which would permit us to accelerate nutraceutical commercialization efforts. The three separate intended acquisitions, if consummated, would form a single operating division of our company. We have not yet entered into a definitive agreement with respect to either of such letters of intent and there is no assurance that we will ever do so. It is possible that an as-yet determined portion of the proceeds in this offering would be applied to complete one or more of such acquisition transactions. However, no prediction can be made, in this regard. (See "Use of Proceeds").

**Business Summary**

Our company is a clinical stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused in the field of oncology. Our proprietary manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications, including dermatology and dentistry. Our proprietary loading technology can infuse a range of molecules from drugs to DNA. Because our company owns control of LMMY, the operations of Exousia AI are presented in the following discussion.

**Our Exosome Vision**

We believe the future of plant-based exosomes is rich with potential. As technology advances, plant exosomes could become a cornerstone of green biotechnology, offering sustainable, efficient and biocompatible solutions across medicine, agriculture and food science, for example. Their natural properties, combined with ongoing research and technological developments, make them an exciting frontier in therapeutic delivery, disease prevention and environmental sustainability.

Within our exosome strategy, we have established three separate divisions in which our planned future activities will operate.

<u>Biotech</u>: This division will create new therapies using exosomes, focusing on cancer.

<u>Cosmeceutical</u>: This division will focus on using exosomes in the multi-billion-dollar skincare industry. We are in the midst of two studies using our plant-based exosomes in skincare treatments.

<u>Nutraceutical</u>: This division will work on adding exosomes to certain anti-aging supplements, IV therapies, tinctures and peptides.

**About Exosomes**

Exosomes were first discovered in the 1980s, when researchers initially observed small vesicles being secreted by cells. These vesicles were believed to be cellular debris or byproducts of cell turnover. The breakthrough came in 1983, when two independent studies - one by John Raposo and colleagues and another by Peter Harding and his team - revealed that exosomes were not just cellular waste, but functional entities with important roles in intercellular communication. The researchers identified exosomes as small, membrane-bound vesicles ranging from 30 to 150 nanometers in diameter, released from multivesicular bodies (MVBs) into the extracellular space. These discoveries challenged earlier assumptions and opened the door to understanding exosomes as key players in various biological processes, including immune response, cell signaling, and disease progression. As the field advanced, it became clear that exosomes contained proteins, lipids, and RNA, positioning them as crucial vehicles for cell-to-cell communication and potential therapeutic applications.

**Exosomes: The "FedEx® of Cells"**

Exosomes are often likened to couriers because they act as delivery vehicles, transporting various molecular cargo, such as proteins, lipids, and RNA, between cells. Just as a courier picks up and delivers packages from one location to another, exosomes carry their cargo from one cell to another, facilitating communication between distant cells. This "delivery" allows exosomes to transfer information that can influence the behavior of recipient cells, such as triggering immune responses, regulating gene expression, or even contributing to disease processes like cancer metastasis. The ability of exosomes to travel through bodily fluids like blood, saliva, and urine, delivering their cargo to specific target cells, underscores their role as highly efficient biological couriers, enabling complex signaling networks within the body.

**Plant-Based Exosomes**

Plant-based exosomes, also known as plant-derived exosomes or extracellular vesicles (EVs), are similar to the exosomes found in animal cells, but they are secreted by plant cells. These vesicles are small, membrane-bound structures that carry various molecular cargo, such as proteins, lipids, RNA, and other biomolecules. Just like animal exosomes, plant-derived exosomes are involved in intercellular communication, though their functions and mechanisms are still being actively researched.

What distinguishes plant-based exosomes from animal-derived exosomes is that they are naturally produced by plants and can be isolated from plant tissues, fruits, seeds, and even plant-based foods. They have gained attention for their potential use in food science, nutrition, and biomedicine due to their bioactive components and potential health benefits.

**Key Features and Potential Applications**

Our company views plant-based exosomes as having many potentially significant capabilities, useful in the following applications, among others:

<u>Health Benefits</u>: Plant exosomes are believed to carry bioactive compounds like small RNAs, proteins, and polyphenols, which can have antioxidant, anti-inflammatory, and anticancer properties. There is increasing interest in using these vesicles as nutraceuticals-biologically active food ingredients that promote health and prevent disease.

<u>Drug Delivery</u>: Plant-derived exosomes are also being explored for their potential to serve as drug delivery systems. They have natural properties that may make them less likely to trigger immune responses compared to synthetic or animal-derived vesicles, offering a potential advantage in clinical applications.

<u>Environmental and Eco-Friendly</u>: Unlike animal-derived exosomes, which can raise ethical and environmental concerns, plant-based exosomes are considered more sustainable and environmentally friendly. They can be isolated from plants that are grown in abundance, making them a renewable resource for various applications.

<u>Viral Immunity and Disease Management</u>: Some research has suggested that plant exosomes may play a role in plant immunity, helping plants resist infections by transporting defensive molecules. This has led to interest in using plant exosomes in immunotherapy for humans, particularly as a way to modulate immune responses in diseases like cancer.

**Why We Are Developing Plant-Based Exosome Products**

Plant-based exosomes will allow us to load these cell couriers with thousands of biomimetic factors, including growth factors, peptides, liposomes, amino acids, and proteins directed explicitly to target inflammation as well as for wound healing angiogenesis and the stimulation of hyaluronic acid, collagen and elastin production.

Furthermore, Plant-based exosomes can be engineered to carry drugs, proteins, or RNA molecules to specific tissues or cells, making them highly promising for targeted drug delivery systems. Exosomes are naturally adept at fusing with cell membranes, which allows them to efficiently deliver their cargo directly to the inside of recipient cells. This makes them ideal for delivering therapeutic agents to targeted locations in the body, minimizing side effects compared to conventional drugs.

**Our Future With Plant-Based Exosomes**

The future of plant-based exosomes is promising, with growing interest in their potential to revolutionize fields like medicine, agriculture, and food science. As research into their properties and applications expands, we are likely to see significant advances in both their use as therapeutic tools and their integration into various industries. Below is a discussion of which areas we believe plant-based exosomes could make a significant impact, in the future.

*<u>Drug Delivery and Targeted Therapy</u>*. One of the most exciting possibilities for plant-based exosomes is their use in targeted drug delivery. Due to their natural ability to carry bioactive molecules (proteins, lipids, RNAs) across cellular membranes, plant exosomes could be engineered to deliver therapeutic drugs, gene therapies, or even vaccines directly to specific cells or tissues. This targeted delivery could help minimize side effects and enhance the effectiveness of treatments for conditions such as cancer, autoimmune diseases, and neurodegenerative disorders.

Future Impact: Researchers are working on optimizing plant exosomes as delivery systems for chemotherapeutic agents, RNA-based therapies (like siRNA or mRNA), and immune modulators, which could offer a safer and more efficient alternative to traditional delivery methods.

*<u>Immunotherapy and Vaccine Development</u>*. Plant exosomes have shown promise in immunotherapy, particularly in their potential to modulate immune responses. Because exosomes can carry and deliver immune-stimulating molecules, they might be used to enhance the immune system's ability to recognize and attack cancer cells or pathogens. Additionally, plant exosomes are being explored for their potential in vaccine delivery, where they could deliver antigens to stimulate a protective immune response without the risk of disease transmission from animal-based products.

Future Impact: Plant exosome-based vaccines and immune therapies could become an affordable, scalable, and safer alternative to current vaccine technologies, with fewer concerns about contamination from animal pathogens.

*<u>Nutraceuticals and Food Supplements</u>*. Plant exosomes are thought to carry bioactive molecules, such as polyphenols, flavonoids, and small RNAs, that have health-promoting effects. These exosomes could be used as nutraceuticals-natural food-based substances that offer health benefits beyond basic nutrition. Since exosomes can protect and deliver their bioactive cargo more effectively than simple nutrients, plant-based exosomes could enhance the bioavailability of nutrients and therapeutic compounds.

Future Impact: We may see the development of new, plant-derived functional foods or supplements, including exosome-enriched products that help in preventing chronic diseases, reducing inflammation, or improving gut health. These products could be more effective and easier to absorb than current supplements.

*<u>Gene Therapy and RNA Delivery</u>*. Plant exosomes can naturally carry and transport small RNA molecules, including miRNA (microRNA) and siRNA (small interfering RNA). These RNA molecules have the potential to regulate gene expression and are of great interest for gene therapy. By using plant exosomes to deliver RNA to target cells, it may be possible to manipulate gene expression in a controlled way for therapeutic purposes.

Future Impact: In the future, plant exosomes could be engineered to deliver RNA therapies for genetic disorders (e.g., cystic fibrosis, muscular dystrophy) and other conditions where gene silencing or activation is needed. This could be a more natural and efficient delivery system compared to viral vectors currently used in gene therapy.

*<u>Cancer Diagnosis and Treatment</u>*. Exosomes, in general, are involved in cell-to-cell communication and can carry molecules that reflect the condition of their originating cells. Plant-based exosomes, due to their biocompatibility and lack of toxicity, could be engineered for use in cancer diagnostics and therapeutics. They might be used to carry tumor-associated antigens or RNA-based treatments that could target and destroy cancer cells.

Future Impact: Plant exosome-based diagnostics could be developed as non-invasive tests for detecting cancer or monitoring treatment response. Additionally, they could play a role in targeting specific cancer cells, improving the precision of cancer therapies while reducing damage to healthy tissue.

*<u>Cosmetic and Skin Care Applications</u>*. Due to their ability to deliver bioactive compounds and proteins, plant-based exosomes are being explored for use in cosmetics and skin care products. These exosomes could be used to deliver anti-aging compounds, moisturizing agents, and other beneficial ingredients directly to skin cells, improving the effectiveness of skin treatments.

Future Impact: Plant exosomes could revolutionize the cosmetic industry by creating new anti-aging formulations, wound healing products, and skin regeneration therapies. Exosome-based cosmetics could be more effective than current formulations, with fewer side effects.

*<u>Environmental and Agricultural Benefits</u>*. Plant exosomes are involved in plant immunity and are being studied for their potential role in plant defense against pathogens. In agriculture, plant-based exosomes could be used as natural pesticides or plant growth regulators to enhance crop protection without the need for synthetic chemicals.

Future Impact: Plant exosomes could be used in agriculture to create sustainable and eco-friendly pest control, enhanced crop resistance to diseases, and even improved plant growth. This could help reduce reliance on harmful chemicals and contribute to more sustainable farming practices.

*<u>Cost-Effective and Scalable Production</u>*. One of the key advantages of plant-based exosomes is the ease of scalable production. Unlike animal or synthetic-based exosome systems, plants can be grown in large quantities, making it possible to produce exosomes at a lower cost. This scalability could facilitate their use in a wide range of commercial applications.

Future Impact: Plant-based exosomes could be mass-produced for therapeutic, industrial, and agricultural uses, leading to the creation of affordable and accessible treatments in areas like gene therapy, drug delivery, and disease prevention.

**Recent Developments**

*<u>Exousia AI Acquisition</u>*. In a January 6, 2025, press release, we announced the completion of our acquisition of Exousia AI. Currently, the activities of Exousia AI are the core of our company's operations.

*<u>Exosome Production</u>*. In a March 25, 2025, press release, we announced the start of our production of mushroom-based exosomes in our Orlando, Florida, lab. To date, we have produced a limited amount of our mushroom-based exosomes, as we continue our efforts in attracting customers for such exosomes and as we complete the formulation of our own consumer products, including topical lotions. We expect that sales of our consumer products will begin during the third quarter of 2025.

*<u>FDA Orphan Drug Status</u>*. In an April 1, 2025, press release, we announced that we had received a response from the FDA regarding our Orphan Drug application filed last year under Exousia AI for our Glioblastoma Multiforme (GBM) treatment using exosomes, wherein we indicated that the FDA had been very responsive in its emails and phone calls and had requested additional information regarding the relevant study being conducted at the University of Central Florida (UCF). The requested information has been provided to the FDA; however, the UCF study has not yet been published, although we are encouraged by the results. We continue to believe that we have a high probability of receiving the requested Orphan Drug status, although no assurance can be made, in this regard.

The FDA has authority to grant Orphan Drug status to a drug or biological product to prevent, diagnose or treat a rare disease or condition. Orphan Drug status qualifies sponsors for incentives, including tax credits for qualified clinical trials, exemption from user fees and a potential of seven years of market exclusivity after approval.

Exousia AI, as sponsor, in support of its application, has submitted to the FDA an animal study to show the efficacy of its exosomal drug product. Obtaining Orphan Drug status is a separate process from seeking approval or licensing. <u>Future human studies in support of the approval process are planned</u>.

To receive Orphan Drug status, sponsors must submit a request to the FDA with a scientific rationale demonstrating a medically plausible basis for expecting the drug to be effective in treating the subject rare disease. This rationale is often supported by preclinical or clinical data. The FDA reviews these requests and, if the criteria are met, grants the Orphan Drug status.

*<u>New President</u>*. In an April 2, 2025, press release, we announced that Matthew Dwyer had become President of our company. Mr. Dwyer continues to perform his duties as President, working in unison with our Chief Executive Officer, Michael Sheikh.

*<u>Name Change</u>*. In an April 3, 2025, press release, we announced that we were continuing to pursue our FINRA Corporate Action submission, to effect a change of corporate name in the trading markets to "Exousia Pro, Inc." and to obtain a new trading symbol. We continue to pursue such submission, although we are unable to predict the timing of FINRA approval.

*<u>Delivery of Exosomes for Trade Show</u>*. In an April 8, 2025, we announced receipt of an order for 500 billion exosomes produced by us, with such order demonstrating our ability to supply dried exosomes, a shelf-life extending feature. We expect that orders for our exosomes will begin in earnest during the third quarter of 2025, as we implement our marketing strategies.

*<u>Business Subdivisions</u>*. In an April 18, 2025, press release, we announced our management's determination to establish three operating divisions, each within a separate subsidiary (to be formed): Biotech, Cosmeceutical and Nutraceutical.

<u>Biotech</u>: This division will develop new therapies using exosomes, focusing on cancer.

<u>Cosmeceutical</u>: This division will focus on using exosomes in the multi-billion-dollar skincare industry, including sales of our company's own products.

<u>Nutraceutical</u>: This division will work on adding exosomes to certain anti-aging supplements, IV therapies, tinctures and peptides.

Our primary strategy for commencing activities within each business division is through joint ventures with companies already operating in each market segment. To date, we have not entered into any such agreement.

*<u>Glioblastoma Study</u>*. In an April 21, 2025, press release, we discussed a Spaces interview of our Scientific Advisory Board member, Marvin S. Hausman, MD, wherein Dr. Hausman discussed a published paper (available online at https://pmc.ncbi.nlm.nih.gov/articles/PMC10297980) showing that the NANOG Expression therapy being employed in our UCF-conducted Glioblastoma (GMB) study reduced the resistance of the cancer stem cells in GMB. The results of our UCF-conducted study are expected to be published in the near future. However, we are unable to provide the exact timing of such publication.

*<u>Completion of Preclinical Trial for Glioblastoma</u>*. In an April 29, 2025, press release, we announced the early completion of the UCF study that supports our FDA Orphan Drug application and provided an explanation of the study's procedures. While the UCF study has not yet been published, we believe such publication will occur in the near future.

*<u>Web Series</u>*. In an April 30, 2025, press release, we announced a weekly web series featuring Marvin D. Hausman, MD, a member of our Scientific Advisory Board. We expect that this web series will be launched, on a full-time basis, in February 2026.

*<u>Exosome-CBD Delivery Study</u>*. In a September 29, 2025, press release, we announced that we have initiated a study designed to demonstrate the dramatically enhanced efficacy of CBD-loaded exosomes in oral delivery. This research is predicated on the known ability of our proprietary exosomes to survive the digestive tract and deliver their payload directly to the small intestine. We expect study results during Q1 2026.

*<u>Orphan Drug Designation Obtained from FDA</u>*. In an October 28, 2025, press release, we announced that we had received Orphan Drug Designation from the FDA for malignant Glioma, aka Glioblastoma multiforme (GBM). The Orphan Drug Designation application approval provides significant opportunities for advancing our company's cancer therapy, as it moves into the next clinical phases. The time frame for our clinical phases is dependent upon our obtaining needed capital, of which there is no assurance.

*<u>Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms</u>*. In a December 2, 2025, press release, we announced the execution of an exclusive licensing agreement between our subsidiary, Exousia Pro Holding Management, LLC, and the University of Central Florida (UCF) concerning its groundbreaking technology for both the diagnosis and treatment of cancer using exosomes. Our ability to capitalize on this license is dependent upon our obtaining needed capital, of which there is no assurance.

*<u>Maxasome<sup>(TM)</sup> Product</u>*. In a December 5, 2025, press release, we announced the introduction of our flagship nutraceutical, Maxasome™. Derived exclusively from 100% pure Exosome-Like Nanoparticles (ELNs) extracted from the high-value Yellow Oyster Mushroom (Pleurotus citrinopileatus), Maxasome™ is an all-natural, multi-modal cytoprotective agent designed to deliver unparalleled cellular defense and extend health span. The product will be offered to consumers on a monthly subscription basis, aligning with our strategy to build recurring revenue within the high-growth longevity and wellness market. Our ability to begin significant commercial production and sales efforts with respect to Maxasome™ are dependent upon our obtaining needed capital, of which there is no assurance.

*<u>Letters of Intent</u>*. In a December 11, 2025, press release, we announced the execution of letters of intent for the acquisition of a tele-health platform, which would permit us to accelerate nutraceutical commercialization efforts. The three separate intended acquisitions, if consummated, would form a single operating division of our company. We have not yet entered into a definitive agreement with respect to either of such letters of intent and there is no assurance that we will ever do so. It is possible that an as-yet determined portion of the proceeds in this offering would be applied to complete one or more of such acquisition transactions. However, no prediction can be made, in this regard. (See "Use of Proceeds").

**UCF Study**

Exousia AI is the sponsor of a preclinical research study by the University of Central Florida (UCF) designed to investigate the therapeutic potential of exosome-mediated delivery of nucleic acid medicine to enhance Temozolomide (TMZ) therapy for Glioblastoma Multiforme (GBM) using an in vivo model. The preclinical trial studied 32 immunodeficient humanized mice (CIEA NOG mouse) which carry a human immunes system which better replicates GBM immune interactions. Human GBM excised from a patient was cultured and then implanted in a hemisphere of the mouse brain. After 30 days of tumor growth, the mice were randomized into four equal subgroups: control, temozolomide (TMZ) treatment, exosome treatment, and a TMZ-exosome combination therapy. After seven days of treatment the mice were sacrificed and their brains were preserved for image analysis. The observations focused on tumor size, weight changes, and brain slice analysis. Additional tissue antibody staining analysis will be conducted to detect the boundary or presence of cancer cells. The insights from this study are expected to show if combination exosomal therapy can overcome the chemoresistance of glioma stem cells, which represents a major obstacle to effective glioblastoma treatment.

UCF's study report is expected to be published in the near future. Nevertheless, Exousia AI has been able to obtain sufficient information from UCF, such that it has been able to respond to the FDA's information requests regarding its Orphan Drug application.

**Our Lab**

![](image_058.jpg)

Our Orlando, Florida, lab is equipped with a range of advanced tools and instruments designed to support precise, high-performance research across various scientific disciplines. The equipment described below enhances our capabilities in sample preparation, analysis and storage.

<u>Z327-K Refrigerated Universal Centrifuge, 120V</u>: The refrigerated Z327-K offer a wide assortment of rotor options (up to 19), making it ideal for a wide variety of research applications. Rotor exchange between swing out, micro, or high volume fixed angle rotors is very simple and can be done in a matter of seconds. The Z327-K features rear mounted refrigeration system, optimized for saving space on the lab bench at only 40 cm wide.

<u>Thermo Savant DNA120 SpeedVac Concentrator</u>: The ThermoSavant DNA Speed Vacuum Model DNA 120, is a dedicated centrifugal vacuum concentration system for drying low volume ethanol or isopropanol-water precipitates of DNA and RNA. This design incorporates a glass cover, ammonia post-trap and Ammonia Neutralizing Solution for fully automated, unattended, odor-free drying. The post-trap is connected on the back, left side of the unit. It is easily maintained and replaced. The Savant DNA SpeedVac combines centrifugal force with vacuum for bump-free sample drying. Vacuum is supplied by an integral, oil-free vacuum pump with an automatic bleeder valve.

The Savant DNA120 SpeedVac has a chamber heater that counteracts evaporative sample cooling and accelerates solvent evaporation rates to shorten drying times. The operator can select LOW (ambient), MEDIUM (43 °C), or HIGH (65°C) drying rates with the 3-position switch on the front panel.

The Savant DNA SpeedVac is equipped with polypropylene vacuum fittings to avoid leaks and resist corrosion. A chemical trap kit (DTK120R) and disposable cartridge (DC120R) should be used for trapping volatile radioactivity when the system is dedicated for drying down radio labeled materials.

<u>Ultracentrifuge Z 273 K</u>: The Ultracentrifuge Z 273 K is a high-performance instrument used for separating components of different densities within a liquid sample. With a rotor capable of speeds up to 20,000 x g, this ultracentrifuge is particularly useful for the purification of proteins, nucleic acids, and viruses, as well as for isolating cellular organelles and subcellular components. The 220.78 rotor provides precise control, allowing for consistent and reliable separations across a variety of applications, including molecular biology and biochemistry.

<u>Homogenizer</u>: The Homogenizer is an essential tool for sample preparation, used to break down biological or chemical samples into uniform suspensions. It operates by applying high shear forces to cells or tissues, disrupting them into smaller particles or homogenizing them for further analysis. Whether for protein extraction, DNA/RNA isolation, or sample preparation for microscopy, this piece of equipment ensures consistent sample quality and preparation efficiency.

<u>Hyper-Sensitive Scale</u>: Our Hyper-Sensitive Scale is designed for the most accurate weighing tasks, capable of measuring ultra-small quantities with incredible precision. This scale is vital for experiments where exact measurements of chemicals, powders, or small amounts of substances are required. Its high sensitivity ensures reliable results in quantitative analysis, ensuring the accuracy of experimental conditions.

<u>Fume Hood</u>: The Fume Hood is an essential safety device that provides a controlled environment for handling hazardous chemicals or biological samples. It is designed to prevent exposure to toxic fumes, vapors, and particulate matter by using a ventilation system that draws harmful substances away from the user. The fume hood helps maintain a safe workspace, ensuring that potentially dangerous reactions, solvents, and compounds can be used with minimal risk.

<u>Microscope</u>: The Microscope in our lab offers high magnification capabilities, essential for observing fine details of biological samples, tissues, and microorganisms. This advanced imaging tool allows researchers to investigate samples at the cellular and sub-cellular levels, making it indispensable for applications in microbiology, cell biology, histology, and material science. The microscope's high-resolution optics ensure accurate imaging for both routine and advanced investigations.

<u>Fridges/Freezers</u>: Our Fridges and Freezers are crucial for the proper storage of reagents, biological samples, and chemical compounds that require temperature-controlled environments. The fridges maintain a stable temperature range for materials that must remain cold but not frozen, while the freezers provide deep-freeze conditions for long-term storage of samples, such as enzymes, antibodies, or DNA/RNA. This equipment is vital for ensuring sample integrity and preventing degradation over time.

<u>Electronic Pipette and Micropipettes</u>: The Electronic Pipette and Micropipettes in our lab are precision instruments for transferring small, accurate volumes of liquids. The electronic pipette offers programmable settings to reduce the risk of human error, allowing for reproducible and precise liquid handling. Micropipettes are designed for applications that require extreme accuracy, such as PCR preparation, enzyme assays, and cell culture work. These pipettes contribute to consistency in research by ensuring the correct volume is dispensed every time.

**Intellectual Property**

*<u>Progenicyte License</u>*. Effective January 1, 2025, Exousia AI (which was then-named Exousia Pro, Inc.) entered into an Alliance Agreement (the "Progenicyte Agreement") with Progenicyte Japan CO., LTD. ("Progenicyte"), with respect to a business alliance regarding the implementation of certain technologies (the "Licensed Technologies") in Exousia AI's exosome products. In accordance with the terms of the Progenicyte Agreement, Exousia AI is owned 30% by Progenicyte and 70% by our company. In addition, Exousia AI pays Progenicyte a license fee with respect to the Licensed Technologies of $16,667 per month.

The Licensed Technologies relate to a Progenicyte invention known as "A Novel Method to Load the Desired Nucleic Acid Into Exosomes as a Nucleic Acid Drug Delivery System." The Licensed Technologies are the subject of a USPTO 371 PCT (Patent Cooperation Treaty) Patent Application PCT/JP2024/009529, filed March 13, 2023, which claims priority to Japanese Patent Application 2022-040244, filed March 15, 2022.

*<u>Proprietary</u>*. In the transaction by which we acquired Exousia AI, we also acquired the following intellectual property:

• Those serotonin assay(s) being developed by Dr. Kiminobu Sugaya at the University of Central Florida, including, but not limited to, preclinical and clinical data deriving therefrom or associated therewith.

• Exosome development protocol currently active at the laboratory of Dr. Kiminobu Sugaya at the University of Central Florida, including blood samples sent from the laboratory of Dr. Viviana Trezza and analysis data therefor obtained by Fabrizio Ascone.

In addition, we own additional proprietary intellectual properties (the "Proprietary IP") that we consider key to our business plans, as follows:

• A Novel Method to Load the Desired
 Nucleic Acid into Exosomes as a Nucleic Acid Drug Delivery System;

• Differential Sequence of Exosomal
 Nanog Dna as a Potential Diagnostic Cancer Marker; and

• Delivery
 of Gene Expression Modulating Agents for Therapy Against Cancer and Viral Infection.

By combining the Licensed Technologies with the Proprietary IP, we believe we will be able to produce products that will be extremely effective in assisting in the treatment of many diseases, including certain cancers. A portion of the proceeds of this offering will be used to fund Investigational New Drug trials for our future products. (See "[Use of Proceeds](#a_006)").

*<u>Trademark</u>*. We own the "ExousiaPRO" trademark. We intend to register such trademark with the U.S. Patent and Trademark Office in the near future. This mark is important to us, and we intend to, directly or indirectly, maintain and protect this and any future marks we develop and their respective registrations.

**Sourcing**

It is our objective to produce all plant-based exosomes needed in our business operations. However, until such time, we intend to source our mammalian exosomes from suppliers in the United States. We expect no difficulties in obtaining needed supplies of such exosomes.

**Competition**

We are in competition with companies that are larger, more established and better capitalized than are we. The medical products development industry and the consumer medical products industry are highly competitive, rapidly evolving and subject to constant change. The number of competitors in each of these industries is substantial. We expect that, if our products establish a market niche, competition will arise from a variety of sources, including from large health-related companies to other smaller national and regional health-related companies.

Many of our potential competitors possess:

• greater
 financial, technical, personnel, promotional and marketing resources;

• longer
 operating histories;

• greater
 name recognition; and

• larger
 consumer bases.

We cannot assure you that we will be able to compete effectively in our extremely competitive industry.

**Government Regulations**

By obtaining the Orphan Drug Designation from the FDA regarding our Glioblastoma Multiforme (GBM) treatment using exosomes, we have become subject to all FDA and other relevant rules and regulations. To date, we have maintained compliance with such rules and regulations and anticipate that we will continue to do so in the future.

**Litigation**

In July 2025, we filed a lawsuit against our former Sole Officer and Director, Donald Steinberg, styled Exousia Pro, Inc., a Florida corporation, formerly known as Marijuana, Inc. and as GRN Holding Corporation vs. Donald Steinberg and Securities Transfer Corporation, a nominal defendant, in the Circuit Court of the Court of the Twentieth Judicial District in and for Lee County, Florida. In the lawsuit, we seek the cancellation of all shares issued by our company pursuant to a stock exchange agreement (the "Exchange Agreement") with Marijuana, Inc., a now-dissolved Florida corporation, the control person of which was Donald Steinberg, our former sole officer and director who was in such positions at the time of the Exchange Agreement. Pursuant to the Stock Exchange Agreement, a company owned by Mr. Steinberg was issued 3,063,000 shares. However, shortly after the consummation of the Exchange Agreement, Mr. Steinberg caused the dissolution of the acquired company. The series of transactions surrounding the Exchange Agreement, which we believe to have been fraudulent, is the basis of a lawsuit filed by us against Mr. Steinberg, wherein we seek the rescission of the Exchange Agreement and the cancellation of all of the shares of common stock issued pursuant thereto.

In September 2025, following a hearing, significant protections for our shareholders have been established. While the motion for a Temporary Restraining Order (TRO) was not heard due to a lack of available court time, a mutually agreed-upon standstill order was executed on all shares held by Mr. Steinberg, representing approximately 10.5% of the shares outstanding.

In December, 2025, the Court denied motions to dismiss filed by Mr. Steinberg and Kimberly Carlson.

**Properties**

We lease our principal office located in St. Petersburg, Florida, at a monthly rental of $150. We lease our 1,000 square foot lab space in Orlando, Florida, at a monthly rental of $2,160.83. We own no real property.

**Employees**

In addition to our two executive officers, we currently have one part-time employee. Upon our obtaining additional funding, including through this offering, we expect that we would hire a small number of additional employees. We have used, and, in the future, expect to use, the services of certain outside consultants and advisors as needed on a consulting basis.

**MANAGEMENT'S DISCUSSION AND ANALYSIS OF**

**FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

**Cautionary Statement**

The following discussion and analysis should be read in conjunction with our unaudited financial statements and related notes, beginning on page F-1 of this Offering Circular.

Our actual results may differ materially from those anticipated in the following discussion, as a result of a variety of risks and uncertainties, including those described under Cautionary Statement Regarding Forward-Looking Statements and Risk Factors. We assume no obligation to update any of the forward-looking statements included herein.

**Recent Change in Control**

Effective October 30, 2024, a change in control of our company occurred. On such date, Earth Onyx, LLC, a company owned by our former Sole Director and Officer, sold 100 shares (the "Control Shares"), or 100% of the outstanding shares, of our Series A Preferred Stock to our current Sole Director and Chief Executive Officer. Mr. Sheikh paid $60,000 in cash and delivered a promissory note (the "Closing Note") to Earth Onyx, LLC in payment of the Control Shares. The Closing Note has a principal amount of $100,000 and is due on the later of 60 days from October 30, 2024, and the date on which Mr. Steinberg shall have delivered ready-to-file federal tax returns for the years ended December 31, 2022 and 2023, of our company. Mr. Sheikh and Earth Onyx, LLC entered into Pledge Agreement, to secure Mr. Sheikh's payment obligations under the Closing Note.

**Acquisition of Exousia AI**

On December 31, 2024, pursuant to a stock purchase agreement, we acquired Exousia Ai, Inc. (Exousia AI). Exousia AI's assets embody a joint venture with a Japanese biotech company to manufacture and deliver mammalian and plant-based exosomes containing nucleic acids, such as DNA and mRNA to tissues and cells. We have not generated any revenues to date and we intend to continue to fund research and development through funding from third parties in the form of debt, equity or a combination thereof, until such time as our operations have commenced and revenues generated.

The acquisition of Exousia AI by our company, whereby our company was determined to be the legal and accounting acquirer. However, our company was deemed a "Shell Company" prior to the acquisition, with no substantial operations and continuing operations, and was deemed to be the "Successor" entity, with Exousia AI being deemed the "Predecessor" entity.

**Plan and Agreement of Reorganization – Exousia AI**

On November 11, 2025, pursuant to a Plan and Agreement of Reorganization (the Reorganization Agreement), LMMY acquired our 70%-owned subsidiary, Exousia Ai, in exchange for shares of LMMY common stock. Following the closing of the Reorganization Agreement, our company holds 41,223,000 shares, or approximately 51% (as measured after the transaction), of LMMY common stock. Our company's President, Matthew Dwyer, serves as LMMY's sole officer and director.

The transaction with LMMY was pursued and consummated by the Company, after the Company's Board of Directors had determined, after investigating the LMMY opportunity, that the best interests of the Company and its shareholders would be best served by acquiring a controlling interest in LMMY, in exchange for its ownership in Exousia Ai.

**Recent Letters of Intent**

In December 11, 2025, we executed letters of intent for the acquisition of a tele-health platform, which would permit us to accelerate nutraceutical commercialization efforts. The three separate intended acquisitions, if consummated, would form a single operating division of our company. We have not yet entered into a definitive agreement with respect to either of such letters of intent and there is no assurance that we will ever do so. It is possible that an as-yet determined portion of the proceeds in this offering would be applied to complete one or more of such acquisition transactions. However, no prediction can be made, in this regard. (See "Use of Proceeds" and "Business").

**Summary of Critical Accounting Estimates**

The following significant accounting policies require management estimates and assumptions which may result in material impacts to the Company's financial condition.

*<u>Goodwill and Indefinite-Lived Intangible Assets</u>*. The Company has goodwill and certain indefinite-lived intangible assets that have been recorded in connection with the acquisition of a business. Goodwill and indefinite-lived assets are not amortized but instead tested for impairment at least annually. Goodwill represents the excess of the purchase price of an acquired business over the estimated fair value of the underlying net tangible and intangible assets acquired. The Company tests goodwill resulting from acquisitions for impairment annually, or whenever events or changes in circumstances indicate an impairment. For purposes of the goodwill impairment test, the Company has determined that it currently operates as a single reporting unit. If it is determined that an impairment has occurred, the Company adjusts the carrying value accordingly and charges the impairment as an operating expense in the period the determination is made. Although the Company believes goodwill is appropriately stated in the consolidated financial statements, changes in strategy or market conditions could significantly impact these judgments and require an adjustment to the recorded balance. There were no impairments during the periods presented.

*<u>Long Lived Assets</u>*. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates the recoverability of long-lived assets based upon forecasted undiscounted cash flows. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Should impairment in value be indicated, the carrying value of long-lived assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. Assets to be disposed of are reported at the lower of the carrying amount or the fair value, less costs to sell.

*<u>Income Taxes</u>*. The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company has incurred net operating losses in prior years for financial-reporting and tax-reporting purposes. Accordingly, for Federal income tax purposes, the benefit for income taxes has been offset entirely by a valuation allowance against the related federal and state deferred tax asset for the years ended December 31, 2024 and 2023.

*<u>Fair Value Measurements</u>*. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs).

The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under are described as follows:

• Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date.

• Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

• Level 3 – Inputs that are unobservable and significant for the asset or liability.

Fair value is determined based on the price that would be received for an asset or paid to transfer a liability in an orderly transaction based on market participants. Factors that the Company considered when estimating the fair value of its convertible notes payable included quoted market prices of the Company's common stock.

*<u>Convertible Debt Instruments</u>*. The Company follows ASC 480-10, Distinguishing Liabilities from Equity in its evaluation of the accounting for a hybrid instrument. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception; (b) variations in something other than the fair value of the issuer's equity shares; or (c) variations inversely related to changes in the fair value of the issuer's equity shares. Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with remeasurements reported in change on fair value expense in the accompanying Statements of Operations.

**Change in "Shell Company" Status**

With the acquisition of Exousia AI, our company exited "shell company" status. As a result, Exousia AI is being deemed a "Predecessor" company. As such, the following discussion and analysis of unaudited financial statements for the periods presented prior to the acquisition date of December 31, 2024, are those of the Predecessor. Our company's results of operations as of and after the acquisition date of December 31, 2024, are those of the "Successor."

**Results of Operations**

*<u>For The Nine Months Ended September 30, 2025, Compared to the Nine Months Ended September 30, 2024</u>*.

*Revenues*. We generated $500 in revenues during the nine months ended September 30, 2025, and incurred $4,972 in cost of revenues, resulting in a gross loss of $4,472. During the nine months ended September 30, 2024, we generated no revenues.

*Operating Expenses*. Operating expenses were $379,794 and $34,529 for the nine months ended September 30, 2025 and 2024, respectively. The increase in operating expenses is a primarily the result of increases in consulting and professional fees during the nine months ended September 30, 2025, as compared to the 2024 period. Increases are the result of commencement of the biotech business during the fourth quarter of 2024.

*Loss from Operations*. We had operating losses of $384,266 and $34,529 for the nine months ended September 30, 2025 and 2024, respectively. The increase in operating loss is a result of the operating losses and revenues as discussed above.

*Other Income and Expenses*. We reported total other income of $54,182 and $0 for the nine months ended September 30, 2025 and 2024, respectively. The September 30, 2025 balance consists of fair value of share settled debt.

*Net Loss*. Net loss was $330,084 and $34,529 for the nine months ended September 30, 2025 and 2024, respectively. The increase in net loss for the nine months ended September 30, 2025, is the result of the increase in operating expenses as discussed above.

*<u>For The Year Ended December 31, 2024 Compared to the Year Ended December 31, 2023</u>*.

*Revenues*. We recognized $12,830 in consulting service revenue during the year ended December 31, 2024. We did not have any revenues during the year ended December 31, 2023.

*Operating Expenses*. Operating expenses were $176,832 and $10,384 for the years ended December 31, 2024 and 2023, respectively. The increase, is mainly a result of an increase of $113,002 in research and development, $9,650 in consulting and professional fees and $13, 6771 in general and administrative expenses during the year ended December 31, 2024. There were no consulting and professional fees, $10,000 in research and development and $384 in general and administrative expenses during the year ended December 31, 2023. Increases are the result of commencement of the biotech business during the year ended December 31, 2024.

*Loss from Operations*. We had operating losses of $164,001 and $10,384 for the years ended December 31, 2024 and 2023, respectively. The loss is a result of the operating losses and discussed above.

*Net Loss*. Net loss was $164,001 and $10,384 for the years ended December 31, 2024 and 2023, respectively. Net losses are the result of $164,001 and $10,384 in losses from operations for the years ended December 31, 2024 and 2023 as discussed above, respectively.

**Plan of Operation**

With a portion of the proceeds of this offering, we intend to initiate one or more Investigational New Drug (IND) trials, each of which is expected to study an indication which includes exosomes as part of its composition. We expect that the average cost for an IND trial would be approximately $300,000, payable generally in installments over the life of the study.

*An IND submission is a request to the FDA that allows sponsors to start clinical trials on humans with a new drug or a drug for a new use and ship the investigational drug across state lines for these trials. Once the submission is made, the FDA reviews the IND application to ensure the safety of the study and the rights of the participants; the FDA has 30 days to act on the application or it becomes effective. At such time as an IND application is approved, the sponsor is responsible for submitting updates to the FDA, including changes to the study protocol, sites or principal investigators.*

In addition, with a portion of the proceeds of this offering, we intend to continue to develop topical exosome-infused products for the consumer market. We intend to pursue these efforts as quickly as our access to capital permits.

There is no assurance that we will obtain sufficient funds in this offering, or from other sources, that would permit us to initiate any of the foregoing.

We believe that the proceeds of this offering will satisfy our cash requirements for at least the next twelve months.

**Liquidity and Capital Resources**

We believe the recent acquisition of Exousia AI will allow us to manufacture and deliver for sale mammalian and plant-based exosomes containing nucleic acids, such as DNA and mRNA, to tissues and cells. We have not generated any revenues to date and we intend to continue to fund current operations and research and development through funding from third parties in the form of debt, equity, including in this offering, or a combination thereof, until such time as our operations have commenced and sufficient revenues are generated to support operating expenses. Our ability to succeed in the market will greatly depend on our ability to secure investment funding through the sale of securities. We do not intend to undertake new loans, but, if needed, we believe we will be able to secure loans from private individuals, as well as banking institutions. However, we currently have no additional capital commitments and there is no assurance that we will be able to secure any future capital commitments. We believe that the proceeds of this offering will satisfy our cash requirements for at least the next twelve months.

The following is a discussion and evaluation of our current and long-term assets, liabilities and cash flows.

*<u>At September 30, 2025</u>*.

*Assets*. Total assets were $218,566 and $202,781 as of March 31, 2025 and December 31, 2024, respectively. Total assets as of March 31, 2025 consisted of current assets of $15,885, consisting of cash of $9,010 and prepaid expenses of $6,875, and long-term intangible assets of $202,681. Total assets as of March 31, 2024 consisted of current assets of $100 in cash and long-term intangible assets of $202,681.

*Liabilities*. Total liabilities were $877,895 and $518,923 as of March 31, 2025 and December 31, 2024, respectively, all current liabilities. Current liabilities at March 31, 2025 consisted of $72,978 in accounts payable, $10,688 in accrued interest expenses, $50,000 in accrued product deliverable, $30,000 in accrued compensation, $555,279 in convertible notes payable, $158,850 in notes payable and $100 in notes payable, related party. Current liabilities at December 31, 2024 consisted of $53,319 in accounts payable, $3,207 in accrued interest expenses, $50,000 in accrued product deliverable, $287,746 in convertible notes payable, $124,551 in notes payable and $100 in notes payable, related party.

*Net Cash Used in Operating Activities*. During the three months ended March 31, 2025 and 2024, our operating activities used $80,389 and $32,300 in cash, respectively. The $48,089 increase is mainly due to a $340,887 increase in net loss, partially offset by $242,533 increase in non-cash adjustments such as $241,095 in loss on fair value of share settled debt and a $1,438 in amortization of debt discounts and $50,265 in net changes to operating assets and liabilities.

*Net Cash Provided by Financing Activities.* Financing activities provided $89,299 and $0 in cash during the three months ended March 31, 2025 and 2024, respectively. During the three months ended March 31, 2025, we received $9,299 in cash from notes payable, $50,000 from issuance of a convertible note payable and $30,000 in cash from the issuance of common stock.

The Company had a working capital deficit of $862,010 and $518,823 at March 31, 2025 and December 31, 2024, respectively.

*<u>At December 31, 2024</u>*.

*Assets*. Total assets were $202,781 and $100,000 as of December 31, 2024 and 2023, respectively. Current assets consisted of $100 and $100,000 of cash as of December 31, 2024 and 2023, respectively.

Non-current assets consisted of $202,681 in intangible assets at December 31, 2024. There were no non-current assets at December 31, 2023.

*Liabilities*. Total liabilities were $518,923 and $110,384 as of December 31, 2024 and 2023, and were all current liabilities. Current liabilities at December 31, 2024 consisted of $53,319 in accounts payable, $3,207 in accrued interest expenses, $50,000 in accrued product deliverable, $262,746 in convertible notes payable, $149,551 in notes payable and $100 in notes payable, related party.

Current liabilities at December 31, 2023 consisted of $110,384 in amounts due to its parent company, Ludwig.

*Net Cash Used in Operating Activities*. During the year ended December 31, 2024, our operating activities used $100,000 in cash, compared to $10,384 during the year ended December 31, 2023. The increase is mainly due to a $153,618 increase in net loss, partially offset by $14,002 and $50,000 increases in accounts payable and accrued product deliverable, respectively, during the year ended December 31, 2024 compared to 2023.

*Net Cash Provided by Financing Activities.* Financing activities provided $0 and $110,384 in cash during the years ended December 31, 2024 and 2023, respectively. During the year ended December 31, 2023, we received $110,384 in cash from parent company advances.

The Company had a working capital deficit of $518,823 and 10,384 at December 31, 2024 and 2023, respectively.

**Off-Balance Sheet Arrangements**

As of September 30, 2025, and December 31, 2024, there were no off-balance sheet arrangements.

**Contractual Obligations**

To date, we have entered into one significant long-term obligations that require us to make monthly cash payments of $16,667 under the Exousia AI license agreement with Progenicyte.

**Capital Expenditures**

We made no capital expenditures during the three months ended September 30, 2025, and the year ended December 31, 2024. However, should be obtain proceeds in this offering, or otherwise, we expect to make capital expenditures during the next twelve months. We are unable to predict the amount or timing of any such expenditures.

**DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS**

**Directors and Executive Officers**

The following table sets forth certain information concerning our company's executive management.

---

| | | |
|:---|:---|:---|
| **Name** | **Age** | **Position(s)** |
| Michael Sheikh<br>| 55 | Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer and Director<br>|
| Matthew Dwyer | 60 | President |

---

Our directors serve until a successor is elected and qualified. Our officers are elected by the Board of Directors to a term of one (1) year and serves until their successor(s) is duly elected and qualified, or until they are removed from office.

Certain information regarding the backgrounds of each of our officers and directors is set forth below.

**Michael Sheikh, Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer and Director.** Mr. Sheikh assumed his positions with our company in October 2024. Since May 2020, Mr. Sheikh has served as the Chief Communications Officer of Bioxytran, Inc., a clinical-stage, publicly-traded pharmaceutical company (symbol: BIXT) focused on the development, manufacture and commercialization of antiviral treatments and an oxygen carrier compound to treat hypoxia-related conditions. Mr. Sheikh is a US Air Force Academy graduate and pilot. He has a Bachelor of Science degree in Economics and flew KC-135 tankers and worked as a budget officer in the comptroller's squadron while serving. He has prior experience as a broker and research analyst. After the brokerage industry, he was a business development officer for a variety of specialty finance companies. He is a long-time Biotech Consultant for public or private biotech companies with disruptive technologies. Mr. Sheikh is founder of Resources Unlimited, an investor relations firm. Mr. Sheikh devotes no less than 20 hours per week to our company's business. Our company believes that Mr. Sheikh is capable of serving in his positions with our company, without any impairment.

**Matthew Dwyer, President.** Mr. Dwyer assumed his position with our company in April 2025. For more than the last 10 years, Mr. Dwyer has managed his own investments. In addition, from November 2017 to December 2022, Mr. Dwyer served as an officer and director of JFH Digital E-Commerce Corp., formerly Integrated Cannabis Solutions, Inc. (symbol: IGPK), an online commerce company. Mr. Dwyer has also served variously as an officer and director of the following companies: from November 2017 to November 2021, he was President and Director of Global Consortium, Inc., a company active in the cannabis industry in California; from November 2017 to October 2020, he was President and Director of Trans Global Group, Inc., a specialty products company; from April 2004 to April 2017, he was President and Director of Baron Capital Enterprise, Inc., a consulting company and debt financier; From January 2017 to June 2017, he was President and Director of Experience Art and Design, Inc., a development-stage company that was seeking to acquire an active business. Mr. Dwyer devotes no less than 20 hours per week to our company's business. Our company believes that Mr. Dwyer is capable of serving in his position with our company, without any impairment.

**Scientific Advisory Board**

Our Board of Directors has established a Scientific Advisory Board that is to provide non-binding recommendations to our Board of Directors, particularly with respect to scientific matters related to our business. Certain information regarding the backgrounds of each member of our Scientific Advisory Board is set forth below.

*<u>Marvin S. Hausman, M.D</u>*. The Chairman of the Scientific Advisory Board, Marvin S. Hausman, M.D., currently serves as Chief Science Officer of Ludwig Enterprises, Inc., a publicly-traded company (symbol: LUDG) focused on the development of their proprietary mRNA genomic technology, after having served as a Director of Ludwig Enterprises from November 2023 to June 2025, as well as its Chief Executive Officer from September 2023 to August 2024 and as a key consultant from July 2022 to September 2023. In the five years prior to joining Ludwig, Dr. Hausman served as a consultant with various life science companies including Nova Mentis Life Science, Summit Joint Performance and Designer Genomics. Dr. Hausman is an Immunologist and Board-Certified Urological Surgeon with more than 40 years of drug research and development experience with various pharmaceutical companies, including Bristol Myers International, Mead Johnson Pharmaceutical Co., E.R. Squibb, Medco Research, and Axonyx. An accomplished executive with domestic and international experience, Dr. Hausman successfully executed acquisitions of breakthrough medical technology, in conjunction with formation, funding and launch of several corporations. He is a co-founder of Medco Research Inc., a NYSE biopharmaceutical company acquired by King Pharmaceutical Inc, currently a division of Pfizer. He is a founder of Axonyx Inc., acquired by Torrey Pines Therapeutics, Inc. He is a founder of Entia Biosciences, Inc., which designs and develops natural organic antioxidant food-based products to be used as nutritional supplements in humans and animals. He is founder and President of Northwest Medical Research Partners, Inc., a company specializing in the identification and acquisition of breakthrough pharmaceutical and nutraceutical products. Dr. Hausman is a Member of the Board of Governors of New York University School of Medicine Alumni Association. Dr. Hausman received his medical degree from New York University School of Medicine in 1967.

Under our consulting agreement dated June 1, 2025, with Dr. Hausman, for his serving on the Scientific Advisory Board, we are to issue 100,000 shares of our common stock for each year of his service as a member of our Scientific Advisory Board.

In addition, effective May 3, 2025, we entered into a separate consulting agreement with Dr. Hausman, pursuant to which he is to provide consulting services related to product development, product testing and related studies and FDA-related matters. Under this consulting agreement, which has an initial one-year renewable term, we pay Dr. Hausman $10,000 per month. Either our company or Dr. Hausman can terminate this agreement, at any time, upon 30-days' notice.

*<u>Dr. Robert B. Beelman</u>*. Dr. Robert B Beelman is Professor Emeritus of Food Science, Director, Center for Plant and Mushroom Foods for Health, Penn State College of Agricultural Sciences, University Park, Pennsylvania. Dr. Beelman is a distinguished figure in the field of food science. His academic journey began with a BS in Biology from Capital University, followed by an MS and a PhD in Food Technology from The Ohio State University. Dr Beelman works on enhancing the nutritional and medicinal value of cultivated mushrooms, exploring regenerative agricultural practices to improve nutrient density in the food supply, and evaluating ergothioneine as a potential longevity vitamin to mitigate chronic diseases of ageing. He has hypothesized a significant role for soil-borne fungi in increasing ergothioneine levels in crops, which is crucial for human health. His advocacy extends into the realm of regenerative farming, emphasizing the reduction of severe tillage, the use of cover crops, and minimizing synthetic fertilizers and pesticides to boost soil health and, consequently, human health. Dr. Beelman's scholarly contributions not only shed light on the importance of mushrooms and soil health in our diet but also transform our understanding of nutrition and its impact on long-term health outcomes.

Under our consulting agreement dated June 1, 2025, with Dr. Beelman, we are to issue 100,000 shares of our common stock for each year of his service as a member of our Scientific Advisory Board.

*<u>Kyle Ambert, Ph.D</u>*. Dr. Ambert is currently Director of Data Science at Nike, Inc. and has extensive experience in data analytics, machine learning, artificial intelligence and applied analytics. His previous experience includes postings with the National Library of Medicine and Intel Corp. Dr. Ambert holds a PhD in Biomedical Informatics from Oregon Health & Science University. Additionally, Dr. Ambert has interests in the following: applied analytics, multivariate statistics, machine learning and deep learning, text mining and natural language processing, biomedical informatics, distributed computing, information visualization, and behavioral economics. These interests give him skills in technical communication, data analysis, data visualization, analytics, programing, deep learning frameworks, and health and life sciences, all of which we believe are of great value to the Company.

Under our consulting agreement dated June 1, 2025, with Dr. Ambert, we are to issue 100,000 shares of our common stock for each year of his service as a member of our Scientific Advisory Board.

*<u>Zachary T. Bitzer, Ph.D</u>*. Dr. Bitzer is currently Assistant Professor, Department of Public Health Sciences Institute of Energy and the Environment Cancer Institute, Cancer Control Penn State Center for Research on Tobacco and Health. Dr. Bitzer received his Ph.D. in Food Science from Penn State University in 2014 and is currently an Assistant Professor of Public Health Sciences at Penn State University College of Medicine in Hershey, PA. His primary research interest is environmental toxicology, specifically the creation and interaction of toxins within the human body. He also explores the development of novel biomarkers for measuring exposure levels. Currently, his work focuses on toxins and oxidants (e.g., free radicals, aldehydes) generated by tobacco products and e-cigarettes. He is also interested in how dietary phytochemicals can mitigate oxidative stress and inflammation.

Under our consulting agreement dated June 1, 2025, with Dr. Bitzer, we are to issue 100,000 shares of our common stock for each year of his service as a member of our Scientific Advisory Board.

*<u>Anthony Smith, Ph.D</u>*. Dr. Anthony Smith manages Trengove Consulting, a private consulting firm specializing in natural product development, pharmacognosy, regulatory compliance, R&D-to-market strategies and executive learning in biochemistry and neuroscience. He received his Ph.D in Molecular & Cellular Biology from Oregon State University at the Linus Pauling Institute where he specialized in biochemistry, metabolic-aging and nutritional health. In addition to his work with Trengove, Dr. Smith serves as Psilocybin Neuroscience Professor and Lead Instructor with Bodhi Academy in Colorado and Oregon and is a Senior Advisor (Pharmacology) for ITB Solutions (Toronto, ON) and Vetr Animal Health (Grants Pass, OR).

Prior to focusing on teaching, training and consulting, Dr. Smith worked in medical device design & manufacturing, natural product R&D, and biomedical research while serving as a leading international authority on aging, dietary supplementation and cardiovascular disease. He has technical and leadership experience in managing commercial laboratories, drug and medical device manufacturing, and commercial research initiatives. He brings over 20 years of natural product research, quality assurance, product development, manufacturing and regulatory expertise to his projects.

Under our consulting agreement dated June 1, 2025, with Dr. Smith, we are to issue 100,000 shares of our common stock for each year of his service as a member of our Scientific Advisory Board.

**Conflicts of Interest**

At the present time, we do not foresee any direct conflict between our officers and directors, their other business interests and their involvement in our company.

**Corporate Governance**

We do not have a separate Compensation Committee, Audit Committee or Nominating Committee. These functions are conducted by our Board of Directors acting as a whole.

During the year ended December 31, 2024, our Board of Directors, did not hold a meeting, but took all necessary actions by written consent in lieu of a meeting.

**Independence of Board of Directors**

Our Sole Director is not independent, within the meaning of definitions established by the SEC or any self-regulatory organization. We are not currently subject to any law, rule or regulation requiring that all or any portion of our Board of Directors include independent directors.

**Shareholder Communications with Our Board of Directors**

Our company welcomes comments and questions from our shareholders. Shareholders should direct all communications to our Chief Executive Officer, Michael Sheikh, at our executive offices. However, while we appreciate all comments from shareholders, we may not be able to respond individually to all communications. We attempt to address shareholder questions and concerns in our press releases and documents filed with OTC Markets, so that all shareholders have access to information about us at the same time. Mr. Sheikh collects and evaluates all shareholder communications. All communications addressed to our directors and executive officers will be reviewed by those parties, unless the communication is clearly frivolous.

**Code of Ethics**

As of the date of this Offering Circular, our Board of Directors has not adopted a code of ethics with respect to our directors, officers and employees.

**EXECUTIVE COMPENSATION**

**In General**

As of the date of this Offering Circular, there are no annuity, pension or retirement benefits proposed to be paid to officers, directors or employees of our company, pursuant to any presently existing plan provided by, or contributed to, our company.

**Compensation Summary**

The following table summarizes information concerning the compensation awarded, paid to or earned by, our executive officers.

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name and Principal Position** | **Year**<br> **Ended**<br> **12/31** | **Salary**<br> **($)** | **Bonus**<br> **($)** | **Stock**<br> **Awards**<br> **($)** | **Option**<br> **Awards**<br> **($)** | **Non-Equity Incentive Plan Compensation**<br> **($)** | **Non-qualified**<br> **Deferred**<br> **Compensation**<br> **Earnings**<br> **($)** | **All Other Compen-**<br> **sation**<br> **($)** | **Total**<br> **($)** |
| Michael Sheikh<sup>(1)</sup><br> *Chief Executive Officer, Secretary* | 2024<br> 2023 | ---<br> --- | ---<br> --- | --- <br>--- | --- <br>--- | --- <br>--- | --- <br>--- | --- <br>--- | ---<br> --- |
| Matthew Dwyer<sup>(2)</sup><br> *President* | 2024<br> 2023 | ---<br> --- | ---<br> --- | --- <br>--- | --- <br>--- | --- <br>--- | --- <br>--- | --- <br>--- | ---<br> --- |
| Donald Steinberg <br>Former Chief Executive Officer | 2024<br> 2023 | ---<br> --- | ---<br> --- | --- <br>--- | --- <br>--- | --- <br>--- | --- <br>--- | --- <br>--- | ---<br> --- |

---

(1) (2) This person was not an officer of our company, until October 2024. This person was not an officer of our company, until April 2025.

**Outstanding Option Awards**

The following table provides certain information regarding unexercised options to purchase common stock, stock options that have not vested and equity-incentive plan awards outstanding as of the date of this Offering Circular, for each named executive officer.

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Option Awards** | **Option Awards** | **Option Awards** | **Option Awards** | **Option Awards** | **Stock Awards** | **Stock Awards** | **Stock Awards** | **Stock Awards** |
| <br>**Name** | <br>**Number of**<br> **Securities**<br> **Underlying**<br> **Unexercised**<br> **Options (#)**<br> **Exercisable** | <br>**Number of**<br> **Securities**<br> **Underlying**<br> **Unexercised**<br> **Options (#)**<br> **Unexercisable** | <br> **Equity**<br> **Incentive**<br> **Plan**<br> **Awards:**<br> **Number of**<br> **Securities**<br> **Underlying**<br> **Unexercised**<br> **Unearned**<br> **Options (#)** | <br>**Option**<br> **Exercise**<br> **Price ($)** | <br>**Option**<br> **Expiration**<br> **Date** | <br>**Number of**<br> **Shares or**<br> **Units of**<br> **Stock That**<br> **Have Not**<br> **Vested (#)** | <br>**Market**<br> **Value of**<br> **Shares or**<br> **Units of**<br> **Stock That**<br> **Have Not**<br> **Vested ($)** | <br> **Equity**<br> **Incentive**<br> **Plan Awards:**<br> **Number of**<br> **Unearned**<br> **Shares, Units**<br> **or Other**<br> **Rights That**<br> **Have Not**<br> **Vested (#)** | **Equity**<br> **Incentive**<br> **Plan Awards:**<br> **Market or**<br> **Payout Value**<br> **of Unearned**<br> **Shares, Units**<br> **or Other**<br> **Rights That**<br> **Have Not**<br> **Vested ($)** |
| Michael Sheikh | --- | --- | --- | --- | n/a | --- | n/a | --- | --- |
| Matthew Dwyer | --- | --- | --- | --- | n/a | --- | n/a | --- | --- |

---

**Employment Agreements**

We have not entered into employments agreements with either of our executive officers.

**Outstanding Equity Awards**

During the years ended December 31, 2024 and 2023, our Board of Directors made no equity awards and no such award is pending.

**Long-Term Incentive Plans**

We currently have no long-term incentive plans.

**Director Compensation**

Our Sole Director receive no compensation for his serving as a Director of our company.

**SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT**

The table below does not give effect to certain events, as follows:

<u>Series B Convertible Preferred Stock Conversion</u>. The table below does not give effect to the issuance of shares of our common stock upon conversion of the outstanding shares of Series B Convertible Preferred Stock. However, the Series B Convertible Preferred Stock is convertible as follows: each share of the Series B Convertible Preferred Stock shall be convertible into 4,700 shares of our common stock (currently, a total of 47,000,000 shares of our common stock); a holder of shares of Series B Convertible Preferred Stock shall be required to convert all of such holder's shares of Series B Convertible Preferred Stock, should any such holder exercise its rights of conversion; the Series B Convertible Preferred Stock may be converted into shares of our common stock any time after the date that is six months immediately following the effective date of our common stock's uplisting to any tier of the NASDAQ Stock Market (including NASDAQ Capital Market), the NYSE American or any successor to such markets. (See "[Risk Factors](#a_004)—Risks Related to a Purchase of the Offered Shares" and "Dilution—Ownership Dilution").

In light of the caveats stated in the foregoing paragraphs, the following table sets forth, as of the date of this Offering Circular, information regarding beneficial ownership of our common stock by the following: (a) each person, or group of affiliated persons, known by our company to be the beneficial owner of more than five percent of any class of our voting securities; (b) each of our directors; (c) each of the named executive officers; and (d) all directors and executive officers as a group. Beneficial ownership is determined in accordance with the rules of the SEC, based on voting or investment power with respect to the securities. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of common stock underlying convertible instruments, if any, held by that person are deemed to be outstanding if the convertible instrument is exercisable within 60 days of the date hereof.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Share Ownership Before This Offering** | **Share Ownership Before This Offering** | **Share Ownership After This Offering** | **Share Ownership After This Offering** | |
| <br>**Name of Shareholder** | **Number of Shares**<br> **Beneficially**<br> **Owned** | **%**<br> **Beneficially**<br> **Owned(1)** | **Number of Shares**<br> **Beneficially**<br> **Owned** | **%**<br> **Beneficially**<br> **Owned(2)** | <br>**Effective Voting Power** |
| **Common Stock** |  |  |  |  |  |
| Executive Officers and Directors |  |  |  |  |  |
| Michael Sheikh | 0 | 0% | 0 | 0% | See Note 4 |
| Matthew Dwyer | 0 | 0% | 0 | 0% | and Note 9 |
| Officers and directors, as a group (2 persons)**<sup>(3)</sup>** | 0 | 0% | 0 | 0% |  |
| 5% Owners |  |  |  |  |  |
| Donald Steinberg**<sup>(5)</sup>** | 5237511 | 11.74% | 5237511 | 8.78% |  |
| Edward Petrullo**<sup>(6)</sup>** | 2950000 | 6.61% | 2950000 | 4.95% |  |
| Zawi Now LLC**<sup>(7)</sup>** | 3000000 | 6.72% | 3000000 | 5.03% |  |
| **Series A Preferred Stock<sup>(8)</sup>** |  |  |  |  |  |
| Michael Sheikh | 100 | 100% | 100 | 100% |  |
| **Series B Convertible**<br> **Preferred Stock<sup>(9)</sup>** |  |  |  |  |  |
| Ludwig Enterprises, Inc.**<sup>(10)</sup>** | 10000 | 100% | 10000 | 100% |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Based on (a) 44,623,470 shares of common stock outstanding, which includes (1)
41,048,470 issued shares and (2) 3,575,000 unissued Conversion Shares that underlie the unconverted Subject Convertible Notes, (b) 100
shares of Series A Preferred Stock and (c) 10,000 shares of Series B Convertible Preferred Stock, respectively, before this offering.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Based on (a) 59,623,470 shares of common stock outstanding, assuming the sale
of all 14,916,666 of the Remaining Company Offered Shares and the issuance of all 3,575,000 of the unissued Conversion Shares that underlie
the unconverted Subject Convertible Notes (the Remaining Selling Shareholder Offered Shares), (b) 100 shares of Series A Preferred Stock
issued and (c) 10,000 shares of Series B Convertible Preferred Stock, respectively, after this offering

&nbsp;&nbsp;&nbsp;&nbsp;(3) In addition to the share ownership of our officers and directors, each of our Advisory Board
members, Marvin S. Hausman, M.D. and Robert B. Beelman, owns 100,000 shares of our common stock.

&nbsp;&nbsp;&nbsp;&nbsp;(4) Our Chief Executive Officer, Michael Sheikh, owns all of the outstanding shares of Series
A Preferred Stock. Mr. Sheikh will, therefore, be able to control the management and affairs of our company, as well as matters requiring
the approval by our shareholders, including the election of directors, any merger, consolidation or sale of all or substantially all
of our assets, and any other significant corporate transaction. (See Note 8).

&nbsp;&nbsp;&nbsp;&nbsp;(5) Of the shares indicated as owned by Mr. Steinberg, 613,000 shares are owned of record by
Mr. Steinberg, 650,000 shares are owned of record by Blue Ridge Enterprises LLC and 3,974,511 shares are owned by Earth Onyx LLC. Mr.
Steinberg's address is 9772 Silvercreek Court, Estero, Florida 33928.

&nbsp;&nbsp;&nbsp;&nbsp;(6) This shareholder's address is 2524 S. El Paridiso, Unit 33, Mesa, Arizona 85202.

&nbsp;&nbsp;&nbsp;&nbsp;(7) Kimberly Carlson is the owner of this entity; this entity's address is 9772 Silvercreek
Court, Estero, Florida 33928.

&nbsp;&nbsp;&nbsp;&nbsp;(8) The holders of the Series
 A Preferred Stock shall, as a class, have rights in all matters requiring shareholder approval
 to a number of votes equal to two (2) times the sum of: (a) the total number of shares of
 common stock which are issued and outstanding at the time of any election or vote by the
 shareholders; plus (b) the number of votes allocated to shares of Preferred Stock issued
 and outstanding of any other class that shall have voting rights. The Series A Preferred
 Stock possess no rights of conversion

&nbsp;&nbsp;&nbsp;&nbsp;(9) Each share of the Series B Convertible Preferred Stock shall be convertible into 4,700 shares
of our common stock; a holder of shares of Series B Convertible Preferred Stock shall be required to convert all of such holder's
shares of Series B Convertible Preferred Stock, should any such holder exercise its rights of conversion; the Series B Convertible Preferred
Stock may be converted into shares of our common stock any time after the date that is six months immediately following the effective
date of our common stock's uplisting to any tier of the NASDAQ Stock Market (including NASDAQ Capital Market), the NYSE American
or any successor to such markets.

&nbsp;&nbsp;&nbsp;&nbsp;(10) Charles Todd, Jr. is the Chief Executive Officer of this shareholder; this shareholder's
address is 8950 SW 74th Court, Suite 2201-A149, Miami, Florida 33156.

**CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS**

**Change-in-Control Transactions**

Effective October 30, 2024, a change in control of our company occurred. On such date, Earth Onyx, LLC, a company owned by our former Sole Director and Officer, sold 100 shares (the "Control Shares"), or 100% of the outstanding shares, of our Series A Preferred Stock to our current Sole Director and Chief Executive Officer. Mr. Sheikh paid $60,000 in cash and delivered a promissory note (the "Closing Note") to Earth Onyx, LLC in payment of the Control Shares. The Closing Note has a principal amount of $100,000 and is due on the later of 60 days from October 30, 2024, and the date on which Mr. Steinberg shall have delivered ready-to-file federal tax returns for the years ended December 31, 2022 and 2023, of our company. Mr. Sheikh and Earth Onyx, LLC entered into Pledge Agreement, to secure Mr. Sheikh's payment obligations under the Closing Note.

**Acquisition of Exouisia AI**

Effective December 31, 2024, pursuant to a stock purchase agreement with Ludwig Enterprises, Inc. (Ludwig), a publicly-traded company (symbol: LUDG), we acquired 100% of Exousia Ai, Inc., a Wyoming corporation (Exousia AI), and related assets, in consideration of a $100,000 promissory note (the Ludwig Note), the principal and interest of which is due on December 31, 2025, and 10,000 shares of our Series B Convertible Preferred Stock. In conjunction with the issuance of the Ludwig Note, we entered into a pledge agreement with Ludwig Enterprises, to secure our timely payment of the Ludwig Note.

**Stock Exchange Agreement**

On May 22, 2023, our company entered into a stock exchange agreement (the "Exchange Agreement") with Marijuana, Inc., a now-dissolved Florida corporation, the control person of which was Donald Steinberg, our former sole officer and director who was in such positions at the time of the Exchange Agreement. Pursuant to the Stock Exchange Agreement, a company owned by Mr. Steinberg was issued 3,063,000 shares. However, shortly after the consummation of the Exchange Agreement, Mr. Steinberg caused the dissolution of the acquired company. The series of transactions surrounding the Exchange Agreement, which we believe to have been fraudulent, is the basis of a lawsuit filed by us against Mr. Steinberg, wherein we seek the rescission of the Exchange Agreement and the cancellation of all of the shares of common stock issued pursuant thereto. (See "Business – Litigation").

**LEGAL MATTERS**

Certain legal matters with respect to the Offered Shares, the Company Offered Shares and the Selling Shareholder Offered Shares, offered by this Offering Circular will be passed upon by Newlan Law Firm, PLLC.

Prior to the date of this Offering Circular, Newlan Law Firm, PLLC had been the beneficial holder of three of the Subject Convertible Notes in the total principal amount of $97,500. We had issued such Subject Convertible Notes to NLF Support Services, LLC, a Selling Shareholder and a wholly-owned service subsidiary of Newlan Law Firm, PLLC, pursuant to two separate legal services agreements with Newlan Law Firm, PLLC. In September 2025, NLF Support Services, LLC, converted the principal and accrued interest all three of the Subject Convertible Notes into a total of 670,569 Conversion Shares and, subsequently, sold all of such shares for cash at the then-offering price applicable to Selling Shareholders of $0.15 per share, a total amount of $100,585.

Currently, Newlan Law Firm, PLLC is the beneficial holder of one of the unconverted Subject Convertible Notes in the principal amount of $100,000. We issued such Subject Convertible Notes to NLF Support Services, LLC, the Selling Shareholder, a wholly-owned service subsidiary of Newlan Law Firm, PLLC, pursuant to two separate legal services agreements with Newlan Law Firm, PLLC.

After the qualification of this offering by the SEC, the unconverted Subject Convertible Note currently held by Newlan Law Firm, PLLC will, by its terms, be convertible into the Conversion Shares at $0.10 per converted share. Following any such issuances, we intend to file a supplement to this Offering Circular pursuant to Rule 253(g)(2), wherein the exact number of Conversion Shares (which are Selling Shareholder Offered Shares) issued in payment of the Subject Convertible Notes held by Newlan Law Firm, PLLC will be disclosed.

**WHERE YOU CAN FIND MORE INFORMATION**

We have filed an offering statement on Form 1-A with the SEC under the Securities Act with respect to the common stock offered by this Offering Circular. This Offering Circular, which constitutes a part of the offering statement, does not contain all of the information set forth in the offering statement or the exhibits and schedules filed therewith. For further information with respect to us and our common stock, please see the offering statement and the exhibits and schedules filed with the offering statement. Statements contained in this Offering Circular regarding the contents of any contract or any other document that is filed as an exhibit to the offering statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the offering statement. The offering statement, including its exhibits and schedules, may be inspected without charge at the public reference room maintained by the SEC, located at 100 F Street, N.E., Room 1580, Washington, D.C. 20549, and copies of all or any part of the offering statement may be obtained from such offices upon the payment of the fees prescribed by the SEC. Please call the SEC at 1-800-SEC-0330 for further information about the public reference room. The SEC also maintains an Internet website that contains all information regarding companies that file electronically with the SEC. The address of the site is www.sec.gov.

**INDEX TO FINANCIAL STATEMENTS**

---

| | |
|:---|:---|
|  | **<u>Page</u>** |
| <u>Unaudited Financial Statements For the Nine Months Ended September 30, 2025 and 2024</u> | <u>Unaudited Financial Statements For the Nine Months Ended September 30, 2025 and 2024</u> |
| [Consolidated Balance Sheets at September 30, 2025, and December 31, 2024 (unaudited)](#a_019) | F-2 |
| [Consolidated Statements of Operations For the Nine Months Ended September 30, 2025 and 2024 (unaudited)](#a_020) | F-3 |
| [Consolidated Statements of Changes in Stockholders' Equity (Deficit) For the Nine Months Ended September 30, 2025 and 2024 (unaudited)](#a_026) | F-4 |
| [Consolidated Statements of Cash Flows For the Nine Months Ended September 30, 2025 and 2024 (unaudited)](#a_022) | F-5 |
| [Notes to Unaudited Consolidated Financial Statements](#a_023) | F-6 |
| <u>Unaudited Financial Statements For the Years Ended December 31, 2024 and 2023</u> | <u>Unaudited Financial Statements For the Years Ended December 31, 2024 and 2023</u> |
| [Consolidated Balance Sheets at December 31, 2024 and 2023 (unaudited)](#a_024) | F-12 |
| [Consolidated Statements of Operations For the Years Ended December 31, 2024 and 2023 (unaudited)](#a_025) | F-13 |
| [Consolidated Statements of Changes in Stockholders' Equity (Deficit) For the Years Ended December 31, 2024 and 2023 (unaudited)](#a_026)  | F-14 |
| [Consolidated Statements of Cash Flows For the Years Ended December 31, 2024 and 2023 (unaudited)](#a_027) | F-15 |
| [Notes to Unaudited Consolidated Financial Statements](#a_028) | F-16 |

---

**Exouisa Pro, Inc.**

**(formerly Marijuana, Inc. and GRN Holding Corporation)**

**Consolidated Balance Sheets**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | September 30, <br>2025 | December 31, <br>2024 |
| ASSETS |  |  |
| Current Assets: |  |  |
| Cash | $3006 | $100 |
| Prepaid expenses | 10125 |  |
| Total Current Assets | 13131 | 100 |
| Long-Term Assets: |  |  |
| Intangible assets, net | 182413 | 202681 |
| Total Long-Term Assets | 182413 | 202681 |
| Total Assets | $195544 | $202781 |
| LIABILITIES AND STOCKHOLDER DEFICIT |  |  |
| Current Liabilities: |  |  |
| Accounts payable | $211072 | $53319 |
| Other current liabilities | 465708 | 465604 |
| Total Current Liabilities | 676780 | 518923 |
| Total Liabilities | 676780 | 518923 |
| Stockholders' Deficit: |  |  |
| Preferred Series A stock, $0.001 par value, 100 and 100 shares authorized, 100 and 100 issued and outstanding, respectively |  |  |
| Preferred Series B stock, $0.001 par value, 10,000 and 10,000 shares authorized, 10,000 and 10,000 shares issued and outstanding, respectively | 10 | 10 |
| Common stock, $0.001 par value, 25,000,000 and 25,000,000 shares authorized, 40,607,067 and 35,094,567 shares issued and outstanding, respectively | 40607 | 35095 |
| Additional paid-in capital | 12816309 | 12656821 |
| Accumulated deficit | (13338152) | (13008068) |
| Total stockholders' deficit | (481226) | (316142) |
| Total Liabilities and Stockholders' Deficit | $195554 | $202781 |

---

*The accompanying notes are an integral part of these unaudited financial statements.*

 

 

**Exousia Pro, Inc.**

**(formerly Marijuana, Inc. and GRN Holding Corporation)**

**Consolidated Statements of Operations**

**For the Nine Months Ended September 30, 2025 and 2024**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Successor** | **Predecessor** |
|  | For the <br>Nine Months Ended <br>9/30/25 | For the <br>Nine Months Ended <br>9/30/24 |
| REVENUES | $500 | $— |
| Cost of Revenues | 4972 |  |
| Gross Margin | (4472) |  |
| COSTS AND EXPENSES |  |  |
| General and administrative expenses | 379794 | 34529 |
| Total Costs and Expenses | 379794 | 34529 |
| Loss From Operations | (384266) | (34529) |
| OTHER INCOME (EXPENSE) |  |  |
| Fair value of share settled debt | 54182 |  |
| Total Other Income (Expense) | 54182 |  |
| Net income (loss) | $(330084) | $(34529) |
| Basic income (loss) per common share | $0.00 | $(0.00) |
| Fully diluted income (loss) per common share | $0.01 | $(0.00) |
| Basic weighted average common shares outstanding | 39536496 | 100 |
| Fully diluted weighted average common shares outstanding | 42565865 | 100 |

---

*The accompanying notes are an integral part of these unaudited financial statements.*

**Exousia Pro, Inc.**

**(formerly Marijuana, Inc. and GRN Holding Corporation)** 

**Consolidated Statement of Stockholders' Equity (Deficit)**

**For the Nine Months Ended September 30, 2025 and 2024**

**(unaudited)**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Successor** | | | | | | | | | |
|  | Preferred Stock <br>Series A | Preferred Stock <br>Series A | Preferred Stock <br>Series B | Preferred Stock <br>Series B | Common Stock | Common Stock | Additional <br>Paid-In | Accumulated | Total <br>Stockholders' |
|  | Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | Deficit |
| Balance, December 31, 2024 | 100 | $— | 10000 | $10 | 35094567 | $35095 | $12656821 | $(13008068) | $(316142) |
| Common stock issued for cash |  |  |  |  | 5512500 | 5512 | 159488 |  | 165000 |
| Net loss for the nine months ended September 30, 2025 |  |  |  |  |  |  |  | (330084) | (330084) |
| Balance, September 30, 2025 | 100 | $— | 10000 | $10 | 40607067 | $40607 | $12816309 | $(13338152) | $(481226) |

---

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Predecessor** | | | | | | | | | |
|  | Preferred Stock <br>Series A | Preferred Stock <br>Series A | Preferred Stock <br>Series B | Preferred Stock <br>Series B | Common Stock | Common Stock | Additional <br>Paid-In | Accumulated | Total <br>Stockholders' |
|  | Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | Deficit |
| Balance, December 31, 2023 |  | $— |  | $— | 10000 | $10 | $(10) | $(10384) | $(10384) |
| Net loss for the nine months ended September 30, 2024 |  |  |  |  |  |  |  | (66828) | (66828) |
| Balance, September 30, 2024 |  | $— |  | $— | 10000 | $10 | $(10) | $(77212) | $(77212) |

---

*The accompanying notes are an integral part of these unaudited financial statements.*

 

**Exousia Pro, Inc.**

**(formerly Marijuana, Inc. and GRN Holding Corporation)** 

**Consolidated Statements of Cash Flows**

**For the Nine Months Ended September 30, 2025 and 2024**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Succesor** | **Predecessor** |
|  | For the <br>Nine Months Ended <br>9/30/25 | For the <br>Nine Months Ended <br>9/30/24 |
| Cash Flows From Operating Activities: |  |  |
| Net loss | $(330084) | $(66828) |
| Adjustments to reconcile net loss to net cash (used) provided by operating activities: |  |  |
| Amortization of debt discount | 10134 |  |
| Amortization of debt discount | 5178 |  |
| Fair value of share settled debt | (27175) |  |
| Changes in operating assets and liabilities: |  |  |
| Prepaid expenses | (12000) |  |
| Accounts payable | 98545 |  |
| Accrued interest | 42162 |  |
| Net cash used in operating activities | (213240) | (66828) |
| Cash Flows From Financing Activities: |  |  |
| Proceeds from the issuance of convertible notes payable | 50000 | **—** |
| Proceed from the issuance of common stock | 165000 |  |
| Proceeds from the issuance of notes payable | 1146 |  |
| Proceeds from parent company advances |  | 15207 |
| Net cash provided by financing activities | 216146 | 15207 |
| Net change in cash | 2906 | (51621) |
| Cash, beginning of period | 100 | 100000 |
| Cash, end of period | $36628 | $48379 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: |  |  |
| Cash paid for interest | $— | $— |
| Cash paid for taxes | $— | $— |

---

*The accompanying notes are an integral part of these unaudited financial statements.*

**Exousia Pro, Inc.**

**(formerly Marijuana, Inc. and GRN Holding Corporation)**

**Notes to Unaudited Consolidated Financial Statements**

**Nine Months Ended September 30, 2025**

**(unaudited)**

**<br> NOTE 1 - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES**

The financial statements presented are those of Marijuana Inc. and subsidiaries, a Florida corporation (formerly GRN Holding Corporation) (the "Company" or "Successor"). The Company was incorporated in the State of Nevada on April 28, 2010, as Norman Cay Development, Inc. The Company's corporate name changed to Discovery Gold Corp., in July 2012. The Company's corporate name changed to became GRN Holding Corporation, in November 2019. The Company's corporate name changed to Marijuana, Inc., in October 2024. The Company is currently pursuing a change of corporate name in the trading markets to "Exousia Pro, Inc." and obtaining a new trading symbol, but are unable to predict the timing of approval.

On December 31, 2024, pursuant to a Stock Purchase Agreement between the Company and Ludwig Enterprises, Inc., the Company acquired Exousia AI, Inc. ("Exousia AI or the "Predecessor"), incorporated on June 3, 2023 in the state of Wyoming. Exousia AI assets embody a joint venture with a Japanese biotech company to manufacture and deliver mammalian and plant-based exosomes containing nucleic acids, such as DNA and mRNA to tissues and cells.

***Basis of Presentation***

 ****

The unaudited consolidated financial statements and related disclosures have been prepared using the accrual basis of accounting in accordance with Generally Accepted Accounting Principles ("GAAP") of the United States. The Company has elected a calendar year-end.

Marijuana Inc. was designated a "Shell Company" prior to its acquisition of Exousia AI, resulting in Exousia AI being deemed a "Predecessor" company. The accompanying unaudited financial statements and notes for the periods presented prior to the acquisition date of December 31, 2024 are those of the Predecessor. The Company's unaudited consolidated financial statements and notes as of and after the acquisition date of December 31, 2024 are those of the Successor.

***Revenue Recognition Policy***

We recognize revenue in accordance with the provisions of Accounting Series Codification ("ASC") 606, Revenue From Contracts With Customers ("ASC 606"), which provides guidance on the recognition, presentation, and disclosure of revenue in financial statements. ASC 606 outlines the basic criteria that must be met to recognize revenue and provides guidance for disclosure related to revenue recognition policies. In general, the Company recognizes revenue based on the allocation of the transaction price to each performance obligation as each performance obligation in a contract is satisfied.

The Company manufactures and delivers mammalian and plant-based exosomes containing nucleic acids, such as DNA and mRNA to tissues and cells for use on commercial applications such as cosmetics. Revenue recognition for the sale of exosomes are based on the allocation of the transaction price to each performance obligation as each performance obligation in a contract is satisfied, title or access to exosomes are transferred and amounts are due are collected or collectible.

The Company recognized $500 of revenue from the sale and delivery of exosomes during the six months ended June 30, 2025.

 **

***Goodwill and Indefinite-Lived Intangible Assets***

 **

The Company has goodwill and certain indefinite-lived intangible assets that have been recorded in connection with the acquisition of a business. Goodwill and indefinite-lived assets are not amortized but instead are tested for impairment at least annually. Goodwill represents the excess of the purchase price of an acquired business over the estimated fair value of the underlying net tangible and intangible assets acquired. The Company tests goodwill resulting from acquisitions for impairment annually, or whenever events or changes in circumstances indicate an impairment. For purposes of the goodwill impairment test, the Company has determined that it currently operates as a single reporting unit. If it is determined that an impairment has occurred, the Company adjusts the carrying value accordingly and charges the impairment as an operating expense in the period the determination is made. Although the Company believes goodwill is appropriately stated in the consolidated financial statements, changes in strategy or market conditions could significantly impact these judgments and require an adjustment to the recorded balance. There were no impairments during the periods presented.

***Fair Value of Financial Instruments***

ASC 820, *Fair Value Measurements* ("ASC 820") and ASC 825, *Financial Instruments* ("ASC 825"), requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. It establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument's categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. It prioritizes the inputs into three levels that may be used to measure fair value:

Level 1 - Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2 - Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3 - Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The carrying values of cash, as well as accounts payable, accrued interest, deferred revenue and related part payables approximate fair value. Pursuant to ASC 820 and 825, the fair value of cash is determined based on "Level 1" inputs, which consist of quoted prices in active markets for identical assets. A convertible note of the Company is required to be recorded at fair value on a recurring basis. Fair value is determined based on the price that would be received for an asset or paid to transfer a liability in an orderly transaction based on market participants. Factors that the Company considered when estimating the fair value of its convertible notes payable included quoted market prices of the Company's common stock. The level of the convertible notes payable is considered as Level 1.

***New Accounting Pronouncements***

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements. The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

***Basic and Diluted Loss Per Share***

Basic net loss per share is computed on the basis of the weighted average number of common shares outstanding during each year. Diluted net loss per share is computed similar to basic net loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company uses the "if-converted" method for calculating the earnings per share impact of outstanding convertible debentures, whereby the securities are assumed converted, related debt discount amortization and fair value adjustments are added back to net income (loss) and an earnings per incremental share is computed. Options, warrants and their equivalents are included in EPS calculations through the treasury stock method. In periods where losses are reported, the weighted-average number of common stock outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive.

***Convertible Debt Instruments***

 ****

The Company follows ASC 480-10, Distinguishing Liabilities from Equity in its evaluation of the accounting for a hybrid instrument. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception; (b) variations in something other than the fair value of the issuer's equity shares; or (c) variations inversely related to changes in the fair value of the issuer's equity shares. Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with remeasurements reported in change on fair value expense in the accompanying Statements of Operations.

**NOTE 2 - RELATED PARTY TRANSACTIONS**

The Company's Sole Director, Michael Sheikh, made a $100 advance to the Company during December 2024 to open a bank account. The advance is due on demand and bears no interest. The balance was $100 as of June 30, 2025, and December 31, 2024, respectively.

**NOTE 3 - ALLIANCE AGREEMENT** 

On January 20, 2025, the Company executed an Alliance Agreement with Progenicyte Japan CO., LTD, which is embodied in the Company's subsidiary, Exousia Pro, Inc. Through Exousia Pro, the Company now holds the worldwide license in perpetuity for Progenicyte's patent covering the loading of Exosomes. Exousia Pro is required to pay Progenictye the sum of $16,667 a month and issue it 30% of Exousia Pro's equity as payment for the exclusive worldwide license. As of September 30, 2025, no equity payment has been made.

**NOTE 4 - NOTES AND CONVERTIBLE NOTES PAYABLE**

**<u>Convertible Notes Payable</u>**

In accordance with ASC 480, *Distinguishing Liabilities from Equity*, the Company evaluates its hybrid convertible debt instruments with unconditional obligations allowing settlement by issuing a variable number of its equity shares to determine proper classification and accounting. The Company classifies the hybrid convertible debt instruments as a liability upon being convertible at the option of the holders due to the conversion terms being based on fixed monetary amounts known at inception, in this case, settlement with a variable number of the Company's equity shares. As such, conversion options are carried as a liability at fair value at each balance sheet date with a re-measurement reported as a change in fair value of share-settled debt in other (income) expense in the accompanying condensed statements of operations.

 ****

During March 2025, the Company issued and delivered a $65,000 convertible note. The convertible note has a $15,000 face discount, bears interest at 8% per annum, is due October 30, 2025, and is convertible into shares of Company common stock at any time at a 25% discount to the then-trading price; provided, however, that the holder of the convertible note may not convert into a number of shares of common stock that would cause the holder to exceed 9.99% ownership of Company common stock. In addition, the convertible note carries rights of qualification and rights of registration. Should the Consulting Note be converted into shares of common stock of the Company that are the subject of an Offering Statement on Form 1-A (the "Reg A") or a Registration Statement on Form S-1 (the "S-1"), the conversion price would be equal to the offering price of the shares offered under the Reg A or the S-1, as the case may be. The balance of the convertible note was $65,000, the fair value of the conversion option was $8,564 and the unamortized debt discount was $11,822 at September 30, 2025. Amortization of face value debt discount is being done over the life of the convertible note and was $5,178 for the nine months ended Septmber 30, 2025.

 **

***Consulting Agreement***

 **

Pursuant to a consulting agreement, the Company issued and delivered a $200,000 convertible note to Donald Steinberg. The convertible note bears interest at 8% per annum, is due October 30, 2025, and is convertible into shares of Company common stock at any time at a 25% discount to the then-trading price; provided, however, that the holder of the convertible note may not convert into a number of shares of common stock that would cause the holder to exceed 9.99% ownership of Company common stock. In addition, the convertible note carries rights of qualification and rights of registration. Should the Consulting Note be converted into shares of common stock of the Company that are the subject of an Offering Statement on Form 1-A (the "Reg A") or a Registration Statement on Form S-1 (the "S-1"), the conversion price would be equal to the offering price of the shares offered under the Reg A or the S-1, as the case may be. The balance of the consulting agreement convertible note was $200,000 and $200,000 at September 30, 2025 and December 31, 2024, respectively. The fair value of the conversion option was $27,007 and $62,746 at September 30, 2025 and December 31, 2024, respectively.

During the nine months ended September 30, 2025, the Company recognized a $27,175 gain in fair value as a result of the conversion options on convertible debt.

Effective September 30, 2025, the Company cancelled the consulting agreement and the convertible note with Donald Steinberg, due to non-performance.

**<u>Notes Payable</u>**

***Legal Services***

Pursuant to a legal services agreement, the Company issued and delivered a $25,000 convertible note to NLF Support Services, LLC. The convertible note bears interest at 8% per annum, is due November 18, 2025 and automatically converts into shares of the Company's common stock on the date on which the Company's offering circular with respect to the offering of Common Stock pursuant to Regulation A is first "qualified" by the SEC and any other relevant state or other jurisdictional qualification. On the qualification date, the outstanding balance, including accrued interest at the rate equal to the price of the Regulation A offering. The balance of the legal services Note was $25,000 and $25,000 at September 30, 2025 and December 31, 2024, respectively.

***Acquisition***

On December 31, 2024, the Company and Ludwig Enterprises, Inc. (the "LUDG") entered into a Stock Purchase Agreement, pursuant to which the Company issued a $100,000 principal amount promissory note (the "Purchaser Note"). The Purchaser Note bears interest at eight percent (8%) per annum, with principal and accrued interest due December 31, 2025 and is secured by all of the asset of Exousia AI. During the year ended December 31, 2024, a third party company lent the Company a total of $24,551 in advances to pay corporate expenses. The balance of the Purchaser Note was $100,000 and $100,000 at September 30, 2025 and December 31, 2024, respectively.

***Advances Payable***

During the year ended December 31, 2024, a third party company lent the Company a total of $24,551 in advances to pay corporate expenses. The amounts are due on demand, unsecured and accrue interest at 8% per annum. The balance of the advances was $24,551 and $24,551 at June 30, 2025 and December 31, 2024, respectively.

During the nine months ended September 30, 2025, a third-party company lent the Company a total of $9,903 in advances to pay corporate expenses and repaid $8,756. The amounts are due on demand, unsecured and accrue interest at 8% per annum. The balance of the advances was $1,147 and $9,299 at September 30, 2025 and December 31, 2024, respectively.

T

**NOTE 5 - STOCKHOLDERS' EQUITY**

**<u>Common Stock</u>**

During the nine months ended September 30, 2025, the Company sold 5,512,500 shares of common stock for $165,000 in cash, or an average of $0.03 per share.

**<u>Preferred Stock</u>**

The Company is authorized to issue 10,000,000 shares of Preferred Stock, par value $0.001 per share, of which 100 shares have been designated Series A Preferred Stock and of which 10,000 shares have been designated Series B

***Series A Preferred Stock***

The holders of the Series A Preferred Stock shall be entitled to cast that number of votes equal to the total number of votes cast, plus one share to equal a majority of shares eligible to vote on any matter, or an always super majority voting right, in all matters requiring shareholder approval.

In April 2022, the Company issued Donald Steinberg, as the newly appointed CEO of the Company, 100 shares of Series A Preferred Stock as compensation. In June 2022, Mr. Steinberg transferred the 100 Shares of Series A Preferred Stock to Earth Onyx LLC, an entity controlled by him. On October 30, 2024, Mr. Steinberg sold the 100 shares of Series A Preferred Stock to Michael Sheikh.

***Series B Convertible Preferred Stock***

Each share of Series B Convertible Preferred Stock shall be entitled to one (1) vote in all matters requiring shareholder approval. Dividends: The Series B Convertible Preferred Stock shall be treated pari passu with the Company's common stock, except that the dividend on each share of Series B Convertible Preferred Stock shall be equal to the amount of the dividend declared and paid on each share of the Common Stock multiplied by the Conversion Rate. Liquidation: Upon any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, payments to the holders of Series B Convertible Preferred Stock shall be treated pari passu with the Common Stock, except that the payment on each share of Series B Convertible Preferred Stock shall be equal to the amount of the payment on each share of the Common Stock multiplied by the Conversion Rate. Conversion: Each share of the Series B Convertible Preferred Stock shall be convertible into Four Thousand Seven Hundred (4,700) shares of the Common Stock; a holder of shares of Series B Convertible Preferred Stock shall be required to convert all of such holder's shares of Series B Convertible Preferred Stock, should any such holder exercise his, her or its rights of conversion; the Series B Convertible Preferred Stock may be converted into shares of the Common Stock any time after the date that is six months immediately following the effective date of the Common Stock's uplisting to any tier of the NASDAQ Stock Market (including NASDAQ Capital Market), the NYSE American or any successor to such markets.

In December 2024, the Company issued 10,000 shares of Series B Convertible Preferred Stock to Ludwig Enterprises, Inc., pursuant to a Stock Purchase Agreement.

**NOTE 6 - LEASE**

On January 15, 2025, the Company executed a one-year lease agreement with Wellspring USA for lab space located in Orlando, Florida. The lease provides for renewals annually at the option of the Company. The leased premises is comprised of 1,000 square feet and the monthly rental payment is $2,161.

**NOTE 7 - GOING CONCERN**

The Company's consolidated financial statements are prepared using Generally Accepted Accounting Principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has recently accumulated losses since its inception and has had negative cash flows from operations, which raise substantial doubt about its ability to continue as a going concern. Management's plans with respect to alleviating the adverse financial conditions that caused management to express substantial doubt about the Company's ability to continue as a going concern are as follows:

The ability to continue the Company's operations depends on its ability to generate and grow revenue and results of operations as well as our ability to access capital markets when necessary to accomplish strategic objectives. The Company expects to continue to incur losses for the immediate future and will need additional equity or debt financing until the Company can achieve profitability and positive cash flows from operating activities. The Company's future capital requirements for operations will depend on many factors, including the ability to generate revenues and obtain capital.

There can be no assurance that The Company will be able to achieve its business plans, raise any more required capital or secure the financing necessary to achieve its current operating plan. The ability of The Company to continue as a going concern is dependent upon its ability to successfully accomplish the plan described in the preceding paragraph and eventually attain profitable operations. The accompanying unaudited consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

**NOTE 8 - LITIGATION**

In June 2025, the Company filed a lawsuit against its former Sole Officer and Director, Donald Steinberg, styled Exousia Pro, Inc., a Florida corporation, formerly known as Marijuana, Inc. and as GRN Holding Corporation vs. Donald Steinberg and Securities Transfer Corporation, a nominal defendant, in the Circuit Court of the Court of the Twentieth Judicial District in and for Lee County, Florida. In the lawsuit, the Company seeks the cancellation of all shares issued by our company pursuant to a stock exchange agreement (the "Exchange Agreement") with Marijuana, Inc., a now-dissolved Florida corporation, the control person of which was Donald Steinberg, the Company's former sole officer and director who was in such positions at the time of the Exchange Agreement. Pursuant to the Stock Exchange Agreement, a company owned by Mr. Steinberg was issued 3,063,000 shares. However, shortly after the consummation of the Exchange Agreement, Mr. Steinberg caused the dissolution of the acquired company. The series of transactions surrounding the Exchange Agreement, which we believe to have been fraudulent, is the basis of a lawsuit filed by us against Mr. Steinberg, wherein we seek the rescission of the Exchange Agreement and the cancellation of all of the 15,500,000 shares of common stock issued pursuant thereto. Although no prediction can be made regarding the outcome of this lawsuit, the Company is confident that it will receive a favorable outcome.

In July 2025, Mr. Steinberg filed a lawsuit against the Company styled Donald Steinberg, Plaintiff v. Michael Sheikh, an individual, and Exousia Pro, Inc., a Florida corporation, in the Circuit Court of the Court of the Twentieth Judicial District in and for Lee County, Florida. In this lawsuit, Mr. Steinberg claims a breach of promissory note. The Company has answered and filed a counterclaim and is seeking a Temporary Restraining Order, requesting that the transfer agent place a hold on any shares (15,500,000) issued as part of the fraudulent transaction conducted by Mr. Steinberg. Although no prediction can be made regarding the outcome of this lawsuit, the Company is confident that it will receive a favorable outcome.

**NOTE 9 - SUBSEQUENT EVENTS**

**Conversions of Notes**

In October 2025, the Company issued a total of 670,569 shares of its common stock in payment of three separate convertible promissory notes (a total of $100,585 in principal and interest).

**Plan and Agreement of Reorganization**

On November 11, 2025, pursuant to a Plan and Agreement of Reorganization (the "Reorganization Agreement"), L A M Y, a Wyoming corporation ("LMMY"), acquired the Company's 70%-owned subsidiary, Exousia Ai, Inc., a Florida corporation ("Exousia Ai"), in exchange for shares of LMMY common stock. Following the closing of the Reorganization Agreement, the Company holds 41,223,000 shares, or approximately 51% (as measured after the transaction), of LMMY common stock. The Company's Chief Executive Officer, Matthew Dwyer, serves as LMMY's sole officer and director.

The transaction with LMMY was pursued and consummated by the Company, after the Company's Board of Directors had determined, after investigating the LMMY opportunity, that the best interests of the Company and its shareholders would be best served by acquiring a controlling interest in LMMY, in exchange for its ownership in Exousia Ai.

Management has evaluated subsequent events through November 19, 2025.

**Exousia Pro, Inc.**

**(formerly Marijuana, Inc. and GRN Holding Corporation)**

**Consolidated Balance Sheets**

**(unaudited)**

---

| | | |
|:---|:---|:---|
| | **Successor** | **Predecessor** |
| <br>ASSETS | **December 31, 2024** | **December 31, 2023** |
| &nbsp;&nbsp;Current Assets: |  |  |
| &nbsp;&nbsp;&nbsp;Cash | $100 | $100000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets | 100 | 100000 |
| &nbsp;&nbsp;Long-Term Assets: |  |  |
| &nbsp;&nbsp;&nbsp;Intangible assets | 202681 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Long-Term Assets | 202681 |  |
| &nbsp;&nbsp;Total Assets | $202781 | $100000 |
| &nbsp;&nbsp;LIABILITIES AND STOCKHOLDER DEFICIT |  |  |
| &nbsp;&nbsp;Current Liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $53319 | $— |
| &nbsp;&nbsp;&nbsp;Accrued interest payable | 3207 |  |
| &nbsp;&nbsp;&nbsp;Accrued product deliverable | 50000 |  |
| &nbsp;&nbsp;&nbsp;Convertible notes payable | 287746 |  |
| &nbsp;&nbsp;&nbsp;Notes payable | 124551 |  |
| &nbsp;&nbsp;&nbsp;Notes payable, related party | 100 |  |
| &nbsp;&nbsp;&nbsp;Due to parent |  | 110384 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Current Liabilities | 518923 | 110384 |
| &nbsp;&nbsp;Total Liabilities | 518923 | 110384 |
| &nbsp;&nbsp;Stockholders' Deficit: |  |  |
| &nbsp;&nbsp;&nbsp;Preferred Series A stock, $0.001 par value, 100 and 100 shares authorized, 100 and 100 issued and outstanding, respectively |  |  |
| &nbsp;&nbsp;&nbsp;Preferred Series B stock, $0.001 par value, 10,000 and 10,000 shares authorized, 10,000 and 0 shares issued and outstanding, respectively | 10 |  |
| &nbsp;&nbsp;&nbsp;Common stock, $0.001 par value, 750,000,000 and 750,000,000 shares authorized, 35,094,567 and 100 shares issued and outstanding, respectively | 35095 | 10 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 126568217 | (10) |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (13008068) | (10384) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' deficit | (316142) | (10384) |
| &nbsp;&nbsp;Total Liabilities and Stockholders' Deficit | $202781 | $100000 |

---

*The accompanying notes are an integral part of these unaudited financial statements.*

**Exousia Pro, Inc.**

**(formerly Marijuana, Inc. and GRN Holding Corporation)**

**Consolidated Statements of Operations**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Predecessor** | **Predecessor** |
|  | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|  | **2024** | **2023** |
| REVENUES | $12830 | $— |
| &nbsp;&nbsp;COSTS AND EXPENSES |  |  |
| &nbsp;&nbsp;&nbsp;Operating expenses | 30118 |  |
| &nbsp;&nbsp;&nbsp;Consulting and professional fees | 9650 |  |
| &nbsp;&nbsp;&nbsp;General and administrative | 14061 | 384 |
| &nbsp;&nbsp;&nbsp;Research and development | 123002 | 10000 |
| &nbsp;&nbsp;&nbsp;Total Costs and Expenses | 176831 | 10384 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss From Operations | (164001) | (10384) |
| &nbsp;&nbsp;Loss before income taxes | (164001) | (10384) |
| &nbsp;&nbsp;Provision for income taxes |  |  |
| &nbsp;&nbsp;Net loss | (164001) | (10384) |
| &nbsp;&nbsp;Basic and fully diluted loss per common share | $(1640.01) | $(103.84) |
| &nbsp;&nbsp;Basic weighted average common shares outstanding | 100 | 100 |

---

 

*The accompanying notes are an integral part of these unaudited financial statements.*

 

 

**Exousia Pro, Inc.**

**(formerly Marijuana, Inc. and GRN Holding Corporation)**

**Consolidated Statement of Changes in Stockholders' Equity**

**For the Years Ended December 31, 2024, and April 30, 2024**

**(unaudited)**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Preferred Stock Series A** | **Preferred Stock Series A** | **Preferred Stock Series B** | **Preferred Stock Series B** | **Common Stock** | **Common Stock** | **Additional Paid-In Capital** | **Accumulated Deficit** | **Total**<br> **Stockholders' Deficit**  |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** |  |  |  |
| Predecessor |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Balance at inception June 6, 2023 |  | $— |  | $— |  | $— | $— | $— | $— |
| &nbsp;&nbsp;Common stock issued for incorporation |  |  |  |  | 10000 | 10 | (10) |  |  |
| &nbsp;&nbsp;Net loss for the period ended December 31, 2023 |  |  |  |  |  |  |  | (10384) | (10384) |
| &nbsp;&nbsp;Balance, December 31, 2023 |  | $— |  | $— | 10000 | $10 | $(10) | $(10384) | $(10384) |
| &nbsp;&nbsp;Successor |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Balance, December 31, 2023 | 100 |  |  |  | 35094567 | 35095 | 12500081 | (12687602) | (152426) |
| &nbsp;&nbsp;Payment of accounts payable by related party contributed to capital |  |  |  |  |  |  | 54069 |  | 54069 |
| &nbsp;&nbsp;Preferred stock series B issued for purchase of Exousia AI |  |  | 10000 | 10 |  |  | 102671 |  | 102681 |
| &nbsp;&nbsp;Net loss for the year ended December 31, 2024<br> (Predecessor) |  |  |  |  |  |  |  | (320466) | (320466) |
| &nbsp;&nbsp;Balance , December 31, 2024 | 100 | $— | 10000 | $10 | 35094567 | $35095 | $12656821 | $(13008068) | $(316142) |

---

*The accompanying notes are an integral part of these unaudited financial statements.*

**Exousia Pro, Inc.**

**(formerly Marijuana, Inc. and GRN Holding Corporation)**

**Consolidated Statements of Cash Flows**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Predecessor** | **Predecessor** |
|  | **For the Years Ended <br> December 31,** | **For the Years Ended <br> December 31,** |
|  | **2024** | **2023** |
| &nbsp;&nbsp;Cash Flows From Operating Activities: |  |  |
| &nbsp;&nbsp;&nbsp;Net loss | $(164002) | $(10384) |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net loss to net |  |  |
| &nbsp;&nbsp;&nbsp; cash (used) provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | 14002 |  |
| &nbsp;&nbsp;&nbsp;Accrued product deliverable | 50000 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities | (100000) | (10384) |
| &nbsp;&nbsp;Cash Flows From Financing Activities: |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from parent company advances |  | 110384 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities |  | 110384 |
| &nbsp;&nbsp;Net change in cash | (100000) | 100000 |
| &nbsp;&nbsp;Cash, beginning of period | 100000 |  |
| &nbsp;&nbsp;Cash, end of period | $— | $100000 |
| &nbsp;&nbsp;SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: |  |  |
| &nbsp;&nbsp;&nbsp;Cash paid for interest | $— | $— |
| &nbsp;&nbsp;&nbsp;Cash paid for taxes | $— | $— |
| &nbsp;&nbsp;NON-CASH INVESTING AND FINANCING ACTIVITIES: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Debt paid by officer and contributed to capital | $71067 | $— |

---

*The accompanying notes are an integral part of these unaudited financial statements.*

**Exousia Pro, Inc.**

**(formerly Marijuana, Inc. and GRN Holding Corporation)**

**Notes to Unaudited Financial Statements**

**Years Ended December 31, 2024, and 2023**

**<br> NOTE 1 - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES**

The financial statements presented are those of Exousia Pro, Inc., a Florida corporation (formerly Marijuana, Inc. and GRN Holding Corporation) and subsidiaries (the "Company" or "Successor"). The Company was incorporated in the State of Nevada on April 28, 2010, as Norman Cay Development, Inc. The Company's corporate name changed to Discovery Gold Corp., in July 2012. The Company's corporate name changed to became GRN Holding Corporation, in November 2019. The Company's corporate name changed to Marijuana, Inc., in October 2024. The Company's corporate name changed to Exousia Pro, Inc., in April 2025.

Effective October 30, 2024, a change in control of the Company occurred. On such date, Earth Onyx, LLC (Donald Steinberg) sold 100 shares, or 100% of the outstanding shares, of the Company's Series A Preferred Stock to Michael Sheikh. In connection with the change in control, Donald Steinberg resigned as the Sole Director and Michael Sheikh was appointed as the new Sole Director. Michael Sheikh now serves as the Chief Executive Officer and Secretary of the Company.

On December 31, 2024, pursuant to a Stock Purchase Agreement between the Company and Ludwig Enterprises, Inc., the Company acquired Exousia AI, Inc. ("Exousia AI" or the "Predecessor"), incorporated on June 3, 2023 in the state of Wyoming. Exousia AI assets embody a joint venture with a Japanese biotech company to manufacture and deliver mammalian and plant-based exosomes containing nucleic acids, such as DNA and mRNA to tissues and cells. See Note 3 – Acquisitions.

***Basis of Presentation***

 ****

The unaudited consolidated financial statements and related disclosures have been prepared using the accrual basis of accounting in accordance with Generally Accepted Accounting Principles ("GAAP") of the United States. The Company has elected a calendar year-end.

The Company was designated a "Shell Company" prior to its acquisition of Exousia AI, resulting in Exousia AI being deemed a "Predecessor" company. The accompanying unaudited financial statements and notes for the periods presented prior to the acquisition date of December 31, 2024, are those of the Predecessor. The Company's unaudited consolidated financial statements and notes as of and after the acquisition date of December 31, 2024, are those of the Successor.

***Cash Equivalents***

The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.

***Use of Estimates***

The preparation of unaudited consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 **

***Goodwill and Indefinite-Lived Intangible Assets***

 **

The Company has goodwill and certain indefinite-lived intangible assets that have been recorded in connection with the acquisition of a business. Goodwill and indefinite-lived assets are not amortized, but instead are tested for impairment at least annually. Goodwill represents the excess of the purchase price of an acquired business over the estimated fair value of the underlying net tangible and intangible assets acquired. The Company tests goodwill resulting from acquisitions for impairment annually, or whenever events or changes in circumstances indicate an impairment. For purposes of the goodwill impairment test, the Company has determined that it currently operates as a single reporting unit. If it is determined that an impairment has occurred, the Company adjusts the carrying value accordingly, and charges the impairment as an operating expense in the period the determination is made. Although the Company believes goodwill is appropriately stated in the consolidated financial statements, changes in strategy or market conditions could significantly impact these judgments and require an adjustment to the recorded balance. There were no impairments during the periods presented.

***Fair Value of Financial Instruments***

ASC 820, *Fair Value Measurements* ("ASC 820") and ASC 825, *Financial Instruments* ("ASC 825"), requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. It establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument's categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. It prioritizes the inputs into three levels that may be used to measure fair value:

Level 1 - Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2 - Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3 - Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The carrying values of cash, as well as accounts payable, accrued interest, deferred revenue and related part payables approximate fair value. Pursuant to ASC 820 and 825, the fair value of cash is determined based on "Level 1" inputs, which consist of quoted prices in active markets for identical assets. A convertible note of the Company is required to be recorded at fair value on a recurring basis. Fair value is determined based on the price that would be received for an asset or paid to transfer a liability in an orderly transaction based on market participants. Factors that the Company considered when estimating the fair value of its convertible notes payable included quoted market prices of the Company's common stock. The level of the convertible notes payable is considered as Level 1.

The following table presents the Company's liabilities that are measured at fair value on a recurring basis, consistent with the fair value hierarchy provisions.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  **<u>December 31, 2024</u>** |  **<u>December 31, 2024</u>** |  **<u>December 31, 2024</u>** |  **<u>December 31, 2024</u>** |  **<u>December 31, 2024</u>** |
|  | **Quoted Prices in Active Markets for Identical Liabilities** | **Significant Other Observable Inputs** | **Significant Unobservable Inputs** |  |
|  | **(Level 1)** | **(Level 2)** | **(Level 3)** | **Total** |
| Liabilities: |  |  |  |  |
| Convertible notes | $62746 | $— | $— | $62746 |
| Total | $62746 | $— | $— | $62746 |

---

***New Accounting Pronouncements***

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements. The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Series Update ("ASU") No. 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures*. ASU 2023-07 improves reportable segment disclosure requirements, primarily through requiring enhanced disclosures about significant segment expenses. ASU 2023-07 also requires disclosure of incremental segment information on an annual and interim basis for all public entities. ASU 2023-07 was effective January 1, 2024 for The Company. The adoption of ASU 2023-07 did not have a significant impact on The Company's consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures* (ASU "2023-09"). ASU 2023-09 address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The amendments require that public business entities provide on an annual basis to (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. ASU 2023-09 also requires all entities disclose on an annual basis the amount of income taxes paid disaggregated by federal, state and foreign and disaggregated by individual jurisdictions for amounts greater than 5% of income taxes paid. ASU 2023-09 is effective for the Company for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years. The Company is currently evaluating the impact the adoption of the standard will have on its consolidated financial statements.

In November 2024, the FASB issued ASU 2024-04, *Debt—Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments* ("ASU 2024-04"). ASU 2024-04 clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. ASU 2024-04 is effective for the Company for fiscal years beginning after December 15, 2025, including interim periods within those fiscal years. The Company is currently evaluating the impact the adoption of the standard will have on its consolidated financial position and results of operations.

Other accounting standards that have been issued by the FASB or other standards-setting bodies are not currently expected to have a material effect on The Company's consolidated financial position, results of operations or cash flows.

***Basic and Diluted Loss Per Share***

The Company presents basic earnings per share (EPS) on the face of the statements of operation. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period including convertible debt, stock options, and warrants, using the treasury stock method, and convertible debt instrument, using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. In periods where losses are reported, the weighted-average number of common stock outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive.

The calculation of basic and diluted net loss per share is as follows:

---

| | | |
|:---|:---|:---|
|  | **For the Years Ended** <br> **December 31,** | **For the Years Ended** <br> **December 31,** |
|  | **2024** | **2023** |
| &nbsp;&nbsp;Basic and Diluted Loss Per Share: |  |  |
| &nbsp;&nbsp;Numerator: |  |  |
| &nbsp;&nbsp;Net loss | $(164001) | $(10384) |
| &nbsp;&nbsp;Denominator: |  |  |
| &nbsp;&nbsp;Weighted average common shares outstanding | 100 | 100 |
| &nbsp;&nbsp;Basic and Diluted net loss per share | $(1640.01) | $(103.84) |

---

***Income Taxes***

The Company records income taxes under the asset and liability method, whereby deferred tax assets and liabilities are recognized based on the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and attributable to operating loss and tax credit carryforwards. Accounting standards regarding income taxes requires a reduction of the carrying amounts of deferred tax assets by a valuation allowance, if based on the available evidence, it is more likely than not that such assets will not be realized. Accordingly, the need to establish valuation allowances for deferred tax assets is assessed at each reporting period based on a "more likely than not" realization threshold. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carryforward periods, the Company's experience with operating loss and tax credit carryforwards not expiring unused, and tax planning alternatives.

Significant judgment is required in evaluating the Company's tax positions and determining its provision for income taxes. During the ordinary course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. Accounting standards regarding uncertainty in income taxes provides a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than 50% likely, based solely on the technical merits, of being sustained on examinations. The Company considers many factors when evaluating and estimating its tax positions and tax benefits, which may require periodic adjustments and which may not accurately anticipate actual outcomes.

***Convertible Debt Instruments***

 ****

The Company follows ASC 480-10, Distinguishing Liabilities from Equity in its evaluation of the accounting for a hybrid instrument. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception; (b) variations in something other than the fair value of the issuer's equity shares; or (c) variations inversely related to changes in the fair value of the issuer's equity shares. Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with remeasurements reported in change on fair value expense in the accompanying Statements of Operations.

**NOTE 2 - RELATED PARTY TRANSACTIONS**

The Company's Sole Director, Michael Sheikh, made a $100 advance to the Company during December 2024 to open a bank account. The advance is due on demand and bears no interest. The balance was $100 as of December 31, 2024.

During October 2024, in conjunction with a change in control transaction, the Company's former chief executive paid $54,069 in accounts payable and contributed the amount to capital.

**NOTE 3 - ACQUISITIONS, JOINT VENTURES AND SHARE EXCHANGE AGREEMENTS**

***Exousia AI***

On December 31, 2024, the Company and Ludwig Enterprises, Inc. (the "LUDG") entered into a Stock Purchase Agreement, as amended (the "Exousia SPA"), pursuant to which the Company purchased 100% ownership of a subsidiary of LUDG, Exousia AI in exchange for delivery of (a) 10,000 shares of Series B Convertible Preferred Stock (the "Series B Shares") and (b) a $100,000 principal amount promissory note (the "Purchaser Note"). The Purchaser Note bears interest at eight percent (8%) per annum, with principal and accrued interest due December 31, 2025. As further consideration for the Company's entering into the Exousia SPA, LUDG agreed to a lock-up of the Series B Shares for the period from December 31, 2024, and expiring on the date that is six months immediately following the effective date of the Company's common stock's uplisting to any tier of the NASDAQ Stock Market (including NASDAQ Capital Market), the NYSE American or any successor to such markets.

In connection with the Exousia SPA, the Company and LUDG entered into a Pledge Agreement (the "Pledge Agreement"), to secure the Company's payment obligations under the Purchaser Note.

The acquisition did not result in a change in voting control, nor are any members of LUDG management or ownership part of Company management or board of directors going forward. As of the acquisition date, LUDG has voting rights on all matters requiring shareholder approval based on one vote per share of Series B, or 10,000 votes. In accordance with the terms of the Convertible Preferred Stock, each share is convertible into 4,700 shares of the Company's common stock any time after six months following the effective date of the Company's common stock uplisting to any tier of the NASDAQ Stock Market. As such, future conversions may result in a change of control.

The Stock Purchase Agreement was accounted for as an acquisition of Exousia AI by Marijuana Inc., whereby Marijuana Inc. was determined to be the legal and accounting acquirer. However, the Company was deemed a "Shell Company" prior to the acquisition, with no substantial operations and continuing operations being those of Exousia AI and was deemed to be the Successor entity, with Exousia AI deemed the Predecessor (See Note 1).

The following table summarized the consideration transferred for the acquisition of Exousia AI:

---

| | |
|:---|:---|
| &nbsp;&nbsp;Preferred stock series B | $102681 |
| &nbsp;&nbsp;Secured promissory notes | 100000 |
| &nbsp;&nbsp;Liabilities assumed | 103319 |
| &nbsp;&nbsp;Acquisition consideration | $306000 |

---

The following table summarized the acquisition date fair value of the purchase price assigned to each asset acquired and liability of Exousia AI assumed:

---

| | |
|:---|:---|
| ASSETS ACQUIRED |  |
| &nbsp;&nbsp;Fair value of intangible assets acquired | $202681 |
| &nbsp;&nbsp;LIABILITIES ASSUMED |  |
| &nbsp;&nbsp;Accounts payable | 53319 |
| &nbsp;&nbsp;Due to joint venture partner | 50000 |
| &nbsp;&nbsp;Total liabilities Assumed | $103319 |

---

LUDG valued the purchase price of the shares of the Series B Convertible Preferred Stock based on cost of the main asset purchased by the Company in the absence of supported and reasonable fair market value approaches. The valuation yielded a valuation of approximately $202,681.

Intangible assets of Exousia AI include the worldwide license for exosome technology, which covers growing and extracting plant-based exosomes and loading them for use as a drug delivery system. The loading process can also be applied to human-derived exosomes. The acquisition includes an ongoing study on using Exosomes to treat Glioblastoma.

The balance on the Purchaser Note was $100,000 at December 31, 2024.

***KRTL International Corporation***

On January 12, 2024, the Company entered an agreement with KRTL International Corporation, by which KRTL would provide the necessary infrastructure, including a Cannabis distribution center and delivery service, to facilitate the distribution and delivery of Viva Bud's products. In compensation for distribution, the Company issued 200,000 shares of its common stock valued at $200 and was to pay KRTL 20% of net income (and stock of equal value) generated from sales of Viva Bud through KRTL's distribution channels. This agreement was terminated in October 2024.

***One World Legends, Inc.***

On August 13, 2023, the Company held a special meeting of the board of directors wherein it was recommended that the Company should enter into a Joint Venture Agreement with One World Legends Inc., and it was further resolved that in anticipation of the Joint Venture Agreement, the Company authorized the issuance of 3,000,000 shares of common stock to One World Legends to constitute the complete and final fulfillment of the share transaction obligations under the Joint Venture Agreement between the Company and One World Legends.

***Viva Marketing, Inc.***

On August 4, 2023, the Company entered into a Business Acquisition Agreement with Viva Marketing Inc., wherein the Company purchased the financial consulting and management of all of Viva Marketing Inc.'s assets and liabilities, in exchange for $100.

***Marijuana Inc. of Florida***

On May 22, 2023, the Company entered into a Share Exchange Agreement with Marijuana Inc. of Florida, wherein the Company received all of the issued and outstanding shares of Marijuana Inc. of Florida in exchange for 15,555,000 shares of the Company's common stock. On July 6, 2023, the Company issued 13,645,000 of the 15,555,000 shares for the share exchange, and another 1,910,000 had yet to be issued to complete the full stock exchange. The Share Exchange Agreement was later amended so only 13,645,000 shares of the Company's common stock were to be issued to complete the acquisition of Marijuana Inc. For stock-based compensation purposes, the 13,645,000 common shares issued on July 6, 2023, were measured at the adjusted close of $0.10 per share as of such date. The Company rescinded this acquisition and is currently seeking the return of the issued shares.

***Mendocino Green, LLC – 2023***

On March 29, 2023, the Company issued 4,000,000 shares of common stock for 100% acquisition of Mendocino Green LLC per a stock purchase agreement dated March 16, 2023. These shares were valued at $0.50 per share and the acquisition was later rescinded and the 4,000,000 shares of common stock were returned and cancelled.

**NOTE 4 - CONVERTIBLE NOTES PAYABLE**

In accordance with ASC 480, *Distinguishing Liabilities from Equity*, the Company evaluates its hybrid convertible debt instruments with unconditional obligations allowing settlement by issuing a variable number of its equity shares to determine proper classification and accounting. The Company classifies the hybrid convertible debt instruments as a liability upon being convertible at the option of the holders due to the conversion terms being based on fixed monetary amounts known at inception, in this case, settlement with a variable number of the Company's equity shares. As such, conversion options are carried as a liability at fair value at each balance sheet date with a re-measurement reported as a change in fair value of share-settled debt in other (income) expense in the accompanying condensed statements of operations.

 **

***Consulting Agreement***

 **

Pursuant to a consulting agreement, the Company issued and delivered a $200,000 convertible note to Donald Steinberg. The convertible note bears interest at 8% per annum, is due October 30, 2025, and is convertible into shares of Company common stock at any time at a 25% discount to the then-trading price; provided, however, that the holder of the convertible note may not convert into a number of shares of common stock that would cause the holder to exceed 9.99% ownership of Company common stock. In addition, the convertible note carries rights of qualification and rights of registration. Should the Consulting Note be converted into shares of common stock of the Company that are the subject of an Offering Statement on Form 1-A (the "Reg A") or a Registration Statement on Form S-1 (the "S-1"), the conversion price would be equal to the offering price of the shares offered under the Reg A or the S-1, as the case may be.

***Legal Services***

 ****

Pursuant to a legal services agreement, the Company issued and delivered a $25,000 convertible note to NLF Support Services, LLC. The convertible note bears interest at 8% per annum, is due November 18, 2025 and automatically converts into shares of the Company's common stock on the date on which the Company's offering circular with respect to the offering of Common Stock pursuant to Regulation A is first "qualified" by the SEC and any other relevant state or other jurisdictional qualification. On the qualification date, the outstanding balance, including accrued interest at the rate equal to the price of the Regulation A offering.

The Company's convertible notes payable consist of the following at:

---

| | | |
|:---|:---|:---|
|  | **December 31,** | **December 31,** |
|  | **2024** | **2023** |
| &nbsp;&nbsp;Convertible note payable, interest at 8%, unsecured, due October 30, 2025 | $262746 | $— |
| &nbsp;&nbsp;Convertible note payable, interest at 8%, unsecured, due November 18, 2025 | 25000 |  |
| &nbsp;&nbsp;Total: | 287746 |  |
| &nbsp;&nbsp;Less: current portion | $(287746) | $— |
| &nbsp;&nbsp;Long-term notes payable | $— | $— |

---

During the year ended December 31, 2024, the Company recognized a $62,746 loss in fair value as a result of the conversion options on the above-mentioned convertible debt.

**NOTE 5 - PREFERRED STOCK**

The Company is authorized to issue 10,000,000 shares of Preferred Stock, par value $0.001 per share, of which 100 shares have been designated Series A Preferred Stock and of which 10,000 shares have been designated Series B.

***Series A Preferred Stock***

The holders of the Series A Preferred Stock have rights in all matters requiring shareholder approval to a number of votes equal to two (2) times the sum of: (a) the total number of shares of common stock which are issued and outstanding at the time of any election or vote by the shareholders; plus (b) the number of votes allocated to shares of Preferred Stock issued and outstanding of any other class that shall have voting rights. The Series A Preferred Stock possess no rights of conversion.

In April 2022, the Company issued Donald Steinberg, as the newly appointed CEO of the Company, 100 shares of Series A Preferred Stock as compensation. In June 2022, Mr. Steinberg transferred such 100 Shares of Series A Preferred Stock to Earth Onyx LLC, an entity controlled by him. On October 30, 2024, Mr. Steinberg sold such 100 shares of Series A Preferred Stock to Michael Sheikh.

***Series B Convertible Preferred Stock***

Each share of Series B Convertible Preferred Stock shall be entitled to one (1) vote in all matters requiring shareholder approval. Dividends: The Series B Convertible Preferred Stock shall be treated pari passu with the Company's common stock, except that the dividend on each share of Series B Convertible Preferred Stock shall be equal to the amount of the dividend declared and paid on each share of the Common Stock multiplied by the Conversion Rate. Liquidation: Upon any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, payments to the holders of Series B Convertible Preferred Stock shall be treated pari passu with the Common Stock, except that the payment on each share of Series B Convertible Preferred Stock shall be equal to the amount of the payment on each share of the Common Stock multiplied by the Conversion Rate. Conversion: Each share of the Series B Convertible Preferred Stock shall be convertible into Four Thousand Seven Hundred (4,700) shares of the Common Stock; a holder of shares of Series B Convertible Preferred Stock shall be required to convert all of such holder's shares of Series B Convertible Preferred Stock, should any such holder exercise his, her or its rights of conversion; the Series B Convertible Preferred Stock may be converted into shares of the Common Stock any time after the date that is six months immediately following the effective date of the Common Stock's uplisting to any tier of the NASDAQ Stock Market (including NASDAQ Capital Market), the NYSE American or any successor to such markets.

In December 2024, the Company issued 10,000 shares of Series B Convertible Preferred Stock to Ludwig Enterprises, Inc., pursuant to a Stock Purchase Agreement. See Note 3 Acquisitions, Joint Ventures and Share Exchange Agreements.

**NOTE 6 - GOING CONCERN**

The Company's consolidated financial statements are prepared using Generally Accepted Accounting Principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has recently accumulated losses since its inception and has had negative cash flows from operations, which raise substantial doubt about its ability to continue as a going concern. Management's plans with respect to alleviating the adverse financial conditions that caused management to express substantial doubt about the Company's ability to continue as a going concern are as follows:

The ability to continue the Company's operations depends on its ability to generate and grow revenue and results of operations as well as our ability to access capital markets when necessary to accomplish strategic objectives. The Company expects to continue to incur losses for the immediate future and will need additional equity or debt financing until the Company can achieve profitability and positive cash flows from operating activities. The Company's future capital requirements for operations will depend on many factors, including the ability to generate revenues and obtain capital.

There can be no assurance that The Company will be able to achieve its business plans, raise any more required capital or secure the financing necessary to achieve its current operating plan. The ability of The Company to continue as a going concern is dependent upon its ability to successfully accomplish the plan described in the preceding paragraph and eventually attain profitable operations. The accompanying unaudited consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

**NOTE 7 - SUBSEQUENT EVENTS**

***Lease***

On January 15, 2025, the Company executed a lease agreement with Wellspring USA for lab space located in Orlando, Florida. The leased premises is comprised of 1,000 square feet and the monthly rental payment is $2,161.

***Alliance Agreement***

 ****

On January 20, 2025, the Company executed an Alliance Agreement with Progenicyte Japan CO., LTD, which is embodied in the Company's subsidiary, Exousia Pro, Inc. Through Exousia Pro, the Company now holds the worldwide license in perpetuity for Progenicyte's patent covering the loading of Exosomes. Exousia Pro is required to pay Progenictye the sum of $16,667 a month and issue it 30% of Exousia Pro's equity as payment for the exclusive worldwide license.

***Other***

Management has evaluated subsequent events through March 24, 2025.

**PART III – EXHIBITS**

**Index to Exhibits**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference to:** | **Incorporated by Reference to:** | **Incorporated by Reference to:** | |
| <br>**Exhibit No.:** | <br>**Description of Exhibit** | **Form** | **Date** | **Exhibit** | <br>**Filed/**<br> **Furnished Herewith** |
| <br> **2. Charter and Bylaws** | <br> **2. Charter and Bylaws** | <br> **2. Charter and Bylaws** |  |  |  |
| 2.1 | [Articles of Conversion filed 8/4/2023](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex2x1.htm) | 1-A | 6/18/2025 | 2.1 |  |
| 2.2 | [Articles of Amendment - Name Change filed 11/13/2023](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex2x2.htm) | 1-A | 6/18/2025 | 2.2 |  |
| 2.3 | [Articles of Amendment - Authorized Share Reduction filed 12/20/2024](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex2x3.htm) | 1-A | 6/18/2025 | 2.3 |  |
| 2.4 | [Articles of Amendment - Series B Designation filed 3/24/2025](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex2x4.htm) | 1-A | 6/18/2025 | 2.4 |  |
| 2.5 | [Articles of Amendment - Name Change filed 4/2/2025](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex2x5.htm) | 1-A | 6/18/2025 | 2.5 |  |
| 2.6 | [Bylaws](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex2x6.htm) | 1-A | 6/18/2025 | 2.6 |  |
| <br> **4. Subscription Agreement** | <br> **4. Subscription Agreement** | <br> **4. Subscription Agreement** |  |  |  |
| 4.1 | [Subscription Agreement](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex4x1.htm) | 1-A | 6/18/2025 | 4.1 |  |
| <br> **6. Material Agreements** | <br> **6. Material Agreements** | <br> **6. Material Agreements** |  |  |  |
| 6.1 <br>| [Stock Purchase Agreement between the Company and Ludwig Enterprises, Inc.](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex6x1.htm) | 1-A | 6/18/2025 | 6.1 |  |
| 6.2 | [Secured Promissory Note dated 12/31/2024, $100,000 principal amount, in favor of Ludwig Enterprises, Inc.](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex6x2.htm) | 1-A | 6/18/2025 | 6.2 |  |
| 6.3 | [Pledge Agreement between the Company and Ludwig Enterprises, Inc.](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex6x3.htm) | 1-A | 6/18/2025 | 6.3 |  |
| 6.4 | [Scientific Advisory Board Consulting Agreement between the Company and Robert B. Beelman](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex6x4.htm) | 1-A | 6/18/2025 | 6.4 |  |
| 6.5 | [Scientific Advisory Board Consulting Agreement between the Company and Marvin S. Hausman, M.D.](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex6x5.htm) | 1-A | 6/18/2025 | 6.5 |  |
| 6.6 | [Legal Services Agreement dated 11/18/2024 between the Company and Newlan Law Firm, PLLC](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex6x6.htm) | 1-A | 6/18/2025 | 6.6 |  |
| 6.7 | [8% Promissory Note dated 11/18/2024, $25,000 principal amount, in favor of NLF Support Services, LLC](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex6x7.htm) | 1-A | 6/18/2025 | 6.7 |  |
| 6.8 | [Legal Services Agreement dated 6/10/2025 between the Company and Newlan Law Firm, PLLC](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex6x8.htm) | 1-A | 6/18/2025 | 6.8 |  |
| 6.9 | [8% Promissory Note dated 6/10/2025, $20,000 principal amount, in favor of NLF Support Services, LLC](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex6x9.htm) | 1-A | 6/18/2025 | 6.9 |  |
| 6.10 | [8% Promissory Note dated 6/10/2025, $52,500 principal amount, in favor of NLF Support Services, LLC](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex6x10.htm) | 1-A | 6/18/2025 | 6.10 |  |
| 6.11 | [Stock Purchase Agreement between the Company and Ned Bass](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex6x11.htm) | 1-A | 6/18/2025 | 6.11 |  |
| 6.12 | [Stock Purchase Agreement between the Company and Jeff Leavitt](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex6x12.htm) | 1-A | 6/18/2025 | 6.12 |  |
| 6.13 | [Stock Purchase Agreement between the Company and Billy Mitchell](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex6x13.htm) | 1-A | 6/18/2025 | 6.13 |  |
| 6.14 | [Securities Purchase Agreement between the Company and Fusion Star Media, Inc.](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex6x14.htm) | 1-A | 6/18/2025 | 6.14 |  |
| 6.15 | [Convertible Promissory Note dated 2/24/2025, $65,000 principal amount, in favor of Fusion Star Media, Inc.](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex6x15.htm) | 1-A | 6/18/2025 | 6.15 |  |
| 6.16 | [Alliance Agreement between the Company and Progenicyte Japan CO., LTD.](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex6x16.htm) | 1-A | 6/18/2025 | 6.16 |  |
| 6.17 | [Scientific Advisory Board Consulting Agreement between the Company and Zachary T. Bitzer, PhD](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex6x17.htm) | 1-A | 6/18/2025 | 6.17 |  |
| 6.18 | [Scientific Advisory Board Consulting Agreement between the Company and Kyle H. Ambert, PhD](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex6x18.htm) | 1-A | 6/18/2025 | 6.18 |  |
| 6.19 | [Consulting Agreement between the Company and Marvin S. Hausman, MD](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex6x19.htm) | 1-A | 6/18/2025 | 6.19 |  |
| 6.20 | [Scientific Advisory Board Consulting Agreement between the Company and Anthony Smith, PhD](http://www.sec.gov/Archives/edgar/data/1492448/000155335025000059/ex6x20.htm) | 1-A | 6/18/2025 | 6.20 |  |
| 6.21 | [Legal Services Agreement dated December 17, 2025, between the Company and Newlan Law Firm, PLLC](maji_ex6z21.htm) |  |  |  | X |
| 6.22 | [Consulting Agreement between the Company and Red Phoenix Rising, LLC](maji_ex6z22.htm) |  |  |  | X |
| 6.23 | [Letter of Intent between the Company and Jumpstart Rx, LLC](maji_ex6z23.htm) |  |  |  | X |
| 6.24 | [Letter of Intent between the Company and Mascot Alliance, LLC](maji_ex6z24.htm) |  |  |  | X |
| 6.25 | [Letter of Intent between the Company and Island 40 Group, LLC](maji_ex6z25.htm) |  |  |  | X |
| 6.26 | [Plan and Agreement of Reorganization between L A M Y, a Wyoming corporation, and the shareholders of Exousia AI, Inc.](maji_ex6z26.htm) |  |  |  | X |
| 6.27 | [Convertible Promissory Note dated December 17, 2025, $100,000 principal amount, in favor of Newlan Law Firm, PLLC](maji_ex6z27.htm) |  |  |  | X |
| 6.28 | [Convertible Promissory Note dated December 17, 2025, $125,000 principal amount, in favor of Red Phoenix Rising, LLC](maji_ex6z28.htm) |  |  |  | X |
| 6.29 | [Convertible Promissory Note dated December 17, 2025, $125,000 principal amount, in favor of Red Phoenix Rising, LLC](maji_ex6z29.htm) |  |  |  | X |
| 6.30 | [Convertible Promissory Note dated December 17, 2025, $125,000 principal amount, in favor of Red Phoenix Rising, LLC](maji_ex6z30.htm) |  |  |  | X |
| <br> **11. Consents** | <br> **11. Consents** | <br> **11. Consents** |  |  |  |
| 11.1 | [Consent of Newlan Law Firm, PLLC (see Exhibit 12.1)](maji_ex12z1.htm) |  |  |  | X |
| <br> **12. Opinion re: Legality** | <br> **12. Opinion re: Legality** | <br> **12. Opinion re: Legality** |  |  |  |
| 12.1 | [Opinion of Newlan Law Firm, PLLC](maji_ex12z1.htm) |  |  |  | X |

---

**SIGNATURES**

Pursuant to the requirements of Regulation A, the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form 1-A and has duly caused this offering statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of St. Petersburg, State of Florida, on December 30, 2025.

---

| | |
|:---|:---|
| **Exousia Pro, Inc.** | **Exousia Pro, Inc.** |
| By: | */s/ Michael Sheikh* |
|  | Michael Sheikh |
|  | Chief Executive Officer |

---

This Offering Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| By: | */s/ Michael Sheikh* | December 30, 2025 |
|  | Michael Sheikh |  |
|  | Chief Executive Officer, Acting Chief Financial Officer [Principal Accounting Officer], Secretary and Director |  |

---

---

| | | |
|:---|:---|:---|
| By: | */s/ Matthew Dwyer* | December 30, 2025 |
|  | Matthew Dwyer |  |
|  | President |  |

---

## Ex1A-6

**EXHIBIT 6.21**

**LEGAL SERVICES AGREEMENT**

This Legal Services Agreement (the ***"Agreement"***) dated as of, and to be effective as of, December 17, 2025 (the ***"Effective Date"***), is by and between Newlan Law Firm, PLLC, by and through its Managing Member, Eric Newlan (***"Attorney"***), and Exousia Pro, Inc., a Florida corporation (***"MAJI"***).

<u>RECITALS</u>

**WHEREAS,** currently, MAJI desires for Attorney to serve as its general legal counsel and to be responsible for corporate and securities matters for MAJI (collectively, the ***"Corporate and Securities Work"***); and

**WHEREAS,** Attorney desires to serve as general legal counsel for MAJI and be responsible for the Corporate and Securities Work, as described in the foregoing Recital; and

**WHEREAS,** Attorney and MAJI desire to enter into an agreement for legal services, on the terms and subject to the conditions set forth herein.

**NOW, THEREFORE,** in consideration of the premises and the mutual covenants, agreements, and considerations herein contained, the parties hereto agree as follows:

**1. Corporate and Securities Work.** The "Corporate and Securities Work" to be completed by Attorney under this Agreement shall include:

**(a)**the preparation of all documentation as may be necessary to effect acquisition transactions, on such terms and conditions as the Board of Directors of MAJI shall determine;

**(b)**the preparation of all documentation OTC Markets filings of MAJI;

**(c)**the ongoing assignments related to MAJI's currently qualified Offering Statement on Form 1-A (including issuance opinions, as requested, and Blue Sky matters), including any post-qualification amendments thereto;

**(d)**the review of press releases, tweets and other shareholder communications proposed to be published by MAJI; and

**(e)**the preparation of all necessary board and shareholder actions and minutes as may be required by MAJI; and

**(f)** the review or drafting of various agreements within Attorney's area of practice through December 31, 2026.

**2. Payments to Attorney.** In consideration of Attorney's entering into this Agreement, MAJI shall deliver the following to Attorney a $100,000.00 principal amount promissory note (the ***"Work Note"***), in the form of <u>Exhibit A</u> attached hereto, and shall include Attorney as a selling shareholder in MAJI's current Regulation A offering with respect to all of the shares of common stock (the ***"Conversion Shares"***) underlying the Work Note.

MAJI agrees and acknowledges that the Work Note is fully earned as of the Effective Date of this Agreement, in consideration of Attorney's execution of this Agreement and concomitant acceptance of his duties as set forth in this Agreement, **<u>the full execution of which will limit Attorney's ability to engage in other potential client relationships with other parties</u>**. The Company hereby agrees to furnish any documentation necessary for Attorney to deposit the Conversion Shares with a FINRA registered broker/dealer, once any applicable holding period shall have elapsed.

**3. Term of Agreement.** This Agreement shall extend from the Effective Date through December 31, 2026 (the ***"Term"***).

**4. Representations of MAJI.** MAJI represents and warrants to Attorney that:

**(a)**MAJI will cooperate fully and timely with Attorney to enable Attorney to perform Attorney's obligations hereunder.

**(b)**The execution and performance of this Agreement by MAJI has been duly authorized by the Board of Directors of MAJI.

**(c)**The performance by MAJI of this Agreement will not violate any applicable court decree, law or regulation, nor will it violate any provisions of the organizational documents of MAJI or any contractual obligation by which MAJI may be bound.

**(d)**MAJI will make its best efforts to qualify the Offering Statement.

**5. Representations of Attorney.** Attorney represents and warrants to MAJI that:

**(a)**Attorney is acquiring the Work Note for Attorney's own account and not with a present view towards the public sale or distribution thereof, except pursuant to sales registered or exempted from registration under the Securities Act of 1933, as amended (the ***"1933 Act"***); *provided, however*, that by making the representations herein, Attorney does not agree to hold any of the Conversion Shares for any minimum or other specific term and reserves the right to dispose of the Conversion Shares at any time in accordance with, or pursuant to, a registration statement or an exemption under the 1933 Act.

**(b)**Attorney is an "accredited investor" as that term is defined in Rule 501(a) of Regulation D.

**(c)**Attorney understands that the Work Note and the Conversion Shares are being issued to Attorney in reliance upon specific exemptions from the registration requirements of United States federal and state securities laws and that MAJI is relying upon the truth and accuracy of, and Attorney's compliance with, the representations, warranties, agreements, acknowledgments and understandings of Attorney set forth herein, in order to determine the availability of such exemptions.

**(d)**Attorney understands that, until such time as the Work Note and the Conversion Shares shall have been registered under the 1933 Act or may be sold pursuant to Rule 144, Rule 144A under the 1933 Act, Regulation S, or other applicable exemption without any restriction as to the number of securities as of a particular date that can then be immediately sold, the Notes and the Conversion Shares may bear a restrictive legend in substantially the following form (and a stop-transfer order may be placed against transfer thereof):

"NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144, RULE 144A, REGULATION S, OR OTHER APPLICABLE EXEMPTION UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES."

**(e)**The execution and performance of this Agreement by Attorney has been duly authorized by the governing body of Attorney.

**(f)**The performance by Attorney of this Agreement will not violate any applicable court decree, law or regulation, nor will it violate any provisions of the organizational documents of Attorney or any contractual obligation by which Attorney may be bound.

**6. Non-Public Information.** Until such time as the same may become publicly known, the parties agree that any information provided to either of them by the other of a confidential nature will not be revealed or disclosed to any person or entity, except in the performance of this Agreement, and upon completion of Attorney's services and upon the written request of MAJI, any original documentation provided by MAJI will be returned to it. Attorney will not directly or indirectly buy or sell any securities of MAJI at any time when Attorney is privy to non-public information.

**7. Notices.** All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and, unless otherwise specified herein, shall be (a) personally served, (b) deposited in the mail, registered or certified, return receipt requested, postage prepaid, (c) delivered by reputable air courier service with charges prepaid, or (d) transmitted by hand delivery, telegram, e-mail or facsimile, addressed as set forth below or to such other address as such party shall have specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (1) upon hand delivery or delivery by e-mail or facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (2) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for such communications shall be:

---

| | |
|:---|:---|
| If to MAJI, to: | Exousia Pro, Inc., Attention: Michael Sheikh |
|  | 7901 4th Street N, #23494, St. Petersburg, Florida 33702 |
|  | E-mail: sheikh@the-lift.com |
| If to Attorney, to: | Newlan Law Firm, PLLC, Attention: Eric Newlan |
|  | 2201 Long Prairie Road, Suite 107-762 |
|  | Flower Mound, Texas 75022 |
|  | E-mail: eric@newlanpllc.com |

---

**8. Miscellaneous.**

**(a)**In the event of a dispute between the parties, both Consultant and the Company agree to settle said dispute through the American Arbitration Association (the "Association") at the Association's Dallas, Texas, offices, in accordance with the then-current rules of the Association; the award given by the arbitrators shall be binding and a judgment can be obtained on any such award in any court of competent jurisdiction. It is expressly agreed that the arbitrators, as part of their award, can award attorneys fees to the prevailing party.

**(b)**This Agreement is not assignable in whole or in any part, and shall be binding upon the parties, their heirs, representatives, successors or assigns.

**(c)**This Agreement may be executed in multiple counterparts which shall be deemed an original. It shall not be necessary that each party execute each counterpart, or that any one counterpart be executed by more than one party, if each party executes at least one counterpart.

**(d)**This Agreement shall be governed by, and construed in accordance with, the laws of the State of Texas.

**[ SIGNATURE PAGE FOLLOWS ]**

**[ <u>Signature Page to Legal Services Agreement</u> ]**

**IN WITNESS WHEREOF,** the parties hereto have executed this Agreement as of the day and year first written above.

---

| | | | |
|:---|:---|:---|:---|
| **MAJI:** | **MAJI:** | **ATTORNEY:** | **ATTORNEY:** |
| EXOUSIA PRO, INC. | EXOUSIA PRO, INC. | NEWLAN LAW FIRM, PLLC | NEWLAN LAW FIRM, PLLC |
| By: | */s/ Michael Sheikh* | By: | */s/ Eric Newlan* |
|  | Michael Sheikh |  | Eric Newlan |
|  | Chief Executive Officer |  | Managing Member |

---

**<u>EXHIBIT A</u>**

**Form of Work Note**

**THIS NOTE, AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR THE APPLICABLE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED OR OTHERWISE TRANSFERRED UNLESS REGISTERED UNDER THE ACT AND UNDER APPLICABLE STATE SECURITIES LAWS, OR UNLESS AN OPINION OF COUNSEL, REASONABLY SATISFACTORY TO THE MAKER, IS OBTAINED TO THE EFFECT THAT SUCH PLEDGE, SALE, ASSIGNMENT OR TRANSFER IS EXEMPT FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND SUCH STATE SECURITIES LAWS.**

---

| | |
|:---|:---|
| **Principal Amount: $100,000.00** | **Issue Date: December 17, 2025** |

---

**EXOUSIA PRO, INC.**

**CONVERTIBLE PROMISSORY NOTE**

FOR VALUE RECEIVED, Exousia Pro, Inc., a Florida corporation (hereinafter called the ***"Borrower"***), hereby promises to pay to the order of Newlan Law Firm, PLLC, or registered assigns (the ***"Holder"***), the sum of $100,000.00 together with any interest as set forth herein, on December 17, 2026 (the ***"Maturity Date"***), including interest on the unpaid principal balance hereof at the rate of eight percent (8%) (the ***"Interest Rate"***) per annum from the date hereof (the ***"Issue Date"***) until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment. This note (the "Note") shall contain an original issue discount (***"OID"***) of $0.00, which shall be included in the Principal Amount of this Note.

This Note may not be prepaid in whole or in part except as otherwise explicitly set forth herein. Any amount of principal or interest on this Note which is not paid when due shall bear interest at the rate of twelve percent (12%) per annum from the due date thereof until the same is paid (***"Default Interest"***). Interest shall commence accruing on the date that the Holder pays the full Purchase Price to the Borrower and shall be computed on the basis of a 365-day year and the actual number of days elapsed. All payments due hereunder (to the extent not converted into common stock, $0.001 par value per share (the ***"Common Stock"***) in accordance with the terms hereof) shall be made in lawful money of the United States of America. All payments shall be made at such address as the Holder shall hereafter give to the Borrower by written notice made in accordance with the provisions of this Note.

This Note is free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the Borrower and will not impose personal liability upon the holder thereof.

The following terms shall apply to this Note:

**ARTICLE I. CONVERSION RIGHTS**

**1.1Conversion Right.** The Holder shall have the right from time to time, and at any time beginning on the Issue Date to convert all or any part of the outstanding and unpaid amount of this Note into fully paid and non-assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or, in the event of a recapitalization or merger, any shares of capital stock or other securities of the Borrower into which such Common Stock shall hereafter be changed or reclassified at the conversion price (the ***"Conversion Price"***) determined as provided herein (a ***"Conversion"***) [The foregoing is not a ratchet provision; in the event of a recapitalization or

merger, if common shareholder receive any other shares or interests, i.e., shares of a different issuer in the event of a merger, the Note will convert into such shares. That is the Note conversion rights will follow the merger]; *provided, however*, that in no event shall the Holder be entitled to convert any portion of this Note in excess of that portion of this Note upon conversion of which the sum of (1) the number of shares of Common Stock beneficially owned by the Holder and its affiliates (other than shares of Common Stock which may be deemed beneficially owned through the ownership of the unconverted portion of the Notes or the unexercised or unconverted portion of any other security of the Borrower subject to a limitation on conversion or exercise analogous to the limitations contained herein) and (2) the number of shares of Common Stock issuable upon the conversion of the portion of this Note with respect to which the determination of this proviso is being made, would result in beneficial ownership by the Holder and its affiliates of more than 4.99% of the outstanding shares of Common Stock. For purposes of the proviso to the immediately preceding sentence, beneficial ownership shall be determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Regulations 13D-G thereunder, except as otherwise provided in clause (1) of such proviso. *<u>The beneficial ownership limitations on conversion as set forth in the section may NOT be waived by the Holder</u>*. The number of shares of Common Stock to be issued upon each conversion of this Note shall be determined by dividing the Conversion Amount (as defined below) by the applicable Conversion Price then in effect on the date specified in the notice of conversion, in the form attached hereto as Exhibit A (the "Notice of Conversion"), delivered to the Borrower by the Holder in accordance with Section 1.4 below; provided that the Notice of Conversion is submitted by facsimile or e-mail (or by other means resulting in, or reasonably expected to result in, notice) to the Borrower before 6:00 p.m., New York, New York time on such conversion date (the ***"Conversion Date"***); however, if the Notice of Conversion is sent after 6:00pm, New York, New York time the Conversion Date shall be the next business day. The term "Conversion Amount" means, with respect to any conversion of this Note, the sum of (1) the principal amount of this Note to be converted in such conversion plus (2) accrued and unpaid interest, if any, on such principal amount at the interest rates provided in this Note to the Conversion Date, plus (3) at the Holder's option, Default Interest, if any, on the amounts referred to in the immediately preceding clauses (1) and/or (2) plus (4) at the Holder's option, any amounts owed to the Holder pursuant to Sections 1.4 hereof.

**1.1.1Rights of Qualification.** The Holder shall have the right, which may be exercised at the Holder's sole discretion, to convert any amount due under this Note into shares of any qualified Regulation A Offering under the Securities Act of 1933, as amended (the ***"Securities Act"***) of Borrower during the term of the any such Regulation A Offering. The number of shares to be issued upon any such conversion shall be in accordance with Section 1.2 of this Note. In conjunction with the rights granted to the Holder under this Section 1.1.1, Borrower shall, as may be required and while any amount due under this Note remains outstanding, (1) identify the Holder as a selling shareholder in each of its Regulation A Offering Circulars; and (2) qualify and allocate a sufficient number of shares of Common Stock to repay the remaining balance under the Note in full.

**1.2Conversion Price.** The Conversion Price shall equal the Variable Conversion Price (as defined herein) (subject to equitable adjustments for stock splits, stock dividends or rights offerings by the Borrower relating to the Borrower's securities or the securities of any subsidiary of the Borrower, combinations, recapitalization, reclassifications, extraordinary distributions and similar events). The "Variable Conversion Price" shall mean 75% multiplied by the Market Price (as defined herein) (representing a discount rate of 25%). "Market Price" means the closing price for the Common Stock on the trading day immediately preceding the date of any conversion. "Trading Day" shall mean any day on which the Common Stock is tradable for any period on the OTC, or on the principal securities exchange or other securities market on which the Common Stock is then being traded.

**Notwithstanding the foregoing paragraph, should the Holder exercise its conversion rights pursuant to Section 1.1.1 of this Note, the Conversion Price shall be equal to the then-current offering price of the applicable Regulation A Offering Statement.**

**1.3Authorized Shares.** The Borrower covenants that during the period the conversion right exists, the Borrower will reserve from its authorized and unissued Common Stock a sufficient number of shares, free from preemptive rights, to provide for the issuance of Common Stock upon the full conversion of this Note issued pursuant to the Purchase Agreement (the ***"Reserved Amount"***). The Reserved Amount shall be increased (or decreased with the written consent of the Holder) from time to time in accordance with the Borrower's obligations hereunder. The Borrower represents that upon issuance, such shares will be duly and validly issued, fully paid and

non-assessable. In addition, if the Borrower shall issue any securities or make any change to its capital structure which would change the number of shares of Common Stock into which the Notes shall be convertible at the then current Conversion Price, the Borrower shall at the same time make proper provision so that thereafter there shall be a sufficient number of shares of Common Stock authorized and reserved, free from preemptive rights, for conversion of the outstanding Note. The Borrower (i) acknowledges that it has irrevocably instructed its transfer agent to issue certificates for the Common Stock issuable upon conversion of this Note, and (ii) agrees that its issuance of this Note shall constitute full authority to its officers and agents who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for shares of Common Stock in accordance with the terms and conditions of this Note. If, at any time the Borrower does not maintain the Reserved Amount it will be considered an Event of Default under Section 3.2 of the Note.

**1.4Method of Conversion.**

**(a)Mechanics of Conversion.** As set forth in Section 1.1 hereof, from time to time, and at any time, ending on the later of: (i) the Maturity Date and (ii) the date of payment of the Default Amount, this Note may be converted by the Holder in whole or in part at any time from time to time after the Issue Date, by A) submitting to the Borrower a Notice of Conversion (by facsimile, e-mail or other reasonable means of communication dispatched on the Conversion Date prior to 6:00 p.m., New York, New York time) and (B) subject to Section 1.4(b), surrendering this Note at the principal office of the Borrower (upon payment in full of any amounts owed hereunder).

**(b)Surrender of Note Upon Conversion.** Notwithstanding anything to the contrary set forth herein, upon conversion of this Note in accordance with the terms hereof, the Holder shall not be required to physically surrender this Note to the Borrower unless the entire unpaid principal amount of this Note is so converted. The Holder and the Borrower shall maintain records showing the principal amount so converted and the dates of such conversions or shall use such other method, reasonably satisfactory to the Holder and the Borrower, so as not to require physical surrender of this Note upon each such conversion.

**(c)Delivery of Common Stock Upon Conversion.** Upon receipt by the Borrower from the Holder of a facsimile transmission or e-mail (or other reasonable means of communication) of a Notice of Conversion meeting the requirements for conversion as provided in this Section 1.4, the Borrower shall issue and deliver or cause to be issued and delivered to or upon the order of the Holder certificates for the Common Stock issuable upon such conversion within three (3) business days after such receipt (the ***"Deadline"***) (and, solely in the case of conversion of the entire unpaid principal amount hereof, surrender of this Note) in accordance with the terms hereof and the Purchase Agreement. Upon receipt by the Borrower of a Notice of Conversion, the Holder shall be deemed to be the holder of record of the Common Stock issuable upon such conversion, the outstanding principal amount and the amount of accrued and unpaid interest on this Note shall be reduced to reflect such conversion, and, unless the Borrower defaults on its obligations hereunder, all rights with respect to the portion of this Note being so converted shall forthwith terminate except the right to receive the Common Stock or other securities, cash or other assets, as herein provided, on such conversion. If the Holder shall have given a Notice of Conversion as provided herein, the Borrower's obligation to issue and deliver the certificates for Common Stock shall be absolute and unconditional, irrespective of the absence of any action by the Holder to enforce the same, any waiver or consent with respect to any provision thereof, the recovery of any judgment against any person or any action to enforce the same, any failure or delay in the enforcement of any other obligation of the Borrower to the holder of record, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder of any obligation to the Borrower, and irrespective of any other circumstance which might otherwise limit such obligation of the Borrower to the Holder in connection with such conversion.

**(d)Delivery of Common Stock by Electronic Transfer.** In lieu of delivering physical certificates representing the Common Stock issuable upon conversion, provided the Borrower is participating in the Depository Trust Company (***"DTC"***) Fast Automated Securities Transfer (***"FAST"***) program, upon request of the Holder and its compliance with the provisions set forth herein, the Borrower shall use its best efforts to cause its transfer agent to electronically transmit the Common Stock issuable upon conversion to the Holder by crediting the account of Holder's Prime Broker with DTC through its Deposit Withdrawal Agent Commission (***"DWAC"***) system.

**(e)Failure to Deliver Common Stock Prior to Deadline.** Without in any way limiting the Holder's right to pursue other remedies, including actual damages and/or equitable relief, the parties agree that if delivery of the Common Stock issuable upon conversion of this Note is not delivered by the Deadline (3 business days after receipt of Conversion Notice) due to action and/or inaction of the Borrower, the Borrower shall pay to the Holder $500 per day in cash, for each day beyond the Deadline that the Borrower fails to deliver such Common Stock (the ***"Fail to Deliver Fee"***); provided; however that the Fail to Deliver Fee shall not be due if the failure is a result of a third party (i.e., transfer agent; and not the result of any failure to pay such transfer agent) despite the best efforts of the Borrower to effect delivery of such Common Stock. Such cash amount shall be paid to Holder by the fifth day of the month following the month in which it has accrued or, at the option of the Holder (by written notice to the Borrower by the first day of the month following the month in which it has accrued), shall be added to the principal amount of this Note, in which event interest shall accrue thereon in accordance with the terms of this Note and such additional principal amount shall be convertible into Common Stock in accordance with the terms of this Note. The Borrower agrees that the right to convert is a valuable right to the Holder. The damages resulting from a failure, attempt to frustrate, interference with such conversion right are difficult if not impossible to qualify. Accordingly, the parties acknowledge that the liquidated damages provision contained in this Section 1.4(e) are justified.

**1.5Concerning the Shares.** The shares of Common Stock issuable upon conversion of this Note may not be sold or transferred unless: (i) the Borrower or its transfer agent shall have been furnished by the Holder with an opinion of counsel (which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that the shares to be sold or transferred may be sold or transferred pursuant to an exemption from such registration (such as Rule 144 or a successor rule) (***"Rule 144"***); or (ii) such shares are transferred to an "affiliate" (as defined in Rule 144) of the Borrower who agrees to sell or otherwise transfer the shares only in accordance with this Section 1.5 and who is an Accredited Investor (as defined in the Purchase Agreement).

**1.6Effect of Certain Events.**

**(a)Effect of Merger, Consolidation, Etc.** At the option of the Holder, the sale, conveyance or disposition of all or substantially all of the assets of the Borrower, the effectuation by the Borrower of a transaction or series of related transactions in which more than 50% of the voting power of the Borrower is disposed of, or the consolidation, merger or other business combination of the Borrower with or into any other Person (as defined below) or Persons when the Borrower is not the survivor shall be deemed to be an Event of Default (as defined in Article III) pursuant to which the Borrower shall be required to pay to the Holder upon the consummation of and as a condition to such transaction an amount equal to the Default Amount (as defined in Article III). "Person" shall mean any individual, corporation, limited liability company, partnership, association, trust or other entity or organization.

**(b)Adjustment Due to Merger, Consolidation, Etc.** If, at any time when this Note is issued and outstanding and prior to conversion of all of the Note, there shall be any merger, consolidation, exchange of shares, recapitalization, reorganization, or other similar event, as a result of which shares of Common Stock of the Borrower shall be changed into the same or a different number of shares of another class or classes of stock or securities of the Borrower or another entity, or in case of any sale or conveyance of all or substantially all of the assets of the Borrower other than in connection with a plan of complete liquidation of the Borrower, then the Holder of this Note shall thereafter have the right to receive upon conversion of this Note, upon the basis and upon the terms and conditions specified herein and in lieu of the shares of Common Stock immediately theretofore issuable upon conversion, such stock, securities or assets which the Holder would have been entitled to receive in such transaction had this Note been converted in full immediately prior to such transaction (without regard to any limitations on conversion set forth herein), and in any such case appropriate provisions shall be made with respect to the rights and interests of the Holder of this Note to the end that the provisions hereof (including, without limitation, provisions for adjustment of the Conversion Price and of the number of shares issuable upon conversion of the Note) shall thereafter be applicable, as nearly as may be practicable in relation to any securities or assets thereafter deliverable upon the conversion hereof.

The Borrower shall not affect any transaction described in this Section 1.6(b) unless (a) it first gives, to the extent practicable, ten (10) days prior written notice (but in any event at least five (5) days prior written notice) of the record date of the special meeting of shareholders to approve, or if there is no such record date, the consummation of, such merger, consolidation, exchange of shares, recapitalization, reorganization or other similar event or sale of assets (during which time the Holder shall be entitled to convert this Note) and (b) the resulting successor or acquiring entity (if not the Borrower) assumes by written instrument the obligations of this Note. The above provisions shall similarly apply to successive consolidations, mergers, sales, transfers or share exchanges.

**(c)Adjustment Due to Distribution.** If the Borrower shall declare or make any distribution of its assets (or rights to acquire its assets) to holders of Common Stock as a dividend, stock repurchase, by way of return of capital or otherwise (including any dividend or distribution to the Borrower's shareholders in cash or shares (or rights to acquire shares) of capital stock of a subsidiary (i.e., a spin-off)) (a ***"Distribution"***), then the Holder of this Note shall be entitled, upon any conversion of this Note after the date of record for determining shareholders entitled to such Distribution, to receive the amount of such assets which would have been payable to the Holder with respect to the shares of Common Stock issuable upon such conversion had such Holder been the holder of such shares of Common Stock on the record date for the determination of shareholders entitled to such Distribution. [NOTE: This is not a ratchet provision, it simply prohibits the issuer from effecting a distribution of assets or stock while attempting to avoid conversion or payment of the note (i.e., in the event of an asset distribution which renders the company a shell company, without the foregoing language, although it would be a default, the note holder would be left with little other remedies to attempt to be repaid from the spin off entity). Note that the language does not change the conversion price formula.]

**1.7Prepayment.** This Note may be prepaid at any time without penalty. The Holder's conversion rights herein shall not be affected in any way until the Note is fully paid (funds received by the Holder).

**ARTICLE II. CERTAIN COVENANTS**

**2.1Sale of Assets.** So long as the Borrower shall have any obligation under this Note, the Borrower shall not, sell, lease or otherwise dispose of any significant portion of its assets outside the ordinary course of business. Any consent to the disposition of any assets may not be unreasonably withheld as long as such disposition does not render the Borrower a "shell company" as such term is defined in Rule 144.

**ARTICLE III. EVENTS OF DEFAULT**

If any of the following events of default (each, an ***"Event of Default"***) shall occur:

**3.1Failure to Pay Principal and Interest.** The Borrower fails to pay the principal hereof or interest thereon when due on this Note, whether at maturity or upon acceleration and such breach continues for a period of five (5) days after written notice from the Holder.

**3.2Conversion and the Shares.** The Borrower fails to issue shares of Common Stock to the Holder (or announces or threatens in writing that it will not honor its obligation to do so) upon exercise by the Holder of the conversion rights of the Holder in accordance with the terms of this Note, fails to transfer or cause its transfer agent to transfer (issue) (electronically or in certificated form) any certificate for shares of Common Stock issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by this Note, the Borrower directs its transfer agent not to transfer or delays, impairs, and/or hinders its transfer agent in transferring (or issuing) (electronically or in certificated form) any certificate for shares of Common Stock to be issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by this Note, or fails to remove (or directs its transfer agent not to remove or impairs, delays, and/or hinders its transfer agent from removing) any restrictive legend (or to withdraw any stop transfer instructions in respect thereof) on any certificate for any shares of Common Stock issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by this Note (or makes any written announcement, statement or threat that it does not intend to honor the obligations described in this paragraph) and any such failure shall continue uncured (or any written announcement, statement or threat not to honor its obligations shall not be rescinded in writing) for three (3) business days after the Holder shall have delivered a Notice of Conversion. It is an obligation of the Borrower to remain current in its obligations to its transfer agent. It shall be an event of default of this Note, if a conversion of this Note is delayed, hindered or frustrated due to a balance owed by the Borrower to its transfer agent. If at the option of the Holder, the Holder advances any funds to the Borrower's transfer agent in order to process a conversion, such advanced funds shall be paid by the Borrower to the Holder within forty-eight (48) hours of a demand from the Holder.

**3.3Breach of Covenants.** The Borrower breaches any material covenant or other material term or condition contained in this Note and any collateral documents including but not limited to the Purchase Agreement and such breach continues for a period of twenty (20) days after written notice thereof to the Borrower from the Holder.

**3.4Breach of Representations and Warranties.** Any representation or warranty of the Borrower made herein or in any agreement, statement or certificate given in writing pursuant hereto or in connection herewith (including, without limitation, the Purchase Agreement), shall be false or misleading in any material respect when made and the breach of which has (or with the passage of time will have) a material adverse effect on the rights of the Holder with respect to this Note or the Purchase Agreement.

**3.5Receiver or Trustee.** The Borrower or any subsidiary of the Borrower shall make an assignment for the benefit of creditors, or apply for or consent to the appointment of a receiver or trustee for it or for a substantial part of its property or business, or such a receiver or trustee shall otherwise be appointed.

**3.6Bankruptcy.** Bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings, voluntary or involuntary, for relief under any bankruptcy law or any law for the relief of debtors shall be instituted by or against the Borrower or any subsidiary of the Borrower.

**3.7Delisting of Common Stock.** The Borrower shall fail to maintain the listing of the Common Stock on at least one of the OTC (which specifically includes the quotation platforms maintained by the OTC Markets Group) or an equivalent replacement exchange, the Nasdaq National Market, the Nasdaq SmallCap Market, the New York Stock Exchange, or the American Stock Exchange.

**3.8[Omitted].**

**3.9Liquidation.** Any dissolution, liquidation, or winding up of Borrower or any substantial portion of its business.

**3.10Cessation of Operations.** Any cessation of operations by Borrower rendering the Borrower a "shell company" as such term is defined in Rule 144, or Borrower admits it is otherwise generally unable to pay its debts as such debts become due, provided, however, that any disclosure of the Borrower's ability to continue as a "going concern" shall not be an admission that the Borrower cannot pay its debts as they become due.

**3.11Financial Statement Restatement.** The restatement of any financial statements filed by the Borrower with OTC Markets at any time after 180 days after the Issuance Date for any date or period until this Note is no longer outstanding, if the result of such restatement would, by comparison to the un-restated financial statement, have constituted a material adverse effect on the rights of the Holder with respect to this Note.

**3.12Replacement of Transfer Agent.** In the event that the Borrower proposes to replace its transfer agent, the Borrower fails to provide, prior to the effective date of such replacement, a fully executed Irrevocable Transfer Agent Instructions in a form as initially delivered pursuant to the Purchase Agreement (including but not limited to the provision to irrevocably reserve shares of Common Stock in the Reserved Amount) signed by the successor transfer agent to Borrower and the Borrower.

**ARTICLE IV. MISCELLANEOUS**

**4.1Failure or Indulgence Not Waiver.** No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privileges. All rights and remedies existing hereunder are cumulative to, and not exclusive of, any rights or remedies otherwise available.

**4.2Notices.** All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for such communications shall be:

---

| | |
|:---|:---|
| If to the Borrower: | Exousia Pro, Inc. |
|  | 7901 4th Street N #23494 |
|  | St. Petersburg, Florida 33702 |
|  | Attention: Chief Executive Officer |
|  | E-mail: |
| If to the Holder: | Newlan Law Firm, PLLC |
|  | 2201 Long Prairie Road, Suite 107-762 |
|  | Flower Mound, Texas 75022 |
|  | Attention: Eric Newlan, Managing Member |
|  | E-mail: eric@newlanpllc.com |

---

**4.3Amendments.** This Note and any provision hereof may only be amended by an instrument in writing signed by the Borrower and the Holder. The term "Note" and all reference thereto, as used throughout this instrument, shall mean this instrument (and the other Notes issued pursuant to the Purchase Agreement) as originally executed, or if later amended or supplemented, then as so amended or supplemented.

**4.4Assignability.** This Note shall be binding upon the Borrower and its successors and assigns, and shall inure to be the benefit of the Holder and its successors and assigns. Each transferee of this Note must be an "accredited investor" (as defined in Rule 501(a) of the Securities and Exchange Commission). Notwithstanding anything in this Note to the contrary, this Note may be assigned by the Holder without the consent of the Borrower.

**4.5Cost of Collection.** If default is made in the payment of this Note, the Borrower shall pay the Holder hereof costs of collection, including reasonable attorneys' fees.

**4.6Governing Law.** This Note shall be governed by and construed in accordance with the laws of the State of Nevada without regard to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated by this Note shall be brought only in the state courts of Nevada or in the federal courts located in Las Vegas, Nevada . The parties to this Note hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. The Borrower and Holder waive trial by jury. The prevailing party shall be entitled to recover from the other party its reasonable attorney's fees and costs. In the event that any provision of this Note or any other agreement delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement. Each party hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding in connection with this Note, any agreement or any other document delivered in connection with this Note by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Note and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

**4.7Purchase Agreement.** By its acceptance of this Note, each party agrees to be bound by the applicable terms of the Purchase Agreement.

**4.8Remedies.** The Borrower acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder, by vitiating the intent and purpose of the transaction contemplated hereby. Accordingly, the Borrower acknowledges that the remedy at law for a breach of its obligations under this Note will be inadequate and agrees, in the event of a breach or threatened breach by the Borrower of the provisions of this Note, that the Holder shall be entitled, in addition to all other available remedies at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining, preventing or curing any breach of this Note and to enforce specifically the terms and provisions thereof, without the necessity of showing economic loss and without any bond or other security being required.

**IN WITNESS WHEREOF,** Borrower has caused this Note to be signed in its name by its duly authorized officer on ____________, 202__.

---

| | |
|:---|:---|
| EXOUSIA PRO, INC. | EXOUSIA PRO, INC. |
|  | **<u>Exemplar</u>** |
| By: |  |
|  | Michael Sheikh |
|  | Chief Executive Officer |

---

**EXHIBIT A**

**FORM OF NOTICE OF CONVERSION**

The undersigned hereby elects to convert $_________ principal amount and $_________ of accrued interest of the Note (defined below) into that number of shares of Common Stock to be issued pursuant to the conversion of the Note (***"Common Stock"***) as set forth below, of Exousia Pro, Inc., a Nevada corporation (the ***"Borrower"***), according to the conditions of the convertible note of the Borrower dated as of December 17, 2024 (the ***"Note"***), as of the date written below. No fee will be charged to the Holder for any conversion, except for transfer taxes, if any.

Box Checked as to applicable instructions:

⃞ The Borrower shall electronically transmit the Common Stock issuable pursuant to this Notice of Conversion to the account of the undersigned or its nominee with DTC through its Deposit Withdrawal Agent Commission system ("DWAC Transfer").

Name of DTC Prime Broker:   <br> Account Number:  

⃞ The undersigned hereby requests that the Borrower issue a certificate or certificates for the number of shares of Common Stock set forth below (which numbers are based on the Holder's calculation attached hereto) in the name(s) specified immediately below or, if additional space is necessary, on an attachment hereto:

---

| | |
|:---|:---|
| Date of conversion: |  |
| Applicable Conversion Price: | $|
| Number of shares of common stock to be issued <br> pursuant to conversion of the Notes: |  |
| Amount of Principal Balance due remaining <br> under the Note after this conversion: |  |

---

---

| |
|:---|
| [ Name of Holder ] |
| By: |

---

## Ex1A-6

**EXHIBIT 6.22**

**BUSINESS DEVELOPMENT CONSULTING AGREEMENT**

This Business Development Consulting Agreement (the ***"Agreement"***) is made as of the 11th day of December, 2025 (the ***"Effective Date"***), by and between Red Phoenix Rising, LLC (***"Consultant"***), and Exousia Pro, Inc., a Florida corporation (the ***"Company"***).

**WHEREAS,** the Company has, as a key component of its business development strategies for its Exousia Health division, determined to seek one or more acquisitions of compatible businesses; and

**WHEREAS,** Consultant has indicated that it possesses significant contacts within the industry in which Exousia Health operates that could yield acquisition opportunities for the Company; and

**WHEREAS,** the Company desires to hire Consultant and Consultant is willing to accept the Company as a client.

**NOW, THEREFORE,** in consideration of the mutual covenants herein contained, it is agreed:

**1. Services.** The Company hereby engages Consultant, on a non-exclusive basis, to introduce the Company to active companies (collectively, ***"Target Companies"***) that would, if acquired by the Company, serve to further the development of the Exousia Health business and, if necessary, to facilitate the Company's entering into a letter of intent (each a ***"Letter of Intent"***) relating to a proposed business acquisition transaction with each of such companies. In this regard, Consultant agrees that the Company shall be under any obligation to execute any Letter of Intent, in its sole discretion.

It is further agreed that Consultant shall have no authority to bind the Company to any contract or obligation or to transact any business in the Company's name or on behalf of the Company, in any manner. It is further the agreement of the parties that Consultant shall not provide any services relating to the trading of stock. The parties intend that Consultant shall perform its services required hereunder as an independent contractor.

**2. Term.** The term of this Agreement shall commence on the Effective Date and shall continue for a period of six (6) months.

**3. Consideration.** In consideration of the services to be performed by Consultant, for each Letter of Intent executed with a Target Company, the Company agrees to pay to Consultant the sum of $125,000.00, payable by delivery of a promissory note, in the form of <u>Exhibit A</u> attached hereto.

As further consideration for Consultant's entering into this Agreement, the Company agrees that Consultant shall be named as a selling shareholder with respect to the shares of common stock underlying each of the promissory notes that may be delivered to Consultant hereunder, in the Company's current Regulation A offering (SEC File No. 024-12629).

**4. Representations and Warranties of the Company.** The Company represents and warrants to Consultant that:

**A.**The Company will cooperate fully and timely with Consultant to enable Consultant to perform his obligations hereunder.

**B.**The execution and performance of this Agreement by the Company has been duly authorized by the Board of Directors of the Company.

**C.**The performance by the Company of this Agreement will not violate any applicable court decree, law or regulation, nor will it violate any provisions of the organizational documents of the Company or any contractual obligation by which the Company may be bound.

**5. Representations and Warranties of Consultant.** Consultant represents and warrants to the Company that:

**A.**Consultant will cooperate fully and timely with the Company to facilitate the Company's stated intentions for entering into this Agreement.

**B.**The execution and performance of this Agreement by Consultant has been duly authorized by the governing body of Consultant.

**C.**The performance by Consultant of this Agreement will not violate any applicable court decree, law or regulation, nor will it violate any provisions of the organizational documents of Consultant or any contractual obligation by which Consultant may be bound.

**6. Notices.** All notices hereunder shall be in writing and addressed to the party at its last known address, and shall be given by personal delivery, by certified mail (return receipt requested), Express Mail or by national or international overnight courier.

Notices will be deemed given upon the earlier of actual receipt of three (3) business days after being mailed or delivered to such courier service.

**7. Miscellaneous.**

**A.**In the event of a dispute between the parties arising out of this Agreement, both Consultant and the Company agree to submit such dispute to arbitration before the American Arbitration Association (the ***"Association"***) at its Miami, Florida, offices, in accordance with the then-current rules of the Association; the award given by the arbitrators shall be binding and a judgment may be obtained on any such award in any court of competent jurisdiction. It is expressly agreed that the arbitrators, as part of their award, may award attorneys' fees to the prevailing party.

**B.**This Agreement is not assignable in whole or in any part, and shall be binding upon the parties, their heirs, representatives, successors or assigns.

**C.**This Agreement may be executed in multiple counterparts which, taken together, shall be deemed an original. It shall not be necessary that each party execute each counterpart, or that any one counterpart be executed by more than one party, if each party executes at least one counterpart.

**D.**This Agreement shall be governed by, and construed in accordance with, the laws of the State of Florida.

**IN WITNESS WHEREOF,** the parties hereto have caused this Agreement to be duly executed as of the date first above written.

---

| | | | |
|:---|:---|:---|:---|
| **COMPANY:** | **COMPANY:** | **CONSULTANT** | **CONSULTANT** |
| EXOUSIA PRO, INC. | EXOUSIA PRO, INC. | RED PHOENIX RISING, LLC | RED PHOENIX RISING, LLC |
| By: | *<u>/s/ Michael Sheikh</u>* | By: | *<u>/s/ Thomas Roland</u>* |
|  | Matthew Dwyer |  | Thomas Roland |
|  | President |  | Managing Member |

---

**<u>EXHIBIT A</u>**

**Form of Promissory Note**

**THIS NOTE, AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR THE APPLICABLE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED OR OTHERWISE TRANSFERRED UNLESS REGISTERED UNDER THE ACT AND UNDER APPLICABLE STATE SECURITIES LAWS, OR UNLESS AN OPINION OF COUNSEL, REASONABLY SATISFACTORY TO THE MAKER, IS OBTAINED TO THE EFFECT THAT SUCH PLEDGE, SALE, ASSIGNMENT OR TRANSFER IS EXEMPT FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND SUCH STATE SECURITIES LAWS.**

------

---

| | |
|:---|:---|
| **Principal Amount: $125,000.00** | **Issue Date: __________, 202__** |

---

**EXOUSIA PRO, INC.**

**CONVERTIBLE PROMISSORY NOTE**

FOR VALUE RECEIVED, Exousia Pro, Inc., a Florida corporation (hereinafter called the ***"Borrower"***), hereby promises to pay to the order of Red Phoenix Rising, LLC, or registered assigns (the ***"Holder"***), the sum of $125,000.00 together with any interest as set forth herein, on December 16, 2026 (the ***"Maturity Date"***), including interest on the unpaid principal balance hereof at the rate of eight percent (8%) (the ***"Interest Rate"***) per annum from the date hereof (the ***"Issue Date"***) until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment. This note (the "Note") shall contain an original issue discount (***"OID"***) of $0.00, which shall be included in the Principal Amount of this Note.

This Note may not be prepaid in whole or in part except as otherwise explicitly set forth herein. Any amount of principal or interest on this Note which is not paid when due shall bear interest at the rate of twelve percent (12%) per annum from the due date thereof until the same is paid (***"Default Interest"***). Interest shall commence accruing on the date that the Holder pays the full Purchase Price to the Borrower and shall be computed on the basis of a 365-day year and the actual number of days elapsed. All payments due hereunder (to the extent not converted into common stock, $0.001 par value per share (the ***"Common Stock"***) in accordance with the terms hereof) shall be made in lawful money of the United States of America. All payments shall be made at such address as the Holder shall hereafter give to the Borrower by written notice made in accordance with the provisions of this Note.

This Note is free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the Borrower and will not impose personal liability upon the holder thereof.

The following terms shall apply to this Note:

**ARTICLE I. CONVERSION RIGHTS**

**1.1Conversion Right.** The Holder shall have the right from time to time, and at any time beginning on the Issue Date to convert all or any part of the outstanding and unpaid amount of this Note into fully paid and non-assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or, in the event of a recapitalization or merger, any shares of capital stock or other securities of the Borrower into which such Common Stock shall hereafter be changed or reclassified at the conversion price (the ***"Conversion Price"***) determined as provided herein (a ***"Conversion"***) [The foregoing is not a ratchet provision; in the event of a recapitalization or merger, if common shareholder receive any other shares or interests, i.e., shares of a different issuer in the event of a

merger, the Note will convert into such shares. That is the Note conversion rights will follow the merger]; *provided, however*, that in no event shall the Holder be entitled to convert any portion of this Note in excess of that portion of this Note upon conversion of which the sum of (1) the number of shares of Common Stock beneficially owned by the Holder and its affiliates (other than shares of Common Stock which may be deemed beneficially owned through the ownership of the unconverted portion of the Notes or the unexercised or unconverted portion of any other security of the Borrower subject to a limitation on conversion or exercise analogous to the limitations contained herein) and (2) the number of shares of Common Stock issuable upon the conversion of the portion of this Note with respect to which the determination of this proviso is being made, would result in beneficial ownership by the Holder and its affiliates of more than 4.99% of the outstanding shares of Common Stock. For purposes of the proviso to the immediately preceding sentence, beneficial ownership shall be determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Regulations 13D-G thereunder, except as otherwise provided in clause (1) of such proviso. *<u>The beneficial ownership limitations on conversion as set forth in the section may NOT be waived by the Holder</u>*. The number of shares of Common Stock to be issued upon each conversion of this Note shall be determined by dividing the Conversion Amount (as defined below) by the applicable Conversion Price then in effect on the date specified in the notice of conversion, in the form attached hereto as Exhibit A (the "Notice of Conversion"), delivered to the Borrower by the Holder in accordance with Section 1.4 below; provided that the Notice of Conversion is submitted by facsimile or e-mail (or by other means resulting in, or reasonably expected to result in, notice) to the Borrower before 6:00 p.m., New York, New York time on such conversion date (the ***"Conversion Date"***); however, if the Notice of Conversion is sent after 6:00pm, New York, New York time the Conversion Date shall be the next business day. The term "Conversion Amount" means, with respect to any conversion of this Note, the sum of (1) the principal amount of this Note to be converted in such conversion plus (2) accrued and unpaid interest, if any, on such principal amount at the interest rates provided in this Note to the Conversion Date, plus (3) at the Holder's option, Default Interest, if any, on the amounts referred to in the immediately preceding clauses (1) and/or (2) plus (4) at the Holder's option, any amounts owed to the Holder pursuant to Sections 1.4 hereof.

**1.1.1Rights of Qualification.** The Holder shall have the right, which may be exercised at the Holder's sole discretion, to convert any amount due under this Note into shares of any qualified Regulation A Offering under the Securities Act of 1933, as amended (the ***"Securities Act"***) of Borrower during the term of the any such Regulation A Offering. The number of shares to be issued upon any such conversion shall be in accordance with Section 1.2 of this Note. In conjunction with the rights granted to the Holder under this Section 1.1.1, Borrower shall, as may be required and while any amount due under this Note remains outstanding, (1) identify the Holder as a selling shareholder in each of its Regulation A Offering Circulars; and (2) qualify and allocate a sufficient number of shares of Common Stock to repay the remaining balance under the Note in full.

**1.2Conversion Price.** The Conversion Price shall equal the Variable Conversion Price (as defined herein) (subject to equitable adjustments for stock splits, stock dividends or rights offerings by the Borrower relating to the Borrower's securities or the securities of any subsidiary of the Borrower, combinations, recapitalization, reclassifications, extraordinary distributions and similar events). The "Variable Conversion Price" shall mean 75% multiplied by the Market Price (as defined herein) (representing a discount rate of 25%). "Market Price" means the closing price for the Common Stock on the trading day immediately preceding the date of any conversion. "Trading Day" shall mean any day on which the Common Stock is tradable for any period on the OTC, or on the principal securities exchange or other securities market on which the Common Stock is then being traded.

**Notwithstanding the foregoing paragraph, should the Holder exercise its conversion rights pursuant to Section 1.1.1 of this Note, the Conversion Price shall be equal to the then-current offering price of the applicable Regulation A Offering Statement.**

**1.3Authorized Shares.** The Borrower covenants that during the period the conversion right exists, the Borrower will reserve from its authorized and unissued Common Stock a sufficient number of shares, free from preemptive rights, to provide for the issuance of Common Stock upon the full conversion of this Note issued pursuant to the Purchase Agreement (the ***"Reserved Amount"***). The Reserved Amount shall be increased (or decreased with the written consent of the Holder) from time to time in accordance with the Borrower's obligations hereunder. The Borrower represents that upon issuance, such shares will be duly and validly issued, fully paid and non-assessable. In addition, if the Borrower shall issue any securities or make any change to its capital structure which would change the number of shares of Common Stock into which the Notes shall be convertible at the then current Conversion Price, the Borrower shall at the same time make proper provision so that thereafter there shall be a sufficient number of shares of Common Stock authorized and reserved, free from preemptive rights, for conversion of the outstanding Note. The Borrower (i) acknowledges that it has irrevocably instructed its transfer agent to issue certificates for the Common Stock issuable upon conversion of this Note, and (ii) agrees that its issuance of this Note shall constitute full authority to its officers and agents who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for shares of Common Stock in accordance with the terms and conditions of this Note. If, at any time the Borrower does not maintain the Reserved Amount it will be considered an Event of Default under Section 3.2 of the Note.

**1.4Method of Conversion.**

**(a)Mechanics of Conversion.** As set forth in Section 1.1 hereof, from time to time, and at any time, ending on the later of: (i) the Maturity Date and (ii) the date of payment of the Default Amount, this Note may be converted by the Holder in whole or in part at any time from time to time after the Issue Date, by (A) submitting to the Borrower a Notice of Conversion (by facsimile, e-mail or other reasonable means of communication dispatched on the Conversion Date prior to 6:00 p.m., New York, New York time) and (B) subject to Section 1.4(b), surrendering this Note at the principal office of the Borrower (upon payment in full of any amounts owed hereunder).

**(b)Surrender of Note Upon Conversion.** Notwithstanding anything to the contrary set forth herein, upon conversion of this Note in accordance with the terms hereof, the Holder shall not be required to physically surrender this Note to the Borrower unless the entire unpaid principal amount of this Note is so converted. The Holder and the Borrower shall maintain records showing the principal amount so converted and the dates of such conversions or shall use such other method, reasonably satisfactory to the Holder and the Borrower, so as not to require physical surrender of this Note upon each such conversion.

**(c)Delivery of Common Stock Upon Conversion.** Upon receipt by the Borrower from the Holder of a facsimile transmission or e-mail (or other reasonable means of communication) of a Notice of Conversion meeting the requirements for conversion as provided in this Section 1.4, the Borrower shall issue and deliver or cause to be issued and delivered to or upon the order of the Holder certificates for the Common Stock issuable upon such conversion within three (3) business days after such receipt (the ***"Deadline"***) (and, solely in the case of conversion of the entire unpaid principal amount hereof, surrender of this Note) in accordance with the terms hereof and the Purchase Agreement. Upon receipt by the Borrower of a Notice of Conversion, the Holder shall be deemed to be the holder of record of the Common Stock issuable upon such conversion, the outstanding principal amount and the amount of accrued and unpaid interest on this Note shall be reduced to reflect such conversion, and, unless the Borrower defaults on its obligations hereunder, all rights with respect to the portion of this Note being so converted shall forthwith terminate except the right to receive the Common Stock or other securities, cash or other assets, as herein provided, on such conversion. If the Holder shall have given a Notice of Conversion as provided herein, the Borrower's obligation to issue and deliver the certificates for Common Stock shall be absolute and unconditional, irrespective of the absence of any action by the Holder to enforce the same, any waiver or consent with respect to any provision thereof, the recovery of any judgment against any person or any action to enforce the same, any failure or delay in the enforcement of any other obligation of the Borrower to the holder of record, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder of any obligation to the Borrower, and irrespective of any other circumstance which might otherwise limit such obligation of the Borrower to the Holder in connection with such conversion.

**(d)Delivery of Common Stock by Electronic Transfer.** In lieu of delivering physical certificates representing the Common Stock issuable upon conversion, provided the Borrower is participating in the Depository Trust Company (***"DTC"***) Fast Automated Securities Transfer (***"FAST"***) program, upon request of the Holder and its compliance with the provisions set forth herein, the Borrower shall use its best efforts to cause its transfer agent to electronically transmit the Common Stock issuable upon conversion to the Holder by crediting the account of Holder's Prime Broker with DTC through its Deposit Withdrawal Agent Commission (***"DWAC"***) system.

**(e)Failure to Deliver Common Stock Prior to Deadline.** Without in any way limiting the Holder's right to pursue other remedies, including actual damages and/or equitable relief, the parties agree that if delivery of the Common Stock issuable upon conversion of this Note is not delivered by the Deadline (3 business days after receipt of Conversion Notice) due to action and/or inaction of the Borrower, the Borrower shall pay to the Holder $500 per day in cash, for each day beyond the Deadline that the Borrower fails to deliver such Common Stock (the ***"Fail to Deliver Fee"***); provided; however that the Fail to Deliver Fee shall not be due if the failure is a result of a third party (i.e., transfer agent; and not the result of any failure to pay such transfer agent) despite the best efforts of the Borrower to effect delivery of such Common Stock. Such cash amount shall be paid to Holder by the fifth day of the month following the month in which it has accrued or, at the option of the Holder (by written notice to the Borrower by the first day of the month following the month in which it has accrued), shall be added to the principal amount of this Note, in which event interest shall accrue thereon in accordance with the terms of this Note and such additional principal amount shall be convertible into Common Stock in accordance with the terms of this Note. The Borrower agrees that the right to convert is a valuable right to the Holder. The damages resulting from a failure, attempt to frustrate, interference with such conversion right are difficult if not impossible to qualify. Accordingly, the parties acknowledge that the liquidated damages provision contained in this Section 1.4(e) are justified.

**1.5Concerning the Shares.** The shares of Common Stock issuable upon conversion of this Note may not be sold or transferred unless: (i) the Borrower or its transfer agent shall have been furnished by the Holder with an opinion of counsel (which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that the shares to be sold or transferred may be sold or transferred pursuant to an exemption from such registration (such as Rule 144 or a successor rule) (***"Rule 144"***); or (ii) such shares are transferred to an "affiliate" (as defined in Rule 144) of the Borrower who agrees to sell or otherwise transfer the shares only in accordance with this Section 1.5 and who is an Accredited Investor (as defined in the Purchase Agreement).

**1.6Effect of Certain Events.**

**(a)Effect of Merger, Consolidation, Etc.** At the option of the Holder, the sale, conveyance or disposition of all or substantially all of the assets of the Borrower, the effectuation by the Borrower of a transaction or series of related transactions in which more than 50% of the voting power of the Borrower is disposed of, or the consolidation, merger or other business combination of the Borrower with or into any other Person (as defined below) or Persons when the Borrower is not the survivor shall be deemed to be an Event of Default (as defined in Article III) pursuant to which the Borrower shall be required to pay to the Holder upon the consummation of and as a condition to such transaction an amount equal to the Default Amount (as defined in Article III). "Person" shall mean any individual, corporation, limited liability company, partnership, association, trust or other entity or organization.

**(b)Adjustment Due to Merger, Consolidation, Etc.** If, at any time when this Note is issued and outstanding and prior to conversion of all of the Note, there shall be any merger, consolidation, exchange of shares, recapitalization, reorganization, or other similar event, as a result of which shares of Common Stock of the Borrower shall be changed into the same or a different number of shares of another class or classes of stock or securities of the Borrower or another entity, or in case of any sale or conveyance of all or substantially all of the assets of the Borrower other than in connection with a plan of complete liquidation of the Borrower, then the Holder of this Note shall thereafter have the right to receive upon conversion of this Note, upon the basis and upon the terms and conditions specified herein and in lieu of the shares of Common Stock immediately theretofore issuable upon conversion, such stock, securities or assets which the Holder would have been entitled to receive in such transaction had this Note been converted in full immediately prior to such transaction (without regard to any limitations on conversion set forth herein), and in any such case appropriate provisions shall be made with respect to the rights and interests of the Holder of this Note to the end that the provisions hereof (including, without limitation, provisions for adjustment of the Conversion Price and of the number of shares issuable upon conversion of the Note) shall thereafter be applicable, as nearly as may be practicable in relation to any securities or assets thereafter deliverable upon the conversion hereof.

The Borrower shall not affect any transaction described in this Section 1.6(b) unless (a) it first gives, to the extent practicable, ten (10) days prior written notice (but in any event at least five (5) days prior written notice) of the record date of the special meeting of shareholders to approve, or if there is no such record date, the consummation of, such merger, consolidation, exchange of shares, recapitalization, reorganization or other similar event or sale of assets (during which time the Holder shall be entitled to convert this Note) and (b) the resulting successor or acquiring entity (if not the Borrower) assumes by written instrument the obligations of this Note. The above provisions shall similarly apply to successive consolidations, mergers, sales, transfers or share exchanges.

**(c)Adjustment Due to Distribution.** If the Borrower shall declare or make any distribution of its assets (or rights to acquire its assets) to holders of Common Stock as a dividend, stock repurchase, by way of return of capital or otherwise (including any dividend or distribution to the Borrower's shareholders in cash or shares (or rights to acquire shares) of capital stock of a subsidiary (i.e., a spin-off)) (a ***"Distribution"***), then the Holder of this Note shall be entitled, upon any conversion of this Note after the date of record for determining shareholders entitled to such Distribution, to receive the amount of such assets which would have been payable to the Holder with respect to the shares of Common Stock issuable upon such conversion had such Holder been the holder of such shares of Common Stock on the record date for the determination of shareholders entitled to such Distribution. [NOTE: This is not a ratchet provision, it simply prohibits the issuer from effecting a distribution of assets or stock while attempting to avoid conversion or payment of the note (i.e., in the event of an asset distribution which renders the company a shell company, without the foregoing language, although it would be a default, the note holder would be left with little other remedies to attempt to be repaid from the spin off entity). Note that the language does not change the conversion price formula.]

**1.7Prepayment.** This Note may be prepaid at any time without penalty. The Holder's conversion rights herein shall not be affected in any way until the Note is fully paid (funds received by the Holder).

**ARTICLE II. CERTAIN COVENANTS**

**2.1Sale of Assets.** So long as the Borrower shall have any obligation under this Note, the Borrower shall not, sell, lease or otherwise dispose of any significant portion of its assets outside the ordinary course of business. Any consent to the disposition of any assets may not be unreasonably withheld as long as such disposition does not render the Borrower a "shell company" as such term is defined in Rule 144.

**ARTICLE III. EVENTS OF DEFAULT**

If any of the following events of default (each, an ***"Event of Default"***) shall occur:

**3.1Failure to Pay Principal and Interest.** The Borrower fails to pay the principal hereof or interest thereon when due on this Note, whether at maturity or upon acceleration and such breach continues for a period of five (5) days after written notice from the Holder.

**3.2Conversion and the Shares.** The Borrower fails to issue shares of Common Stock to the Holder (or announces or threatens in writing that it will not honor its obligation to do so) upon exercise by the Holder of the conversion rights of the Holder in accordance with the terms of this Note, fails to transfer or cause its transfer agent to transfer (issue) (electronically or in certificated form) any certificate for shares of Common Stock issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by this Note, the Borrower directs its transfer agent not to transfer or delays, impairs, and/or hinders its transfer agent in transferring (or issuing) (electronically or in certificated form) any certificate for shares of Common Stock to be issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by this Note, or fails to remove (or directs its transfer agent not to remove or impairs, delays, and/or hinders its transfer agent from removing) any restrictive legend (or to withdraw any stop transfer instructions in respect thereof) on any certificate for any shares of Common Stock issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by this Note (or makes any written announcement, statement or threat that it does not intend to honor the obligations described in this paragraph) and any such failure shall continue uncured (or any written announcement, statement or threat not to honor its obligations shall not be rescinded in writing) for three (3) business days after the Holder shall have delivered a Notice of Conversion. It is an obligation of the Borrower to remain current in its obligations to its transfer agent. It shall be an event of default of this Note, if a conversion of this Note is delayed, hindered or frustrated due to a balance owed by the Borrower to its transfer agent. If at the option of the Holder, the Holder advances any funds to the Borrower's transfer agent in order to process a conversion, such advanced funds shall be paid by the Borrower to the Holder within forty-eight (48) hours of a demand from the Holder.

**3.3Breach of Covenants.** The Borrower breaches any material covenant or other material term or condition contained in this Note and any collateral documents including but not limited to the Purchase Agreement and such breach continues for a period of twenty (20) days after written notice thereof to the Borrower from the Holder.

**3.4Breach of Representations and Warranties.** Any representation or warranty of the Borrower made herein or in any agreement, statement or certificate given in writing pursuant hereto or in connection herewith (including, without limitation, the Purchase Agreement), shall be false or misleading in any material respect when made and the breach of which has (or with the passage of time will have) a material adverse effect on the rights of the Holder with respect to this Note or the Purchase Agreement.

**3.5Receiver or Trustee.** The Borrower or any subsidiary of the Borrower shall make an assignment for the benefit of creditors, or apply for or consent to the appointment of a receiver or trustee for it or for a substantial part of its property or business, or such a receiver or trustee shall otherwise be appointed.

**3.6Bankruptcy.** Bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings, voluntary or involuntary, for relief under any bankruptcy law or any law for the relief of debtors shall be instituted by or against the Borrower or any subsidiary of the Borrower.

**3.7Delisting of Common Stock.** The Borrower shall fail to maintain the listing of the Common Stock on at least one of the OTC (which specifically includes the quotation platforms maintained by the OTC Markets Group) or an equivalent replacement exchange, the Nasdaq National Market, the Nasdaq SmallCap Market, the New York Stock Exchange, or the American Stock Exchange.

**3.8[Omitted].**

**3.9Liquidation.** Any dissolution, liquidation, or winding up of Borrower or any substantial portion of its business.

**3.10Cessation of Operations.** Any cessation of operations by Borrower rendering the Borrower a "shell company" as such term is defined in Rule 144, or Borrower admits it is otherwise generally unable to pay its debts as such debts become due, provided, however, that any disclosure of the Borrower's ability to continue as a "going concern" shall not be an admission that the Borrower cannot pay its debts as they become due.

**3.11Financial Statement Restatement.** The restatement of any financial statements filed by the Borrower with OTC Markets at any time after 180 days after the Issuance Date for any date or period until this Note is no longer outstanding, if the result of such restatement would, by comparison to the un-restated financial statement, have constituted a material adverse effect on the rights of the Holder with respect to this Note.

**3.12Replacement of Transfer Agent.** In the event that the Borrower proposes to replace its transfer agent, the Borrower fails to provide, prior to the effective date of such replacement, a fully executed Irrevocable Transfer Agent Instructions in a form as initially delivered pursuant to the Purchase Agreement (including but not limited to the provision to irrevocably reserve shares of Common Stock in the Reserved Amount) signed by the successor transfer agent to Borrower and the Borrower.

**ARTICLE IV. MISCELLANEOUS**

**4.1Failure or Indulgence Not Waiver.** No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privileges. All rights and remedies existing hereunder are cumulative to, and not exclusive of, any rights or remedies otherwise available.

**4.2Notices.** All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for such communications shall be:

---

| | |
|:---|:---|
| If to the Borrower: | Exousia Pro, Inc. |
|  | 7901 4th Street N #23494 |
|  | St. Petersburg, Florida 33702 |
|  | Attention: President |
|  | E-mail: matt@exousiapro.com |
| If to the Holder: | Red Phoenix Rising, LLC |
|  | 11085 Watercrest Circle East |
|  | Parkland, Florida 33076 |
|  | Attention: Thomas Roland, Managing Member |
|  | E-mail: tom.roland25@gmail.com |

---

**4.3Amendments.** This Note and any provision hereof may only be amended by an instrument in writing signed by the Borrower and the Holder. The term "Note" and all reference thereto, as used throughout this instrument, shall mean this instrument (and the other Notes issued pursuant to the Purchase Agreement) as originally executed, or if later amended or supplemented, then as so amended or supplemented.

**4.4Assignability.** This Note shall be binding upon the Borrower and its successors and assigns, and shall inure to be the benefit of the Holder and its successors and assigns. Each transferee of this Note must be an "accredited investor" (as defined in Rule 501(a) of the Securities and Exchange Commission). Notwithstanding anything in this Note to the contrary, this Note may be assigned by the Holder without the consent of the Borrower.

**4.5Cost of Collection.** If default is made in the payment of this Note, the Borrower shall pay the Holder hereof costs of collection, including reasonable attorneys' fees.

**4.6Governing Law.** This Note shall be governed by and construed in accordance with the laws of the State of Nevada without regard to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated by this Note shall be brought only in the state courts of Nevada or in the federal courts located in Las Vegas, Nevada . The parties to this Note hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. The Borrower and Holder waive trial by jury. The prevailing party shall be entitled to recover from the other party its reasonable attorney's fees and costs. In the event that any provision of this Note or any other agreement delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement. Each party hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding in connection with this Note, any agreement or any other document delivered in connection with this Note by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Note and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

**4.7Purchase Agreement.** By its acceptance of this Note, each party agrees to be bound by the applicable terms of the Purchase Agreement.

**4.8Remedies.** The Borrower acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder, by vitiating the intent and purpose of the transaction contemplated hereby. Accordingly, the Borrower acknowledges that the remedy at law for a breach of its obligations under this Note will be inadequate and agrees, in the event of a breach or threatened breach by the Borrower of the provisions of this Note, that the Holder shall be entitled, in addition to all other available remedies at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining, preventing or curing any breach of this Note and to enforce specifically the terms and provisions thereof, without the necessity of showing economic loss and without any bond or other security being required.

**IN WITNESS WHEREOF,** Borrower has caused this Note to be signed in its name by its duly authorized officer on ____________, 202__.

---

| | |
|:---|:---|
| EXOUSIA PRO, INC. | EXOUSIA PRO, INC. |
|  | **<u>Exemplar</u>** |
| By: |  |
|  | Michael Sheikh |
|  | President |

---

**EXHIBIT A**

**FORM OF NOTICE OF CONVERSION**

The undersigned hereby elects to convert $_________ principal amount and $_________ of accrued interest of the Note (defined below) into that number of shares of Common Stock to be issued pursuant to the conversion of the Note (***"Common Stock"***) as set forth below, of Raadr, Inc., a Nevada corporation (the ***"Borrower"***), according to the conditions of the convertible note of the Borrower dated as of December 9, 2024 (the ***"Note"***), as of the date written below. No fee will be charged to the Holder for any conversion, except for transfer taxes, if any.

Box Checked as to applicable instructions:

⃞The Borrower shall electronically transmit the Common Stock issuable pursuant to this Notice of Conversion to the account of the undersigned or its nominee with DTC through its Deposit Withdrawal Agent Commission system ("DWAC Transfer").

Name of DTC Prime Broker:   <br> Account Number:  

⃞The undersigned hereby requests that the Borrower issue a certificate or certificates for the number of shares of Common Stock set forth below (which numbers are based on the Holder's calculation attached hereto) in the name(s) specified immediately below or, if additional space is necessary, on an attachment hereto:

---

| | |
|:---|:---|
| Date of conversion: |  |
| Applicable Conversion Price: | $|
| Number of shares of common stock to be issued <br> pursuant to conversion of the Notes: |  |
| Amount of Principal Balance due remaining <br> under the Note after this conversion: |  |

---

---

| |
|:---|
| [ Name of Holder ] |
| By: |

---

## Ex1A-6

**EXHIBIT 6.23**

**EXOUSIA PRO, INC.**

**7901 4th Street N #23494**

**St. Petersburg, Florida 33702**

December 11, 2025

Jumpstart Rx, LLC<br> Casey Barksdale<br> 3900 SW 30<sup>th</sup> Avenue<br> Fort Lauderdale, FL 33312

**<u>Letter of Intent</u>**

Gentlemen:

This Letter of Intent summarizes certain terms under which our company (Exousia Pro) would acquire ownership, certain business opportunities and/or other assets (collectively, the "Target") from your company Jumpstart Rx, LLC., This proposed transaction is sometimes referred to as the "Transaction."

**<u>NON-BINDING TERMS</u>**

This paragraph and Sections 1 through 4 are not legally binding on either party. They would serve as the non-binding basis for an initial draft of a definitive agreement for the Transaction (the "Definitive Agreement"), which would be provided by Exousia Pro. We currently contemplate that the Definitive Agreement would include, among others, the following terms:

1. The Definitive Agreement would provide for Exousia Pro's acquisition of the Target from Jumpstart Rx, LLC., in exchange for Eight Million Dollars ($8,000,000) in a combination of cash and stock of Exousia Pro, that is being paid for NuevistraMed, LLC. The form of the Definitive Agreement would be determined by us, in consultation with our respective legal counsel and accountants.

2. We would attempt to negotiate and execute the Definitive Agreement by January 31, 2026, and would target the closing of the Definitive Agreement for approximately five (5) days thereafter, all in accordance with the terms of Definitive Agreement.

3. The Definitive Agreement would contain other terms and conditions that would be customary for transactions of this type, including customary representations, warranties, covenants and indemnities.

**<u>BINDING TERMS</u>**

This paragraph and Sections 4 through 11, which are referred to collectively as the "Binding Terms," are the legally binding and enforceable agreements of Exousia Pro and Jumpstart Rx, LLC.

4.<u>Exclusivity</u>. Throughout the period that begins on the date of this Letter of Intent and ends on the date that is 60 days from the date of mutual execution of this Letter of Intent (the "Exclusivity Period"), Jumpstart Rx, LLC., will not, directly or indirectly, solicit, initiate, seek or encourage any inquiry, proposal or offer from, furnish any information to, or participate in any discussions or negotiations with, any person regarding any purchase or other disposition of the Opportunities.

5.<u>Confidentiality</u>. The terms and existence of this Letter of Intent, and the content and existence of discussions regarding the Transaction, are confidential information and protected from disclosure by the existing Mutual Non-Disclosure and Non-Circumvention Agreement dated December 11, 2025, between our companies, which will remain in full force and effect pursuant to its terms. Notwithstanding the foregoing and the existing Mutual Non-Disclosure and Non-Circumvention Agreement, the parties agree that (a) disclosure regarding the content and existence of this Letter of Intent properly made under applicable securities laws shall not be a violation of this paragraph 5 and (b) you may disclose the existence and terms of this Letter of Intent to your professional service providers.

6.<u>Expenses</u>. Except to the extent expressly stated otherwise in the Definitive Agreement, each of Exousia Pro and Jumpstart Rx, LLC., will be responsible for and bear all of its respective costs and expenses incurred at any time in connection with pursuing or consummating the Transaction.

7.<u>No Other Obligations or Claims</u>. Nothing herein obligates either party to enter into or continue any discussions or negotiations with, solicit or accept any proposal from or enter into any definitive agreement with, the other party. Except for the Binding Terms, unless and until a final definitive agreement between the parties regarding a transaction has been executed and delivered (or except as expressly provided in any binding written agreement that either of the parties may enter into in the future), (a) neither party will be under any legal obligation of any kind regarding such a transaction by virtue of this Letter and (b) no past or future action, course of conduct or failure to act regarding a transaction, or relating to the negotiation of the terms of a transaction or the Definitive Agreement, will give rise to or serve as a basis for any obligation or other liability on the part of either party.

8.<u>Waiver and Amendment</u>. No failure or delay by either party in exercising any right, power or privilege under this Letter of Intent will operate as a waiver thereof, nor will any single or partial exercise thereof preclude any other or further exercise of any right, power or privilege hereunder. No term in this Letter of Intent can be waived or amended except in a writing signed by each party.

9.<u>Entire Agreement</u>. Other than existing confidentiality rights and obligations in any written agreement between the parties, this Letter of Intent contains the entire agreement between the parties regarding the subject matter hereof and supersedes all prior agreements or understandings between the parties with respect thereto.

10.<u>Counterparts</u>. This Letter of Intent may be executed in counterparts, each of which will be deemed an original, and all of which will constitute the same agreement.

If Jumpstart Rx, LLC., is in agreement, please sign below and return a fully executed copy of this Letter of Intent to Exousia Pro.

Very truly yours,

**Exousia Pro, Inc.**

*<u>/s/ Matthew Dwyer</u>*

Matthew Dwyer

President

**AGREED AND ACCEPTED:**

**Jumpstart Rx, LLC**

By: *<u>/s/ Casey Barksdale</u>*

Name: Casey Barksdale

Title: Managing Member

## Ex1A-6

**EXHIBIT 6.24**

**EXOUSIA PRO, INC.**

**7901 4th Street N #23494**

**St. Petersburg, Florida 33702**

December 16, 2025

Mascot Alliance, LLC<br> Kevin Singer

3900 SW 30<sup>th</sup> Avenue<br> Fort Lauderdale, FL 33312

**<u>Letter of Intent</u>**

Gentlemen:

This Letter of Intent summarizes certain terms under which our company ("Exousia Pro") would acquire ownership and/or other assets (collectively, the "Target") from your company, Mascot Alliance, LLC ("Mascot Alliance"), This proposed transaction is sometimes referred to as the "Transaction."

**<u>NON-BINDING TERMS</u>**

This paragraph and Sections 1 through 4 are not legally binding on either party. They would serve as the non-binding basis for an initial draft of a definitive agreement for the Transaction (the "Definitive Agreement"), which would be provided by Exousia Pro. We currently contemplate that the Definitive Agreement would include, among others, the following terms:

1. The Definitive Agreement would provide for Exousia Pro's acquisition of the Target from Mascot Alliance, LLC., in exchange for Five Million Dollars ($5,000,000) in a combination of cash and stock of Exousia Pro. The form of the Definitive Agreement would be determined by us, in consultation with our respective legal counsel and accountants.

2. We would attempt to negotiate and execute the Definitive Agreement by January 31, 2026, and would target the closing of the Definitive Agreement for approximately five (5) days thereafter, all in accordance with the terms of Definitive Agreement.

3. The Definitive Agreement would contain other terms and conditions that would be customary for transactions of this type, including customary representations, warranties, covenants and indemnities, as acceptable to the parties.

**<u>BINDING TERMS</u>**

This paragraph and Sections 4 through 11, which are referred to collectively as the "Binding Terms," are the legally binding and enforceable agreements of Exousia Pro and Mascot Alliance.

4.<u>Exclusivity</u>. Throughout the period that begins on the date of this Letter of Intent and ends on the date that is 60 days from the date of mutual execution of this Letter of Intent (the "Exclusivity Period"), Mascot Alliance, will not, directly or indirectly, solicit, initiate, seek or encourage any inquiry, proposal or offer from, furnish any information to, or participate in any discussions or negotiations with, any person regarding any purchase or other disposition of the Target. In the event a Definitive Agreement is not entered into, executed and delivered by and between the parties on or prior to the end 5p.m. est on a date which is the last day of the Exclusivity Period, the terms and provisions of provision of Section 4A. are hereby rendered null and void, ab initio.

4A.<u>Break-up Fee</u>. Notwithstanding the Exclusivity Period set forth in Paragraph 4, should Mascot Alliance enter into a definitive agreement regarding the sale of the Target to a party with whom Mascot Alliance previously entered into a letter of intent, then Mascot Alliance shall, by written notice (the "Termination Notice"), terminate this Letter of Intent and decline to enter into the Definitive Agreement. In such case, Mascot Alliance shall be subject to the obligation to pay a $250,000 break-up fee (the "Breakup Fee") to Exousia Pro within five (5) business days immediately following the date of the Termination Notice. The parties agree that the liability to pay the Break-up Fee shall accrue whether or not Mascot Alliance shall have delivered a Termination Notice. The parties further agree that the Break-up Fee shall be paid in cash by wire transfer of immediately available funds.

5.<u>Confidentiality</u>. The terms and existence of this Letter of Intent, and the content and existence of discussions regarding the Transaction, are confidential information and protected from disclosure by the existing Mutual Non-Disclosure and Non-Circumvention Agreement dated December 12, 2025, between our companies, which will remain in full force and effect pursuant to its terms. Notwithstanding the foregoing and the existing Mutual Non-Disclosure and Non-Circumvention Agreement, the parties agree that (a) disclosure regarding the content and existence of this Letter of Intent properly made under applicable securities laws shall not be a violation of this paragraph 5 and (b) you may disclose the existence and terms of this Letter of Intent to your professional service providers.

6.<u>Expenses</u>. Except to the extent expressly stated otherwise in the Definitive Agreement, each of Exousia Pro and Mascot Alliance, LLC., will be responsible for and bear all of its respective costs and expenses incurred at any time in connection with pursuing or consummating the Transaction.

7.<u>No Other Obligations or Claims</u>. Nothing herein obligates either party to enter into or continue any discussions or negotiations with, solicit or accept any proposal from or enter into any definitive agreement with, the other party. Except for the Binding Terms, unless and until a final definitive agreement between the parties regarding a transaction has been executed and delivered (or except as expressly provided in any binding written agreement that either of the parties may enter into in the future), (a) neither party will be under any legal obligation of any kind regarding such a transaction by virtue of this Letter and (b) no past or future action, course of conduct or failure to act regarding a transaction, or relating to the negotiation of the terms of a transaction or the Definitive Agreement, will give rise to or serve as a basis for any obligation or other liability on the part of either party.

8.<u>Waiver and Amendment</u>. No failure or delay by either party in exercising any right, power or privilege under this Letter of Intent will operate as a waiver thereof, nor will any single or partial exercise thereof preclude any other or further exercise of any right, power or privilege hereunder. No term in this Letter of Intent can be waived or amended except in a writing signed by each party.

9.<u>Entire Agreement</u>. Other than existing confidentiality rights and obligations in any written agreement between the parties, this Letter of Intent contains the entire agreement between the parties regarding the subject matter hereof and supersedes all prior agreements or understandings between the parties with respect thereto.

10.<u>Counterparts</u>. This Letter of Intent may be executed in counterparts, each of which will be deemed an original, and all of which will constitute the same agreement.

11.<u>Disputes</u>. If any legal action or any other proceeding is brought for the enforcement of this Agreement, the successful or prevailing party shall be entitled to recover reasonable attorneys' fees and other costs incurred in connection with such action or proceeding and any appeal hereunder, in addition to any other remedies available. This Agreement shall be construed, interpreted, and applied in accordance with the laws of the State of Florida (excluding its body of law controlling conflicts of law). Venue shall exclusively lie and only be in the 17th Judicial Circuit in and for Broward County, Florida. THE PARTIES HEREBY IRREVOACBLE AND UNCONDITIONALLY WAIVE ANY RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING, OR COUNTERCLAIM (WHETHER BASED UPON CONTRACT, TORT, OR OTHERWISE) RELATING TO OR ARISING OUT OF THIS AGREEMENT.

This Letter of Intent is non-binding and is merely a reflection of the parties' understanding of some of the general terms of the proposed transaction and upon which understanding the parties are willing to proceed with further discussions and negotiations, which may result in a Definitive Agreement, if, as and only to the extent same is executed and delivered by and between the parties.

If Mascot Alliance is in agreement, please sign below and return a fully executed copy of this Letter of Intent to Exousia Pro.

Very truly yours,

**Exousia Pro, Inc.**

By: *<u>/s/ Matthew Dwyer</u>*

Matthew Dwyer, President

**AGREED AND ACCEPTED:**

**Mascot Alliance, LLC**

By: *<u>/s/ Kevin Singer</u>*

Kevin Singer, Manager

## Ex1A-6

**EXHIBIT 6.25**

**EXOUSIA PRO, INC.**

**7901 4th Street N #23494**

**St. Petersburg, Florida 33702**

December 11, 2025

Island 40 Group, LLC<br> Casey Barksdale<br> 3900 SW 30<sup>th</sup> Avenue<br> Fort Lauderdale, FL 33312

**<u>Letter of Intent</u>**

Gentlemen:

This Letter of Intent summarizes certain terms under which our company (Exousia Pro) would acquire ownership, certain business opportunities and/or other assets (collectively, the "Target") from your company Island 40 Group, LLC., This proposed transaction is sometimes referred to as the "Transaction."

**<u>NON-BINDING TERMS</u>**

This paragraph and Sections 1 through 4 are not legally binding on either party. They would serve as the non-binding basis for an initial draft of a definitive agreement for the Transaction (the "Definitive Agreement"), which would be provided by Exousia Pro. We currently contemplate that the Definitive Agreement would include, among others, the following terms:

1. The Definitive Agreement would provide for Exousia Pro's acquisition of the Target from Island 40 Group, LLC., in exchange for Eight Million Dollars ($8,000,000) in a combination of cash and stock of Exousia Pro. The form of the Definitive Agreement would be determined by us, in consultation with our respective legal counsel and accountants.

2. We would attempt to negotiate and execute the Definitive Agreement by January 31, 2026, and would target the closing of the Definitive Agreement for approximately five (5) days thereafter, all in accordance with the terms of Definitive Agreement.

3. The Definitive Agreement would contain other terms and conditions that would be customary for transactions of this type, including customary representations, warranties, covenants and indemnities.

**<u>BINDING TERMS</u>**

This paragraph and Sections 4 through 11, which are referred to collectively as the "Binding Terms," are the legally binding and enforceable agreements of Exousia Pro and Island 40 Group, LLC.

4.<u>Exclusivity</u>. Throughout the period that begins on the date of this Letter of Intent and ends on the date that is 60 days from the date of mutual execution of this Letter of Intent (the "Exclusivity Period"), Island 40 Group, LLC., will not, directly or indirectly, solicit, initiate, seek or encourage any inquiry, proposal or offer from, furnish any information to, or participate in any discussions or negotiations with, any person regarding any purchase or other disposition of the Opportunities.

4A.<u>Break-up Fee</u>. Notwithstanding the Exclusivity Period set forth in Paragraph 4, should Island 40 Group, LLC. enter into a definitive agreement regarding the sale of the Target to a party with whom Island 40 Group LLC. previously entered into a letter of intent, then Island 40 Group LLC. shall, by written notice (the "Termination Notice"), terminate this Letter of Intent and decline to enter into the Definitive Agreement. In such case, Island 40 Group LLC. shall be subject to the obligation to pay a $250,000 break-up fee (the "Breakup Fee") to Exousia Pro within five (5) business days immediately following the date of the Termination Notice. The parties agree that the liability to pay the Break-up Fee shall accrue whether or not Island 40 Group LLC shall have delivered a Termination Notice. The parties further agree that the Break-up Fee shall be paid in cash by wire transfer of immediately available funds.

5.<u>Confidentiality</u>. The terms and existence of this Letter of Intent, and the content and existence of discussions regarding the Transaction, are confidential information and protected from disclosure by the existing Mutual Non-Disclosure and Non-Circumvention Agreement dated December 11, 2025, between our companies, which will remain in full force and effect pursuant to its terms. Notwithstanding the foregoing and the existing Mutual Non-Disclosure and Non-Circumvention Agreement, the parties agree that (a) disclosure regarding the content and existence of this Letter of Intent properly made under applicable securities laws shall not be a violation of this paragraph 5 and (b) you may disclose the existence and terms of this Letter of Intent to your professional service providers.

6.<u>Expenses</u>. Except to the extent expressly stated otherwise in the Definitive Agreement, each of Exousia Pro and Island 40 Group, LLC., will be responsible for and bear all of its respective costs and expenses incurred at any time in connection with pursuing or consummating the Transaction.

7.<u>No Other Obligations or Claims</u>. Nothing herein obligates either party to enter into or continue any discussions or negotiations with, solicit or accept any proposal from or enter into any definitive agreement with, the other party. Except for the Binding Terms, unless and until a final definitive agreement between the parties regarding a transaction has been executed and delivered (or except as expressly provided in any binding written agreement that either of the parties may enter into in the future), (a) neither party will be under any legal obligation of any kind regarding such a transaction by virtue of this Letter and (b) no past or future action, course of conduct or failure to act regarding a transaction, or relating to the negotiation of the terms of a transaction or the Definitive Agreement, will give rise to or serve as a basis for any obligation or other liability on the part of either party.

8.<u>Waiver and Amendment</u>. No failure or delay by either party in exercising any right, power or privilege under this Letter of Intent will operate as a waiver thereof, nor will any single or partial exercise thereof preclude any other or further exercise of any right, power or privilege hereunder. No term in this Letter of Intent can be waived or amended except in a writing signed by each party.

9.<u>Entire Agreement</u>. Other than existing confidentiality rights and obligations in any written agreement between the parties, this Letter of Intent contains the entire agreement between the parties regarding the subject matter hereof and supersedes all prior agreements or understandings between the parties with respect thereto.

10.<u>Counterparts</u>. This Letter of Intent may be executed in counterparts, each of which will be deemed an original, and all of which will constitute the same agreement.

If Island 40 Group, LLC., is in agreement, please sign below and return a fully executed copy of this Letter of Intent to Exousia Pro.

Very truly yours,

**Exousia Pro, Inc.**

*<u>/s/ Matthew Dwyer</u>*

Matthew Dwyer

President

**AGREED AND ACCEPTED:**

**Island 40 Group, LLC**

By: *<u>/s/ Casey Barksdale</u>*

Name: Casey Barksdale

Title: Managing Member

## Ex1A-6

**EXHIBIT 6.26**

**PLAN AND AGREEMENT OF REORGANIZATION**

This Plan and Agreement of Reorganization (the ***"Plan of Reorganization"***) is entered into as of the 11th day of November, 2025, by and among L A M Y, a Wyoming corporation (***"Purchaser"***), and those persons executing this Plan of Reorganization below, all of whom are shareholders of Exousia Ai, Inc., a Florida corporation (the ***"Acquired Corporation"***). These persons, as a group, are sometimes referred to collectively in this Plan of Reorganization as the ***"Shareholders"***. The Shareholders own, in the aggregate, 100% of all of the outstanding shares of capital stock of the Acquired Corporation.

This Plan of Reorganization comprises a reorganization within the meaning of Section 368(a)(1)(B) of the Internal Revenue Code of 1986, as amended. Purchaser will acquire from the Shareholders all of the issued and outstanding shares of capital stock of Acquired Corporation, in exchange solely for shares of voting stock of Purchaser. Under this Plan of Reorganization, Acquired Corporation will become a wholly-owned subsidiary of Purchaser.

In order to consummate this Plan of Reorganization, Purchaser and the Shareholders, in consideration of the mutual covenants and on the basis of the representations and warranties set forth, agree as follows:

**Article 1. Exchange of Capital Stock.**

**1.01.Transfer of Acquired Corporation's Capital Stock.** Subject to the terms and conditions of this Plan of Reorganization, the Shareholders will transfer and deliver to Purchaser, on or before the Closing Date, certificates for shares of capital stock of Acquired Corporation, duly endorsed in blank, as follows:

---

| | |
|:---|:---|
| <br> **Name of Shareholder** | **Shares of Capital Stock**<br> **of Acquired Corporation** |

---

Exousia Pro Holding Management, LLC Progenicyte Japan CO., LTD. 70,000 shares of Common Stock 30,000 shares of Series A Preferred Stock

**1.02.Consideration for Transfer.** In exchange for the number of shares transferred by the Shareholders pursuant to Section 1.01, Purchaser shall issue and cause to be delivered to the Shareholders, on the Closing Date, a total of 62,223,000 shares of common stock of Purchaser (the ***"Purchaser Common Stock"***), as follows:

---

| | |
|:---|:---|
| <br> **Name of Shareholder** | **Shares of Purchaser**<br> **Common Stock** |

---

Exousia Pro Holding Management, LLC Progenicyte Japan CO., LTD. <u> 41,223,000 shares 21,000,000 shares</u>

---

| | |
|:---|:---|
| Total Shares | 62,223,000 shares |

---

**1.03.The Closing; Closing Date.** Unless this Plan of Reorganization shall have been terminated and the transactions herein contemplated shall have been abandoned, the closing date of this Plan of Reorganization (the ***"Closing"***) will take place on the business day upon satisfaction of the conditions set forth in Article 6 (or as soon as practicable thereafter following satisfaction or waiver of the conditions set forth in Article 6) (the ***"Closing Date"***), at such time and location as may be agreed upon by Parent and Acquired Company.

Consummation shall include the delivery by the Shareholders of their respective shares of capital stock of Acquired Corporation and the delivery by Purchaser of the Purchaser Common Stock, as provided in Sections 1.01 and 1.02 of this Plan of Reorganization, respectively.

**Article 2. Representations and Warranties of the Shareholders.**

The Shareholders, and each of them, represent and warrant, as of the date of this Plan of Reorganization and as of the Closing Date, as follows:

**2.01.Organization and Standing of Acquired Corporation.** Acquired Corporation is a corporation duly organized, validly existing and in good standing under the laws of the State of Florida, with corporate power to own property and carry on its business as it is now being conducted. Acquired Corporation is qualified to transact business as a foreign corporation and is in good standing in all jurisdictions in which it carries on business or in which any of its principal properties are located.

**2.02.Subsidiaries.** Acquired Corporation has no subsidiaries nor any interest in any other corporation, firm, partnership or other juridical entity.

**2.03.Capitalization.** Acquired Corporation has an authorized capitalization of 100,000,000 shares of $.001 par value common stock and 5,000,000 shares of $.001 par value preferred stock. As of the date of this Plan of Reorganization, 70,000 shares of $.001 par value common stock are issued and outstanding, fully paid and non-assessable and 30,000 shares of $.001 par value Series A Preferred Stock are issued and outstanding, fully paid and non-assessable. There are no outstanding subscriptions, options, contracts, commitments or demands relating to the authorized but unissued capital stock of Acquired Corporation or other agreements of any character under which Acquired Corporation would be obligated to issue or purchase shares of its capital stock.

**2.04.Financial Statements.** The Shareholders shall deliver to Purchaser, prior to Closing, unaudited financial statements of Acquired Corporation for the years ended December 31, 2024 and 2023. All such financial statements shall have been prepared in accordance with generally accepted accounting principles (GAAP), such financial statements are capable of PCAOB audit and the Shareholders shall cause Acquired Corporation to deliver to Purchaser, prior to the 75th day following the Closing, audited financial statements for the years ended December 31, 2024 and 2023.

In addition, Purchaser acknowledges receipt of Acquired Corporation's unaudited financial statements for the nine months ended September 30, 2025. September 30, 2025, is referred to as the ***"Financial Statement Date"***.

**2.05.Operations Since Financial Statement Date.** Since the Financial Statement Date, Acquired Corporation has not, and prior to the Closing Date will not have, without written consent to Purchaser:

**(a)**Issued or sold any stock, bond or other corporate securities;

**(b)**Except for current liabilities incurred and obligations entered into in the usual and ordinary course of business, incurred any absolute or contingent obligation, including long-term debt;

**(c)**Except for current liabilities shown on the balance sheet and current liabilities incurred since the Financial Statement Date in the usual and ordinary course of business, discharged or satisfied any lien or encumbrance, or paid any obligation or liability;

**(d)**Mortgaged, pledged or subjected to lien any of its assets;

**(e)**Except in the usual and ordinary course of business, sold or transferred any of its tangible assets, or canceled any debts or claims, or waived any rights of substantial value;

**(f)**Sold, assigned or transferred any patents, formulas, trademarks, trade names, copyrights, licenses, or other intangible assets;

**(g)**Incurred any materially adverse losses or damage, or become involved in any strikes or other labor disputes; or

**(h)**Entered into any transaction other than in the usual and ordinary course of business.

**2.06.Title to Assets.** Acquired Corporation has good and marketable title to all its assets; none of such assets is subject to any mortgage, pledge, lien, charge, security interest, encumbrance or restriction.

**2.07.Schedule of Assets.** Prior to the Closing Date, Acquired Corporation will have delivered to Purchaser a separate <u>Schedule of Assets</u>, specifically referring to this Section 2.07, containing a true and complete:

**(a)**Legal description of all real property owned by Acquired Corporation and any real property for which Acquired Corporation has an option to purchase, or holds a leasehold interest;

**(b)**Aged list of accounts receivable as of the Closing Date;

**(c)**List of all capitalized machinery, tools, equipment and rolling stock owned by Acquired Corporation that sets forth any liens, claims, encumbrances, charges, restrictions, covenants and conditions concerning the listed items;

**(d)**Description of all machinery, tools, equipment and rolling stock in which Acquired Corporation has a leasehold interest, with a description of each interest;

**(e)**List of all Internet domain names in which Acquired Corporation has an interest, ownership or otherwise;

**(f)**List of all patents, patent licenses, trademarks, trademark registrations, trade names, copyrights, and copyright registrations owned by Acquired Corporation, including copies thereof; and

**(g)**List of all fire and other casualty and liability insurance policies of Acquired Corporation in effect at the time of delivery of such schedule, including copies thereof.

**2.08.Indebtedness.**

**(a)**Acquired Corporation presently has no outstanding indebtedness other than liabilities incurred in the usual and ordinary course of business. Acquired Corporation is not in default with respect to any terms or conditions of any indebtedness.

**(b)**Acquired Corporation has not made any assignment for the benefit of creditors, nor has any involuntary or voluntary petition in bankruptcy been filed by or against Acquired Corporation.

**2.09.Litigation.**

**(a)**Acquired Corporation is not party to, nor has it been threatened with, any litigation or governmental proceeding. Acquired Corporation is not aware of any facts that might result in any action, suit or other proceeding that would result in any material adverse change in the business or financial condition of Acquired Corporation.

**(b)**Acquired Corporation is not infringing on, or otherwise acting adversely to, any copyrights, trademark rights, patent rights or licenses owned by any other person, and there is no pending claim or threatened action with respect to such rights. Acquired Corporation is not obligated to make any payments in the form of royalties, fees, or otherwise to any owner or licensor of any patent, trademark, trade name or copyright.

**2.10.Compliance With Law and Other Instruments.** The business operations of Acquired Corporation have been, and currently are being, conducted in accordance with all applicable laws, rules and regulations of all authorities, including, without limitation, state franchise registration and/or business opportunity laws and regulations, or laws similar thereto. Acquired Corporation is not in violation of, or in default under, any term or provision of its Certificate of Incorporation, its bylaws or of any lien, mortgage, lease, agreement, instrument, order, judgment or decree, or any other type of restriction that would prevent consummation of the exchange of securities contemplated by this Plan of Reorganization.

**2.11.Contractual Obligations.** Acquired Corporation is not a party to, or bound by, any written or oral:

**(a)**Contract not made in the usual and ordinary course of business;

**(b)**Employment or consultant contract that is not terminable at will without cost or other liability to Acquired Corporation or any successor;

**(c)**Contract with any labor union;

**(d)**Bonus, pension, profit-sharing, retirement, stock option, hospitalization, group insurance or similar plan providing employee benefits;

**(e)**Any real or personal property lease as lessor;

**(f)**Advertising contract or contract for public relations services;

**(g)**Purchase, supply or service contracts in excess of $50,000 each, or in the aggregate of $50,000 for all such contracts;

**(h)**Deed of trust, mortgage, conditional sales contract, security agreement, pledge agreement, trust receipt or any other agreement subjecting any of the assets or properties of Acquired Corporation to a lien, encumbrance or other restriction;

**(i)**Term contract continuing for a period of more than 30 days that is not terminable without liability to Acquired Corporation or its successors; or

**(j)**Contract that contains a redetermination of price or similar type of provision.

Acquired Corporation has performed all obligations required to be performed by it to date and is not in material default under any of the contracts, leases or other arrangements by which it is bound. None of the parties with whom Acquired Corporation has contractual arrangements are in default of their obligations.

**2.12.Changes in Compensation.** Since the Financial Statement Date, Acquired Corporation has not granted any general pay increase to employees or changed the rate of compensation, commission or bonus payable to any officer, employee, director, agent or shareholder.

**2.13.Records.** All of the account books, minute books, stock certificate books and stock transfer ledgers of Acquired Corporation are complete and accurate.

**2.14.Taxes.** Acquired Corporation has filed all required income tax returns as of the date of this Plan of Reorganization. Acquired Corporation owes no income taxes.

**2.15.Full Disclosure.** As of the Closing Date, the Shareholders will, and will have caused Acquired Corporation to, have disclosed all events, conditions and facts materially affecting the business and prospects of Acquired Corporation. Neither the Shareholders nor Acquired Corporation has withheld knowledge of any events, conditions and facts that it has reasonable ground to know may materially affect the business and prospects of Acquired Corporation. None of the representations and warranties made by the Shareholders in this Plan of Reorganization, or set forth in any other instrument furnished to Purchaser, contain any untrue statement of a material fact, fail to state material facts or fail to state facts necessary to make the statements of fact made not misleading.

**2.16.Ownership of Acquired Corporation's Capital Stock.** Each of the Shareholders executing this Plan of Reorganization is, on the date of this Plan of Reorganization, and on the Closing Date will be, the lawful owner of the number of shares of capital stock of Acquired Corporation that is set forth opposite each such Shareholder's name in Section 1.01 of this Plan of Reorganization. Each of the Shareholders executing this Plan of Reorganization has the legal right and power to sell, assign and transfer the shares of such Shareholder of the capital stock of Acquired Corporation. The delivery of the described shares to the Purchaser pursuant to the provisions of this Plan of Reorganization will transfer valid title to the shares free and clear of all liens, encumbrances, claims and other restrictions of any kind.

**2.17.Waiver of Preemptive Rights; No Rights of Refusal.** Each of the Shareholders executing this Plan of Reorganization has waived, and does hereby waive, any preemptive or prescriptive right to purchase shares of Acquired Corporation that each such Shareholder has or may have had in the past. None of the Shareholders executing this Plan of Reorganization is subject to a right of first refusal as to his, her or its common stock of Acquired Corporation.

**2.18.No Brokers or Finders.** All negotiations related to this Plan of Reorganization on the part of each of the Shareholders executing this Plan of Reorganization have been accomplished solely by such Shareholders without the assistance of any person employed as a broker or finder. None of the Shareholders executing this Plan of Reorganization has done anything to give rise to any valid claims against Purchaser or Acquired Corporation for a brokerage commission, finder's fee or any similar charge.

**Article 3. Representations and Warranties of Purchaser.**

**3.01.Securities Act Disclosure - Information With Respect to Purchaser.** Purchaser files annual and other periodic reports with the SEC pursuant to the Securities Exchange Act of 1934 (the ***"1934 Act"***). The periodic reports, as filed with the SEC by Purchaser, are incorporated herein by this reference. Purchaser represents and warrants that the information contained in the documents incorporated by reference accurately reflects its business operations and current financial condition.

**3.02.Organization and Standing of Purchaser.** Purchaser is a corporation duly organized, validly existing and in good standing under the laws of the State of Wyoming, with corporate power to own property and carry on its business as it is now being conducted.

**3.03.Subsidiaries.** Purchaser has no subsidiaries.

**3.04.Capitalization.** Purchaser has an authorized capitalization of 100,000,000 shares of common stock of the par value of $.001 per share, of which 7,777,000 shares are issued, outstanding and fully paid, as of the date of this Plan of Reorganization. There are no outstanding options, contracts, calls, commitments or demands relating to the authorized but unissued capital stock of Purchaser.

**3.05.Financial Statements.** A copy of Purchaser's unaudited financial statements for the six months ended July 31, 2025, has been delivered previously to the Shareholders and are made a part hereof. Such financial statements present fairly the financial condition of Purchaser as of the date thereof.

**3.06.Financial Condition Since July 31, 2025.** Since July 31, 2025, Purchaser has not made any transfer of any of its operating assets other than in the ordinary course of business.

**3.07.Title to Assets.** All book assets of Purchaser are in existence and in its possession, are in good condition and repair and conform to all applicable laws, regulations and ordinances. Purchaser has good and marketable title to all of its assets and holds such assets subject to no mortgage, lien or encumbrance.

**3.08.Status of Purchaser Common Stock.** The Purchaser Common Stock an the shares of Purchaser Preferred Stock to be issued and delivered to the Shareholders pursuant to the terms of this Plan of Reorganization will be validly authorized and issued, and will be fully paid and non-assessable. No shareholder of Purchaser will have any preemptive right of subscription or purchase with respect to the Purchaser Common Stock to be issued and delivered hereunder.

**3.09.Indebtedness.** Purchaser has no single outstanding indebtedness in excess of $50,000.

**3.10.Litigation.** Purchaser is not a party to, nor has it been threatened with, any litigation or governmental proceeding that could have a materially adverse affect on the transactions contemplated by this Plan of Reorganization or on the financial condition of Purchaser.

**3.11.Purchaser's Authority.** The execution and performance of this Plan of Reorganization have been duly authorized by all requisite corporate action. This Plan of Reorganization constitutes a valid and binding obligation of Purchaser, in accordance with its terms. No provision of the Purchaser's Articles of Incorporation, Bylaws, minutes, share certificates or contracts prevents Purchaser from delivering good title to the Purchaser Common Stock in the manner contemplated by this Plan of Reorganization.

**3.12.Brokers and Finders.** All negotiations on the part of the Purchaser related to this Plan of Reorganization have been accomplished solely by the Purchaser without the assistance of any person employed as a broker or finder. The Purchaser has done nothing to give rise to any valid claims against the Shareholders for a brokerage commission, finder's fee or any similar charge.

**3.13.Taxes.** Purchaser has filed all required income tax returns. Purchaser owes no income taxes.

**3.14.Full Disclosure.** As of the Closing Date, Purchaser will have disclosed to the Shareholders all events, conditions and facts materially affecting the business and prospects of Purchaser. Purchaser has not withheld knowledge of any events, conditions or facts it has reasonable ground to know may materially affect the business and prospects of Purchaser. None of the representations and warranties made by the Purchaser in this Plan of Reorganization or set forth in any other instrument furnished to the Shareholders contain any untrue statement of a material fact, fail to state material facts or fail to state facts necessary to make the statements of fact made not misleading.

**Article 4. Conduct of Business of Acquired Corporation Pending Closing Date.**

**4.01.Conduct of Business in Its Usual and Ordinary Course.** Acquired Corporation shall carry on its business in substantially the same manner as previous to the date of execution of this Plan of Reorganization, and to:

**(a)**Continue in full force the amount and scope of insurance coverage carried prior to that date;

**(b)**Maintain its business organization and keep it intact, to retain its present employees and to maintain its goodwill with suppliers, customers and others having business relationships with it;

**(c)**Exercise due diligence in safeguarding and maintaining confidential reports and data used in its business; and

**(d)**Maintain its assets and properties in good condition and repair, and not sell or otherwise dispose of any of its assets or properties, except sales of inventory in the usual and ordinary course of business.

**4.02.Satisfy Conditions Precedent.** Acquired Corporation shall satisfy all conditions precedent contained in this Plan of Reorganization.

**4.03.Access to Information and Documents.**

**(a)**The Shareholders shall, and shall cause Acquired Corporation to, afford the officers and representatives of Purchaser, from the date of this Plan of Reorganization until consummation hereof, full access during normal business hours to all properties, books, accounts, contracts, commitments and any other records of any kind of Acquired Corporation. Sufficient access shall be allowed to provide Purchaser with full opportunity to make any investigation it desires to make of Acquired Corporation and to keep itself fully informed of the affairs of Acquired Corporation.

**(b)**In addition, the Shareholders shall, and shall cause Acquired Corporation to, permit Purchaser to make extracts or copies of all such books, accounts, contracts, commitments and records, and to furnish to Purchaser, on demand, any further financial and operating data of Acquired Corporation as Purchaser reasonably requests.

**(c)**Purchaser will use any information obtained under this paragraph only for its own purposes in connection with the consummation of the transaction contemplated by this Plan of Reorganization, and will not divulge the information to any other person. In the event the transaction contemplated by this Plan of Reorganization is not consummated within ninety (90) days of the date of mutual execution, all documents or information gathered by Purchaser hereunder will be returned to Acquired Corporation forthwith, unless such period shall be extended by mutual consent.

**4.04.Negative Covenants.** Except with the prior written consent of Purchaser, the Shareholders shall cause Acquired Corporation not to:

**(a)**Incur any liabilities, other than current liabilities incurred in the usual and ordinary course of business;

**(b)**Incur any mortgage, lien, pledge, hypothecation, charge, encumbrance or restriction of any kind;

**(c)**Become a party to any contract, or renew, extend or modify any existing contract, except in the usual and ordinary course of business;

**(d)**Make any capital expenditures, except for ordinary repairs, maintenance and replacement;

**(e)**Declare or pay any dividend, or make any other distribution, to shareholders;

**(f)**Purchase, retire or redeem any shares of its capital stock;

**(g)**Issue or sell any warrants, rights or options to acquire any shares of its capital stock;

**(h)**Amend its Articles of Incorporation or Bylaws;

**(i)**Pay or agree to pay any bonus, increase in compensation, pension or severance pay to any director, shareholder, officer, consultant, agent or employee;

**(j)**Discharge or satisfy any lien or encumbrance, nor pay any obligation or liability, except current liabilities shown on the Financial Statement dated September 30, 2025, or incurred in the usual and ordinary course of business since that date;

**(k)**Merge or consolidate with any other entity;

**(l)**Enter into any transactions or take any acts that would constitute a breach of the representations and warranties contained in this Plan of Reorganization; and

**(m)**Institute, settle, or agree to settle, any action or proceeding before any court or governmental body.

**4.05.Consultation.** Acquired Corporation will consult with Purchaser at all times until the Closing Date with respect to the operation and conduct of Acquired Corporation's business.

**Article 5. Conduct of Business of Purchaser Pending Closing Date.**

**5.01.Conduct of Business in Its Ordinary Course.** Purchaser will carry on its business in substantially the same manner as before the date of execution of this Plan of Reorganization.

**5.02.Satisfy Conditions Precedent.** Purchaser will use its best efforts to satisfy all conditions precedent contained in this Plan of Reorganization.

**5.03.Access to Information and Documents.**

**(a)**Purchaser will provide the Shareholders, from the date of this Plan of Reorganization until the consummation hereof, full access during normal business hours to all properties, books, accounts, contracts, commitments and records of Purchaser. Sufficient access shall be allowed to provide the Shareholders with full opportunity to make any investigation they desire to make of Purchaser and to keep themselves fully informed of the affairs of Purchaser.

**(b)**Purchaser will permit the Shareholders to make extracts or copies of all books, accounts, contracts, commitments and records. Additionally, Purchaser will furnish to the Shareholders, within three (3) days after demand, any further financial and operating data and other information concerning its business and assets that the Shareholders reasonably requests.

**(c)**The Shareholders will use any information obtained under this paragraph only for their own purposes in connection with the consummation of the transaction contemplated by this Plan of Reorganization, and will not divulge the information to any other person. In the event the transaction contemplated hereby is not consummated within ninety (90) days of the date of mutual execution, all documents or information gathered by the Shareholders hereunder will be returned to Purchaser forthwith, unless such period shall be extended by mutual consent.

**Article 6. Reserved.**

**Article 7. Conditions Precedent to Obligations of Shareholders.**

**7.01.Conditions Precedent to Closing.** The obligations of the Shareholders, and each of them, to consummate this Plan of Reorganization shall be subject to the conditions precedent specified in this Article 7.

**7.02.Truth of Representations and Warranties and Compliance With Covenants.** The representations and warranties of Purchaser contained in this Plan of Reorganization shall be true as of the Closing Date with the same effect as though made on the Closing Date. Purchaser shall have performed all obligations and complied with all covenants required by this Plan of Reorganization to be performed or complied with by it prior to the Closing Date. Purchaser shall deliver to the Shareholders a certificate, in the form of Exhibit 7.02 attached hereto and made a part hereof, dated as of the Closing Date and signed by the Chief Executive Officer of Purchaser, certifying the truth of the representations and warranties.

**7.03.Resignations and Appointments.** The current sole officer and director of Purchaser shall have delivered to Purchaser his written resignation from all positions with Purchaser and Purchaser shall have delivered to the Shareholders a true and correct copy of resolutions of the Board of Directors of Purchaser accepting such resignation of the current sole officer and director, effective as of Closing, and electing Matthew Dwyer as the sole officer and director of Purchaser, effective immediately upon the Closing.

**7.04.No Restrictions.** No action or proceeding by any governmental body or agency shall have been threatened, asserted or instituted to prohibit the consummation of the transactions contemplated herein.

**Article 8. Conditions Precedent to Obligations of Purchaser.**

**8.01.Conditions Precedent to Closing.** The obligations of Purchaser to consummate this Plan of Reorganization shall be subject to the conditions precedent specified in this Article 8.

**8.02.Truth of Representations and Warranties and Compliance With Covenants.** The representations and warranties of the Shareholders, and each of them, contained in this Plan of Reorganization shall be true as of the Closing Date, with the same effect as though made on the Closing Date.

The Shareholders, and each of them, shall have performed all obligations and complied with all covenants required by this Plan of Reorganization to be performed or complied with by them prior to the Closing Date.

The Shareholders shall deliver to Purchaser a certificate, in the form of Exhibit 8.02 attached hereto and made a part hereof, dated the Closing Date and signed by each of them, certifying the truth of the representations and warranties.

**8.03.Retention of Officers and Directors.** The present officers and directors of Acquired Corporation shall remain in office subsequent to the Closing and until their earlier resignation or removal.

**8.04.No Restrictions.** No action or proceeding by any governmental body or agency shall be threatened, asserted or instituted that prohibits the consummation of the transactions contemplated herein.

**8.05.No Contracts Terminated.** Acquired Corporation shall not have terminated any contracts prior to the Closing Date that, in the aggregate, would materially and adversely affect its business.

**8.06.No Damage to Assets.** At the Closing Date, the machinery, equipment, inventory or other tangible property of Acquired Corporation shall not be damaged by fire, flood, accident, labor strife, act of war or any other cause beyond the reasonable power and control of Acquired Corporation or the Shareholders to an extent that substantially affects the value of the property and assets. Loss or damage shall be considered to affect substantially the value of the properties and assets within the meaning of this paragraph, if the book value of the properties and assets lost or damaged exceeds ten percent (10%) of the total book value of all assets of Acquired Corporation.

**Article 9. Survival of Warranties and Indemnification.**

**9.01.Nature and Survival of Representations and Warranties.** All statements of fact contained in this Plan of Reorganization, or in any memorandum, certificate, letter, document or other instrument delivered by or on behalf of Acquired Corporation, Purchaser or the Shareholders pursuant to this Plan of Reorganization shall be deemed representations and warranties made by any such party, respectively, to each other party under this Plan of Reorganization. The covenants, representations and warranties of Purchaser and the Shareholders shall survive the Closing Date, and all inspections, examinations, or audits on behalf of the parties and the Shareholders for a period of one year following the Closing Date, except that the same shall survive for a period of three years with respect to issues relating to fraud and federal income taxes.

**9.02.Indemnification by the Shareholders.** The Shareholders, and each of them, jointly and severally, agree to indemnify and hold Purchaser, its officers, agents and attorneys harmless after the date of this Plan of Reorganization in respect to any damages as defined in this Section 9.02. Damages, as used in this paragraph, shall include any claim, action, demand, loss, cost, expense, liability, penalty and other damage, including, but not limited to, attorney's fees and other costs and expenses incurred attempting to avoid damages or in enforcing this indemnity, resulting to Purchaser from:

**(a)**Any materially inaccurate representation made by the Shareholders in, or pursuant to, this Plan of Reorganization;

**(b)**Material breach of any of the warranties by the Shareholders in, or pursuant to, this Plan of Reorganization; or

**(c)**Material breach or default of any of the obligations to be performed by the Shareholders under this Plan of Reorganization.

The Shareholders, and each of them, jointly and severally, shall be required to reimburse Purchaser for any payment made or loss suffered by Purchaser, at any time after the Closing Date, based on the judgment of any arbitrator or any court of competent jurisdiction or pursuant to a bona fide compromise or settlement of claims, demands or actions with respect to any damages described in this paragraph.

**9.03.Indemnification by Purchaser.** Purchaser agrees to indemnify and hold the Shareholders, and each of them, harmless after the date of this Plan of Reorganization in respect to any damages as defined in this Section 9.03. Damages, as used in this paragraph, shall include any claim, action, demand, loss, cost, expense, liability, penalty and other damage, including, but not limited to, attorney's fees and other costs and expenses incurred attempting to avoid damages or in enforcing this indemnity, resulting to the Shareholders from:

**(a)**Any materially inaccurate representation made by, or on behalf of, Purchaser in, or pursuant to, this Plan of Reorganization;

**(b)**Material breach of any warranty by Purchaser in, or pursuant to, this Plan of Reorganization; or

**(c)**Material breach or default of any of the obligations to be performed by Purchaser under this Plan of Reorganization.

Purchaser shall be required to reimburse the Shareholders, and each of them, for any payment made or loss suffered by the Shareholders, at any time after the Closing Date, based on the judgment of any arbitrator or any court of competent jurisdiction or pursuant to a bona fide compromise or settlement of claims, demands or actions with respect to any damages described in this paragraph.

**9.04.Expenses.** The Shareholders, and each of them, including Acquired Corporation, shall pay all of their own expenses incurred by them arising out of this Plan of Reorganization and the transactions contemplated in this Plan of Reorganization, including, but not limited to, all fees and expenses of their counsel and accountants. Whether or not this Plan of Reorganization is terminated, each of the parties shall bear all of their respective expenses incurred by them in connection with this Plan of Reorganization and in the consummation of the transactions contemplated by, and in preparation of, this Plan of Reorganization.

**Article 10. Compliance with Securities Laws.**

**10.01.Unregistered Stock Under Federal Securities Act.** The Shareholders, and each of them, acknowledge that the shares of the Purchaser Common Stock to be delivered to the Shareholders pursuant to this Plan of Reorganization have not been registered under the Securities Act of 1933, as amended (the ***"1933 Act"***), and that, therefore, the shares of Purchaser Common Stock are not transferable, except as permitted under various exemptions contained in the 1933 Act and the Rules of the Securities and Exchange Commission (the ***"SEC"***) under the 1933 Act. The provisions contained in this Section 10.01 are intended to ensure compliance with the 1933 Act.

**10.02No Distribution of Stock to Public.** The Shareholders, and each of them, represent and warrant to Purchaser that the Shareholders are acquiring the shares of the Purchaser Common Stock under this Plan of Reorganization for the Shareholders' respective accounts for investment, and not for the purpose of resale or any other distribution of the shares. The Shareholders, and each of them, also represent and warrant that the Shareholders have no present intention of disposing of all or any part of such shares at any particular time, for any particular price or on the happening of any particular circumstances. The Shareholders, and each of them, acknowledge that Purchaser is relying on the truth and accuracy of the warranties and representations set forth in this paragraph in issuing the shares, without first registering the shares under the 1933 Act.

**10.03No Transfers in Violation of the 1933 Act.** The Shareholders, and each of them, covenant and represent that none of the shares of Purchaser Common Stock that will be issued to the Shareholders pursuant to this Plan of Reorganization will be offered, sold, assigned, pledged, transferred or otherwise disposed of, except after full compliance with all of the applicable provisions of the 1933 Act and the rules and regulations of the SEC under the 1933 Act. Therefore, the Shareholders, and each of them, agree not to sell or otherwise dispose of any of the shares of the Purchaser Common Stock received pursuant to this Plan of Reorganization, unless the Shareholders:

**(a)**Have delivered to Purchaser a written legal opinion in form and substance satisfactory to counsel for Purchaser, to the effect that the disposition is permissible under the terms of the 1933 Act and regulations under the 1933 Act;

**(b)**Have complied with the registration and prospectus requirements of the 1933 Act relating to such a disposition; or

**(c)**Have presented Purchaser satisfactory evidence that such a disposition is exempt from registration under the 1933 Act.

Purchaser shall place a stop transfer order against transfer of shares, until one of the conditions set forth in this Section 10.03 has been met.

**10.04Investment Legend.** The Shareholders, and each of them, agree that the book entry statements evidencing the Purchaser Common Stock to be delivered to the Shareholders hereunder will bear the following, or substantially similar, legend affixed thereto:

"THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN TAKEN FOR INVESTMENT. THE SECURITIES MAY NOT BE SOLD OR OFFERED FOR SALE UNLESS A REGISTRATION STATEMENT UNDER THE FEDERAL SECURITIES ACT OF 1933, AS AMENDED, IS IN EFFECT AS TO THE SECURITIES, OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT IS IN FACT APPLICABLE TO SUCH OFFER OR SALE."

**10.05Indemnification by the Shareholders.** If, at any time in the future, the Shareholders, or any of them, sell or otherwise dispose of any of the shares of Purchaser Common Stock in violation of the provisions of the 1933 Act or the Rules and Regulations of the SEC promulgated thereunder, or any similar federal or state law, rule or regulation that may then be in effect, the Shareholders, and each of them, agree to indemnify and hold harmless Purchaser against any claims, liabilities, penalties, costs and expenses that may be asserted against or suffered by Purchaser as a result of such disposition.

**Article 11. Termination.**

**11.01.Default.** Purchaser or the Shareholders, acting as a group, may, by written notice, on or at any time prior to the Closing Date, terminate this Plan of Reorganization by notice to the other party in the event:

**(a)**One party has determined that any material representation of the other party is untrue;

**(b)**The other party has defaulted under the Plan of Reorganization by failing to perform any of its covenants and agreements contained in this Plan of Reorganization; and

**(c)**Each default has not been fully cured within three (3) days after receipt of the notice specifying particularly the nature of the default.

**11.02.Delay.** If consummation of the transaction specified in this Plan of Reorganization has not occurred by 11:59 p.m., Eastern Time, on November 17, 2025, any party that is not in default in the timely performance of any of its covenants and conditions may terminate this Plan of Reorganization subsequent to that time by giving written notice of termination to the other party. The written notice of termination shall be effective upon the delivery of the notice in person to an officer of the party or, if served by mail or overnight courier, upon the receipt of the notice by such party.

**11.03.Damage or Loss – Acquired Corporation.** Purchaser may, at its option, terminate this Plan of Reorganization prior to the Closing Date, if Acquired Corporation has suffered any damage, destruction or loss (whether or not covered by insurance) that materially and adversely affects the property, business or financial condition of Acquired Corporation. Damage, destruction or loss shall be considered materially and adversely to affect the properties, business or financial condition of Acquired Corporation if the book or market value (whichever is lower) of the assets damaged, destroyed or lost exceeds ten percent (10%) in book or market value (whichever is lower) of all assets of Acquired Corporation.

**11.04.Damage or Loss – Purchaser.** The Shareholders, acting as a group, may, at their option, terminate this Plan of Reorganization prior to the Closing Date, if Purchaser has suffered any damage, destruction or loss (whether or not covered by insurance) that materially and adversely affects the property, business or financial condition of Purchaser. Damage, destruction or loss shall be considered materially and adversely to affect the properties, business or financial condition of Purchaser if the book or market value (whichever is lower) of the assets damaged, destroyed or lost exceeds ten percent (10%) in book or market value (whichever is lower) of all assets of Purchaser.

**Article 12. Miscellaneous.**

**12.01.Public Announcements.** Purchaser shall have the exclusive right to issue one ore more press releases or otherwise make any public statements with respect to the existence of this Plan of Reorganization or the transactions contemplated herein; provided, however, that the Shareholders shall have the right to pre-approve any such press release or public statements, which approval shall not be unreasonably withheld.

**12.02.Amendments.** This Plan of Reorganization may be amended or modified at any time and in any manner only by an instrument in writing executed by all parties.

**12.03.Waiver.** Either Purchaser or the Shareholders, acting as a group, may, in writing:

**(a)Extension of Time.** Extend the time, to a date certain, for the performance of any of the obligations of any other party to this Plan of Reorganization.

**(b)Waiving Inaccuracies.** Waive any inaccuracies and misrepresentations contained in this Plan of Reorganization or any document delivered pursuant hereto made by any other party to this Plan of Reorganization.

**(c)Waiving Compliance With Covenants.** Waive compliance with any of the covenants or performance of any obligations contained in this Plan of Reorganization by any other party to this Plan of Reorganization.

**(d)Waiving Satisfaction of Condition Precedent or Condition Subsequent.** Waive the fulfillment of any condition precedent or condition subsequent to the performance by any other party to the Plan of Reorganization.

**12.04.Dispute Resolution.**

**(a)Negotiation.** If a dispute arises out of or relates to this Plan of Reorganization or the breach thereof, within twenty (20) days of receipt of written notice of a dispute, the parties shall attempt in good faith to resolve such dispute by negotiation.

**(b)Mediation.** If the dispute cannot be settled through such negotiations, the parties agree to try in good faith to settle the dispute by mediation within 20 days immediately following the 20-day period set forth in paragraph 12.04(a), in Dallas, Texas, under the Commercial Mediation Rules of the American Arbitration Association (***"AAA"***).

**(c)Arbitration.** If the dispute cannot be settled by mediation as set forth in Section 12.04(b), the parties agree to submit the dispute to binding arbitration in Dallas, Texas, under applicable Wyoming and Federal law. Such demand shall set forth the names of the other party or parties. The arbitration provided for in this Section 12.04(c) shall be conducted under the auspices of the AAA, utilizing the AAA's applicable rules for arbitration of commercial disputes, and shall be decided by one arbitrator. Except as otherwise provided herein, the Arbitrators shall have the authority to award any remedy or relief a state or Federal court of the State of Wyoming could order or grant, including, without limitation, specific performance, the awarding of compensatory damages, the issuance of an injunction and other equitable relief, but specifically excluding punitive damages. The Arbitrators' decision shall be issued with findings of fact and conclusions of law and shall be non-appealable. If the remedy sought is a monetary award, each party shall simultaneously, on the twentieth business day following the commencement of the arbitration, submit to the Arbitrators the amount that party believes should be awarded, and with respect to compensatory damages, the Arbitrators shall make an award in whichever of the two amounts they deem most reasonable.

**12.05.Assignment.**

**(a)**Neither this Plan of Reorganization nor any right created hereby shall be assignable by either the Shareholders or Purchaser, without the prior written consent of the other, except by the laws of succession.

**(b)**Except as otherwise limited elsewhere herein, this Plan of Reorganization shall be binding on, and inure to the benefit of, the respective successors and assigns of the parties.

**(c)**Nothing in this Plan of Reorganization, expressed or implied, is intended to confer upon any person, other than the parties and their successors, any rights or remedies under this Plan of Reorganization.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**12.06.Notices.** Any notice or other communication required or permitted by this Plan of Reorganization must be in writing and shall be deemed to be properly given when delivered in person to an officer of the other party, when deposited in the United States mails for transmittal by certified or registered mail, postage prepaid, or when deposited with a public telegraph company for transmittal, charges prepaid, provided that the communication is addressed:

---

| | |
|:---|:---|
| **(a)** If to Purchaser: | L A M Y |
|  | 201 Allen Street |
|  | Unit 10104 |
|  | New York, New York 10002 |
|  | E-mail: lmmyceo@163.com |
| **(b)** If to Acquired Corporation: | Exousia Ai, Inc. |
|  | 7901 4th Street N #23494 |
|  | St. Petersburg, Florida 33702 |
|  | E-mail: w2572002@gmail.com |
| **(c)** If to the Shareholders: | Exousia Pro Holding Management, LLC |
|  | 7901 4th Street N #23494 |
|  | St. Petersburg, Florida 33702 |
|  | E-mail: w2572002@gmail.com |
|  | Progenicyte Japan CO., LTD. |
|  | 6 Chome-9-1 Minatojima Nakamachi |
|  | Chuo Ward |
|  | Kobe, Hyogo, 650-0046, Japan |
|  | E-mail: suh@progenicytejapan.com |

---

**12.07.Paragraph Headings.** Paragraph and other headings contained in this Plan of Reorganization are for reference purposes only and shall not affect in any way the meaning or interpretation of this Plan of Reorganization.

**12.08.Entire Agreement.** This instrument and the exhibits to this instrument contain the entire agreement between the parties with respect to the transaction contemplated by this Plan of Reorganization. It may be executed in any number of counterparts, but the aggregate of the counterparts together constitute only one and the same instrument.

**12.09.Effect of Partial Invalidity.** In the event that any one or more of the provisions contained in this Plan of Reorganization shall for any reason be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Plan of Reorganization, but this Plan of Reorganization shall be constructed as if it never contained any such invalid, illegal or unenforceable provisions.

**12.10.Counterparts.** This Plan of Reorganization may be executed in one or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement.

**12.11.Controlling Law.** The validity, interpretation and performance of this Plan of Reorganization shall be controlled by and construed under the laws of the State of Wyoming.

**12.12.Specific Performance.** The parties declare that it is impossible to measure in money the damages that will accrue to a party or its successors as a result of the other parties' failure to perform any of the obligations under this Plan of Reorganization. Therefore, if a party or its successor institutes any action or proceeding to enforce the provisions of this Plan of Reorganization, any party opposing such action or proceeding agrees that specific performance may be sought and obtained for any breach of this Plan of Reorganization.

**[ SIGNATURE PAGE FOLLOWS ]**

**[ Signature Page to Plan and Agreement of Reorganization ]**

Executed by Purchaser and the Shareholders as of the date first above written.

---

| | |
|:---|:---|
| **PURCHASER:** | **PURCHASER:** |
| L A M Y | L A M Y |
| By: | *<u>/s/ Shengwu Zhang</u>* |
|  | Shengwu Zhang |
|  | Chief Executive Officer |
| **SHAREHOLDERS:** | **SHAREHOLDERS:** |
| EXOUSIA PRO HOLDING MANAGEMENT, LLC | EXOUSIA PRO HOLDING MANAGEMENT, LLC |
| By: | *<u>/s/ Matthew Dwyer</u>* |
|  | Matthew Dwyer |
|  | President |
| as to 70,000 shares of common stock | as to 70,000 shares of common stock |
| PROGENICYTE JAPAN CO., LTD. | PROGENICYTE JAPAN CO., LTD. |
| By: | *<u>/s/ Neung Suh</u>* |
|  | Neung Suh |
|  | CEO |
| as to 30,000 shares of Series A Preferred Stock | as to 30,000 shares of Series A Preferred Stock |

---

**Exhibit 7.02**

**Certificate**

**Certificate of the Shareholders**

The undersigned (the ***"Shareholders"***), being the owners of 100% of the outstanding capital stock of Exousia Ai, Inc., a Florida corporation (***"Exousia Ai"***), hereby certify and affirm that each of the following is true and correct:

1. The representations and warranties of the Shareholders in that certain Plan and Agreement of Reorganization (the ***"Plan of Reorganization"***) among L A M Y, a Wyoming corporation (***"Purchaser"***), and the Shareholders to which this Certificate relates are true and correct in all material respects on the date of this Certificate and, except for those representations and warranties which address matters only as of a particular date, with the same force and effect as if made as of this date.

2. Exousia Ai is a corporation duly organized and existing under the laws of the State of Florida and has the corporate power and authority to own its properties and carry on its business in the manner in which such business is conducted.

3. Exousia Ai has performed or complied with, in all material respects, all agreements and covenants required of it by that certain Plan of Reorganization to which this Certificate relates.

4. The Shareholders, and each of them, are under no legal disability with respect to entering into, and performing under, the Plan of Reorganization.

5. The Shareholders, and each of them, are the lawful owners of the number of shares of capital stock of Exousia Ai that is set forth opposite each of the Shareholder's name in Section 1.01 of the Plan of Reorganization. The Shareholders, and each of them, have the legal right and power to sell, assign and transfer their respective shares of the capital stock of Acquired Corporation. The delivery of the described shares by the Shareholders pursuant to the provisions of the Plan of Reorganization will transfer valid title to the shares free and clear of all liens, encumbrances, claims and other restrictions, other than securities law-related restrictions, of any kind.

6. The shares of capital stock of Exousia Ai that are subject to the Plan of Reorganization are fully paid and non-assessable and, when transferred and sold on the Closing Date of the Plan of Reorganization, will be free and clear of any liens, claims and encumbrances.

Certified and affirmed this ____ day of November, 2025.

**SHAREHOLDERS:**

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXOUSIA PRO HOLDING MANAGEMENT, LLC<br> **<u>Exemplar</u>**<br> By: ________________________<br> Matthew Dwyer<br> President | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PROGENICYTE JAPAN CO., LTD.<br> **<u>Exemplar</u>**<br> By: ________________________<br> Neung Suh<br> CEO |

---

**Exhibit 8.02**

**Certificate of Purchaser**

**Certificate of Purchaser**

The undersigned, the duly elected and acting Chief Executive Officer of L A M Y, a Wyoming corporation (***"Purchaser"***), hereby certifies and affirms that each of the following is true and correct:

1. The representations and warranties of Purchaser contained in that certain Plan and Agreement of Reorganization (the ***"Plan of Reorganization"***) among Purchaser and the shareholders of Exousia Ai, Inc., a Florida corporation (the ***"Acquired Corporation"***) to which this Certificate relates are true and correct in all material respects on the date of this Certificate and, except for those representations and warranties which address matters only as of a particular date, with the same force and effect as if made as of this date.

2. Purchaser is a corporation duly organized and existing under the laws of the State of Wyoming, and has the power and authority to own its properties and carry on its business in the manner in which such business is conducted.

3. The execution, delivery and performance by Purchaser of the Plan of Reorganization, in accordance with the terms and provisions of the Plan of Reorganization, have been duly authorized by appropriate corporate action of Purchaser.

4. Purchaser has full power, right and authority to enter into the Plan of Reorganization and to perform its obligations under the Plan of Reorganization, and the Plan of Reorganization is the legal, valid and binding obligation of Purchaser and is enforceable against Purchaser in accordance with its terms.

5. The Purchaser Common Stock to be issued pursuant to the Plan of Reorganization will be, upon issuance and delivery pursuant to the terms of the Plan of Reorganization, validly issued, fully paid and non-assessable.

Certified and affirmed this ____ day of November, 2025.

**<u>Exemplar</u>**

______________________________

Shengwu Zhang

Chief Executive Officer

L A M Y

(a Wyoming corporation)

## Ex1A-6

**EXHIBIT 6.27**

**THIS NOTE, AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR THE APPLICABLE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED OR OTHERWISE TRANSFERRED UNLESS REGISTERED UNDER THE ACT AND UNDER APPLICABLE STATE SECURITIES LAWS, OR UNLESS AN OPINION OF COUNSEL, REASONABLY SATISFACTORY TO THE MAKER, IS OBTAINED TO THE EFFECT THAT SUCH PLEDGE, SALE, ASSIGNMENT OR TRANSFER IS EXEMPT FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND SUCH STATE SECURITIES LAWS.**

---

| | |
|:---|:---|
| **Principal Amount: $100,000.00** | **Issue Date: December 17, 2025** |

---

**EXOUSIA PRO, INC.**

**CONVERTIBLE PROMISSORY NOTE**

FOR VALUE RECEIVED, Exousia Pro, Inc., a Florida corporation (hereinafter called the ***"Borrower"***), hereby promises to pay to the order of Newlan Law Firm, PLLC, or registered assigns (the ***"Holder"***), the sum of $100,000.00 together with any interest as set forth herein, on December 17, 2026 (the ***"Maturity Date"***), including interest on the unpaid principal balance hereof at the rate of eight percent (8%) (the ***"Interest Rate"***) per annum from the date hereof (the ***"Issue Date"***) until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment. This note (the "Note") shall contain an original issue discount (***"OID"***) of $0.00, which shall be included in the Principal Amount of this Note.

This Note may not be prepaid in whole or in part except as otherwise explicitly set forth herein. Any amount of principal or interest on this Note which is not paid when due shall bear interest at the rate of twelve percent (12%) per annum from the due date thereof until the same is paid (***"Default Interest"***). Interest shall commence accruing on the date that the Holder pays the full Purchase Price to the Borrower and shall be computed on the basis of a 365-day year and the actual number of days elapsed. All payments due hereunder (to the extent not converted into common stock, $0.001 par value per share (the ***"Common Stock"***) in accordance with the terms hereof) shall be made in lawful money of the United States of America. All payments shall be made at such address as the Holder shall hereafter give to the Borrower by written notice made in accordance with the provisions of this Note.

This Note is free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the Borrower and will not impose personal liability upon the holder thereof.

The following terms shall apply to this Note:

**ARTICLE I. CONVERSION RIGHTS**

**1.1Conversion Right.** The Holder shall have the right from time to time, and at any time beginning on the Issue Date to convert all or any part of the outstanding and unpaid amount of this Note into fully paid and non-assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or, in the event of a recapitalization or merger, any shares of capital stock or other securities of the Borrower into which such Common Stock shall hereafter be changed or reclassified at the conversion price (the ***"Conversion Price"***) determined as provided herein (a ***"Conversion"***) [The foregoing is not a ratchet provision; in the event of a recapitalization or merger, if common shareholder receive any other shares or interests, i.e., shares of a different issuer in the event of a merger, the Note will convert into such shares. That is the Note conversion rights will follow the merger]; *provided, however*, that in no event shall the Holder be entitled to convert any portion of this Note in excess of that portion of this Note upon conversion of which the sum of (1) the number of shares of Common Stock beneficially owned by the Holder and its affiliates (other than shares of Common Stock which may be deemed beneficially owned through the ownership of the unconverted portion of the Notes or the unexercised or unconverted portion of any other security of the Borrower subject to a limitation on conversion or exercise analogous to the limitations contained herein) and (2) the number of shares of Common Stock issuable upon the conversion of the portion of this Note with respect to which the determination of this proviso is being made, would result in beneficial ownership by the Holder and its affiliates of more than 4.99% of the outstanding shares of Common Stock. For purposes of the proviso to the immediately preceding sentence, beneficial ownership shall be determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Regulations 13D-G thereunder, except as otherwise provided in clause

(1) of such proviso. *<u>The beneficial ownership limitations on conversion as set forth in the section may NOT be waived by the Holder</u>*. The number of shares of Common Stock to be issued upon each conversion of this Note shall be determined by dividing the Conversion Amount (as defined below) by the applicable Conversion Price then in effect on the date specified in the notice of conversion, in the form attached hereto as Exhibit A (the "Notice of Conversion"), delivered to the Borrower by the Holder in accordance with Section 1.4 below; provided that the Notice of Conversion is submitted by facsimile or e-mail (or by other means resulting in, or reasonably expected to result in, notice) to the Borrower before 6:00 p.m., New York, New York time on such conversion date (the ***"Conversion Date"***); however, if the Notice of Conversion is sent after 6:00pm, New York, New York time the Conversion Date shall be the next business day. The term "Conversion Amount" means, with respect to any conversion of this Note, the sum of (1) the principal amount of this Note to be converted in such conversion plus (2) accrued and unpaid interest, if any, on such principal amount at the interest rates provided in this Note to the Conversion Date, plus (3) at the Holder's option, Default Interest, if any, on the amounts referred to in the immediately preceding clauses (1) and/or (2) plus (4) at the Holder's option, any amounts owed to the Holder pursuant to Sections 1.4 hereof.

**1.1.1Rights of Qualification.** The Holder shall have the right, which may be exercised at the Holder's sole discretion, to convert any amount due under this Note into shares of any qualified Regulation A Offering under the Securities Act of 1933, as amended (the ***"Securities Act"***) of Borrower during the term of the any such Regulation A Offering. The number of shares to be issued upon any such conversion shall be in accordance with Section 1.2 of this Note. In conjunction with the rights granted to the Holder under this Section 1.1.1, Borrower shall, as may be required and while any amount due under this Note remains outstanding, (1) identify the Holder as a selling shareholder in each of its Regulation A Offering Circulars; and (2) qualify and allocate a sufficient number of shares of Common Stock to repay the remaining balance under the Note in full.

**1.2Conversion Price.** The Conversion Price shall equal the Variable Conversion Price (as defined herein) (subject to equitable adjustments for stock splits, stock dividends or rights offerings by the Borrower relating to the Borrower's securities or the securities of any subsidiary of the Borrower, combinations, recapitalization, reclassifications, extraordinary distributions and similar events). The "Variable Conversion Price" shall mean 75% multiplied by the Market Price (as defined herein) (representing a discount rate of 25%). "Market Price" means the closing price for the Common Stock on the trading day immediately preceding the date of any conversion. "Trading Day" shall mean any day on which the Common Stock is tradable for any period on the OTC, or on the principal securities exchange or other securities market on which the Common Stock is then being traded.

**Notwithstanding the foregoing paragraph, should the Holder exercise its conversion rights pursuant to Section 1.1.1 of this Note, the Conversion Price shall be equal to the then-current offering price of the applicable Regulation A Offering Statement.**

**1.3Authorized Shares.** The Borrower covenants that during the period the conversion right exists, the Borrower will reserve from its authorized and unissued Common Stock a sufficient number of shares, free from preemptive rights, to provide for the issuance of Common Stock upon the full conversion of this Note issued pursuant to the Purchase Agreement (the ***"Reserved Amount"***). The Reserved Amount shall be increased (or decreased with the written consent of the Holder) from time to time in accordance with the Borrower's obligations hereunder. The Borrower represents that upon issuance, such shares will be duly and validly issued, fully paid and non-assessable. In addition, if the Borrower shall issue any securities or make any change to its capital structure which would change the number of shares of Common Stock into which the Notes shall be convertible at the then current Conversion Price, the Borrower shall at the same time make proper provision so that thereafter there shall be a sufficient number of shares of Common Stock authorized and reserved, free from preemptive rights, for conversion of the outstanding Note. The Borrower (i) acknowledges that it has irrevocably instructed its transfer agent to issue certificates for the Common Stock issuable upon conversion of this Note, and (ii) agrees that its issuance of this Note shall constitute full authority to its officers and agents who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for shares of Common Stock in accordance with the terms and conditions of this Note. If, at any time the Borrower does not maintain the Reserved Amount it will be considered an Event of Default under Section 3.2 of the Note.

**1.4Method of Conversion.**

**(a)Mechanics of Conversion.** As set forth in Section 1.1 hereof, from time to time, and at any time, ending on the later of: (i) the Maturity Date and (ii) the date of payment of the Default Amount, this Note may be converted by the Holder in whole or in part at any time from time to time after the Issue Date, by A) submitting to the Borrower a Notice of Conversion (by facsimile, e-mail or other reasonable means of communication dispatched on the Conversion Date prior to 6:00 p.m., New York, New York time) and (B) subject to Section 1.4(b), surrendering this Note at the principal office of the Borrower (upon payment in full of any amounts owed hereunder).

**(b)Surrender of Note Upon Conversion.** Notwithstanding anything to the contrary set forth herein, upon conversion of this Note in accordance with the terms hereof, the Holder shall not be required to physically surrender this Note to the Borrower unless the entire unpaid principal amount of this Note is so converted. The Holder and the Borrower shall maintain records showing the principal amount so converted and the dates of such conversions or shall use such other method, reasonably satisfactory to the Holder and the Borrower, so as not to require physical surrender of this Note upon each such conversion.

**(c)Delivery of Common Stock Upon Conversion.** Upon receipt by the Borrower from the Holder of a facsimile transmission or e-mail (or other reasonable means of communication) of a Notice of Conversion meeting the requirements for conversion as provided in this Section 1.4, the Borrower shall issue and deliver or cause to be issued and delivered to or upon the order of the Holder certificates for the Common Stock issuable upon such conversion within three (3) business days after such receipt (the ***"Deadline"***) (and, solely in the case of conversion of the entire unpaid principal amount hereof, surrender of this Note) in accordance with the terms hereof and the Purchase Agreement. Upon receipt by the Borrower of a Notice of Conversion, the Holder shall be deemed to be the holder of record of the Common Stock issuable upon such conversion, the outstanding principal amount and the amount of accrued and unpaid interest on this Note shall be reduced to reflect such conversion, and, unless the Borrower defaults on its obligations hereunder, all rights with respect to the portion of this Note being so converted shall forthwith terminate except the right to receive the Common Stock or other securities, cash or other assets, as herein provided, on such conversion. If the Holder shall have given a Notice of Conversion as provided herein, the Borrower's obligation to issue and deliver the certificates for Common Stock shall be absolute and unconditional, irrespective of the absence of any action by the Holder to enforce the same, any waiver or consent with respect to any provision thereof, the recovery of any judgment against any person or any action to enforce the same, any failure or delay in the enforcement of any other obligation of the Borrower to the holder of record, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder of any obligation to the Borrower, and irrespective of any other circumstance which might otherwise limit such obligation of the Borrower to the Holder in connection with such conversion.

**(d)Delivery of Common Stock by Electronic Transfer.** In lieu of delivering physical certificates representing the Common Stock issuable upon conversion, provided the Borrower is participating in the Depository Trust Company (***"DTC"***) Fast Automated Securities Transfer (***"FAST"***) program, upon request of the Holder and its compliance with the provisions set forth herein, the Borrower shall use its best efforts to cause its transfer agent to electronically transmit the Common Stock issuable upon conversion to the Holder by crediting the account of Holder's Prime Broker with DTC through its Deposit Withdrawal Agent Commission (***"DWAC"***) system.

**(e)Failure to Deliver Common Stock Prior to Deadline.** Without in any way limiting the Holder's right to pursue other remedies, including actual damages and/or equitable relief, the parties agree that if delivery of the Common Stock issuable upon conversion of this Note is not delivered by the Deadline (3 business days after receipt of Conversion Notice) due to action and/or inaction of the Borrower, the Borrower shall pay to the Holder $500 per day in cash, for each day beyond the Deadline that the Borrower fails to deliver such Common Stock (the ***"Fail to Deliver Fee"***); provided; however that the Fail to Deliver Fee shall not be due if the failure is a result of a third party (i.e., transfer agent; and not the result of any failure to pay such transfer agent) despite the best efforts of the Borrower to effect delivery of such Common Stock. Such cash amount shall be paid to Holder by the fifth day of the month following the month in which it has accrued or, at the option of the Holder (by written notice to the Borrower by the first day of the month following the month in which it has accrued), shall be added to the principal amount of this Note, in which event interest shall accrue thereon in accordance with the terms of this Note and such additional principal amount shall be convertible into Common Stock in accordance with the terms of this Note. The Borrower agrees that the right to convert is a valuable right to the Holder. The damages resulting from a failure, attempt to frustrate, interference with such conversion right are difficult if not impossible to qualify. Accordingly, the parties acknowledge that the liquidated damages provision contained in this Section 1.4(e) are justified.

**1.5Concerning the Shares.** The shares of Common Stock issuable upon conversion of this Note may not be sold or transferred unless: (i) the Borrower or its transfer agent shall have been furnished by the Holder with an opinion of counsel (which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that the shares to be sold or transferred may be sold or transferred pursuant to an exemption from such registration (such as Rule 144 or a successor rule) (***"Rule 144"***); or (ii) such shares are transferred to an "affiliate" (as defined in Rule 144) of the Borrower who agrees to sell or otherwise transfer the shares only in accordance with this Section 1.5 and who is an Accredited Investor (as defined in the Purchase Agreement).

**1.6Effect of Certain Events.**

**(a)Effect of Merger, Consolidation, Etc.** At the option of the Holder, the sale, conveyance or disposition of all or substantially all of the assets of the Borrower, the effectuation by the Borrower of a transaction or series of related transactions in which more than 50% of the voting power of the Borrower is disposed of, or the consolidation, merger or other business combination of the Borrower with or into any other Person (as defined below) or Persons when the Borrower is not the survivor shall be deemed to be an Event of Default (as defined in Article III) pursuant to which the Borrower shall be required to pay to the Holder upon the consummation of and as a condition to such transaction an amount equal to the Default Amount (as defined in Article III). "Person" shall mean any individual, corporation, limited liability company, partnership, association, trust or other entity or organization.

**(b)Adjustment Due to Merger, Consolidation, Etc.** If, at any time when this Note is issued and outstanding and prior to conversion of all of the Note, there shall be any merger, consolidation, exchange of shares, recapitalization, reorganization, or other similar event, as a result of which shares of Common Stock of the Borrower shall be changed into the same or a different number of shares of another class or classes of stock or securities of the Borrower or another entity, or in case of any sale or conveyance of all or substantially all of the assets of the Borrower other than in connection with a plan of complete liquidation of the Borrower, then the Holder of this Note shall thereafter have the right to receive upon conversion of this Note, upon the basis and upon the terms and conditions specified herein and in lieu of the shares of Common Stock immediately theretofore issuable upon conversion, such stock, securities or assets which the Holder would have been entitled to receive in such transaction had this Note been converted in full immediately prior to such transaction (without regard to any limitations on conversion set forth herein), and in any such case appropriate provisions shall be made with respect to the rights and interests of the Holder of this Note to the end that the provisions hereof (including, without limitation, provisions for adjustment of the Conversion Price and of the number of shares issuable upon conversion of the Note) shall thereafter be applicable, as nearly as may be practicable in relation to any securities or assets thereafter deliverable upon the conversion hereof.

The Borrower shall not affect any transaction described in this Section 1.6(b) unless (a) it first gives, to the extent practicable, ten (10) days prior written notice (but in any event at least five (5) days prior written notice) of the record date of the special meeting of shareholders to approve, or if there is no such record date, the consummation of, such merger, consolidation, exchange of shares, recapitalization, reorganization or other similar event or sale of assets (during which time the Holder shall be entitled to convert this Note) and (b) the resulting successor or acquiring entity (if not the Borrower) assumes by written instrument the obligations of this Note. The above provisions shall similarly apply to successive consolidations, mergers, sales, transfers or share exchanges.

**(c)Adjustment Due to Distribution.** If the Borrower shall declare or make any distribution of its assets (or rights to acquire its assets) to holders of Common Stock as a dividend, stock repurchase, by way of return of capital or otherwise (including any dividend or distribution to the Borrower's shareholders in cash or shares (or rights to acquire shares) of capital stock of a subsidiary (i.e., a spin-off)) (a ***"Distribution"***), then the Holder of this Note shall be entitled, upon any conversion of this Note after the date of record for determining shareholders entitled to such Distribution, to receive the amount of such assets which would have been payable to the Holder with respect to the shares of Common Stock issuable upon such conversion had such Holder been the holder of such shares of Common Stock on the record date for the determination of shareholders entitled to such Distribution. [NOTE: This is not a ratchet provision, it simply prohibits the issuer from effecting a distribution of assets or stock while attempting to avoid conversion or payment of the note (i.e., in the event of an asset distribution which renders the company a shell company, without the foregoing language, although it would be a default, the note holder would be left with little other remedies to attempt to be repaid from the spin off entity). Note that the language does not change the conversion price formula.]

**1.7Prepayment.** This Note may be prepaid at any time without penalty. The Holder's conversion rights herein shall not be affected in any way until the Note is fully paid (funds received by the Holder).

**ARTICLE II. CERTAIN COVENANTS**

**2.1Sale of Assets.** So long as the Borrower shall have any obligation under this Note, the Borrower shall not, sell, lease or otherwise dispose of any significant portion of its assets outside the ordinary course of business. Any consent to the disposition of any assets may not be unreasonably withheld as long as such disposition does not render the Borrower a "shell company" as such term is defined in Rule 144.

**ARTICLE III. EVENTS OF DEFAULT**

If any of the following events of default (each, an ***"Event of Default"***) shall occur:

**3.1Failure to Pay Principal and Interest.** The Borrower fails to pay the principal hereof or interest thereon when due on this Note, whether at maturity or upon acceleration and such breach continues for a period of five (5) days after written notice from the Holder.

**3.2Conversion and the Shares.** The Borrower fails to issue shares of Common Stock to the Holder (or announces or threatens in writing that it will not honor its obligation to do so) upon exercise by the Holder of the conversion rights of the Holder in accordance with the terms of this Note, fails to transfer or cause its transfer agent to transfer (issue) (electronically or in certificated form) any certificate for shares of Common Stock issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by this Note, the Borrower directs its transfer agent not to transfer or delays, impairs, and/or hinders its transfer agent in transferring (or issuing) (electronically or in certificated form) any certificate for shares of Common Stock to be issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by this Note, or fails to remove (or directs its transfer agent not to remove or impairs, delays, and/or hinders its transfer agent from removing) any restrictive legend (or to withdraw any stop transfer instructions in respect thereof) on any certificate for any shares of Common Stock issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by this Note (or makes any written announcement, statement or threat that it does not intend to honor the obligations described in this paragraph) and any such failure shall continue uncured (or any written announcement, statement or threat not to honor its obligations shall not be rescinded in writing) for three (3) business days after the Holder shall have delivered a Notice of Conversion. It is an obligation of the Borrower to remain current in its obligations to its transfer agent. It shall be an event of default of this Note, if a conversion of this Note is delayed, hindered or frustrated due to a balance owed by the Borrower to its transfer agent. If at the option of the Holder, the Holder advances any funds to the Borrower's transfer agent in order to process a conversion, such advanced funds shall be paid by the Borrower to the Holder within forty-eight (48) hours of a demand from the Holder.

**3.3Breach of Covenants.** The Borrower breaches any material covenant or other material term or condition contained in this Note and any collateral documents including but not limited to the Purchase Agreement and such breach continues for a period of twenty (20) days after written notice thereof to the Borrower from the Holder.

**3.4Breach of Representations and Warranties.** Any representation or warranty of the Borrower made herein or in any agreement, statement or certificate given in writing pursuant hereto or in connection herewith (including, without limitation, the Purchase Agreement), shall be false or misleading in any material respect when made and the breach of which has (or with the passage of time will have) a material adverse effect on the rights of the Holder with respect to this Note or the Purchase Agreement.

**3.5Receiver or Trustee.** The Borrower or any subsidiary of the Borrower shall make an assignment for the benefit of creditors, or apply for or consent to the appointment of a receiver or trustee for it or for a substantial part of its property or business, or such a receiver or trustee shall otherwise be appointed.

**3.6Bankruptcy.** Bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings, voluntary or involuntary, for relief under any bankruptcy law or any law for the relief of debtors shall be instituted by or against the Borrower or any subsidiary of the Borrower.

**3.7Delisting of Common Stock.** The Borrower shall fail to maintain the listing of the Common Stock on at least one of the OTC (which specifically includes the quotation platforms maintained by the OTC Markets Group) or an equivalent replacement exchange, the Nasdaq National Market, the Nasdaq SmallCap Market, the New York Stock Exchange, or the American Stock Exchange.

**3.8[Omitted].**

**3.9Liquidation.** Any dissolution, liquidation, or winding up of Borrower or any substantial portion of its business.

**3.10Cessation of Operations.** Any cessation of operations by Borrower rendering the Borrower a "shell company" as such term is defined in Rule 144, or Borrower admits it is otherwise generally unable to pay its debts as such debts become due, provided, however, that any disclosure of the Borrower's ability to continue as a "going concern" shall not be an admission that the Borrower cannot pay its debts as they become due.

**3.11Financial Statement Restatement.** The restatement of any financial statements filed by the Borrower with OTC Markets at any time after 180 days after the Issuance Date for any date or period until this Note is no longer outstanding, if the result of such restatement would, by comparison to the un-restated financial statement, have constituted a material adverse effect on the rights of the Holder with respect to this Note.

**3.12Replacement of Transfer Agent.** In the event that the Borrower proposes to replace its transfer agent, the Borrower fails to provide, prior to the effective date of such replacement, a fully executed Irrevocable Transfer Agent Instructions in a form as initially delivered pursuant to the Purchase Agreement (including but not limited to the provision to irrevocably reserve shares of Common Stock in the Reserved Amount) signed by the successor transfer agent to Borrower and the Borrower.

**ARTICLE IV. MISCELLANEOUS**

**4.1Failure or Indulgence Not Waiver.** No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privileges. All rights and remedies existing hereunder are cumulative to, and not exclusive of, any rights or remedies otherwise available.

**4.2Notices.** All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for such communications shall be:

---

| | |
|:---|:---|
| If to the Borrower: | Exousia Pro, Inc. |
|  | 7901 4th Street N #23494 |
|  | St. Petersburg, Florida 33702 |
|  | Attention: Chief Executive Officer |
|  | E-mail: matt@exousiapro.com |

---

---

| | |
|:---|:---|
| If to the Holder: | Newlan Law Firm, PLLC |
|  | 2201 Long Prairie Road, Suite 107-762 |
|  | Flower Mound, Texas 75022 |
|  | Attention: Eric Newlan, Managing Member |
|  | E-mail: eric@newlanpllc.com |

---

**4.3Amendments.** This Note and any provision hereof may only be amended by an instrument in writing signed by the Borrower and the Holder. The term "Note" and all reference thereto, as used throughout this instrument, shall mean this instrument (and the other Notes issued pursuant to the Purchase Agreement) as originally executed, or if later amended or supplemented, then as so amended or supplemented.

**4.4Assignability.** This Note shall be binding upon the Borrower and its successors and assigns, and shall inure to be the benefit of the Holder and its successors and assigns. Each transferee of this Note must be an "accredited investor" (as defined in Rule 501(a) of the Securities and Exchange Commission). Notwithstanding anything in this Note to the contrary, this Note may be assigned by the Holder without the consent of the Borrower.

**4.5Cost of Collection.** If default is made in the payment of this Note, the Borrower shall pay the Holder hereof costs of collection, including reasonable attorneys' fees.

**4.6Governing Law.** This Note shall be governed by and construed in accordance with the laws of the State of Nevada without regard to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated by this Note shall be brought only in the state courts of Nevada or in the federal courts located in Las Vegas, Nevada. The parties to this Note hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. The Borrower and Holder waive trial by jury. The prevailing party shall be entitled to recover from the other party its reasonable attorney's fees and costs. In the event that any provision of this Note or any other agreement delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement. Each party hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding in connection with this Note, any agreement or any other document delivered in connection with this Note by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Note and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

**4.7Purchase Agreement.** By its acceptance of this Note, each party agrees to be bound by the applicable terms of the Purchase Agreement.

**4.8Remedies.** The Borrower acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder, by vitiating the intent and purpose of the transaction contemplated hereby. Accordingly, the Borrower acknowledges that the remedy at law for a breach of its obligations under this Note will be inadequate and agrees, in the event of a breach or threatened breach by the Borrower of the provisions of this Note, that the Holder shall be entitled, in addition to all other available remedies at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining, preventing or curing any breach of this Note and to enforce specifically the terms and provisions thereof, without the necessity of showing economic loss and without any bond or other security being required.

**IN WITNESS WHEREOF,** Borrower has caused this Note to be signed in its name by its duly authorized officer on December 17, 2025.

---

| | |
|:---|:---|
| EXOUSIA PRO, INC. | EXOUSIA PRO, INC. |
| By: |  |
|  | Michael Sheikh |
|  | Chief Executive Officer |

---

**EXHIBIT A**

**FORM OF NOTICE OF CONVERSION**

The undersigned hereby elects to convert $_________ principal amount and $_________ of accrued interest of the Note (defined below) into that number of shares of Common Stock to be issued pursuant to the conversion of the Note (***"Common Stock"***) as set forth below, of Exousia Pro, Inc., a Nevada corporation (the ***"Borrower"***), according to the conditions of the convertible note of the Borrower dated as of December 17, 2025 (the ***"Note"***), as of the date written below. No fee will be charged to the Holder for any conversion, except for transfer taxes, if any.

Box Checked as to applicable instructions:

◻The Borrower shall electronically transmit the Common Stock issuable pursuant to this Notice of Conversion to the account of the undersigned or its nominee with DTC through its Deposit Withdrawal Agent Commission system ("DWAC Transfer").

Name of DTC Prime Broker:   <br> Account Number:  

◻The undersigned hereby requests that the Borrower issue a certificate or certificates for the number of shares of Common Stock set forth below (which numbers are based on the Holder's calculation attached hereto) in the name(s) specified immediately below or, if additional space is necessary, on an attachment hereto:

---

| | |
|:---|:---|
| Date of conversion: |  |
| Applicable Conversion Price: | $|
| Number of shares of common stock to be <br> issued pursuant to conversion of the Notes: |  |
| Amount of Principal Balance due <br> remaining under the Note after this conversion: |  |

---

---

| |
|:---|
| [ Name of Holder ] |
| By: |

---

## Ex1A-6

**EXHIBIT 6.28**

**THIS NOTE, AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR THE APPLICABLE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED OR OTHERWISE TRANSFERRED UNLESS REGISTERED UNDER THE ACT AND UNDER APPLICABLE STATE SECURITIES LAWS, OR UNLESS AN OPINION OF COUNSEL, REASONABLY SATISFACTORY TO THE MAKER, IS OBTAINED TO THE EFFECT THAT SUCH PLEDGE, SALE, ASSIGNMENT OR TRANSFER IS EXEMPT FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND SUCH STATE SECURITIES LAWS.**

---

| | |
|:---|:---|
| **Principal Amount: $125,000.00** | **Issue Date: December 17, 2025** |

---

**EXOUSIA PRO, INC.**

**CONVERTIBLE PROMISSORY NOTE**

FOR VALUE RECEIVED, Exousia Pro, Inc., a Florida corporation (hereinafter called the ***"Borrower"***), hereby promises to pay to the order of Red Phoenix Rising, LLC, or registered assigns (the ***"Holder"***), the sum of $125,000.00 together with any interest as set forth herein, on December 17, 2026 (the ***"Maturity Date"***), including interest on the unpaid principal balance hereof at the rate of eight percent (8%) (the ***"Interest Rate"***) per annum from the date hereof (the ***"Issue Date"***) until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment. This note (the "Note") shall contain an original issue discount (***"OID"***) of $0.00, which shall be included in the Principal Amount of this Note.

This Note may not be prepaid in whole or in part except as otherwise explicitly set forth herein. Any amount of principal or interest on this Note which is not paid when due shall bear interest at the rate of twelve percent (12%) per annum from the due date thereof until the same is paid (***"Default Interest"***). Interest shall commence accruing on the date that the Holder pays the full Purchase Price to the Borrower and shall be computed on the basis of a 365-day year and the actual number of days elapsed. All payments due hereunder (to the extent not converted into common stock, $0.001 par value per share (the ***"Common Stock"***) in accordance with the terms hereof) shall be made in lawful money of the United States of America. All payments shall be made at such address as the Holder shall hereafter give to the Borrower by written notice made in accordance with the provisions of this Note.

This Note is free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the Borrower and will not impose personal liability upon the holder thereof.

The following terms shall apply to this Note:

**ARTICLE I. CONVERSION RIGHTS**

**1.1Conversion Right.** The Holder shall have the right from time to time, and at any time beginning on the Issue Date to convert all or any part of the outstanding and unpaid amount of this Note into fully paid and non-assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or, in the event of a recapitalization or merger, any shares of capital stock or other securities of the Borrower into which such Common Stock shall hereafter be changed or reclassified at the conversion price (the ***"Conversion Price"***) determined as provided herein (a ***"Conversion"***) [The foregoing is not a ratchet provision; in the event of a recapitalization or

merger, if common shareholder receive any other shares or interests, i.e., shares of a different issuer in the event of a merger, the Note will convert into such shares. That is the Note conversion rights will follow the merger]; *provided, however*, that in no event shall the Holder be entitled to convert any portion of this Note in excess of that portion of this Note upon conversion of which the sum of (1) the number of shares of Common Stock beneficially owned by the Holder and its affiliates (other than shares of Common Stock which may be deemed beneficially owned through the ownership of the unconverted portion of the Notes or the unexercised or unconverted portion of any other security of the Borrower subject to a limitation on conversion or exercise analogous to the limitations contained herein) and (2) the number of shares of Common Stock issuable upon the conversion of the portion of this Note with respect to which the determination of this proviso is being made, would result in beneficial ownership by the Holder and its affiliates of more than 4.99% of the outstanding shares of Common Stock. For purposes of the proviso to the immediately preceding sentence, beneficial ownership shall be determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Regulations 13D-G thereunder, except as otherwise provided in clause (1) of such proviso. *<u>The beneficial ownership limitations on conversion as set forth in the section may NOT be waived by the Holder</u>*. The number of shares of Common Stock to be issued upon each conversion of this Note shall be determined by dividing the Conversion Amount (as defined below) by the applicable Conversion Price then in effect on the date specified in the notice of conversion, in the form attached hereto as Exhibit A (the "Notice of Conversion"), delivered to the Borrower by the Holder in accordance with Section 1.4 below; provided that the Notice of Conversion is submitted by facsimile or e-mail (or by other means resulting in, or reasonably expected to result in, notice) to the Borrower before 6:00 p.m., New York, New York time on such conversion date (the ***"Conversion Date"***); however, if the Notice of Conversion is sent after 6:00pm, New York, New York time the Conversion Date shall be the next business day. The term "Conversion Amount" means, with respect to any conversion of this Note, the sum of (1) the principal amount of this Note to be converted in such conversion plus (2) accrued and unpaid interest, if any, on such principal amount at the interest rates provided in this Note to the Conversion Date, plus (3) at the Holder's option, Default Interest, if any, on the amounts referred to in the immediately preceding clauses (1) and/or (2) plus (4) at the Holder's option, any amounts owed to the Holder pursuant to Sections 1.4 hereof.

**1.1.1Rights of Qualification.** The Holder shall have the right, which may be exercised at the Holder's sole discretion, to convert any amount due under this Note into shares of any qualified Regulation A Offering under the Securities Act of 1933, as amended (the ***"Securities Act"***) of Borrower during the term of the any such Regulation A Offering. The number of shares to be issued upon any such conversion shall be in accordance with Section 1.2 of this Note. In conjunction with the rights granted to the Holder under this Section 1.1.1, Borrower shall, as may be required and while any amount due under this Note remains outstanding, (1) identify the Holder as a selling shareholder in each of its Regulation A Offering Circulars; and (2) qualify and allocate a sufficient number of shares of Common Stock to repay the remaining balance under the Note in full.

**1.2Conversion Price.** The Conversion Price shall equal the Variable Conversion Price (as defined herein) (subject to equitable adjustments for stock splits, stock dividends or rights offerings by the Borrower relating to the Borrower's securities or the securities of any subsidiary of the Borrower, combinations, recapitalization, reclassifications, extraordinary distributions and similar events). The "Variable Conversion Price" shall mean 75% multiplied by the Market Price (as defined herein) (representing a discount rate of 25%). "Market Price" means the closing price for the Common Stock on the trading day immediately preceding the date of any conversion. "Trading Day" shall mean any day on which the Common Stock is tradable for any period on the OTC, or on the principal securities exchange or other securities market on which the Common Stock is then being traded.

**Notwithstanding the foregoing paragraph, should the Holder exercise its conversion rights pursuant to Section 1.1.1 of this Note, the Conversion Price shall be equal to the then-current offering price of the applicable Regulation A Offering Statement.**

**1.3Authorized Shares.** The Borrower covenants that during the period the conversion right exists, the Borrower will reserve from its authorized and unissued Common Stock a sufficient number of shares, free from preemptive rights, to provide for the issuance of Common Stock upon the full conversion of this Note issued pursuant to the Purchase Agreement (the ***"Reserved Amount"***). The Reserved Amount shall be increased (or decreased with the written consent of the Holder) from time to time in accordance with the Borrower's obligations hereunder. The Borrower represents that upon issuance, such shares will be duly and validly issued, fully paid and non-assessable. In addition, if the Borrower shall issue any securities or make any change to its capital structure which would change the number of shares of Common Stock into which the Notes shall be convertible at the then current Conversion Price, the Borrower shall at the same time make proper provision so that thereafter there shall be a sufficient number of shares of Common Stock authorized and reserved, free from preemptive rights, for conversion of the outstanding Note. The Borrower (i) acknowledges that it has irrevocably instructed its transfer agent to issue certificates for the Common Stock issuable upon conversion of this Note, and (ii) agrees that its issuance of this Note shall constitute full authority to its officers and agents who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for shares of Common Stock in accordance with the terms and conditions of this Note. If, at any time the Borrower does not maintain the Reserved Amount it will be considered an Event of Default under Section 3.2 of the Note.

**1.4Method of Conversion.**

**(a)Mechanics of Conversion.** As set forth in Section 1.1 hereof, from time to time, and at any time, ending on the later of: (i) the Maturity Date and (ii) the date of payment of the Default Amount, this Note may be converted by the Holder in whole or in part at any time from time to time after the Issue Date, by (A) submitting to the Borrower a Notice of Conversion (by facsimile, e-mail or other reasonable means of communication dispatched on the Conversion Date prior to 6:00 p.m., New York, New York time) and (B) subject to Section 1.4(b), surrendering this Note at the principal office of the Borrower (upon payment in full of any amounts owed hereunder).

**(b)Surrender of Note Upon Conversion.** Notwithstanding anything to the contrary set forth herein, upon conversion of this Note in accordance with the terms hereof, the Holder shall not be required to physically surrender this Note to the Borrower unless the entire unpaid principal amount of this Note is so converted. The Holder and the Borrower shall maintain records showing the principal amount so converted and the dates of such conversions or shall use such other method, reasonably satisfactory to the Holder and the Borrower, so as not to require physical surrender of this Note upon each such conversion.

**(c)Delivery of Common Stock Upon Conversion.** Upon receipt by the Borrower from the Holder of a facsimile transmission or e-mail (or other reasonable means of communication) of a Notice of Conversion meeting the requirements for conversion as provided in this Section 1.4, the Borrower shall issue and deliver or cause to be issued and delivered to or upon the order of the Holder certificates for the Common Stock issuable upon such conversion within three (3) business days after such receipt (the ***"Deadline"***) (and, solely in the case of conversion of the entire unpaid principal amount hereof, surrender of this Note) in accordance with the terms hereof and the Purchase Agreement. Upon receipt by the Borrower of a Notice of Conversion, the Holder shall be deemed to be the holder of record of the Common Stock issuable upon such conversion, the outstanding principal amount and the amount of accrued and unpaid interest on this Note shall be reduced to reflect such conversion, and, unless the Borrower defaults on its obligations hereunder, all rights with respect to the portion of this Note being so converted shall forthwith terminate except the right to receive the Common Stock or other securities, cash or other assets, as herein provided, on such conversion. If the Holder shall have given a Notice of Conversion as provided herein, the Borrower's obligation to issue and deliver the certificates for Common Stock shall be absolute and unconditional, irrespective of the absence of any action by the Holder to enforce the same, any waiver or consent with respect to any provision thereof, the recovery of any judgment against any person or any action to enforce the same, any failure or delay in the enforcement of any other obligation of the Borrower to the holder of record, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder of any obligation to the Borrower, and irrespective of any other circumstance which might otherwise limit such obligation of the Borrower to the Holder in connection with such conversion.

**(d)Delivery of Common Stock by Electronic Transfer.** In lieu of delivering physical certificates representing the Common Stock issuable upon conversion, provided the Borrower is participating in the Depository Trust Company (***"DTC"***) Fast Automated Securities Transfer (***"FAST"***) program, upon request of the Holder and its compliance with the provisions set forth herein, the Borrower shall use its best efforts to cause its transfer agent to electronically transmit the Common Stock issuable upon conversion to the Holder by crediting the account of Holder's Prime Broker with DTC through its Deposit Withdrawal Agent Commission (***"DWAC"***) system.

**(e)Failure to Deliver Common Stock Prior to Deadline.** Without in any way limiting the Holder's right to pursue other remedies, including actual damages and/or equitable relief, the parties agree that if delivery of the Common Stock issuable upon conversion of this Note is not delivered by the Deadline (3 business days after receipt of Conversion Notice) due to action and/or inaction of the Borrower, the Borrower shall pay to the Holder $500 per day in cash, for each day beyond the Deadline that the Borrower fails to deliver such Common Stock (the ***"Fail to Deliver Fee"***); provided; however that the Fail to Deliver Fee shall not be due if the failure is a result of a third party (i.e., transfer agent; and not the result of any failure to pay such transfer agent) despite the best efforts of the Borrower to effect delivery of such Common Stock. Such cash amount shall be paid to Holder by the fifth day of the month following the month in which it has accrued or, at the option of the Holder (by written notice to the Borrower by the first day of the month following the month in which it has accrued), shall be added to the principal amount of this Note, in which event interest shall accrue thereon in accordance with the terms of this Note and such additional principal amount shall be convertible into Common Stock in accordance with the terms of this Note. The Borrower agrees that the right to convert is a valuable right to the Holder. The damages resulting from a failure, attempt to frustrate, interference with such conversion right are difficult if not impossible to qualify. Accordingly, the parties acknowledge that the liquidated damages provision contained in this Section 1.4(e) are justified.

**1.5Concerning the Shares.** The shares of Common Stock issuable upon conversion of this Note may not be sold or transferred unless: (i) the Borrower or its transfer agent shall have been furnished by the Holder with an opinion of counsel (which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that the shares to be sold or transferred may be sold or transferred pursuant to an exemption from such registration (such as Rule 144 or a successor rule) (***"Rule 144"***); or (ii) such shares are transferred to an "affiliate" (as defined in Rule 144) of the Borrower who agrees to sell or otherwise transfer the shares only in accordance with this Section 1.5 and who is an Accredited Investor (as defined in the Purchase Agreement).

**1.6Effect of Certain Events.**

**(a)Effect of Merger, Consolidation, Etc.** At the option of the Holder, the sale, conveyance or disposition of all or substantially all of the assets of the Borrower, the effectuation by the Borrower of a transaction or series of related transactions in which more than 50% of the voting power of the Borrower is disposed of, or the consolidation, merger or other business combination of the Borrower with or into any other Person (as defined below) or Persons when the Borrower is not the survivor shall be deemed to be an Event of Default (as defined in Article III) pursuant to which the Borrower shall be required to pay to the Holder upon the consummation of and as a condition to such transaction an amount equal to the Default Amount (as defined in Article III). "Person" shall mean any individual, corporation, limited liability company, partnership, association, trust or other entity or organization.

**(b)Adjustment Due to Merger, Consolidation, Etc.** If, at any time when this Note is issued and outstanding and prior to conversion of all of the Note, there shall be any merger, consolidation, exchange of shares, recapitalization, reorganization, or other similar event, as a result of which shares of Common Stock of the Borrower shall be changed into the same or a different number of shares of another class or classes of stock or securities of the Borrower or another entity, or in case of any sale or conveyance of all or substantially all of the assets of the Borrower other than in connection with a plan of complete liquidation of the Borrower, then the Holder of this Note shall thereafter have the right to receive upon conversion of this Note, upon the basis and upon the terms and conditions specified herein and in lieu of the shares of Common Stock immediately theretofore issuable upon conversion, such stock, securities or assets which the Holder would have been entitled to receive in such transaction had this Note been converted in full immediately prior to such transaction (without regard to any limitations on conversion set forth herein), and in any such case appropriate provisions shall be made with respect to the rights and interests of the Holder of this Note to the end that the provisions hereof (including, without limitation, provisions for adjustment of the Conversion Price and of the number of shares issuable upon conversion of the Note) shall thereafter be applicable, as nearly as may be practicable in relation to any securities or assets thereafter deliverable upon the conversion hereof.

The Borrower shall not affect any transaction described in this Section 1.6(b) unless (a) it first gives, to the extent practicable, ten (10) days prior written notice (but in any event at least five (5) days prior written notice) of the record date of the special meeting of shareholders to approve, or if there is no such record date, the consummation of, such merger, consolidation, exchange of shares, recapitalization, reorganization or other similar event or sale of assets (during which time the Holder shall be entitled to convert this Note) and (b) the resulting successor or acquiring entity (if not the Borrower) assumes by written instrument the obligations of this Note. The above provisions shall similarly apply to successive consolidations, mergers, sales, transfers or share exchanges.

**(c)Adjustment Due to Distribution.** If the Borrower shall declare or make any distribution of its assets (or rights to acquire its assets) to holders of Common Stock as a dividend, stock repurchase, by way of return of capital or otherwise (including any dividend or distribution to the Borrower's shareholders in cash or shares (or rights to acquire shares) of capital stock of a subsidiary (i.e., a spin-off)) (a ***"Distribution"***), then the Holder of this Note shall be entitled, upon any conversion of this Note after the date of record for determining shareholders entitled to such Distribution, to receive the amount of such assets which would have been payable to the Holder with respect to the shares of Common Stock issuable upon such conversion had such Holder been the holder of such shares of Common Stock on the record date for the determination of shareholders entitled to such Distribution. [NOTE: This is not a ratchet provision, it simply prohibits the issuer from effecting a distribution of assets or stock while attempting to avoid conversion or payment of the note (i.e., in the event of an asset distribution which renders the company a shell company, without the foregoing language, although it would be a default, the note holder would be left with little other remedies to attempt to be repaid from the spin off entity). Note that the language does not change the conversion price formula.]

**1.7Prepayment.** This Note may be prepaid at any time without penalty. The Holder's conversion rights herein shall not be affected in any way until the Note is fully paid (funds received by the Holder).

**ARTICLE II. CERTAIN COVENANTS**

**2.1Sale of Assets.** So long as the Borrower shall have any obligation under this Note, the Borrower shall not, sell, lease or otherwise dispose of any significant portion of its assets outside the ordinary course of business. Any consent to the disposition of any assets may not be unreasonably withheld as long as such disposition does not render the Borrower a "shell company" as such term is defined in Rule 144.

**ARTICLE III. EVENTS OF DEFAULT**

If any of the following events of default (each, an ***"Event of Default"***) shall occur:

**3.1Failure to Pay Principal and Interest.** The Borrower fails to pay the principal hereof or interest thereon when due on this Note, whether at maturity or upon acceleration and such breach continues for a period of five (5) days after written notice from the Holder.

**3.2Conversion and the Shares.** The Borrower fails to issue shares of Common Stock to the Holder (or announces or threatens in writing that it will not honor its obligation to do so) upon exercise by the Holder of the conversion rights of the Holder in accordance with the terms of this Note, fails to transfer or cause its transfer agent to transfer (issue) (electronically or in certificated form) any certificate for shares of Common Stock issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by this Note, the Borrower directs its transfer agent not to transfer or delays, impairs, and/or hinders its transfer agent in transferring (or issuing) (electronically or in certificated form) any certificate for shares of Common Stock to be issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by this Note, or fails to remove (or directs its transfer agent not to remove or impairs, delays, and/or hinders its transfer agent from removing) any restrictive legend (or to withdraw any stop transfer instructions in respect thereof) on any certificate for any shares of Common Stock issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by this Note (or makes any written announcement, statement or threat that it does not intend to honor the obligations described in this paragraph) and any such failure shall continue uncured (or any written announcement, statement or threat not to honor its obligations shall not be rescinded in writing) for three (3) business days after the Holder shall have delivered a Notice of Conversion. It is an obligation of the Borrower to remain current in its obligations to its transfer agent. It shall be an event of default of this Note, if a conversion of this Note is delayed, hindered or frustrated due to a balance owed by the Borrower to its transfer agent. If at the option of the Holder, the Holder advances any funds to the Borrower's transfer agent in order to process a conversion, such advanced funds shall be paid by the Borrower to the Holder within forty-eight (48) hours of a demand from the Holder.

**3.3Breach of Covenants.** The Borrower breaches any material covenant or other material term or condition contained in this Note and any collateral documents including but not limited to the Purchase Agreement and such breach continues for a period of twenty (20) days after written notice thereof to the Borrower from the Holder.

**3.4Breach of Representations and Warranties.** Any representation or warranty of the Borrower made herein or in any agreement, statement or certificate given in writing pursuant hereto or in connection herewith (including, without limitation, the Purchase Agreement), shall be false or misleading in any material respect when made and the breach of which has (or with the passage of time will have) a material adverse effect on the rights of the Holder with respect to this Note or the Purchase Agreement.

**3.5Receiver or Trustee.** The Borrower or any subsidiary of the Borrower shall make an assignment for the benefit of creditors, or apply for or consent to the appointment of a receiver or trustee for it or for a substantial part of its property or business, or such a receiver or trustee shall otherwise be appointed.

**3.6Bankruptcy.** Bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings, voluntary or involuntary, for relief under any bankruptcy law or any law for the relief of debtors shall be instituted by or against the Borrower or any subsidiary of the Borrower.

**3.7Delisting of Common Stock.** The Borrower shall fail to maintain the listing of the Common Stock on at least one of the OTC (which specifically includes the quotation platforms maintained by the OTC Markets Group) or an equivalent replacement exchange, the Nasdaq National Market, the Nasdaq SmallCap Market, the New York Stock Exchange, or the American Stock Exchange.

**3.8[Omitted].**

**3.9Liquidation.** Any dissolution, liquidation, or winding up of Borrower or any substantial portion of its business.

**3.10Cessation of Operations.** Any cessation of operations by Borrower rendering the Borrower a "shell company" as such term is defined in Rule 144, or Borrower admits it is otherwise generally unable to pay its debts as such debts become due, provided, however, that any disclosure of the Borrower's ability to continue as a "going concern" shall not be an admission that the Borrower cannot pay its debts as they become due.

**3.11Financial Statement Restatement.** The restatement of any financial statements filed by the Borrower with OTC Markets at any time after 180 days after the Issuance Date for any date or period until this Note is no longer outstanding, if the result of such restatement would, by comparison to the un-restated financial statement, have constituted a material adverse effect on the rights of the Holder with respect to this Note.

**3.12Replacement of Transfer Agent.** In the event that the Borrower proposes to replace its transfer agent, the Borrower fails to provide, prior to the effective date of such replacement, a fully executed Irrevocable Transfer Agent Instructions in a form as initially delivered pursuant to the Purchase Agreement (including but not limited to the provision to irrevocably reserve shares of Common Stock in the Reserved Amount) signed by the successor transfer agent to Borrower and the Borrower.

**ARTICLE IV. MISCELLANEOUS**

**4.1Failure or Indulgence Not Waiver.** No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privileges. All rights and remedies existing hereunder are cumulative to, and not exclusive of, any rights or remedies otherwise available.

**4.2Notices.** All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for such communications shall be:

---

| | |
|:---|:---|
| If to the Borrower: | Exousia Pro, Inc. |
|  | 7901 4th Street N #23494 |
|  | St. Petersburg, Florida 33702 |
|  | Attention: Chief Executive Officer |
|  | E-mail: MSheikh@exousiapro.com |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;matt@exousiapro.com |
| If to the Holder: | Red Phoenix Rising, LLC |
|  | ___________ |
|  | ___________ |
|  | Attention: Thomas Roland, Managing Member |
|  | E-mail: tom.roland25@gmail.com |

---

**4.3Amendments.** This Note and any provision hereof may only be amended by an instrument in writing signed by the Borrower and the Holder. The term "Note" and all reference thereto, as used throughout this instrument, shall mean this instrument (and the other Notes issued pursuant to the Purchase Agreement) as originally executed, or if later amended or supplemented, then as so amended or supplemented.

**4.4Assignability.** This Note shall be binding upon the Borrower and its successors and assigns, and shall inure to be the benefit of the Holder and its successors and assigns. Each transferee of this Note must be an "accredited investor" (as defined in Rule 501(a) of the Securities and Exchange Commission). Notwithstanding anything in this Note to the contrary, this Note may be assigned by the Holder without the consent of the Borrower.

**4.5Cost of Collection.** If default is made in the payment of this Note, the Borrower shall pay the Holder hereof costs of collection, including reasonable attorneys' fees.

**4.6Governing Law.** This Note shall be governed by and construed in accordance with the laws of the State of Nevada without regard to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated by this Note shall be brought only in the state courts of Nevada or in the federal courts located in Las Vegas, Nevada . The parties to this Note hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. The Borrower and Holder waive trial by jury. The prevailing party shall be entitled to recover from the other party its reasonable attorney's fees and costs. In the event that any provision of this Note or any other agreement delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement. Each party hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding in connection with this Note, any agreement or any other document delivered in connection with this Note by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Note and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

**4.7Purchase Agreement.** By its acceptance of this Note, each party agrees to be bound by the applicable terms of the Purchase Agreement.

**4.8Remedies.** The Borrower acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder, by vitiating the intent and purpose of the transaction contemplated hereby. Accordingly, the Borrower acknowledges that the remedy at law for a breach of its obligations under this Note will be inadequate and agrees, in the event of a breach or threatened breach by the Borrower of the provisions of this Note, that the Holder shall be entitled, in addition to all other available remedies at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining, preventing or curing any breach of this Note and to enforce specifically the terms and provisions thereof, without the necessity of showing economic loss and without any bond or other security being required.

**IN WITNESS WHEREOF,** Borrower has caused this Note to be signed in its name by its duly authorized officer on December 17, 2025.

---

| | |
|:---|:---|
| EXOUSIA PRO, INC. | EXOUSIA PRO, INC. |
| By: | *<u>/s/ Michael Sheikh</u>* |
|  | Michael Sheikh |
|  | Chief Executive Officer |

---

**EXHIBIT A**

**FORM OF NOTICE OF CONVERSION**

The undersigned hereby elects to convert $_________ principal amount and $_________ of accrued interest of the Note (defined below) into that number of shares of Common Stock to be issued pursuant to the conversion of the Note (***"Common Stock"***) as set forth below, of Exousia Pro, Inc., a Florida corporation (the ***"Borrower"***), according to the conditions of the convertible note of the Borrower dated as of December 17, 2025 (the ***"Note"***), as of the date written below. No fee will be charged to the Holder for any conversion, except for transfer taxes, if any.

Box Checked as to applicable instructions:

⃞The Borrower shall electronically transmit the Common Stock issuable pursuant to this Notice of Conversion to the account of the undersigned or its nominee with DTC through its Deposit Withdrawal Agent Commission system ("DWAC Transfer").

Name of DTC Prime Broker:   <br> Account Number:  

⃞The undersigned hereby requests that the Borrower issue a certificate or certificates for the number of shares of Common Stock set forth below (which numbers are based on the Holder's calculation attached hereto) in the name(s) specified immediately below or, if additional space is necessary, on an attachment hereto:

---

| | |
|:---|:---|
| Date of conversion: |  |
| Applicable Conversion Price: | $|
| Number of shares of common stock to be issued <br> pursuant to conversion of the Notes: |  |
| Amount of Principal Balance due remaining <br> under the Note after this conversion: |  |

---

---

| |
|:---|
| [ Name of Holder ] |
| By: |

---

## Ex1A-6

**EXHIBIT 6.29**

**THIS NOTE, AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR THE APPLICABLE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED OR OTHERWISE TRANSFERRED UNLESS REGISTERED UNDER THE ACT AND UNDER APPLICABLE STATE SECURITIES LAWS, OR UNLESS AN OPINION OF COUNSEL, REASONABLY SATISFACTORY TO THE MAKER, IS OBTAINED TO THE EFFECT THAT SUCH PLEDGE, SALE, ASSIGNMENT OR TRANSFER IS EXEMPT FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND SUCH STATE SECURITIES LAWS.**

---

| | |
|:---|:---|
| **Principal Amount: $125,000.00** | **Issue Date: December 17, 2025** |

---

**EXOUSIA PRO, INC.**

**CONVERTIBLE PROMISSORY NOTE**

FOR VALUE RECEIVED, Exousia Pro, Inc., a Florida corporation (hereinafter called the ***"Borrower"***), hereby promises to pay to the order of Red Phoenix Rising, LLC, or registered assigns (the ***"Holder"***), the sum of $125,000.00 together with any interest as set forth herein, on December 17, 2026 (the ***"Maturity Date"***), including interest on the unpaid principal balance hereof at the rate of eight percent (8%) (the ***"Interest Rate"***) per annum from the date hereof (the ***"Issue Date"***) until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment. This note (the "Note") shall contain an original issue discount (***"OID"***) of $0.00, which shall be included in the Principal Amount of this Note.

This Note may not be prepaid in whole or in part except as otherwise explicitly set forth herein. Any amount of principal or interest on this Note which is not paid when due shall bear interest at the rate of twelve percent (12%) per annum from the due date thereof until the same is paid (***"Default Interest"***). Interest shall commence accruing on the date that the Holder pays the full Purchase Price to the Borrower and shall be computed on the basis of a 365-day year and the actual number of days elapsed. All payments due hereunder (to the extent not converted into common stock, $0.001 par value per share (the ***"Common Stock"***) in accordance with the terms hereof) shall be made in lawful money of the United States of America. All payments shall be made at such address as the Holder shall hereafter give to the Borrower by written notice made in accordance with the provisions of this Note.

This Note is free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the Borrower and will not impose personal liability upon the holder thereof.

The following terms shall apply to this Note:

**ARTICLE I. CONVERSION RIGHTS**

**1.1Conversion Right.** The Holder shall have the right from time to time, and at any time beginning on the Issue Date to convert all or any part of the outstanding and unpaid amount of this Note into fully paid and non-assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or, in the event of a recapitalization or merger, any shares of capital stock or other securities of the Borrower into which such Common Stock shall hereafter be changed or reclassified at the conversion price (the ***"Conversion Price"***) determined as provided herein (a ***"Conversion"***) [The foregoing is not a ratchet provision; in the event of a recapitalization or

merger, if common shareholder receive any other shares or interests, i.e., shares of a different issuer in the event of a merger, the Note will convert into such shares. That is the Note conversion rights will follow the merger]; *provided, however*, that in no event shall the Holder be entitled to convert any portion of this Note in excess of that portion of this Note upon conversion of which the sum of (1) the number of shares of Common Stock beneficially owned by the Holder and its affiliates (other than shares of Common Stock which may be deemed beneficially owned through the ownership of the unconverted portion of the Notes or the unexercised or unconverted portion of any other security of the Borrower subject to a limitation on conversion or exercise analogous to the limitations contained herein) and (2) the number of shares of Common Stock issuable upon the conversion of the portion of this Note with respect to which the determination of this proviso is being made, would result in beneficial ownership by the Holder and its affiliates of more than 4.99% of the outstanding shares of Common Stock. For purposes of the proviso to the immediately preceding sentence, beneficial ownership shall be determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Regulations 13D-G thereunder, except as otherwise provided in clause (1) of such proviso. *<u>The beneficial ownership limitations on conversion as set forth in the section may NOT be waived by the Holder</u>*. The number of shares of Common Stock to be issued upon each conversion of this Note shall be determined by dividing the Conversion Amount (as defined below) by the applicable Conversion Price then in effect on the date specified in the notice of conversion, in the form attached hereto as Exhibit A (the "Notice of Conversion"), delivered to the Borrower by the Holder in accordance with Section 1.4 below; provided that the Notice of Conversion is submitted by facsimile or e-mail (or by other means resulting in, or reasonably expected to result in, notice) to the Borrower before 6:00 p.m., New York, New York time on such conversion date (the ***"Conversion Date"***); however, if the Notice of Conversion is sent after 6:00pm, New York, New York time the Conversion Date shall be the next business day. The term "Conversion Amount" means, with respect to any conversion of this Note, the sum of (1) the principal amount of this Note to be converted in such conversion plus (2) accrued and unpaid interest, if any, on such principal amount at the interest rates provided in this Note to the Conversion Date, plus (3) at the Holder's option, Default Interest, if any, on the amounts referred to in the immediately preceding clauses (1) and/or (2) plus (4) at the Holder's option, any amounts owed to the Holder pursuant to Sections 1.4 hereof.

**1.1.1Rights of Qualification.** The Holder shall have the right, which may be exercised at the Holder's sole discretion, to convert any amount due under this Note into shares of any qualified Regulation A Offering under the Securities Act of 1933, as amended (the ***"Securities Act"***) of Borrower during the term of the any such Regulation A Offering. The number of shares to be issued upon any such conversion shall be in accordance with Section 1.2 of this Note. In conjunction with the rights granted to the Holder under this Section 1.1.1, Borrower shall, as may be required and while any amount due under this Note remains outstanding, (1) identify the Holder as a selling shareholder in each of its Regulation A Offering Circulars; and (2) qualify and allocate a sufficient number of shares of Common Stock to repay the remaining balance under the Note in full.

**1.2Conversion Price.** The Conversion Price shall equal the Variable Conversion Price (as defined herein) (subject to equitable adjustments for stock splits, stock dividends or rights offerings by the Borrower relating to the Borrower's securities or the securities of any subsidiary of the Borrower, combinations, recapitalization, reclassifications, extraordinary distributions and similar events). The "Variable Conversion Price" shall mean 75% multiplied by the Market Price (as defined herein) (representing a discount rate of 25%). "Market Price" means the closing price for the Common Stock on the trading day immediately preceding the date of any conversion. "Trading Day" shall mean any day on which the Common Stock is tradable for any period on the OTC, or on the principal securities exchange or other securities market on which the Common Stock is then being traded.

**Notwithstanding the foregoing paragraph, should the Holder exercise its conversion rights pursuant to Section 1.1.1 of this Note, the Conversion Price shall be equal to the then-current offering price of the applicable Regulation A Offering Statement.**

**1.3Authorized Shares.** The Borrower covenants that during the period the conversion right exists, the Borrower will reserve from its authorized and unissued Common Stock a sufficient number of shares, free from preemptive rights, to provide for the issuance of Common Stock upon the full conversion of this Note issued pursuant to the Purchase Agreement (the ***"Reserved Amount"***). The Reserved Amount shall be increased (or decreased with the written consent of the Holder) from time to time in accordance with the Borrower's obligations hereunder. The Borrower represents that upon issuance, such shares will be duly and validly issued, fully paid and non-assessable. In addition, if the Borrower shall issue any securities or make any change to its capital structure which would change the number of shares of Common Stock into which the Notes shall be convertible at the then current Conversion Price, the Borrower shall at the same time make proper provision so that thereafter there shall be a sufficient number of shares of Common Stock authorized and reserved, free from preemptive rights, for conversion of the outstanding Note. The Borrower (i) acknowledges that it has irrevocably instructed its transfer agent to issue certificates for the Common Stock issuable upon conversion of this Note, and (ii) agrees that its issuance of this Note shall constitute full authority to its officers and agents who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for shares of Common Stock in accordance with the terms and conditions of this Note. If, at any time the Borrower does not maintain the Reserved Amount it will be considered an Event of Default under Section 3.2 of the Note.

**1.4Method of Conversion.**

**(a)Mechanics of Conversion.** As set forth in Section 1.1 hereof, from time to time, and at any time, ending on the later of: (i) the Maturity Date and (ii) the date of payment of the Default Amount, this Note may be converted by the Holder in whole or in part at any time from time to time after the Issue Date, by (A) submitting to the Borrower a Notice of Conversion (by facsimile, e-mail or other reasonable means of communication dispatched on the Conversion Date prior to 6:00 p.m., New York, New York time) and (B) subject to Section 1.4(b), surrendering this Note at the principal office of the Borrower (upon payment in full of any amounts owed hereunder).

**(b)Surrender of Note Upon Conversion.** Notwithstanding anything to the contrary set forth herein, upon conversion of this Note in accordance with the terms hereof, the Holder shall not be required to physically surrender this Note to the Borrower unless the entire unpaid principal amount of this Note is so converted. The Holder and the Borrower shall maintain records showing the principal amount so converted and the dates of such conversions or shall use such other method, reasonably satisfactory to the Holder and the Borrower, so as not to require physical surrender of this Note upon each such conversion.

**(c)Delivery of Common Stock Upon Conversion.** Upon receipt by the Borrower from the Holder of a facsimile transmission or e-mail (or other reasonable means of communication) of a Notice of Conversion meeting the requirements for conversion as provided in this Section 1.4, the Borrower shall issue and deliver or cause to be issued and delivered to or upon the order of the Holder certificates for the Common Stock issuable upon such conversion within three (3) business days after such receipt (the ***"Deadline"***) (and, solely in the case of conversion of the entire unpaid principal amount hereof, surrender of this Note) in accordance with the terms hereof and the Purchase Agreement. Upon receipt by the Borrower of a Notice of Conversion, the Holder shall be deemed to be the holder of record of the Common Stock issuable upon such conversion, the outstanding principal amount and the amount of accrued and unpaid interest on this Note shall be reduced to reflect such conversion, and, unless the Borrower defaults on its obligations hereunder, all rights with respect to the portion of this Note being so converted shall forthwith terminate except the right to receive the Common Stock or other securities, cash or other assets, as herein provided, on such conversion. If the Holder shall have given a Notice of Conversion as provided herein, the Borrower's obligation to issue and deliver the certificates for Common Stock shall be absolute and unconditional, irrespective of the absence of any action by the Holder to enforce the same, any waiver or consent with respect to any provision thereof, the recovery of any judgment against any person or any action to enforce the same, any failure or delay in the enforcement of any other obligation of the Borrower to the holder of record, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder of any obligation to the Borrower, and irrespective of any other circumstance which might otherwise limit such obligation of the Borrower to the Holder in connection with such conversion.

**(d)Delivery of Common Stock by Electronic Transfer.** In lieu of delivering physical certificates representing the Common Stock issuable upon conversion, provided the Borrower is participating in the Depository Trust Company (***"DTC"***) Fast Automated Securities Transfer (***"FAST"***) program, upon request of the Holder and its compliance with the provisions set forth herein, the Borrower shall use its best efforts to cause its transfer agent to electronically transmit the Common Stock issuable upon conversion to the Holder by crediting the account of Holder's Prime Broker with DTC through its Deposit Withdrawal Agent Commission (***"DWAC"***) system.

**(e)Failure to Deliver Common Stock Prior to Deadline.** Without in any way limiting the Holder's right to pursue other remedies, including actual damages and/or equitable relief, the parties agree that if delivery of the Common Stock issuable upon conversion of this Note is not delivered by the Deadline (3 business days after receipt of Conversion Notice) due to action and/or inaction of the Borrower, the Borrower shall pay to the Holder $500 per day in cash, for each day beyond the Deadline that the Borrower fails to deliver such Common Stock (the ***"Fail to Deliver Fee"***); provided; however that the Fail to Deliver Fee shall not be due if the failure is a result of a third party (i.e., transfer agent; and not the result of any failure to pay such transfer agent) despite the best efforts of the Borrower to effect delivery of such Common Stock. Such cash amount shall be paid to Holder by the fifth day of the month following the month in which it has accrued or, at the option of the Holder (by written notice to the Borrower by the first day of the month following the month in which it has accrued), shall be added to the principal amount of this Note, in which event interest shall accrue thereon in accordance with the terms of this Note and such additional principal amount shall be convertible into Common Stock in accordance with the terms of this Note. The Borrower agrees that the right to convert is a valuable right to the Holder. The damages resulting from a failure, attempt to frustrate, interference with such conversion right are difficult if not impossible to qualify. Accordingly, the parties acknowledge that the liquidated damages provision contained in this Section 1.4(e) are justified.

**1.5Concerning the Shares.** The shares of Common Stock issuable upon conversion of this Note may not be sold or transferred unless: (i) the Borrower or its transfer agent shall have been furnished by the Holder with an opinion of counsel (which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that the shares to be sold or transferred may be sold or transferred pursuant to an exemption from such registration (such as Rule 144 or a successor rule) (***"Rule 144"***); or (ii) such shares are transferred to an "affiliate" (as defined in Rule 144) of the Borrower who agrees to sell or otherwise transfer the shares only in accordance with this Section 1.5 and who is an Accredited Investor (as defined in the Purchase Agreement).

**1.6Effect of Certain Events.**

**(a)Effect of Merger, Consolidation, Etc.** At the option of the Holder, the sale, conveyance or disposition of all or substantially all of the assets of the Borrower, the effectuation by the Borrower of a transaction or series of related transactions in which more than 50% of the voting power of the Borrower is disposed of, or the consolidation, merger or other business combination of the Borrower with or into any other Person (as defined below) or Persons when the Borrower is not the survivor shall be deemed to be an Event of Default (as defined in Article III) pursuant to which the Borrower shall be required to pay to the Holder upon the consummation of and as a condition to such transaction an amount equal to the Default Amount (as defined in Article III). "Person" shall mean any individual, corporation, limited liability company, partnership, association, trust or other entity or organization.

**(b)Adjustment Due to Merger, Consolidation, Etc.** If, at any time when this Note is issued and outstanding and prior to conversion of all of the Note, there shall be any merger, consolidation, exchange of shares, recapitalization, reorganization, or other similar event, as a result of which shares of Common Stock of the Borrower shall be changed into the same or a different number of shares of another class or classes of stock or securities of the Borrower or another entity, or in case of any sale or conveyance of all or substantially all of the assets of the Borrower other than in connection with a plan of complete liquidation of the Borrower, then the Holder of this Note shall thereafter have the right to receive upon conversion of this Note, upon the basis and upon the terms and conditions specified herein and in lieu of the shares of Common Stock immediately theretofore issuable upon conversion, such stock, securities or assets which the Holder would have been entitled to receive in such transaction had this Note been converted in full immediately prior to such transaction (without regard to any limitations on conversion set forth herein), and in any such case appropriate provisions shall be made with respect to the rights and interests of the Holder of this Note to the end that the provisions hereof (including, without limitation, provisions for adjustment of the Conversion Price and of the number of shares issuable upon conversion of the Note) shall thereafter be applicable, as nearly as may be practicable in relation to any securities or assets thereafter deliverable upon the conversion hereof.

The Borrower shall not affect any transaction described in this Section 1.6(b) unless (a) it first gives, to the extent practicable, ten (10) days prior written notice (but in any event at least five (5) days prior written notice) of the record date of the special meeting of shareholders to approve, or if there is no such record date, the consummation of, such merger, consolidation, exchange of shares, recapitalization, reorganization or other similar event or sale of assets (during which time the Holder shall be entitled to convert this Note) and (b) the resulting successor or acquiring entity (if not the Borrower) assumes by written instrument the obligations of this Note. The above provisions shall similarly apply to successive consolidations, mergers, sales, transfers or share exchanges.

**(c)Adjustment Due to Distribution.** If the Borrower shall declare or make any distribution of its assets (or rights to acquire its assets) to holders of Common Stock as a dividend, stock repurchase, by way of return of capital or otherwise (including any dividend or distribution to the Borrower's shareholders in cash or shares (or rights to acquire shares) of capital stock of a subsidiary (i.e., a spin-off)) (a ***"Distribution"***), then the Holder of this Note shall be entitled, upon any conversion of this Note after the date of record for determining shareholders entitled to such Distribution, to receive the amount of such assets which would have been payable to the Holder with respect to the shares of Common Stock issuable upon such conversion had such Holder been the holder of such shares of Common Stock on the record date for the determination of shareholders entitled to such Distribution. [NOTE: This is not a ratchet provision, it simply prohibits the issuer from effecting a distribution of assets or stock while attempting to avoid conversion or payment of the note (i.e., in the event of an asset distribution which renders the company a shell company, without the foregoing language, although it would be a default, the note holder would be left with little other remedies to attempt to be repaid from the spin off entity). Note that the language does not change the conversion price formula.]

**1.7Prepayment.** This Note may be prepaid at any time without penalty. The Holder's conversion rights herein shall not be affected in any way until the Note is fully paid (funds received by the Holder).

**ARTICLE II. CERTAIN COVENANTS**

**2.1Sale of Assets.** So long as the Borrower shall have any obligation under this Note, the Borrower shall not, sell, lease or otherwise dispose of any significant portion of its assets outside the ordinary course of business. Any consent to the disposition of any assets may not be unreasonably withheld as long as such disposition does not render the Borrower a "shell company" as such term is defined in Rule 144.

**ARTICLE III. EVENTS OF DEFAULT**

If any of the following events of default (each, an ***"Event of Default"***) shall occur:

**3.1Failure to Pay Principal and Interest.** The Borrower fails to pay the principal hereof or interest thereon when due on this Note, whether at maturity or upon acceleration and such breach continues for a period of five (5) days after written notice from the Holder.

**3.2Conversion and the Shares.** The Borrower fails to issue shares of Common Stock to the Holder (or announces or threatens in writing that it will not honor its obligation to do so) upon exercise by the Holder of the conversion rights of the Holder in accordance with the terms of this Note, fails to transfer or cause its transfer agent to transfer (issue) (electronically or in certificated form) any certificate for shares of Common Stock issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by this Note, the Borrower directs its transfer agent not to transfer or delays, impairs, and/or hinders its transfer agent in transferring (or issuing) (electronically or in certificated form) any certificate for shares of Common Stock to be issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by this Note, or fails to remove (or directs its transfer agent not to remove or impairs, delays, and/or hinders its transfer agent from removing) any restrictive legend (or to withdraw any stop transfer instructions in respect thereof) on any certificate for any shares of Common Stock issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by this Note (or makes any written announcement, statement or threat that it does not intend to honor the obligations described in this paragraph) and any such failure shall continue uncured (or any written announcement, statement or threat not to honor its obligations shall not be rescinded in writing) for three (3) business days after the Holder shall have delivered a Notice of Conversion. It is an obligation of the Borrower to remain current in its obligations to its transfer agent. It shall be an event of default of this Note, if a conversion of this Note is delayed, hindered or frustrated due to a balance owed by the Borrower to its transfer agent. If at the option of the Holder, the Holder advances any funds to the Borrower's transfer agent in order to process a conversion, such advanced funds shall be paid by the Borrower to the Holder within forty-eight (48) hours of a demand from the Holder.

**3.3Breach of Covenants.** The Borrower breaches any material covenant or other material term or condition contained in this Note and any collateral documents including but not limited to the Purchase Agreement and such breach continues for a period of twenty (20) days after written notice thereof to the Borrower from the Holder.

**3.4Breach of Representations and Warranties.** Any representation or warranty of the Borrower made herein or in any agreement, statement or certificate given in writing pursuant hereto or in connection herewith (including, without limitation, the Purchase Agreement), shall be false or misleading in any material respect when made and the breach of which has (or with the passage of time will have) a material adverse effect on the rights of the Holder with respect to this Note or the Purchase Agreement.

**3.5Receiver or Trustee.** The Borrower or any subsidiary of the Borrower shall make an assignment for the benefit of creditors, or apply for or consent to the appointment of a receiver or trustee for it or for a substantial part of its property or business, or such a receiver or trustee shall otherwise be appointed.

**3.6Bankruptcy.** Bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings, voluntary or involuntary, for relief under any bankruptcy law or any law for the relief of debtors shall be instituted by or against the Borrower or any subsidiary of the Borrower.

**3.7Delisting of Common Stock.** The Borrower shall fail to maintain the listing of the Common Stock on at least one of the OTC (which specifically includes the quotation platforms maintained by the OTC Markets Group) or an equivalent replacement exchange, the Nasdaq National Market, the Nasdaq SmallCap Market, the New York Stock Exchange, or the American Stock Exchange.

**3.8[Omitted].**

**3.9Liquidation.** Any dissolution, liquidation, or winding up of Borrower or any substantial portion of its business.

**3.10Cessation of Operations.** Any cessation of operations by Borrower rendering the Borrower a "shell company" as such term is defined in Rule 144, or Borrower admits it is otherwise generally unable to pay its debts as such debts become due, provided, however, that any disclosure of the Borrower's ability to continue as a "going concern" shall not be an admission that the Borrower cannot pay its debts as they become due.

**3.11Financial Statement Restatement.** The restatement of any financial statements filed by the Borrower with OTC Markets at any time after 180 days after the Issuance Date for any date or period until this Note is no longer outstanding, if the result of such restatement would, by comparison to the un-restated financial statement, have constituted a material adverse effect on the rights of the Holder with respect to this Note.

**3.12Replacement of Transfer Agent.** In the event that the Borrower proposes to replace its transfer agent, the Borrower fails to provide, prior to the effective date of such replacement, a fully executed Irrevocable Transfer Agent Instructions in a form as initially delivered pursuant to the Purchase Agreement (including but not limited to the provision to irrevocably reserve shares of Common Stock in the Reserved Amount) signed by the successor transfer agent to Borrower and the Borrower.

**ARTICLE IV. MISCELLANEOUS**

**4.1Failure or Indulgence Not Waiver.** No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privileges. All rights and remedies existing hereunder are cumulative to, and not exclusive of, any rights or remedies otherwise available.

**4.2Notices.** All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for such communications shall be:

---

| | |
|:---|:---|
| If to the Borrower: | Exousia Pro, Inc. |
|  | 7901 4th Street N #23494 |
|  | St. Petersburg, Florida 33702 |
|  | Attention: Chief Executive Officer |
|  | E-mail: MSheikh@exousiapro.com |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;matt@exousiapro.com |
| If to the Holder: | Red Phoenix Rising, LLC |
|  | ___________ |
|  | ___________ |
|  | Attention: Thomas Roland, Managing Member |
|  | E-mail: tom.roland25@gmail.com |

---

**4.3Amendments.** This Note and any provision hereof may only be amended by an instrument in writing signed by the Borrower and the Holder. The term "Note" and all reference thereto, as used throughout this instrument, shall mean this instrument (and the other Notes issued pursuant to the Purchase Agreement) as originally executed, or if later amended or supplemented, then as so amended or supplemented.

**4.4Assignability.** This Note shall be binding upon the Borrower and its successors and assigns, and shall inure to be the benefit of the Holder and its successors and assigns. Each transferee of this Note must be an "accredited investor" (as defined in Rule 501(a) of the Securities and Exchange Commission). Notwithstanding anything in this Note to the contrary, this Note may be assigned by the Holder without the consent of the Borrower.

**4.5Cost of Collection.** If default is made in the payment of this Note, the Borrower shall pay the Holder hereof costs of collection, including reasonable attorneys' fees.

**4.6Governing Law.** This Note shall be governed by and construed in accordance with the laws of the State of Nevada without regard to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated by this Note shall be brought only in the state courts of Nevada or in the federal courts located in Las Vegas, Nevada . The parties to this Note hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. The Borrower and Holder waive trial by jury. The prevailing party shall be entitled to recover from the other party its reasonable attorney's fees and costs. In the event that any provision of this Note or any other agreement delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement. Each party hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding in connection with this Note, any agreement or any other document delivered in connection with this Note by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Note and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

**4.7Purchase Agreement.** By its acceptance of this Note, each party agrees to be bound by the applicable terms of the Purchase Agreement.

**4.8Remedies.** The Borrower acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder, by vitiating the intent and purpose of the transaction contemplated hereby. Accordingly, the Borrower acknowledges that the remedy at law for a breach of its obligations under this Note will be inadequate and agrees, in the event of a breach or threatened breach by the Borrower of the provisions of this Note, that the Holder shall be entitled, in addition to all other available remedies at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining, preventing or curing any breach of this Note and to enforce specifically the terms and provisions thereof, without the necessity of showing economic loss and without any bond or other security being required.

**IN WITNESS WHEREOF,** Borrower has caused this Note to be signed in its name by its duly authorized officer on December 17, 2025.

---

| | |
|:---|:---|
| EXOUSIA PRO, INC. | EXOUSIA PRO, INC. |
| By: | *<u>/s/ Michael Sheikh</u>* |
|  | Michael Sheikh |
|  | Chief Executive Officer |

---

**EXHIBIT A**

**FORM OF NOTICE OF CONVERSION**

The undersigned hereby elects to convert $_________ principal amount and $_________ of accrued interest of the Note (defined below) into that number of shares of Common Stock to be issued pursuant to the conversion of the Note (***"Common Stock"***) as set forth below, of Exousia Pro, Inc., a Florida corporation (the ***"Borrower"***), according to the conditions of the convertible note of the Borrower dated as of December 17, 2025 (the ***"Note"***), as of the date written below. No fee will be charged to the Holder for any conversion, except for transfer taxes, if any.

Box Checked as to applicable instructions:

⃞The Borrower shall electronically transmit the Common Stock issuable pursuant to this Notice of Conversion to the account of the undersigned or its nominee with DTC through its Deposit Withdrawal Agent Commission system ("DWAC Transfer").

Name of DTC Prime Broker:   <br> Account Number:  

⃞The undersigned hereby requests that the Borrower issue a certificate or certificates for the number of shares of Common Stock set forth below (which numbers are based on the Holder's calculation attached hereto) in the name(s) specified immediately below or, if additional space is necessary, on an attachment hereto:

---

| | |
|:---|:---|
| Date of conversion: |  |
| Applicable Conversion Price: | $|
| Number of shares of common stock to be issued <br> pursuant to conversion of the Notes: |  |
| Amount of Principal Balance due remaining <br> under the Note after this conversion: |  |

---

---

| |
|:---|
| [ Name of Holder ] |
| By: |

---

## Ex1A-6

**EXHIBIT 6.30**

**THIS NOTE, AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR THE APPLICABLE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED OR OTHERWISE TRANSFERRED UNLESS REGISTERED UNDER THE ACT AND UNDER APPLICABLE STATE SECURITIES LAWS, OR UNLESS AN OPINION OF COUNSEL, REASONABLY SATISFACTORY TO THE MAKER, IS OBTAINED TO THE EFFECT THAT SUCH PLEDGE, SALE, ASSIGNMENT OR TRANSFER IS EXEMPT FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND SUCH STATE SECURITIES LAWS.**

---

| | |
|:---|:---|
| **Principal Amount: $125,000.00** | **Issue Date: December 17, 2025** |

---

**EXOUSIA PRO, INC.**

**CONVERTIBLE PROMISSORY NOTE**

FOR VALUE RECEIVED, Exousia Pro, Inc., a Florida corporation (hereinafter called the ***"Borrower"***), hereby promises to pay to the order of Red Phoenix Rising, LLC, or registered assigns (the ***"Holder"***), the sum of $125,000.00 together with any interest as set forth herein, on December 17, 2026 (the ***"Maturity Date"***), including interest on the unpaid principal balance hereof at the rate of eight percent (8%) (the ***"Interest Rate"***) per annum from the date hereof (the ***"Issue Date"***) until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment. This note (the "Note") shall contain an original issue discount (***"OID"***) of $0.00, which shall be included in the Principal Amount of this Note.

This Note may not be prepaid in whole or in part except as otherwise explicitly set forth herein. Any amount of principal or interest on this Note which is not paid when due shall bear interest at the rate of twelve percent (12%) per annum from the due date thereof until the same is paid (***"Default Interest"***). Interest shall commence accruing on the date that the Holder pays the full Purchase Price to the Borrower and shall be computed on the basis of a 365-day year and the actual number of days elapsed. All payments due hereunder (to the extent not converted into common stock, $0.001 par value per share (the ***"Common Stock"***) in accordance with the terms hereof) shall be made in lawful money of the United States of America. All payments shall be made at such address as the Holder shall hereafter give to the Borrower by written notice made in accordance with the provisions of this Note.

This Note is free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the Borrower and will not impose personal liability upon the holder thereof.

The following terms shall apply to this Note:

**ARTICLE I. CONVERSION RIGHTS**

**1.1Conversion Right.** The Holder shall have the right from time to time, and at any time beginning on the Issue Date to convert all or any part of the outstanding and unpaid amount of this Note into fully paid and non-assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or, in the event of a recapitalization or merger, any shares of capital stock or other securities of the Borrower into which such Common Stock shall hereafter be changed or reclassified at the conversion price (the ***"Conversion Price"***) determined as provided herein (a ***"Conversion"***) [The foregoing is not a ratchet provision; in the event of a recapitalization or

merger, if common shareholder receive any other shares or interests, i.e., shares of a different issuer in the event of a merger, the Note will convert into such shares. That is the Note conversion rights will follow the merger]; *provided, however*, that in no event shall the Holder be entitled to convert any portion of this Note in excess of that portion of this Note upon conversion of which the sum of (1) the number of shares of Common Stock beneficially owned by the Holder and its affiliates (other than shares of Common Stock which may be deemed beneficially owned through the ownership of the unconverted portion of the Notes or the unexercised or unconverted portion of any other security of the Borrower subject to a limitation on conversion or exercise analogous to the limitations contained herein) and (2) the number of shares of Common Stock issuable upon the conversion of the portion of this Note with respect to which the determination of this proviso is being made, would result in beneficial ownership by the Holder and its affiliates of more than 4.99% of the outstanding shares of Common Stock. For purposes of the proviso to the immediately preceding sentence, beneficial ownership shall be determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Regulations 13D-G thereunder, except as otherwise provided in clause (1) of such proviso. *<u>The beneficial ownership limitations on conversion as set forth in the section may NOT be waived by the Holder</u>*. The number of shares of Common Stock to be issued upon each conversion of this Note shall be determined by dividing the Conversion Amount (as defined below) by the applicable Conversion Price then in effect on the date specified in the notice of conversion, in the form attached hereto as Exhibit A (the "Notice of Conversion"), delivered to the Borrower by the Holder in accordance with Section 1.4 below; provided that the Notice of Conversion is submitted by facsimile or e-mail (or by other means resulting in, or reasonably expected to result in, notice) to the Borrower before 6:00 p.m., New York, New York time on such conversion date (the ***"Conversion Date"***); however, if the Notice of Conversion is sent after 6:00pm, New York, New York time the Conversion Date shall be the next business day. The term "Conversion Amount" means, with respect to any conversion of this Note, the sum of (1) the principal amount of this Note to be converted in such conversion plus (2) accrued and unpaid interest, if any, on such principal amount at the interest rates provided in this Note to the Conversion Date, plus (3) at the Holder's option, Default Interest, if any, on the amounts referred to in the immediately preceding clauses (1) and/or (2) plus (4) at the Holder's option, any amounts owed to the Holder pursuant to Sections 1.4 hereof.

**1.1.1Rights of Qualification.** The Holder shall have the right, which may be exercised at the Holder's sole discretion, to convert any amount due under this Note into shares of any qualified Regulation A Offering under the Securities Act of 1933, as amended (the ***"Securities Act"***) of Borrower during the term of the any such Regulation A Offering. The number of shares to be issued upon any such conversion shall be in accordance with Section 1.2 of this Note. In conjunction with the rights granted to the Holder under this Section 1.1.1, Borrower shall, as may be required and while any amount due under this Note remains outstanding, (1) identify the Holder as a selling shareholder in each of its Regulation A Offering Circulars; and (2) qualify and allocate a sufficient number of shares of Common Stock to repay the remaining balance under the Note in full.

**1.2Conversion Price.** The Conversion Price shall equal the Variable Conversion Price (as defined herein) (subject to equitable adjustments for stock splits, stock dividends or rights offerings by the Borrower relating to the Borrower's securities or the securities of any subsidiary of the Borrower, combinations, recapitalization, reclassifications, extraordinary distributions and similar events). The "Variable Conversion Price" shall mean 75% multiplied by the Market Price (as defined herein) (representing a discount rate of 25%). "Market Price" means the closing price for the Common Stock on the trading day immediately preceding the date of any conversion. "Trading Day" shall mean any day on which the Common Stock is tradable for any period on the OTC, or on the principal securities exchange or other securities market on which the Common Stock is then being traded.

**Notwithstanding the foregoing paragraph, should the Holder exercise its conversion rights pursuant to Section 1.1.1 of this Note, the Conversion Price shall be equal to the then-current offering price of the applicable Regulation A Offering Statement.**

**1.3Authorized Shares.** The Borrower covenants that during the period the conversion right exists, the Borrower will reserve from its authorized and unissued Common Stock a sufficient number of shares, free from preemptive rights, to provide for the issuance of Common Stock upon the full conversion of this Note issued pursuant to the Purchase Agreement (the ***"Reserved Amount"***). The Reserved Amount shall be increased (or decreased with the written consent of the Holder) from time to time in accordance with the Borrower's obligations hereunder. The Borrower represents that upon issuance, such shares will be duly and validly issued, fully paid and non-assessable. In addition, if the Borrower shall issue any securities or make any change to its capital structure which would change the number of shares of Common Stock into which the Notes shall be convertible at the then current Conversion Price, the Borrower shall at the same time make proper provision so that thereafter there shall be a sufficient number of shares of Common Stock authorized and reserved, free from preemptive rights, for conversion of the outstanding Note. The Borrower (i) acknowledges that it has irrevocably instructed its transfer agent to issue certificates for the Common Stock issuable upon conversion of this Note, and (ii) agrees that its issuance of this Note shall constitute full authority to its officers and agents who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for shares of Common Stock in accordance with the terms and conditions of this Note. If, at any time the Borrower does not maintain the Reserved Amount it will be considered an Event of Default under Section 3.2 of the Note.

**1.4Method of Conversion.**

**(a)Mechanics of Conversion.** As set forth in Section 1.1 hereof, from time to time, and at any time, ending on the later of: (i) the Maturity Date and (ii) the date of payment of the Default Amount, this Note may be converted by the Holder in whole or in part at any time from time to time after the Issue Date, by (A) submitting to the Borrower a Notice of Conversion (by facsimile, e-mail or other reasonable means of communication dispatched on the Conversion Date prior to 6:00 p.m., New York, New York time) and (B) subject to Section 1.4(b), surrendering this Note at the principal office of the Borrower (upon payment in full of any amounts owed hereunder).

**(b)Surrender of Note Upon Conversion.** Notwithstanding anything to the contrary set forth herein, upon conversion of this Note in accordance with the terms hereof, the Holder shall not be required to physically surrender this Note to the Borrower unless the entire unpaid principal amount of this Note is so converted. The Holder and the Borrower shall maintain records showing the principal amount so converted and the dates of such conversions or shall use such other method, reasonably satisfactory to the Holder and the Borrower, so as not to require physical surrender of this Note upon each such conversion.

**(c)Delivery of Common Stock Upon Conversion.** Upon receipt by the Borrower from the Holder of a facsimile transmission or e-mail (or other reasonable means of communication) of a Notice of Conversion meeting the requirements for conversion as provided in this Section 1.4, the Borrower shall issue and deliver or cause to be issued and delivered to or upon the order of the Holder certificates for the Common Stock issuable upon such conversion within three (3) business days after such receipt (the ***"Deadline"***) (and, solely in the case of conversion of the entire unpaid principal amount hereof, surrender of this Note) in accordance with the terms hereof and the Purchase Agreement. Upon receipt by the Borrower of a Notice of Conversion, the Holder shall be deemed to be the holder of record of the Common Stock issuable upon such conversion, the outstanding principal amount and the amount of accrued and unpaid interest on this Note shall be reduced to reflect such conversion, and, unless the Borrower defaults on its obligations hereunder, all rights with respect to the portion of this Note being so converted shall forthwith terminate except the right to receive the Common Stock or other securities, cash or other assets, as herein provided, on such conversion. If the Holder shall have given a Notice of Conversion as provided herein, the Borrower's obligation to issue and deliver the certificates for Common Stock shall be absolute and unconditional, irrespective of the absence of any action by the Holder to enforce the same, any waiver or consent with respect to any provision thereof, the recovery of any judgment against any person or any action to enforce the same, any failure or delay in the enforcement of any other obligation of the Borrower to the holder of record, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder of any obligation to the Borrower, and irrespective of any other circumstance which might otherwise limit such obligation of the Borrower to the Holder in connection with such conversion.

**(d)Delivery of Common Stock by Electronic Transfer.** In lieu of delivering physical certificates representing the Common Stock issuable upon conversion, provided the Borrower is participating in the Depository Trust Company (***"DTC"***) Fast Automated Securities Transfer (***"FAST"***) program, upon request of the Holder and its compliance with the provisions set forth herein, the Borrower shall use its best efforts to cause its transfer agent to electronically transmit the Common Stock issuable upon conversion to the Holder by crediting the account of Holder's Prime Broker with DTC through its Deposit Withdrawal Agent Commission (***"DWAC"***) system.

**(e)Failure to Deliver Common Stock Prior to Deadline.** Without in any way limiting the Holder's right to pursue other remedies, including actual damages and/or equitable relief, the parties agree that if delivery of the Common Stock issuable upon conversion of this Note is not delivered by the Deadline (3 business days after receipt of Conversion Notice) due to action and/or inaction of the Borrower, the Borrower shall pay to the Holder $500 per day in cash, for each day beyond the Deadline that the Borrower fails to deliver such Common Stock (the ***"Fail to Deliver Fee"***); provided; however that the Fail to Deliver Fee shall not be due if the failure is a result of a third party (i.e., transfer agent; and not the result of any failure to pay such transfer agent) despite the best efforts of the Borrower to effect delivery of such Common Stock. Such cash amount shall be paid to Holder by the fifth day of the month following the month in which it has accrued or, at the option of the Holder (by written notice to the Borrower by the first day of the month following the month in which it has accrued), shall be added to the principal amount of this Note, in which event interest shall accrue thereon in accordance with the terms of this Note and such additional principal amount shall be convertible into Common Stock in accordance with the terms of this Note. The Borrower agrees that the right to convert is a valuable right to the Holder. The damages resulting from a failure, attempt to frustrate, interference with such conversion right are difficult if not impossible to qualify. Accordingly, the parties acknowledge that the liquidated damages provision contained in this Section 1.4(e) are justified.

**1.5Concerning the Shares.** The shares of Common Stock issuable upon conversion of this Note may not be sold or transferred unless: (i) the Borrower or its transfer agent shall have been furnished by the Holder with an opinion of counsel (which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that the shares to be sold or transferred may be sold or transferred pursuant to an exemption from such registration (such as Rule 144 or a successor rule) (***"Rule 144"***); or (ii) such shares are transferred to an "affiliate" (as defined in Rule 144) of the Borrower who agrees to sell or otherwise transfer the shares only in accordance with this Section 1.5 and who is an Accredited Investor (as defined in the Purchase Agreement).

**1.6Effect of Certain Events.**

**(a)Effect of Merger, Consolidation, Etc.** At the option of the Holder, the sale, conveyance or disposition of all or substantially all of the assets of the Borrower, the effectuation by the Borrower of a transaction or series of related transactions in which more than 50% of the voting power of the Borrower is disposed of, or the consolidation, merger or other business combination of the Borrower with or into any other Person (as defined below) or Persons when the Borrower is not the survivor shall be deemed to be an Event of Default (as defined in Article III) pursuant to which the Borrower shall be required to pay to the Holder upon the consummation of and as a condition to such transaction an amount equal to the Default Amount (as defined in Article III). "Person" shall mean any individual, corporation, limited liability company, partnership, association, trust or other entity or organization.

**(b)Adjustment Due to Merger, Consolidation, Etc.** If, at any time when this Note is issued and outstanding and prior to conversion of all of the Note, there shall be any merger, consolidation, exchange of shares, recapitalization, reorganization, or other similar event, as a result of which shares of Common Stock of the Borrower shall be changed into the same or a different number of shares of another class or classes of stock or securities of the Borrower or another entity, or in case of any sale or conveyance of all or substantially all of the assets of the Borrower other than in connection with a plan of complete liquidation of the Borrower, then the Holder of this Note shall thereafter have the right to receive upon conversion of this Note, upon the basis and upon the terms and conditions specified herein and in lieu of the shares of Common Stock immediately theretofore issuable upon conversion, such stock, securities or assets which the Holder would have been entitled to receive in such transaction had this Note been converted in full immediately prior to such transaction (without regard to any limitations on conversion set forth herein), and in any such case appropriate provisions shall be made with respect to the rights and interests of the Holder of this Note to the end that the provisions hereof (including, without limitation, provisions for adjustment of the Conversion Price and of the number of shares issuable upon conversion of the Note) shall thereafter be applicable, as nearly as may be practicable in relation to any securities or assets thereafter deliverable upon the conversion hereof.

The Borrower shall not affect any transaction described in this Section 1.6(b) unless (a) it first gives, to the extent practicable, ten (10) days prior written notice (but in any event at least five (5) days prior written notice) of the record date of the special meeting of shareholders to approve, or if there is no such record date, the consummation of, such merger, consolidation, exchange of shares, recapitalization, reorganization or other similar event or sale of assets (during which time the Holder shall be entitled to convert this Note) and (b) the resulting successor or acquiring entity (if not the Borrower) assumes by written instrument the obligations of this Note. The above provisions shall similarly apply to successive consolidations, mergers, sales, transfers or share exchanges.

**(c)Adjustment Due to Distribution.** If the Borrower shall declare or make any distribution of its assets (or rights to acquire its assets) to holders of Common Stock as a dividend, stock repurchase, by way of return of capital or otherwise (including any dividend or distribution to the Borrower's shareholders in cash or shares (or rights to acquire shares) of capital stock of a subsidiary (i.e., a spin-off)) (a ***"Distribution"***), then the Holder of this Note shall be entitled, upon any conversion of this Note after the date of record for determining shareholders entitled to such Distribution, to receive the amount of such assets which would have been payable to the Holder with respect to the shares of Common Stock issuable upon such conversion had such Holder been the holder of such shares of Common Stock on the record date for the determination of shareholders entitled to such Distribution. [NOTE: This is not a ratchet provision, it simply prohibits the issuer from effecting a distribution of assets or stock while attempting to avoid conversion or payment of the note (i.e., in the event of an asset distribution which renders the company a shell company, without the foregoing language, although it would be a default, the note holder would be left with little other remedies to attempt to be repaid from the spin off entity). Note that the language does not change the conversion price formula.]

**1.7Prepayment.** This Note may be prepaid at any time without penalty. The Holder's conversion rights herein shall not be affected in any way until the Note is fully paid (funds received by the Holder).

**ARTICLE II. CERTAIN COVENANTS**

**2.1Sale of Assets.** So long as the Borrower shall have any obligation under this Note, the Borrower shall not, sell, lease or otherwise dispose of any significant portion of its assets outside the ordinary course of business. Any consent to the disposition of any assets may not be unreasonably withheld as long as such disposition does not render the Borrower a "shell company" as such term is defined in Rule 144.

**ARTICLE III. EVENTS OF DEFAULT**

If any of the following events of default (each, an ***"Event of Default"***) shall occur:

**3.1Failure to Pay Principal and Interest.** The Borrower fails to pay the principal hereof or interest thereon when due on this Note, whether at maturity or upon acceleration and such breach continues for a period of five (5) days after written notice from the Holder.

**3.2Conversion and the Shares.** The Borrower fails to issue shares of Common Stock to the Holder (or announces or threatens in writing that it will not honor its obligation to do so) upon exercise by the Holder of the conversion rights of the Holder in accordance with the terms of this Note, fails to transfer or cause its transfer agent to transfer (issue) (electronically or in certificated form) any certificate for shares of Common Stock issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by this Note, the Borrower directs its transfer agent not to transfer or delays, impairs, and/or hinders its transfer agent in transferring (or issuing) (electronically or in certificated form) any certificate for shares of Common Stock to be issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by this Note, or fails to remove (or directs its transfer agent not to remove or impairs, delays, and/or hinders its transfer agent from removing) any restrictive legend (or to withdraw any stop transfer instructions in respect thereof) on any certificate for any shares of Common Stock issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by this Note (or makes any written announcement, statement or threat that it does not intend to honor the obligations described in this paragraph) and any such failure shall continue uncured (or any written announcement, statement or threat not to honor its obligations shall not be rescinded in writing) for three (3) business days after the Holder shall have delivered a Notice of Conversion. It is an obligation of the Borrower to remain current in its obligations to its transfer agent. It shall be an event of default of this Note, if a conversion of this Note is delayed, hindered or frustrated due to a balance owed by the Borrower to its transfer agent. If at the option of the Holder, the Holder advances any funds to the Borrower's transfer agent in order to process a conversion, such advanced funds shall be paid by the Borrower to the Holder within forty-eight (48) hours of a demand from the Holder.

**3.3Breach of Covenants.** The Borrower breaches any material covenant or other material term or condition contained in this Note and any collateral documents including but not limited to the Purchase Agreement and such breach continues for a period of twenty (20) days after written notice thereof to the Borrower from the Holder.

**3.4Breach of Representations and Warranties.** Any representation or warranty of the Borrower made herein or in any agreement, statement or certificate given in writing pursuant hereto or in connection herewith (including, without limitation, the Purchase Agreement), shall be false or misleading in any material respect when made and the breach of which has (or with the passage of time will have) a material adverse effect on the rights of the Holder with respect to this Note or the Purchase Agreement.

**3.5Receiver or Trustee.** The Borrower or any subsidiary of the Borrower shall make an assignment for the benefit of creditors, or apply for or consent to the appointment of a receiver or trustee for it or for a substantial part of its property or business, or such a receiver or trustee shall otherwise be appointed.

**3.6Bankruptcy.** Bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings, voluntary or involuntary, for relief under any bankruptcy law or any law for the relief of debtors shall be instituted by or against the Borrower or any subsidiary of the Borrower.

**3.7Delisting of Common Stock.** The Borrower shall fail to maintain the listing of the Common Stock on at least one of the OTC (which specifically includes the quotation platforms maintained by the OTC Markets Group) or an equivalent replacement exchange, the Nasdaq National Market, the Nasdaq SmallCap Market, the New York Stock Exchange, or the American Stock Exchange.

**3.8[Omitted].**

**3.9Liquidation.** Any dissolution, liquidation, or winding up of Borrower or any substantial portion of its business.

**3.10Cessation of Operations.** Any cessation of operations by Borrower rendering the Borrower a "shell company" as such term is defined in Rule 144, or Borrower admits it is otherwise generally unable to pay its debts as such debts become due, provided, however, that any disclosure of the Borrower's ability to continue as a "going concern" shall not be an admission that the Borrower cannot pay its debts as they become due.

**3.11Financial Statement Restatement.** The restatement of any financial statements filed by the Borrower with OTC Markets at any time after 180 days after the Issuance Date for any date or period until this Note is no longer outstanding, if the result of such restatement would, by comparison to the un-restated financial statement, have constituted a material adverse effect on the rights of the Holder with respect to this Note.

**3.12Replacement of Transfer Agent.** In the event that the Borrower proposes to replace its transfer agent, the Borrower fails to provide, prior to the effective date of such replacement, a fully executed Irrevocable Transfer Agent Instructions in a form as initially delivered pursuant to the Purchase Agreement (including but not limited to the provision to irrevocably reserve shares of Common Stock in the Reserved Amount) signed by the successor transfer agent to Borrower and the Borrower.

**ARTICLE IV. MISCELLANEOUS**

**4.1Failure or Indulgence Not Waiver.** No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other right, power or privileges. All rights and remedies existing hereunder are cumulative to, and not exclusive of, any rights or remedies otherwise available.

**4.2Notices.** All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for such communications shall be:

---

| | |
|:---|:---|
| If to the Borrower: | Exousia Pro, Inc. |
|  | 7901 4th Street N #23494 |
|  | St. Petersburg, Florida 33702 |
|  | Attention: Chief Executive Officer |
|  | E-mail: MSheikh@exousiapro.com |
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;matt@exousiapro.com |
| If to the Holder: | Red Phoenix Rising, LLC |
|  | ___________ |
|  | ___________ |
|  | Attention: Thomas Roland, Managing Member |
|  | E-mail: tom.roland25@gmail.com |

---

**4.3Amendments.** This Note and any provision hereof may only be amended by an instrument in writing signed by the Borrower and the Holder. The term "Note" and all reference thereto, as used throughout this instrument, shall mean this instrument (and the other Notes issued pursuant to the Purchase Agreement) as originally executed, or if later amended or supplemented, then as so amended or supplemented.

**4.4Assignability.** This Note shall be binding upon the Borrower and its successors and assigns, and shall inure to be the benefit of the Holder and its successors and assigns. Each transferee of this Note must be an "accredited investor" (as defined in Rule 501(a) of the Securities and Exchange Commission). Notwithstanding anything in this Note to the contrary, this Note may be assigned by the Holder without the consent of the Borrower.

**4.5Cost of Collection.** If default is made in the payment of this Note, the Borrower shall pay the Holder hereof costs of collection, including reasonable attorneys' fees.

**4.6Governing Law.** This Note shall be governed by and construed in accordance with the laws of the State of Nevada without regard to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated by this Note shall be brought only in the state courts of Nevada or in the federal courts located in Las Vegas, Nevada . The parties to this Note hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. The Borrower and Holder waive trial by jury. The prevailing party shall be entitled to recover from the other party its reasonable attorney's fees and costs. In the event that any provision of this Note or any other agreement delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement. Each party hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding in connection with this Note, any agreement or any other document delivered in connection with this Note by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Note and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

**4.7Purchase Agreement.** By its acceptance of this Note, each party agrees to be bound by the applicable terms of the Purchase Agreement.

**4.8Remedies.** The Borrower acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder, by vitiating the intent and purpose of the transaction contemplated hereby. Accordingly, the Borrower acknowledges that the remedy at law for a breach of its obligations under this Note will be inadequate and agrees, in the event of a breach or threatened breach by the Borrower of the provisions of this Note, that the Holder shall be entitled, in addition to all other available remedies at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining, preventing or curing any breach of this Note and to enforce specifically the terms and provisions thereof, without the necessity of showing economic loss and without any bond or other security being required.

**IN WITNESS WHEREOF,** Borrower has caused this Note to be signed in its name by its duly authorized officer on December 17, 2025.

---

| | |
|:---|:---|
|  | EXOUSIA PRO, INC. |
| By: | *<u>/s/ Michael Sheikh</u>* |
|  | Michael Sheikh |
|  | Chief Executive Officer |

---

**EXHIBIT A**

**FORM OF NOTICE OF CONVERSION**

The undersigned hereby elects to convert $_________ principal amount and $_________ of accrued interest of the Note (defined below) into that number of shares of Common Stock to be issued pursuant to the conversion of the Note (***"Common Stock"***) as set forth below, of Exousia Pro, Inc., a Florida corporation (the ***"Borrower"***), according to the conditions of the convertible note of the Borrower dated as of December 17, 2025 (the ***"Note"***), as of the date written below. No fee will be charged to the Holder for any conversion, except for transfer taxes, if any.

Box Checked as to applicable instructions:

⃞The Borrower shall electronically transmit the Common Stock issuable pursuant to this Notice of Conversion to the account of the undersigned or its nominee with DTC through its Deposit Withdrawal Agent Commission system ("DWAC Transfer").

Name of DTC Prime Broker:   <br> Account Number:  

⃞The undersigned hereby requests that the Borrower issue a certificate or certificates for the number of shares of Common Stock set forth below (which numbers are based on the Holder's calculation attached hereto) in the name(s) specified immediately below or, if additional space is necessary, on an attachment hereto:

---

| | |
|:---|:---|
| Date of conversion: |  |
| Applicable Conversion Price: | $|
| Number of shares of common stock to be issued <br> pursuant to conversion of the Notes: |  |
| Amount of Principal Balance due remaining <br> under the Note after this conversion: |  |

---

---

| |
|:---|
| [ Name of Holder ] |
| By: |

---

## Ex1A-12

**NEWLAN LAW FIRM, PLLC**

**2201 Long Prairie Road – Suite 107-762**

**Flower Mound, Texas 75022**

**940-367-6154**

December 30, 2025

Exousia Pro, Inc. (formerly Marijuana, Inc.)

7901 4th Street N #23494

St. Petersburg, Florida 33702

Re: <u>Offering Statement on Form 1-A</u>

Gentlemen:

We have been requested by Exousia Pro, Inc., formerly Marijuana, Inc., a Florida corporation (the ***"Company"***), to furnish you with our opinion as to the matters hereinafter set forth in connection with its offering statement on Form 1-A (the ***"Offering Statement"***) relating to the qualification of shares of the Company's common stock under Regulation A promulgated under the Securities Act of 1933, as amended. Specifically, this opinion relates to (a) 15,000,000 shares of the Company's $.001 par value common stock (the ***"Company Shares"***) to be offered by the Company and (b) up to 4,245,569 shares of the Company's $.001 par value common stock (the ***"Selling Shareholder Shares"***) to be offered by NLF Support Services, LLC, Red Phoenix Rising, LLC and Newlan Law Firm, PLLC, as selling shareholders (the ***"Selling Shareholders"***).

In connection with this opinion, we have examined the Offering Statement, the Company's Articles of Incorporation and Bylaws (each as amended to date), copies of the records of corporate proceedings of the Company and such other documents as we have deemed necessary to enable us to render the opinion hereinafter expressed.

For purposes of this opinion, we have assumed the authenticity of all documents submitted to us as originals, the conformity to the originals of all documents submitted to us as copies and the authenticity of the originals of all documents submitted to us as copies. We have also assumed the legal capacity of all natural persons, the genuineness of the signatures of persons signing all documents in connection with which this opinion is rendered, the authority of such persons signing on behalf of the parties thereto other than the Company and the due authorization, execution and delivery of all documents by the parties thereto other than the Company. We have not independently established or verified any facts relevant to the opinions expressed herein, but have relied upon statements and representations of officers and other representatives of the Company and others.

Based upon and subject to the foregoing qualifications, assumptions and limitations and the further limitations set forth below, we are of the opinion that the 15,000,000 Company Shares being offered by the Company will, when issued in accordance with the terms set forth in the Offering Statement, be legally issued, fully paid and non-assessable shares of common stock of the Company. We are of the further opinion that the up to 4,245,569 Selling Shareholder Shares have been duly authorized and, upon issuance, will be validly issued, fully paid and non-assessable shares of common stock of the Company.

Our opinions expressed above is subject to the qualification that we express no opinion as to the applicability of, compliance with, or effect of any laws except the Florida Statutes (including the statutory provisions and reported judicial decisions interpreting the foregoing).

We hereby consent to the use of this opinion as an exhibit to the Offering Statement and to the reference to our name under the caption "Legal Matters" in the Offering Statement and in the offering circular included in the Offering Statement.

Prior to the date hereof, a wholly-owned service subsidiary of this firm, NLF Support Services, LLC, a Selling Shareholder, had been the beneficial holder of three of the Subject Convertible Notes (as defined in the Offering Statement) in the total principal amount of $97,500. The Company had issued such Subject Convertible Notes (as defined in the Offering Statement) pursuant to two separate legal services agreements between the Company and this firm. In September 2025, NLF Support Services, LLC, converted the principal and accrued interest all three of the Subject Convertible Notes (as defined in the Offering Statement) into a total of 670,569 shares of common stock and, subsequently, sold all of such shares for cash at the then-offering price applicable to Selling Shareholders of $0.15 per share, a total amount of $100,585.

As of the date hereof, Newlan Law Firm, PLLC, a Selling Shareholder, is the holder of one of the unconverted Subject Convertible Notes (as defined in the Offering Statement) in the principal amount of $100,000. The Company issued such Subject Convertible Note (as defined in the Offering Statement) to this firm pursuant to a legal services agreements between the Company and this firm.

---

| |
|:---|
| Sincerely, |
| */s/ Newlan Law Firm, PLLC* |
| NEWLAN LAW FIRM, PLLC |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 1-A

### REGULATION A OFFERING STATEMENT
### UNDER THE SECURITIES ACT OF 1933

### Item 1. Issuer Information

**Exact name of issuer:** Exousia Pro, Inc.

**Jurisdiction of Incorporation/Organization:** FL

**Year of Incorporation:** 2010

**CIK:** 0001492448

**I.R.S. Employer Identification Number:** 27-2616571

**Primary Standard Industrial Classification Code:** 8000

**Total number of full-time employees:** 2

**Total number of part-time employees:** 1

**Address of Principal Executive Offices:** 7901 4th Street N #23494, —, St. Petersburg, FL 33702

**Company Phone:** 509-605-6533

**Person to contact:** Eric Newlan

### Financial Statements

**Balance Sheet Information**

| Metric                                   | Amount      |
|:---|:---|
| Cash and Cash Equivalents                | $3006.00    |
| Investment Securities                    | $0.00       |
| Accounts and Notes Receivable            | $0.00       |
| Property, Plant and Equipment (PP&E)     | $0.00       |
| Total Assets                             | $195544.00  |
| Accounts Payable and Accrued Liabilities | $211072.00  |
| Long-Term Debt                           | $0.00       |
| Total Liabilities                        | $676780.00  |
| Total Stockholders' Equity               | $-481226.00 |
| Total Liabilities and Equity             | $195544.00  |

**Statement of Comprehensive Income Information**

| Metric                                    | Amount      |
|:---|:---|
| Total Revenues                            | $500.00     |
| Costs and Expenses Applicable to Revenues | $4972.00    |
| Depreciation and Amortization             | $0.00       |
| Net Income                                | $-330084.00 |
| Earnings Per Share - Basic                | -0.01       |
| Earnings Per Share - Diluted              | -0.01       |

**Auditor Information**

| Metric          | Amount   |
|:---|:---|
| Name of Auditor |  |

### Outstanding Securities

| Class                    |   Outstanding | CUSIP     | Publicly Traded   |
|:---|---:|:---|:---|
| Common Stock             |      41048470 | 36257K208 | OTC Pink          |
| Series A Preferred Stock |           100 | 0000000NA | NA                |

### Item 2. Issuer Eligibility
- [x] The issuer certifies that all of the statements in this part are true.

### Item 3. Application of Rule 262
- [x] The issuer certifies that it is not disqualified and has not been involved in any disqualifying event.

### Item 4. Summary Information Regarding the Offering

**Tier:** Tier1

**Financial Statement Status:** Unaudited

**Type of Securities Offered:** Equity (common or preferred stock)

**Is this a delayed or continuous offering?** Yes

**Was or is the offering to take place within one year after qualification?** No

**Was or is the offering to commence within two days after qualification?** Yes

**Is this a best efforts offering?** Yes

**Was there any solicitation of interest?** No

**Are there any resale securities by affiliates of the issuer?** No

**Offering Amounts**

| Description                                                     | Amount      |
|:---|:---|
| Number of securities offered                                    | 19245569    |
| Number of securities outstanding                                | 41048470    |
| Price per security                                              | $0.09       |
| Issuer's aggregate offering price                               | $1350000.00 |
| Aggregate offering price of securities held by security holders | $382101.00  |
| Aggregate price of securities offered concurrently              | $10000.00   |
| Total aggregate offering price                                  | $1742101.00 |

**Anticipated Fees**

| Service Provider   | Name                  | Fees      |
|:---|:---|:---|
| Auditor            |  |  |
| Legal              | Newlan Law Firm, PLLC | $12500.00 |
| Promoters          |  |  |

**Estimated Net Proceeds to the Issuer:** $1727101.00

### Item 5. Jurisdictions in Which Securities are to be Offered

- All States and Territories

### Item 6. Unregistered Securities Issued or Sold Within One Year

**Name of Such Issuer:** Exousia Pro, Inc.

**Title of Securities Issued:** Series B Convertible Preferred Stock

**Total Amount of Securities Issued:** 10000

**Amount of such securities sold by principal security holders:** 0

**Aggregate consideration:** $200,000; Board of Directors determination

**Basis for aggregate consideration:** —

**Securities Act Exemption:** Section 4(a)(2) of the Securities Act